{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from IPython.core.interactiveshell import InteractiveShell\n",
    "InteractiveShell.ast_node_interactivity = \"all\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import csv\n",
    "import matplotlib.pyplot as plt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_268/3791590101.py:2: DtypeWarning: Columns (53,68) have mixed types. Specify dtype option on import or set low_memory=False.\n",
      "  world_trials = pd.read_csv('https://www.dropbox.com/scl/fi/16p9f92b9sxwyenvb37aj/all_countries_20.csv?rlkey=195nkhqonc9ufxahpbz2s3iwe&dl=1')\n",
      "/tmp/ipykernel_268/3791590101.py:6: DtypeWarning: Columns (10,13,19) have mixed types. Specify dtype option on import or set low_memory=False.\n",
      "  baseline = pd.read_csv('https://www.dropbox.com/scl/fi/2thduro77e68h1uiw4ugo/baseline_measurements.csv?rlkey=gxafeel0gdz9yr8h6sd1kntib&dl=1')\n"
     ]
    }
   ],
   "source": [
    "approved_df = pd.read_csv('https://raw.githubusercontent.com/AndreasPetrou/UCL_dissertation.github.io/main/TA-cancer-recommendations.csv')\n",
    "world_trials = pd.read_csv('https://www.dropbox.com/scl/fi/16p9f92b9sxwyenvb37aj/all_countries_20.csv?rlkey=195nkhqonc9ufxahpbz2s3iwe&dl=1')\n",
    "world_trials_results_dummy = pd.read_csv('https://www.dropbox.com/scl/fi/t54fq8nm67dkymuh3tt6c/uk_results.csv?rlkey=3uyu3ak4tqjl37fz1pmq51vvb&dl=1')\n",
    "interventions = pd.read_csv('https://www.dropbox.com/scl/fi/61azua3h4gpf0buh16zvm/interventions.csv?rlkey=rp5w07cwzhl27sdcoqk26dmez&dl=1')\n",
    "countries = pd.read_csv('https://www.dropbox.com/scl/fi/bysv5hg5t2ia69suzxjo1/countries.csv?rlkey=uu3mm228whu7xjz28684jbw6g&dl=1')\n",
    "baseline = pd.read_csv('https://www.dropbox.com/scl/fi/2thduro77e68h1uiw4ugo/baseline_measurements.csv?rlkey=gxafeel0gdz9yr8h6sd1kntib&dl=1')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# World Trials dataframe"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>NCT04311983</td>\n",
       "      <td>2020-03-31</td>\n",
       "      <td>Interventions to Help More Low-income Smokers ...</td>\n",
       "      <td>Expanding Population-level Interventions to He...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Not Applicable</td>\n",
       "      <td>1982.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT04841135</td>\n",
       "      <td>2021-06-03</td>\n",
       "      <td>Blood Microbiota Signature of Alzheimer's Disease</td>\n",
       "      <td>Analysis of the Blood Signature of the Microbi...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Not Applicable</td>\n",
       "      <td>120.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT03228355</td>\n",
       "      <td>2017-05-24</td>\n",
       "      <td>Headache Inducing Effect of Cromakalim in Migr...</td>\n",
       "      <td>The Effects of Levcromakalim on Cerebral Hemod...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Not Applicable</td>\n",
       "      <td>16.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT05021289</td>\n",
       "      <td>2021-02-01</td>\n",
       "      <td>Guided Imagery on the Perceived Stress Level i...</td>\n",
       "      <td>Effect of the Practice of Guided Imagery on th...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Not Applicable</td>\n",
       "      <td>128.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT03228277</td>\n",
       "      <td>2017-07-17</td>\n",
       "      <td>Olmutinib Trial in T790M (+) NSCLC Patients De...</td>\n",
       "      <td>Phase II, Multicenter, Single-arm, Open-label ...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>25.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Unnamed: 0       nct_id  start_date  \\\n",
       "0           0  NCT04311983  2020-03-31   \n",
       "1           1  NCT04841135  2021-06-03   \n",
       "2           2  NCT03228355  2017-05-24   \n",
       "3           3  NCT05021289  2021-02-01   \n",
       "4           4  NCT03228277  2017-07-17   \n",
       "\n",
       "                                         brief_title  \\\n",
       "0  Interventions to Help More Low-income Smokers ...   \n",
       "1  Blood Microbiota Signature of Alzheimer's Disease   \n",
       "2  Headache Inducing Effect of Cromakalim in Migr...   \n",
       "3  Guided Imagery on the Perceived Stress Level i...   \n",
       "4  Olmutinib Trial in T790M (+) NSCLC Patients De...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  Expanding Population-level Interventions to He...  Active, not recruiting   \n",
       "1  Analysis of the Blood Signature of the Microbi...              Recruiting   \n",
       "2  The Effects of Levcromakalim on Cerebral Hemod...               Completed   \n",
       "3  Effect of the Practice of Guided Imagery on th...               Completed   \n",
       "4  Phase II, Multicenter, Single-arm, Open-label ...               Completed   \n",
       "\n",
       "            phase  enrollment enrollment_type  number_of_arms  results  \n",
       "0  Not Applicable      1982.0          Actual             2.0        0  \n",
       "1  Not Applicable       120.0     Anticipated             3.0        0  \n",
       "2  Not Applicable        16.0          Actual             2.0        0  \n",
       "3  Not Applicable       128.0          Actual             2.0        0  \n",
       "4         Phase 2        25.0          Actual             1.0        0  "
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "world_trials_results_dummy.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "world_trials_results_dummy.drop(['Unnamed: 0'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>nlm_download_date_description</th>\n",
       "      <th>study_first_submitted_date</th>\n",
       "      <th>results_first_submitted_date</th>\n",
       "      <th>disposition_first_submitted_date</th>\n",
       "      <th>last_update_submitted_date</th>\n",
       "      <th>study_first_submitted_qc_date</th>\n",
       "      <th>study_first_posted_date</th>\n",
       "      <th>study_first_posted_date_type</th>\n",
       "      <th>results_first_submitted_qc_date</th>\n",
       "      <th>...</th>\n",
       "      <th>plan_to_share_ipd</th>\n",
       "      <th>plan_to_share_ipd_description</th>\n",
       "      <th>created_at</th>\n",
       "      <th>updated_at</th>\n",
       "      <th>source_class</th>\n",
       "      <th>delayed_posting</th>\n",
       "      <th>expanded_access_nctid</th>\n",
       "      <th>expanded_access_status_for_nctid</th>\n",
       "      <th>fdaaa801_violation</th>\n",
       "      <th>baseline_type_units_analyzed</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT04311983</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2020-03-10</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2023-02-21</td>\n",
       "      <td>2020-03-16</td>\n",
       "      <td>2020-03-17</td>\n",
       "      <td>Actual</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>Yes</td>\n",
       "      <td>The HCRL Data Center will make the datasets an...</td>\n",
       "      <td>2023-05-30 00:49:23.56095</td>\n",
       "      <td>2023-05-30 00:49:23.56095</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04841135</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2021-04-08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2023-04-18</td>\n",
       "      <td>2021-04-08</td>\n",
       "      <td>2021-04-12</td>\n",
       "      <td>Actual</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2023-05-30 00:49:24.204439</td>\n",
       "      <td>2023-05-30 00:49:24.204439</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03228355</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-07-08</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2018-06-18</td>\n",
       "      <td>2017-07-21</td>\n",
       "      <td>2017-07-24</td>\n",
       "      <td>Actual</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>Undecided</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2023-05-29 01:34:59.555663</td>\n",
       "      <td>2023-05-29 01:34:59.555663</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT05021289</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2021-08-18</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2021-08-25</td>\n",
       "      <td>2021-08-23</td>\n",
       "      <td>2021-08-25</td>\n",
       "      <td>Actual</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2023-05-29 01:35:01.096183</td>\n",
       "      <td>2023-05-29 01:35:01.096183</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT03228277</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2017-07-17</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2019-08-25</td>\n",
       "      <td>2017-07-20</td>\n",
       "      <td>2017-07-24</td>\n",
       "      <td>Actual</td>\n",
       "      <td>NaN</td>\n",
       "      <td>...</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2023-05-29 01:35:01.729592</td>\n",
       "      <td>2023-05-29 01:35:01.729592</td>\n",
       "      <td>OTHER</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows × 70 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  nlm_download_date_description study_first_submitted_date  \\\n",
       "0  NCT04311983                            NaN                 2020-03-10   \n",
       "1  NCT04841135                            NaN                 2021-04-08   \n",
       "2  NCT03228355                            NaN                 2017-07-08   \n",
       "3  NCT05021289                            NaN                 2021-08-18   \n",
       "4  NCT03228277                            NaN                 2017-07-17   \n",
       "\n",
       "  results_first_submitted_date disposition_first_submitted_date  \\\n",
       "0                          NaN                              NaN   \n",
       "1                          NaN                              NaN   \n",
       "2                          NaN                              NaN   \n",
       "3                          NaN                              NaN   \n",
       "4                          NaN                              NaN   \n",
       "\n",
       "  last_update_submitted_date study_first_submitted_qc_date  \\\n",
       "0                 2023-02-21                    2020-03-16   \n",
       "1                 2023-04-18                    2021-04-08   \n",
       "2                 2018-06-18                    2017-07-21   \n",
       "3                 2021-08-25                    2021-08-23   \n",
       "4                 2019-08-25                    2017-07-20   \n",
       "\n",
       "  study_first_posted_date study_first_posted_date_type  \\\n",
       "0              2020-03-17                       Actual   \n",
       "1              2021-04-12                       Actual   \n",
       "2              2017-07-24                       Actual   \n",
       "3              2021-08-25                       Actual   \n",
       "4              2017-07-24                       Actual   \n",
       "\n",
       "  results_first_submitted_qc_date  ... plan_to_share_ipd  \\\n",
       "0                             NaN  ...               Yes   \n",
       "1                             NaN  ...               NaN   \n",
       "2                             NaN  ...         Undecided   \n",
       "3                             NaN  ...                No   \n",
       "4                             NaN  ...                No   \n",
       "\n",
       "                       plan_to_share_ipd_description  \\\n",
       "0  The HCRL Data Center will make the datasets an...   \n",
       "1                                                NaN   \n",
       "2                                                NaN   \n",
       "3                                                NaN   \n",
       "4                                                NaN   \n",
       "\n",
       "                   created_at                  updated_at source_class  \\\n",
       "0   2023-05-30 00:49:23.56095   2023-05-30 00:49:23.56095        OTHER   \n",
       "1  2023-05-30 00:49:24.204439  2023-05-30 00:49:24.204439        OTHER   \n",
       "2  2023-05-29 01:34:59.555663  2023-05-29 01:34:59.555663        OTHER   \n",
       "3  2023-05-29 01:35:01.096183  2023-05-29 01:35:01.096183        OTHER   \n",
       "4  2023-05-29 01:35:01.729592  2023-05-29 01:35:01.729592        OTHER   \n",
       "\n",
       "  delayed_posting expanded_access_nctid expanded_access_status_for_nctid  \\\n",
       "0             NaN                   NaN                              NaN   \n",
       "1             NaN                   NaN                              NaN   \n",
       "2             NaN                   NaN                              NaN   \n",
       "3             NaN                   NaN                              NaN   \n",
       "4             NaN                   NaN                              NaN   \n",
       "\n",
       "  fdaaa801_violation baseline_type_units_analyzed  \n",
       "0                NaN                          NaN  \n",
       "1                NaN                          NaN  \n",
       "2                NaN                          NaN  \n",
       "3                NaN                          NaN  \n",
       "4                NaN                          NaN  \n",
       "\n",
       "[5 rows x 70 columns]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "world_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "nct_id_list = world_trials['nct_id'].tolist()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "322824"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "world_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Intevretions dataframe"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>41203722</td>\n",
       "      <td>NCT01578434</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Vitamin D</td>\n",
       "      <td>Vitamin D: 6 lakh IU single im dose Calcium: 7...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>41203723</td>\n",
       "      <td>NCT01578434</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Calcium Carbonate</td>\n",
       "      <td>Calcium: 75 mg/kg calcium daily for 3 months</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>41203724</td>\n",
       "      <td>NCT01578434</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Vitamin D and Calcium</td>\n",
       "      <td>Vitamin D: 6 lakh IU single im dose. along wit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>40903586</td>\n",
       "      <td>NCT03663959</td>\n",
       "      <td>Procedure</td>\n",
       "      <td>Laparoscopic Pectocolpopexy procedure</td>\n",
       "      <td>First, the peritoneal layer above and lateral ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>40903587</td>\n",
       "      <td>NCT02836574</td>\n",
       "      <td>Biological</td>\n",
       "      <td>Renal Autologous Cell Therapy (REACT)</td>\n",
       "      <td>Autologous selected renal cells (SRC).</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         id       nct_id intervention_type  \\\n",
       "0  41203722  NCT01578434              Drug   \n",
       "1  41203723  NCT01578434              Drug   \n",
       "2  41203724  NCT01578434              Drug   \n",
       "3  40903586  NCT03663959         Procedure   \n",
       "4  40903587  NCT02836574        Biological   \n",
       "\n",
       "                                    name  \\\n",
       "0                              Vitamin D   \n",
       "1                      Calcium Carbonate   \n",
       "2                  Vitamin D and Calcium   \n",
       "3  Laparoscopic Pectocolpopexy procedure   \n",
       "4  Renal Autologous Cell Therapy (REACT)   \n",
       "\n",
       "                                         description  \n",
       "0  Vitamin D: 6 lakh IU single im dose Calcium: 7...  \n",
       "1       Calcium: 75 mg/kg calcium daily for 3 months  \n",
       "2  Vitamin D: 6 lakh IU single im dose. along wit...  \n",
       "3  First, the peritoneal layer above and lateral ...  \n",
       "4             Autologous selected renal cells (SRC).  "
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "interventions.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "filtered_interventions = interventions[interventions['nct_id'].isin(nct_id_list)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "Int64Index: 636561 entries, 0 to 771641\n",
      "Data columns (total 5 columns):\n",
      " #   Column             Non-Null Count   Dtype \n",
      "---  ------             --------------   ----- \n",
      " 0   id                 636561 non-null  int64 \n",
      " 1   nct_id             636561 non-null  object\n",
      " 2   intervention_type  636561 non-null  object\n",
      " 3   name               636559 non-null  object\n",
      " 4   description        571675 non-null  object\n",
      "dtypes: int64(1), object(4)\n",
      "memory usage: 29.1+ MB\n"
     ]
    }
   ],
   "source": [
    "filtered_interventions.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "322824"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "filtered_interventions.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_268/4024314354.py:1: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  filtered_interventions['name'] = filtered_interventions['name'].str.lower()\n"
     ]
    }
   ],
   "source": [
    "filtered_interventions['name'] = filtered_interventions['name'].str.lower()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>category</th>\n",
       "      <th>title</th>\n",
       "      <th>units</th>\n",
       "      <th>param_type</th>\n",
       "      <th>param_value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NCT02552121</td>\n",
       "      <td>Hispanic or Latino</td>\n",
       "      <td>Ethnicity (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>NCT02552121</td>\n",
       "      <td>Hispanic or Latino</td>\n",
       "      <td>Ethnicity (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>NCT02552121</td>\n",
       "      <td>Hispanic or Latino</td>\n",
       "      <td>Ethnicity (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>1.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>NCT02552121</td>\n",
       "      <td>Hispanic or Latino</td>\n",
       "      <td>Ethnicity (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>NCT02552121</td>\n",
       "      <td>Hispanic or Latino</td>\n",
       "      <td>Ethnicity (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         nct_id            category                title         units  \\\n",
       "13  NCT02552121  Hispanic or Latino  Ethnicity (NIH/OMB)  Participants   \n",
       "14  NCT02552121  Hispanic or Latino  Ethnicity (NIH/OMB)  Participants   \n",
       "15  NCT02552121  Hispanic or Latino  Ethnicity (NIH/OMB)  Participants   \n",
       "16  NCT02552121  Hispanic or Latino  Ethnicity (NIH/OMB)  Participants   \n",
       "17  NCT02552121  Hispanic or Latino  Ethnicity (NIH/OMB)  Participants   \n",
       "\n",
       "               param_type param_value  \n",
       "13  Count of Participants         0.0  \n",
       "14  Count of Participants         0.0  \n",
       "15  Count of Participants         1.0  \n",
       "16  Count of Participants         0.0  \n",
       "17  Count of Participants         0.0  "
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# keep only the trials that have reported race/ethnicity to create a dataframe including only those.\n",
    "race_df = baseline[baseline['title'].str.contains(r'Race|Ethnicity', case=True, regex=True)]\n",
    "\n",
    "# exclude rows that have 'median' and 'mean' in param_type column\n",
    "race_df = race_df[race_df['param_type'].isin(['Count of Participants', 'Count of Units', 'Number'])]\n",
    "\n",
    "race_df = race_df.iloc[:, [1,5,6,8,9,10]]\n",
    "\n",
    "race_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "110890"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "31593"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "22932"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_df.category.isna().sum()\n",
    "\n",
    "race_df.nct_id.nunique()\n",
    "\n",
    "race_df = race_df.dropna(subset=['category'])\n",
    "\n",
    "race_df.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>category</th>\n",
       "      <th>title</th>\n",
       "      <th>units</th>\n",
       "      <th>param_type</th>\n",
       "      <th>param_value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NCT02552121</td>\n",
       "      <td>Hispanic or Latino</td>\n",
       "      <td>Ethnicity (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>NCT02552121</td>\n",
       "      <td>Hispanic or Latino</td>\n",
       "      <td>Ethnicity (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>NCT02552121</td>\n",
       "      <td>Hispanic or Latino</td>\n",
       "      <td>Ethnicity (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>1.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>NCT02552121</td>\n",
       "      <td>Hispanic or Latino</td>\n",
       "      <td>Ethnicity (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>NCT02552121</td>\n",
       "      <td>Hispanic or Latino</td>\n",
       "      <td>Ethnicity (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         nct_id            category                title         units  \\\n",
       "13  NCT02552121  Hispanic or Latino  Ethnicity (NIH/OMB)  Participants   \n",
       "14  NCT02552121  Hispanic or Latino  Ethnicity (NIH/OMB)  Participants   \n",
       "15  NCT02552121  Hispanic or Latino  Ethnicity (NIH/OMB)  Participants   \n",
       "16  NCT02552121  Hispanic or Latino  Ethnicity (NIH/OMB)  Participants   \n",
       "17  NCT02552121  Hispanic or Latino  Ethnicity (NIH/OMB)  Participants   \n",
       "\n",
       "               param_type param_value  \n",
       "13  Count of Participants         0.0  \n",
       "14  Count of Participants         0.0  \n",
       "15  Count of Participants         1.0  \n",
       "16  Count of Participants         0.0  \n",
       "17  Count of Participants         0.0  "
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_df.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Approved drugs dataframe"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 494 entries, 0 to 493\n",
      "Data columns (total 9 columns):\n",
      " #   Column                                        Non-Null Count  Dtype \n",
      "---  ------                                        --------------  ----- \n",
      " 0   Rec no.                                       494 non-null    int64 \n",
      " 1   TA ID                                         494 non-null    object\n",
      " 2   Year of Publication                           494 non-null    object\n",
      " 3   Process                                       494 non-null    object\n",
      " 4   Technology                                    494 non-null    object\n",
      " 5   Technology type                               494 non-null    object\n",
      " 6   Indication                                    494 non-null    object\n",
      " 7   Categorisation (for specific recommendation)  494 non-null    object\n",
      " 8   Comment                                       494 non-null    object\n",
      "dtypes: int64(1), object(8)\n",
      "memory usage: 34.9+ KB\n"
     ]
    }
   ],
   "source": [
    "approved_df.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Recommended                              208\n",
       "Optimised                                 76\n",
       "Terminated Appraisal - non submission     63\n",
       "Not Recommended                           42\n",
       "Not recommended                           42\n",
       "Recommended (CDF)                         42\n",
       "Optimised (CDF)                           11\n",
       "Only in Research                           9\n",
       "Terminated appraisal - non submission      1\n",
       "Name: Categorisation (for specific recommendation), dtype: int64"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "approved_df[\"Categorisation (for specific recommendation)\"].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "desired_inputs = ['Recommended', 'Optimised', 'Recommended (CDF)', 'Optimised (CDF)']\n",
    "approved_df = approved_df[approved_df['Categorisation (for specific recommendation)'].isin(desired_inputs)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "approved_df['Year of Publication'] = approved_df['Year of Publication'].astype(str).str[:4]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rec no.</th>\n",
       "      <th>TA ID</th>\n",
       "      <th>Year of Publication</th>\n",
       "      <th>Process</th>\n",
       "      <th>Technology</th>\n",
       "      <th>Technology type</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Categorisation (for specific recommendation)</th>\n",
       "      <th>Comment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>3</td>\n",
       "      <td>TA003</td>\n",
       "      <td>2000</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Paclitaxel</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Ovarian cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Guidance has been replaced by TA55. Recommenda...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>6</td>\n",
       "      <td>TA006</td>\n",
       "      <td>2000</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Docetaxel</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Advanced breast cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Guidance has been replaced by TA30. Recommenda...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>7</td>\n",
       "      <td>TA006</td>\n",
       "      <td>2000</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Paclitaxel</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Advanced breast cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Guidance has been replaced by TA30. Recommenda...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>35</td>\n",
       "      <td>TA023</td>\n",
       "      <td>2001</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Temozolomide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Brain cancer (recurrent)</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommendation in line with marketing authoris...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>42</td>\n",
       "      <td>TA025</td>\n",
       "      <td>2001</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Gemcitabine (1st line)</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Pancreatic cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with clinical practice.</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Rec no.  TA ID Year of Publication Process              Technology  \\\n",
       "0        3  TA003                2000     MTA              Paclitaxel   \n",
       "2        6  TA006                2000     MTA               Docetaxel   \n",
       "3        7  TA006                2000     MTA              Paclitaxel   \n",
       "5       35  TA023                2001     MTA            Temozolomide   \n",
       "6       42  TA025                2001     MTA  Gemcitabine (1st line)   \n",
       "\n",
       "  Technology type                Indication  \\\n",
       "0  Pharmaceutical            Ovarian cancer   \n",
       "2  Pharmaceutical    Advanced breast cancer   \n",
       "3  Pharmaceutical    Advanced breast cancer   \n",
       "5  Pharmaceutical  Brain cancer (recurrent)   \n",
       "6  Pharmaceutical        Pancreatic cancer    \n",
       "\n",
       "  Categorisation (for specific recommendation)  \\\n",
       "0                                  Recommended   \n",
       "2                                  Recommended   \n",
       "3                                  Recommended   \n",
       "5                                  Recommended   \n",
       "6                                  Recommended   \n",
       "\n",
       "                                             Comment  \n",
       "0  Guidance has been replaced by TA55. Recommenda...  \n",
       "2  Guidance has been replaced by TA30. Recommenda...  \n",
       "3  Guidance has been replaced by TA30. Recommenda...  \n",
       "5  Recommendation in line with marketing authoris...  \n",
       "6       Recommended in line with clinical practice.   "
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "approved_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Convert 'year of publication' column to datetime\n",
    "approved_df['Year of Publication'] = pd.to_datetime(approved_df['Year of Publication'], format='%Y')\n",
    "\n",
    "# Extract the year\n",
    "approved_df['year'] = approved_df['Year of Publication'].dt.year"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Assuming the column name is 'column_name'\n",
    "duplicates = approved_df.duplicated(subset=['Technology'], keep=False)\n",
    "\n",
    "# Filter the dataframe to show only the duplicate rows\n",
    "duplicate_rows = approved_df[duplicates]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rec no.</th>\n",
       "      <th>TA ID</th>\n",
       "      <th>Year of Publication</th>\n",
       "      <th>Process</th>\n",
       "      <th>Technology</th>\n",
       "      <th>Technology type</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Categorisation (for specific recommendation)</th>\n",
       "      <th>Comment</th>\n",
       "      <th>year</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>3</td>\n",
       "      <td>TA003</td>\n",
       "      <td>2000-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Paclitaxel</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Ovarian cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Guidance has been replaced by TA55. Recommenda...</td>\n",
       "      <td>2000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>6</td>\n",
       "      <td>TA006</td>\n",
       "      <td>2000-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Docetaxel</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Advanced breast cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Guidance has been replaced by TA30. Recommenda...</td>\n",
       "      <td>2000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>7</td>\n",
       "      <td>TA006</td>\n",
       "      <td>2000-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Paclitaxel</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Advanced breast cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Guidance has been replaced by TA30. Recommenda...</td>\n",
       "      <td>2000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>35</td>\n",
       "      <td>TA023</td>\n",
       "      <td>2001-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Temozolomide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Brain cancer (recurrent)</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommendation in line with marketing authoris...</td>\n",
       "      <td>2001</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>42</td>\n",
       "      <td>TA025</td>\n",
       "      <td>2001-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Gemcitabine (1st line)</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Pancreatic cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with clinical practice.</td>\n",
       "      <td>2001</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Rec no.  TA ID Year of Publication Process              Technology  \\\n",
       "0        3  TA003          2000-01-01     MTA              Paclitaxel   \n",
       "2        6  TA006          2000-01-01     MTA               Docetaxel   \n",
       "3        7  TA006          2000-01-01     MTA              Paclitaxel   \n",
       "5       35  TA023          2001-01-01     MTA            Temozolomide   \n",
       "6       42  TA025          2001-01-01     MTA  Gemcitabine (1st line)   \n",
       "\n",
       "  Technology type                Indication  \\\n",
       "0  Pharmaceutical            Ovarian cancer   \n",
       "2  Pharmaceutical    Advanced breast cancer   \n",
       "3  Pharmaceutical    Advanced breast cancer   \n",
       "5  Pharmaceutical  Brain cancer (recurrent)   \n",
       "6  Pharmaceutical        Pancreatic cancer    \n",
       "\n",
       "  Categorisation (for specific recommendation)  \\\n",
       "0                                  Recommended   \n",
       "2                                  Recommended   \n",
       "3                                  Recommended   \n",
       "5                                  Recommended   \n",
       "6                                  Recommended   \n",
       "\n",
       "                                             Comment  year  \n",
       "0  Guidance has been replaced by TA55. Recommenda...  2000  \n",
       "2  Guidance has been replaced by TA30. Recommenda...  2000  \n",
       "3  Guidance has been replaced by TA30. Recommenda...  2000  \n",
       "5  Recommendation in line with marketing authoris...  2001  \n",
       "6       Recommended in line with clinical practice.   2001  "
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "duplicate_rows.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Creating yearly dataframes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "count     337.000000\n",
       "mean     2015.320475\n",
       "std         6.188841\n",
       "min      2000.000000\n",
       "25%      2012.000000\n",
       "50%      2017.000000\n",
       "75%      2020.000000\n",
       "max      2022.000000\n",
       "Name: year, dtype: float64"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "approved_df['year'].describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Get unique years\n",
    "unique_years = approved_df['Year of Publication'].dt.year.unique()\n",
    "\n",
    "# Create separate dataframes based on each year\n",
    "yearly_dataframes = {}\n",
    "for year in unique_years:\n",
    "    yearly_dataframes[year] = approved_df[approved_df['Year of Publication'].dt.year == year].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rec no.</th>\n",
       "      <th>TA ID</th>\n",
       "      <th>Year of Publication</th>\n",
       "      <th>Process</th>\n",
       "      <th>Technology</th>\n",
       "      <th>Technology type</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Categorisation (for specific recommendation)</th>\n",
       "      <th>Comment</th>\n",
       "      <th>year</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>450</th>\n",
       "      <td>1119</td>\n",
       "      <td>TA783</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Daratumumab monotherapy for treating relapsed ...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Relapsed and refractory multiple myeloma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>CDF review of TA510 Optimised recommenation fo...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>451</th>\n",
       "      <td>1120</td>\n",
       "      <td>TA784</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Niraparib</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Maintenance treatment of relapsed, platinum-se...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>CDF review of TA528. Optimised recommendation ...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>453</th>\n",
       "      <td>1122</td>\n",
       "      <td>TA786</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Tucatinib with trastuzumab and capecitabine</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>HER2-positive advanced breast cancer after 2 o...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>454</th>\n",
       "      <td>1123</td>\n",
       "      <td>TA787</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Venetoclax with low dose cytarabine</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Untreated acute myeloid leukaemia when intensi...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for venetoclax with l...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>455</th>\n",
       "      <td>1124</td>\n",
       "      <td>TA788</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Avelumab</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Maintenance treatment of locally advanced or m...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for avelumab for main...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>456</th>\n",
       "      <td>1125</td>\n",
       "      <td>TA789</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Tepotinib</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Advanced non-small-cell lung cancer with MET g...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with the marketing authori...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>458</th>\n",
       "      <td>1132</td>\n",
       "      <td>TA796</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Venetoclax</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Chronic lymphocytic leukaemia</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>CDF review of TA487 Recommended in line with t...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>460</th>\n",
       "      <td>1134</td>\n",
       "      <td>TA798</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Durvalumab</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Maintenance treatment of unresectable non-smal...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>CDF review of TA578 Optimised recommendation f...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>461</th>\n",
       "      <td>1137</td>\n",
       "      <td>TA801</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Pembrolizumab plus chemotherapy</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Untreated, triple-negative, locally recurrent...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for pembrolizumab plu...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>462</th>\n",
       "      <td>1138</td>\n",
       "      <td>TA802</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Cemiplimab</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Advanced cutaneous squamous cell carcinoma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>CDF review of TA592 Optimised recommendation f...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>463</th>\n",
       "      <td>1146</td>\n",
       "      <td>TA810</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Abemaciclib with endocrine therapy</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Adjuvant treatment of hormone receptor-positiv...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>466</th>\n",
       "      <td>1149</td>\n",
       "      <td>TA813</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Asciminib</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Chronic myeloid leukaemia after 2 or more tyro...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>467</th>\n",
       "      <td>1154</td>\n",
       "      <td>TA816</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Alpelisib with fulvestrant</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Hormone receptor-positive, HER2-negative, PIK3...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Replaces TA652 Optimised recommendation for al...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>468</th>\n",
       "      <td>1155</td>\n",
       "      <td>TA817</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Nivolumab</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Invasive urothelial cancer at high risk of rec...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimsed recommendation for nivolumab for the ...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>469</th>\n",
       "      <td>1156</td>\n",
       "      <td>TA818</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Nivolumab with ipilimumab</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Untreated unresectable malignant pleural mesot...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for nivolumab plus ip...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>470</th>\n",
       "      <td>1157</td>\n",
       "      <td>TA819</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Sacituzumab govitecan</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Unresectable triple-negative advanced breast c...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>471</th>\n",
       "      <td>1161</td>\n",
       "      <td>TA823</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Atezolizumab</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Adjuvant treatment of resected non-small-cell ...</td>\n",
       "      <td>Recommended (CDF)</td>\n",
       "      <td>Atezolizumab is recommended for use within the...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>472</th>\n",
       "      <td>1165</td>\n",
       "      <td>TA827</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Oral azacitidine</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Maintenance treatment of acute myeloid leukaem...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>473</th>\n",
       "      <td>1168</td>\n",
       "      <td>TA830</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Pembrolizumab</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Adjuvant treatment of renal cell carcinoma</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>475</th>\n",
       "      <td>1174</td>\n",
       "      <td>TA836</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Palbociclib with fulvestrant</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Hormone receptor-positive, HER2-negative advan...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>CDF review of TA619. Recommended in line with ...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>476</th>\n",
       "      <td>1175</td>\n",
       "      <td>TA837</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Pembrolizumab</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Adjuvant treatment of resected stage 2B or 2C ...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>480</th>\n",
       "      <td>1187</td>\n",
       "      <td>TA849</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Cabozantinib</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Previously treated advanced hepatocellular ca...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Replaces TA582. Optimised recommendation for c...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>482</th>\n",
       "      <td>1189</td>\n",
       "      <td>TA851</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Pembrolizumab</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Neoadjuvant and adjuvant treatment of triple-n...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>483</th>\n",
       "      <td>1190</td>\n",
       "      <td>TA852</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Trifluridine–tipiracil</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Metastatic gastric cancer or gastro-oesophagea...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Rapide review of TA669.  Recommended in line w...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>484</th>\n",
       "      <td>1193</td>\n",
       "      <td>TA855</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Mobocertinib</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>EGFR exon 20 insertion mutation-positive advan...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>485</th>\n",
       "      <td>1195</td>\n",
       "      <td>TA857</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Nivolumab with platinum- and fluoropyrimidine-...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Untreated HER2-negative advanced gastric, gas...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>486</th>\n",
       "      <td>1196</td>\n",
       "      <td>TA858</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Lenvatinib</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Untreated advanced renal cell carcinoma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for lenvatinib with p...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>487</th>\n",
       "      <td>1197</td>\n",
       "      <td>TA858</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Lenvatinib</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Untreated advanced renal cell carcinoma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for lenvatinib with p...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>488</th>\n",
       "      <td>1201</td>\n",
       "      <td>TA862</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Trastuzumab deruxtecan</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>HER2-positive unresectable or metastatic breas...</td>\n",
       "      <td>Recommended (CDF)</td>\n",
       "      <td>Trastuzumab deruxtecan is recommended with man...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>489</th>\n",
       "      <td>1204</td>\n",
       "      <td>TA865</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Nivolumab with fluoropyrimidine- and platinum-...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Untreated unresectable advanced, recurrent, or...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for nivolumab with fl...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>490</th>\n",
       "      <td>1205</td>\n",
       "      <td>TA866</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Regorafenib</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Previously treated metastatic colorectal cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>491</th>\n",
       "      <td>1209</td>\n",
       "      <td>TA870</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Ixazomib with lenalidomide and dexamethasone</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Relapsed or refractory multiple myeloma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Review of TA505. Optimised recommenation for i...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>492</th>\n",
       "      <td>1211</td>\n",
       "      <td>TA872</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Axicabtagene ciloleucel</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Diffuse large B-cell lymphoma and primary medi...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>CDF review of TA559. Recommended in line with ...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>493</th>\n",
       "      <td>1215</td>\n",
       "      <td>TA876</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Nivolumab with chemotherapy</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Neoadjuvant treatment of resectable non-small-...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     Rec no.  TA ID Year of Publication Process  \\\n",
       "450     1119  TA783          2022-01-01     STA   \n",
       "451     1120  TA784          2022-01-01     STA   \n",
       "453     1122  TA786          2022-01-01     STA   \n",
       "454     1123  TA787          2022-01-01     STA   \n",
       "455     1124  TA788          2022-01-01     STA   \n",
       "456     1125  TA789          2022-01-01     STA   \n",
       "458     1132  TA796          2022-01-01     STA   \n",
       "460     1134  TA798          2022-01-01     STA   \n",
       "461     1137  TA801          2022-01-01     STA   \n",
       "462     1138  TA802          2022-01-01     STA   \n",
       "463     1146  TA810          2022-01-01     STA   \n",
       "466     1149  TA813          2022-01-01     STA   \n",
       "467     1154  TA816          2022-01-01     STA   \n",
       "468     1155  TA817          2022-01-01     STA   \n",
       "469     1156  TA818          2022-01-01     STA   \n",
       "470     1157  TA819          2022-01-01     STA   \n",
       "471     1161  TA823          2022-01-01     STA   \n",
       "472     1165  TA827          2022-01-01     STA   \n",
       "473     1168  TA830          2022-01-01     STA   \n",
       "475     1174  TA836          2022-01-01     STA   \n",
       "476     1175  TA837          2022-01-01     STA   \n",
       "480     1187  TA849          2022-01-01     STA   \n",
       "482     1189  TA851          2022-01-01     STA   \n",
       "483     1190  TA852          2022-01-01     STA   \n",
       "484     1193  TA855          2022-01-01     STA   \n",
       "485     1195  TA857          2022-01-01     STA   \n",
       "486     1196  TA858          2022-01-01     MTA   \n",
       "487     1197  TA858          2022-01-01     MTA   \n",
       "488     1201  TA862          2022-01-01     STA   \n",
       "489     1204  TA865          2022-01-01     STA   \n",
       "490     1205  TA866          2022-01-01     STA   \n",
       "491     1209  TA870          2022-01-01     STA   \n",
       "492     1211  TA872          2022-01-01     STA   \n",
       "493     1215  TA876          2022-01-01     STA   \n",
       "\n",
       "                                            Technology Technology type  \\\n",
       "450  Daratumumab monotherapy for treating relapsed ...  Pharmaceutical   \n",
       "451                                          Niraparib  Pharmaceutical   \n",
       "453       Tucatinib with trastuzumab and capecitabine   Pharmaceutical   \n",
       "454               Venetoclax with low dose cytarabine   Pharmaceutical   \n",
       "455                                          Avelumab   Pharmaceutical   \n",
       "456                                         Tepotinib   Pharmaceutical   \n",
       "458                                        Venetoclax   Pharmaceutical   \n",
       "460                                        Durvalumab   Pharmaceutical   \n",
       "461                    Pembrolizumab plus chemotherapy  Pharmaceutical   \n",
       "462                                         Cemiplimab  Pharmaceutical   \n",
       "463                Abemaciclib with endocrine therapy   Pharmaceutical   \n",
       "466                                         Asciminib   Pharmaceutical   \n",
       "467                        Alpelisib with fulvestrant   Pharmaceutical   \n",
       "468                                          Nivolumab  Pharmaceutical   \n",
       "469                         Nivolumab with ipilimumab   Pharmaceutical   \n",
       "470                             Sacituzumab govitecan   Pharmaceutical   \n",
       "471                                       Atezolizumab  Pharmaceutical   \n",
       "472                                  Oral azacitidine   Pharmaceutical   \n",
       "473                                     Pembrolizumab   Pharmaceutical   \n",
       "475                      Palbociclib with fulvestrant   Pharmaceutical   \n",
       "476                                     Pembrolizumab   Pharmaceutical   \n",
       "480                                       Cabozantinib  Pharmaceutical   \n",
       "482                                     Pembrolizumab   Pharmaceutical   \n",
       "483                             Trifluridine–tipiracil  Pharmaceutical   \n",
       "484                                       Mobocertinib  Pharmaceutical   \n",
       "485  Nivolumab with platinum- and fluoropyrimidine-...  Pharmaceutical   \n",
       "486                                         Lenvatinib  Pharmaceutical   \n",
       "487                                         Lenvatinib  Pharmaceutical   \n",
       "488                            Trastuzumab deruxtecan   Pharmaceutical   \n",
       "489  Nivolumab with fluoropyrimidine- and platinum-...  Pharmaceutical   \n",
       "490                                       Regorafenib   Pharmaceutical   \n",
       "491       Ixazomib with lenalidomide and dexamethasone  Pharmaceutical   \n",
       "492                           Axicabtagene ciloleucel   Pharmaceutical   \n",
       "493                       Nivolumab with chemotherapy   Pharmaceutical   \n",
       "\n",
       "                                            Indication  \\\n",
       "450           Relapsed and refractory multiple myeloma   \n",
       "451  Maintenance treatment of relapsed, platinum-se...   \n",
       "453  HER2-positive advanced breast cancer after 2 o...   \n",
       "454  Untreated acute myeloid leukaemia when intensi...   \n",
       "455  Maintenance treatment of locally advanced or m...   \n",
       "456  Advanced non-small-cell lung cancer with MET g...   \n",
       "458                      Chronic lymphocytic leukaemia   \n",
       "460  Maintenance treatment of unresectable non-smal...   \n",
       "461   Untreated, triple-negative, locally recurrent...   \n",
       "462         Advanced cutaneous squamous cell carcinoma   \n",
       "463  Adjuvant treatment of hormone receptor-positiv...   \n",
       "466  Chronic myeloid leukaemia after 2 or more tyro...   \n",
       "467  Hormone receptor-positive, HER2-negative, PIK3...   \n",
       "468  Invasive urothelial cancer at high risk of rec...   \n",
       "469  Untreated unresectable malignant pleural mesot...   \n",
       "470  Unresectable triple-negative advanced breast c...   \n",
       "471  Adjuvant treatment of resected non-small-cell ...   \n",
       "472  Maintenance treatment of acute myeloid leukaem...   \n",
       "473         Adjuvant treatment of renal cell carcinoma   \n",
       "475  Hormone receptor-positive, HER2-negative advan...   \n",
       "476  Adjuvant treatment of resected stage 2B or 2C ...   \n",
       "480   Previously treated advanced hepatocellular ca...   \n",
       "482  Neoadjuvant and adjuvant treatment of triple-n...   \n",
       "483  Metastatic gastric cancer or gastro-oesophagea...   \n",
       "484  EGFR exon 20 insertion mutation-positive advan...   \n",
       "485   Untreated HER2-negative advanced gastric, gas...   \n",
       "486            Untreated advanced renal cell carcinoma   \n",
       "487            Untreated advanced renal cell carcinoma   \n",
       "488  HER2-positive unresectable or metastatic breas...   \n",
       "489  Untreated unresectable advanced, recurrent, or...   \n",
       "490    Previously treated metastatic colorectal cancer   \n",
       "491            Relapsed or refractory multiple myeloma   \n",
       "492  Diffuse large B-cell lymphoma and primary medi...   \n",
       "493  Neoadjuvant treatment of resectable non-small-...   \n",
       "\n",
       "    Categorisation (for specific recommendation)  \\\n",
       "450                                    Optimised   \n",
       "451                                    Optimised   \n",
       "453                                  Recommended   \n",
       "454                                    Optimised   \n",
       "455                                    Optimised   \n",
       "456                                  Recommended   \n",
       "458                                  Recommended   \n",
       "460                                    Optimised   \n",
       "461                                    Optimised   \n",
       "462                                    Optimised   \n",
       "463                                  Recommended   \n",
       "466                                  Recommended   \n",
       "467                                    Optimised   \n",
       "468                                    Optimised   \n",
       "469                                    Optimised   \n",
       "470                                  Recommended   \n",
       "471                            Recommended (CDF)   \n",
       "472                                  Recommended   \n",
       "473                                  Recommended   \n",
       "475                                  Recommended   \n",
       "476                                  Recommended   \n",
       "480                                    Optimised   \n",
       "482                                  Recommended   \n",
       "483                                  Recommended   \n",
       "484                                  Recommended   \n",
       "485                                  Recommended   \n",
       "486                                    Optimised   \n",
       "487                                    Optimised   \n",
       "488                            Recommended (CDF)   \n",
       "489                                    Optimised   \n",
       "490                                  Recommended   \n",
       "491                                    Optimised   \n",
       "492                                  Recommended   \n",
       "493                                  Recommended   \n",
       "\n",
       "                                               Comment  year  \n",
       "450  CDF review of TA510 Optimised recommenation fo...  2022  \n",
       "451  CDF review of TA528. Optimised recommendation ...  2022  \n",
       "453  Recommended in line with marketing authorisati...  2022  \n",
       "454  Optimised recommendation for venetoclax with l...  2022  \n",
       "455  Optimised recommendation for avelumab for main...  2022  \n",
       "456  Recommended in line with the marketing authori...  2022  \n",
       "458  CDF review of TA487 Recommended in line with t...  2022  \n",
       "460  CDF review of TA578 Optimised recommendation f...  2022  \n",
       "461  Optimised recommendation for pembrolizumab plu...  2022  \n",
       "462  CDF review of TA592 Optimised recommendation f...  2022  \n",
       "463  Recommended in line with marketing authorisati...  2022  \n",
       "466  Recommended in line with marketing authorisati...  2022  \n",
       "467  Replaces TA652 Optimised recommendation for al...  2022  \n",
       "468  Optimsed recommendation for nivolumab for the ...  2022  \n",
       "469  Optimised recommendation for nivolumab plus ip...  2022  \n",
       "470  Recommended in line with marketing authorisati...  2022  \n",
       "471  Atezolizumab is recommended for use within the...  2022  \n",
       "472  Recommended in line with marketing authorisati...  2022  \n",
       "473  Recommended in line with marketing authorisati...  2022  \n",
       "475  CDF review of TA619. Recommended in line with ...  2022  \n",
       "476  Recommended in line with marketing authorisati...  2022  \n",
       "480  Replaces TA582. Optimised recommendation for c...  2022  \n",
       "482  Recommended in line with marketing authorisati...  2022  \n",
       "483  Rapide review of TA669.  Recommended in line w...  2022  \n",
       "484  Recommended in line with marketing authorisati...  2022  \n",
       "485  Recommended in line with marketing authorisati...  2022  \n",
       "486  Optimised recommendation for lenvatinib with p...  2022  \n",
       "487  Optimised recommendation for lenvatinib with p...  2022  \n",
       "488  Trastuzumab deruxtecan is recommended with man...  2022  \n",
       "489  Optimised recommendation for nivolumab with fl...  2022  \n",
       "490  Recommended in line with marketing authorisati...  2022  \n",
       "491  Review of TA505. Optimised recommenation for i...  2022  \n",
       "492  CDF review of TA559. Recommended in line with ...  2022  \n",
       "493  Recommended in line with marketing authorisati...  2022  "
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "yearly_dataframes[2022]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "yearly_dataframes[2022].to_csv('/project/approved_drugs_charts_data/drugs_approved_2022.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Niraparib\n",
    "### Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "niraparib\n",
      "mk-4827\n"
     ]
    }
   ],
   "source": [
    "# define the synonyms\n",
    "drug_names = [\n",
    "    \"Niraparib\",\n",
    "    \"1038915-60-4\",\n",
    "    \"MK-4827\",\n",
    "    \"(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide\",\n",
    "    \"MK4827\",\n",
    "    \"Niraparib [USAN]\",\n",
    "    \"2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide\",\n",
    "    \"2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide\",\n",
    "    \"MK 4827\",\n",
    "    \"HMC2H89N35\",\n",
    "    \"CHEMBL1094636\",\n",
    "    \"C19H20N4O\",\n",
    "    \"Niraparib (USAN)\",\n",
    "    \"ZL-2306\",\n",
    "    \"JNJ-64091742\",\n",
    "    \"(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide;MK-4827\",\n",
    "    \"Niraparib [USAN:INN]\",\n",
    "    \"UNII-HMC2H89N35\",\n",
    "    \"MK 4827 (Base)\",\n",
    "    \"3JD\",\n",
    "    \"Zejula (TN)\",\n",
    "    \"NIRAPARIB [INN]\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [\n",
    "    \"Niraparib\",\n",
    "    \"1038915-60-4\",\n",
    "    \"MK-4827\",\n",
    "    \"(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide\",\n",
    "    \"MK4827\",\n",
    "    \"Niraparib [USAN]\",\n",
    "    \"2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide\",\n",
    "    \"2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide\",\n",
    "    \"MK 4827\",\n",
    "    \"HMC2H89N35\",\n",
    "    \"CHEMBL1094636\",\n",
    "    \"C19H20N4O\",\n",
    "    \"Niraparib (USAN)\",\n",
    "    \"ZL-2306\",\n",
    "    \"JNJ-64091742\",\n",
    "    \"(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide;MK-4827\",\n",
    "    \"Niraparib [USAN:INN]\",\n",
    "    \"UNII-HMC2H89N35\",\n",
    "    \"MK 4827 (Base)\",\n",
    "    \"3JD\",\n",
    "    \"Zejula (TN)\",\n",
    "    \"NIRAPARIB [INN]\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1571</th>\n",
       "      <td>40781890</td>\n",
       "      <td>NCT03891615</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Niraparib is a type of drug called a \"PARP inh...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1780</th>\n",
       "      <td>41061453</td>\n",
       "      <td>NCT03806049</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>given orally once daily</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8616</th>\n",
       "      <td>41063002</td>\n",
       "      <td>NCT05261269</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Administered orally once daily</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13127</th>\n",
       "      <td>41063965</td>\n",
       "      <td>NCT03221400</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Niraparib</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21735</th>\n",
       "      <td>41066266</td>\n",
       "      <td>NCT04376073</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>752822</th>\n",
       "      <td>41052751</td>\n",
       "      <td>NCT04826198</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Unit dose: Hard capsule containing 100mg of Ni...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>754123</th>\n",
       "      <td>40899233</td>\n",
       "      <td>NCT04475939</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Niraparib will be administered</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>759961</th>\n",
       "      <td>41057876</td>\n",
       "      <td>NCT03925350</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>300 mg PO daily</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>765165</th>\n",
       "      <td>41201513</td>\n",
       "      <td>NCT03983993</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Given PO</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>767556</th>\n",
       "      <td>40902206</td>\n",
       "      <td>NCT03601923</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Niraparib belongs to a class of anti-cancer ag...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>123 rows × 5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "              id       nct_id intervention_type       name  \\\n",
       "1571    40781890  NCT03891615              Drug  niraparib   \n",
       "1780    41061453  NCT03806049              Drug  niraparib   \n",
       "8616    41063002  NCT05261269              Drug  niraparib   \n",
       "13127   41063965  NCT03221400              Drug  niraparib   \n",
       "21735   41066266  NCT04376073              Drug  niraparib   \n",
       "...          ...          ...               ...        ...   \n",
       "752822  41052751  NCT04826198              Drug  niraparib   \n",
       "754123  40899233  NCT04475939              Drug  niraparib   \n",
       "759961  41057876  NCT03925350              Drug  niraparib   \n",
       "765165  41201513  NCT03983993              Drug  niraparib   \n",
       "767556  40902206  NCT03601923              Drug  niraparib   \n",
       "\n",
       "                                              description  \n",
       "1571    Niraparib is a type of drug called a \"PARP inh...  \n",
       "1780                              given orally once daily  \n",
       "8616                       Administered orally once daily  \n",
       "13127                                           Niraparib  \n",
       "21735   Niraparib 300mg(Body Weigh ≥77 kg)/200mg (Body...  \n",
       "...                                                   ...  \n",
       "752822  Unit dose: Hard capsule containing 100mg of Ni...  \n",
       "754123                     Niraparib will be administered  \n",
       "759961                                    300 mg PO daily  \n",
       "765165                                           Given PO  \n",
       "767556  Niraparib belongs to a class of anti-cancer ag...  \n",
       "\n",
       "[123 rows x 5 columns]"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "119"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "niraparib_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "119"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "niraparib_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT04313504</td>\n",
       "      <td>2020-11-04</td>\n",
       "      <td>Study Evaluating the Efficacy of Niraparib and...</td>\n",
       "      <td>An Open-label, Phase II Study Evaluating the E...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>23.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41126445</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Niraparib &amp; Dostarlimab combination</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT03329937</td>\n",
       "      <td>2018-04-12</td>\n",
       "      <td>Study Evaluating the Antitumor Activity and Sa...</td>\n",
       "      <td>An Open-Label, Single-arm Pilot Study Evaluati...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>21.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41126646</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Niraparib is a potent, orally active, highly s...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT02354586</td>\n",
       "      <td>2015-03-23</td>\n",
       "      <td>A Study of Niraparib in Patients With Ovarian ...</td>\n",
       "      <td>A Phase 2, Open-Label, Single-Arm Study to Eva...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>463.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41127991</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04080284</td>\n",
       "      <td>2019-12-30</td>\n",
       "      <td>Trial of Maintenance With Niraparib- Uterine S...</td>\n",
       "      <td>Trial of Maintenance With Niraparib in Patient...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>45.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41416240</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Study treatment will be administered orally Q ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT04068753</td>\n",
       "      <td>2020-02-26</td>\n",
       "      <td>Niraparib in Combination With Dostarlimab in P...</td>\n",
       "      <td>Phase II Trial of Niraparib in Combination Wit...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>66.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41130568</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Niraparib: 200 mg, oral, once daily, days 1-21</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT04313504  2020-11-04  Study Evaluating the Efficacy of Niraparib and...   \n",
       "1  NCT03329937  2018-04-12  Study Evaluating the Antitumor Activity and Sa...   \n",
       "2  NCT02354586  2015-03-23  A Study of Niraparib in Patients With Ovarian ...   \n",
       "3  NCT04080284  2019-12-30  Trial of Maintenance With Niraparib- Uterine S...   \n",
       "4  NCT04068753  2020-02-26  Niraparib in Combination With Dostarlimab in P...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  An Open-label, Phase II Study Evaluating the E...  Active, not recruiting   \n",
       "1  An Open-Label, Single-arm Pilot Study Evaluati...               Completed   \n",
       "2  A Phase 2, Open-Label, Single-Arm Study to Eva...               Completed   \n",
       "3  Trial of Maintenance With Niraparib in Patient...              Recruiting   \n",
       "4  Phase II Trial of Niraparib in Combination Wit...              Recruiting   \n",
       "\n",
       "     phase  enrollment enrollment_type  number_of_arms  results        id  \\\n",
       "0  Phase 2        23.0     Anticipated             1.0        0  41126445   \n",
       "1  Phase 1        21.0          Actual             1.0        1  41126646   \n",
       "2  Phase 2       463.0          Actual             1.0        1  41127991   \n",
       "3  Phase 2        45.0     Anticipated             1.0        0  41416240   \n",
       "4  Phase 2        66.0     Anticipated             1.0        0  41130568   \n",
       "\n",
       "  intervention_type       name  \\\n",
       "0              Drug  niraparib   \n",
       "1              Drug  niraparib   \n",
       "2              Drug  niraparib   \n",
       "3              Drug  niraparib   \n",
       "4              Drug  niraparib   \n",
       "\n",
       "                                         description  \n",
       "0                Niraparib & Dostarlimab combination  \n",
       "1  Niraparib is a potent, orally active, highly s...  \n",
       "2                                                NaN  \n",
       "3  Study treatment will be administered orally Q ...  \n",
       "4     Niraparib: 200 mg, oral, once daily, days 1-21  "
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "niraparib_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    107\n",
       "1     16\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "niraparib_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Avelumab\n",
    "### Maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "avelumab\n",
      "msb0010718c\n"
     ]
    }
   ],
   "source": [
    "drug_names = [\n",
    "    \"Avelumab\",\n",
    "    \"1537032-82-8\",\n",
    "    \"Bavencio\",\n",
    "    \"KXG2PJ551I\",\n",
    "    \"MSB-0010718C\",\n",
    "    \"Immunoglobulin G1-lambda1, Anti-(Homo sapiens CD274 (Programmed Death Ligand 1, PDL1, pd-l1, B7 Homolog 1, B7H1)), Homo sapiens Monoclonal Antibody\",\n",
    "    \"MSB0010718C\",\n",
    "    \"MSB-0010682\",\n",
    "    \"AVELUMAB (PURPLE BOOK CDER)\",\n",
    "    \"L01XC31\",\n",
    "    \"MSB0010682\",\n",
    "    \"UNII-KXG2PJ551I\",\n",
    "    \"avelumabum\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>3218</th>\n",
       "      <td>41061745</td>\n",
       "      <td>NCT03483883</td>\n",
       "      <td>Drug</td>\n",
       "      <td>avelumab</td>\n",
       "      <td>Avelumab IV 10 mg/kg every 2 weeks</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6233</th>\n",
       "      <td>40906139</td>\n",
       "      <td>NCT03647423</td>\n",
       "      <td>Drug</td>\n",
       "      <td>avelumab</td>\n",
       "      <td>injection</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6854</th>\n",
       "      <td>40782775</td>\n",
       "      <td>NCT03563170</td>\n",
       "      <td>Biological</td>\n",
       "      <td>avelumab</td>\n",
       "      <td>Recombinant human anti-PD-L1 IgG1 monoclonal a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7189</th>\n",
       "      <td>40906796</td>\n",
       "      <td>NCT03147404</td>\n",
       "      <td>Drug</td>\n",
       "      <td>avelumab</td>\n",
       "      <td>Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11451</th>\n",
       "      <td>40908213</td>\n",
       "      <td>NCT03387111</td>\n",
       "      <td>Drug</td>\n",
       "      <td>avelumab</td>\n",
       "      <td>Recombinant human anti-PD-L1 IgG1 monoclonal a...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id       nct_id intervention_type      name  \\\n",
       "3218   41061745  NCT03483883              Drug  avelumab   \n",
       "6233   40906139  NCT03647423              Drug  avelumab   \n",
       "6854   40782775  NCT03563170        Biological  avelumab   \n",
       "7189   40906796  NCT03147404              Drug  avelumab   \n",
       "11451  40908213  NCT03387111              Drug  avelumab   \n",
       "\n",
       "                                             description  \n",
       "3218                  Avelumab IV 10 mg/kg every 2 weeks  \n",
       "6233                                           injection  \n",
       "6854   Recombinant human anti-PD-L1 IgG1 monoclonal a...  \n",
       "7189          Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)  \n",
       "11451  Recombinant human anti-PD-L1 IgG1 monoclonal a...  "
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "200"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "avelumab_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "200"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "avelumab_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05327686</td>\n",
       "      <td>2022-06-30</td>\n",
       "      <td>Testing the Addition of Stereotactic Radiation...</td>\n",
       "      <td>Randomized Phase II Stereotactic Ablative Radi...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>240.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41415842</td>\n",
       "      <td>Biological</td>\n",
       "      <td>avelumab</td>\n",
       "      <td>Given IV</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT03964532</td>\n",
       "      <td>2019-04-17</td>\n",
       "      <td>TALAVE: Induction Talazoparib Followed by Comb...</td>\n",
       "      <td>TALAVE: A Pilot Trial of Induction Talazoparib...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>24.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41128512</td>\n",
       "      <td>Drug</td>\n",
       "      <td>avelumab</td>\n",
       "      <td>Avelumab (formerly MSB0010718C) is a human imm...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT05600127</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>Chemotherapy and Sequential Immunotherapy for ...</td>\n",
       "      <td>Chemotherapy and Sequential Immunotherapy for ...</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>64.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41128765</td>\n",
       "      <td>Drug</td>\n",
       "      <td>avelumab</td>\n",
       "      <td>3 cycles of avelumab (800mg, every 2 weeks)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT03046953</td>\n",
       "      <td>2017-11-14</td>\n",
       "      <td>Avelumab in Relapsed and Refractory Peripheral...</td>\n",
       "      <td>A Phase 2a Trial of Avelumab, an Anti-PDL1 Ant...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>34.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40967077</td>\n",
       "      <td>Drug</td>\n",
       "      <td>avelumab</td>\n",
       "      <td>anti-PDL1 antibody</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT04173507</td>\n",
       "      <td>2020-02-14</td>\n",
       "      <td>Combination Treatment (Talazoparib Plus Avelum...</td>\n",
       "      <td>A Phase II Study of Talazoparib Plus Avelumab ...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>47.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41132101</td>\n",
       "      <td>Drug</td>\n",
       "      <td>avelumab</td>\n",
       "      <td>Given IV</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT05327686  2022-06-30  Testing the Addition of Stereotactic Radiation...   \n",
       "1  NCT03964532  2019-04-17  TALAVE: Induction Talazoparib Followed by Comb...   \n",
       "2  NCT05600127  2022-12-31  Chemotherapy and Sequential Immunotherapy for ...   \n",
       "3  NCT03046953  2017-11-14  Avelumab in Relapsed and Refractory Peripheral...   \n",
       "4  NCT04173507  2020-02-14  Combination Treatment (Talazoparib Plus Avelum...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  Randomized Phase II Stereotactic Ablative Radi...              Recruiting   \n",
       "1  TALAVE: A Pilot Trial of Induction Talazoparib...  Active, not recruiting   \n",
       "2  Chemotherapy and Sequential Immunotherapy for ...      Not yet recruiting   \n",
       "3  A Phase 2a Trial of Avelumab, an Anti-PDL1 Ant...               Completed   \n",
       "4  A Phase II Study of Talazoparib Plus Avelumab ...  Active, not recruiting   \n",
       "\n",
       "             phase  enrollment enrollment_type  number_of_arms  results  \\\n",
       "0          Phase 2       240.0     Anticipated             2.0        0   \n",
       "1  Phase 1/Phase 2        24.0          Actual             1.0        0   \n",
       "2          Phase 2        64.0     Anticipated             1.0        0   \n",
       "3          Phase 2        34.0          Actual             1.0        0   \n",
       "4          Phase 2        47.0          Actual             1.0        1   \n",
       "\n",
       "         id intervention_type      name  \\\n",
       "0  41415842        Biological  avelumab   \n",
       "1  41128512              Drug  avelumab   \n",
       "2  41128765              Drug  avelumab   \n",
       "3  40967077              Drug  avelumab   \n",
       "4  41132101              Drug  avelumab   \n",
       "\n",
       "                                         description  \n",
       "0                                           Given IV  \n",
       "1  Avelumab (formerly MSB0010718C) is a human imm...  \n",
       "2        3 cycles of avelumab (800mg, every 2 weeks)  \n",
       "3                                 anti-PDL1 antibody  \n",
       "4                                           Given IV  "
      ]
     },
     "execution_count": 43,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "avelumab_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    161\n",
       "1     46\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "avelumab_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Tepotinib\n",
    "### Advanced non-small-cell lung cancer with MET gene alterations"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "tepotinib\n",
      "msc2156119j\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    \"Tepotinib\",\n",
    "    \"1100598-32-0\",\n",
    "    \"EMD-1214063\",\n",
    "    \"EMD 1214063\",\n",
    "    \"Tepotinib [INN]\",\n",
    "    \"EMD1214063\",\n",
    "    \"MSC2156119\",\n",
    "    \"MSC-2156119J\",\n",
    "    \"Tepmetko\",\n",
    "    \"Tepotinib [USAN]\",\n",
    "    \"MSC-2156119\",\n",
    "    \"MSC2156119J\",\n",
    "    \"3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile\",\n",
    "    \"1IJV77EI07\",\n",
    "    \"Tepotinib(EMD-1214063)\",\n",
    "    \"Tepotinib (EMD 1214063)\",\n",
    "    \"3-(1-(3-(5-((1-methylpiperidin-4-yl)methoxy)pyrimidin-2-yl)benzyl)-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile\",\n",
    "    \"Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo-3-pyridazinyl)-\",\n",
    "    \"Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-\",\n",
    "    \"3-[1-(3-{5-[(1-Methylpiperidin-4-Yl)methoxy]pyrimidin-2-Yl}benzyl)-6-Oxo-1,6-Dihydropyridazin-3-Yl]benzonitrile\",\n",
    "    \"UNII-1IJV77EI07\",\n",
    "    \"Tepotinib (USAN/INN)\",\n",
    "    \"Tepotinib [USAN:INN]\",\n",
    "    \"TEPOTINIB [WHO-DD]\",\n",
    "    \"MLS006010785\",\n",
    "    \"GTPL8293\",\n",
    "    \"SCHEMBL1296895\",\n",
    "    \"CHEMBL3402762\",\n",
    "    \"DTXSID70149132\",\n",
    "    \"EX-A394\",\n",
    "    \"WHO 9934\",\n",
    "    \"BDBM50065457\",\n",
    "    \"MFCD18452823\",\n",
    "    \"NSC758244\",\n",
    "    \"NSC781256\",\n",
    "    \"NSC800945\",\n",
    "    \"s7067\",\n",
    "    \"CCG-269632\",\n",
    "    \"CS-0647\",\n",
    "    \"DB15133\",\n",
    "    \"NSC-758244\",\n",
    "    \"NSC-781256\",\n",
    "    \"NSC-800945\",\n",
    "    \"SB16609\",\n",
    "    \"compound 22 [PMID: 25736998]\",\n",
    "    \"NCGC00345793-01\",\n",
    "    \"NCGC00345793-08\",\n",
    "    \"AC-35185\",\n",
    "    \"AS-16915\",\n",
    "    \"HY-14721\",\n",
    "    \"SMR004701471\",\n",
    "    \"D11717\",\n",
    "    \"J-002366\",\n",
    "    \"Q27088961\",\n",
    "    \"1100598-30-8\",\n",
    "    \"3-(1-(3-(5-((1-Methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)benzyl)-6-oxo-1,6-dihydro-3-pyridazinyl)benzonitrile\",\n",
    "    \"3-(1-{3-[5-(1-methylpiperidin-4-yl-methoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile\",\n",
    "    \"3-(1-{3-[5-(1-methylpiperidin-4-ylmethoxy)pyrimidin-2-yl]benzyl}-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile\",\n",
    "    \"3-[1,6-Dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]benzonitrile\",\n",
    "    \"3E8\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>44397</th>\n",
       "      <td>41071402</td>\n",
       "      <td>NCT03492437</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tepotinib</td>\n",
       "      <td>Participants will receive single oral dose of ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61580</th>\n",
       "      <td>41078409</td>\n",
       "      <td>NCT02115373</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tepotinib</td>\n",
       "      <td>Participants received a single oral dose of Te...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61581</th>\n",
       "      <td>41078410</td>\n",
       "      <td>NCT02115373</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tepotinib</td>\n",
       "      <td>Participants received a single oral dose of Te...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>122835</th>\n",
       "      <td>41089301</td>\n",
       "      <td>NCT03546608</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tepotinib</td>\n",
       "      <td>Participants will receive a single oral dose o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>302786</th>\n",
       "      <td>41004486</td>\n",
       "      <td>NCT01988493</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tepotinib</td>\n",
       "      <td>Participants randomized to receive Tepotinib r...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              id       nct_id intervention_type       name  \\\n",
       "44397   41071402  NCT03492437              Drug  tepotinib   \n",
       "61580   41078409  NCT02115373              Drug  tepotinib   \n",
       "61581   41078410  NCT02115373              Drug  tepotinib   \n",
       "122835  41089301  NCT03546608              Drug  tepotinib   \n",
       "302786  41004486  NCT01988493              Drug  tepotinib   \n",
       "\n",
       "                                              description  \n",
       "44397   Participants will receive single oral dose of ...  \n",
       "61580   Participants received a single oral dose of Te...  \n",
       "61581   Participants received a single oral dose of Te...  \n",
       "122835  Participants will receive a single oral dose o...  \n",
       "302786  Participants randomized to receive Tepotinib r...  "
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "15"
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [],
   "source": [
    "tepotinib_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "15"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tepotinib_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03531762</td>\n",
       "      <td>2018-05-14</td>\n",
       "      <td>Effect of a Proton Pump Inhibitor on the Pharm...</td>\n",
       "      <td>Phase I, Open-label, Three-Period Crossover St...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>12.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>6.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41161934</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tepotinib</td>\n",
       "      <td>Participants will receive single oral dose of ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01014936</td>\n",
       "      <td>2009-11-30</td>\n",
       "      <td>First-in-Man, Dose-escalation Trial of C-met K...</td>\n",
       "      <td>A Phase I Open-label, Non-randomized, Dose-esc...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>149.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>3.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41164681</td>\n",
       "      <td>Drug</td>\n",
       "      <td>msc2156119j</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT04591431</td>\n",
       "      <td>2020-10-07</td>\n",
       "      <td>The Rome Trial From Histology to Target: the R...</td>\n",
       "      <td>The Rome Trial From Histology to Target: the R...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>384.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41201253</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tepotinib</td>\n",
       "      <td>TT arm</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01988493</td>\n",
       "      <td>2014-01-06</td>\n",
       "      <td>Efficacy, Safety, and Pharmacokinetic of MSC21...</td>\n",
       "      <td>A Multicenter, Randomized, Phase Ib/II Trial t...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>117.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>5.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41004486</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tepotinib</td>\n",
       "      <td>Participants randomized to receive Tepotinib r...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT04647838</td>\n",
       "      <td>2020-01-16</td>\n",
       "      <td>Tepotinib in Solid Tumors Harboring MET Altera...</td>\n",
       "      <td>A Phase II Study of Tepotinib in Patients With...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>100.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41303137</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tepotinib</td>\n",
       "      <td>Tepotinib 500mg (2 tablets of 250mg) per day D...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT03531762  2018-05-14  Effect of a Proton Pump Inhibitor on the Pharm...   \n",
       "1  NCT01014936  2009-11-30  First-in-Man, Dose-escalation Trial of C-met K...   \n",
       "2  NCT04591431  2020-10-07  The Rome Trial From Histology to Target: the R...   \n",
       "3  NCT01988493  2014-01-06  Efficacy, Safety, and Pharmacokinetic of MSC21...   \n",
       "4  NCT04647838  2020-01-16  Tepotinib in Solid Tumors Harboring MET Altera...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  Phase I, Open-label, Three-Period Crossover St...               Completed   \n",
       "1  A Phase I Open-label, Non-randomized, Dose-esc...               Completed   \n",
       "2  The Rome Trial From Histology to Target: the R...  Active, not recruiting   \n",
       "3  A Multicenter, Randomized, Phase Ib/II Trial t...               Completed   \n",
       "4  A Phase II Study of Tepotinib in Patients With...              Recruiting   \n",
       "\n",
       "             phase  enrollment enrollment_type  number_of_arms  results  \\\n",
       "0          Phase 1        12.0          Actual             6.0        0   \n",
       "1          Phase 1       149.0          Actual             3.0        1   \n",
       "2          Phase 2       384.0     Anticipated             2.0        0   \n",
       "3  Phase 1/Phase 2       117.0          Actual             5.0        1   \n",
       "4          Phase 2       100.0     Anticipated             2.0        0   \n",
       "\n",
       "         id intervention_type         name  \\\n",
       "0  41161934              Drug    tepotinib   \n",
       "1  41164681              Drug  msc2156119j   \n",
       "2  41201253              Drug    tepotinib   \n",
       "3  41004486              Drug    tepotinib   \n",
       "4  41303137              Drug    tepotinib   \n",
       "\n",
       "                                         description  \n",
       "0  Participants will receive single oral dose of ...  \n",
       "1                                                NaN  \n",
       "2                                             TT arm  \n",
       "3  Participants randomized to receive Tepotinib r...  \n",
       "4  Tepotinib 500mg (2 tablets of 250mg) per day D...  "
      ]
     },
     "execution_count": 51,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tepotinib_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    9\n",
       "1    7\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tepotinib_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Venetoclax\n",
    "### Chronic lymphocytic leukaemia"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "venetoclax\n",
      "abt-199\n",
      "abt199\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    \"Venetoclax\",\n",
    "    \"1257044-40-8\",\n",
    "    \"ABT-199\",\n",
    "    \"Venclexta\",\n",
    "    \"GDC-0199\",\n",
    "    \"ABT199\",\n",
    "    \"ABT 199\",\n",
    "    \"RG7601\",\n",
    "    \"Venetoclax (ABT199)\",\n",
    "    \"GDC 0199\",\n",
    "    \"RG-7601\",\n",
    "    \"Venetoclax; Abt-199\",\n",
    "    \"Venetoclax(ABT-199)\",\n",
    "    \"4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide\",\n",
    "    \"Venetoclax (ABT-199)\",\n",
    "    \"N54AIC43PW\",\n",
    "    \"ABT-199 (GDC-0199)\",\n",
    "    \"2-(1H-Pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methy\",\n",
    "    \"4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide\",\n",
    "    \"benzamide, 4-(4-((2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl)methyl)-1-piperazinyl)-n-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)-2-(1h-pyrrolo(2,3-b)pyridin-5-yloxy)-\",\n",
    "    \"venclyxto\",\n",
    "    \"BDBM189459\",\n",
    "    \"UNII-N54AIC43PW\",\n",
    "    \"4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(oxan-4-yl)methyl]amino}benzene)sulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide\",\n",
    "    \"4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-n-({3-nitro-4-[(tetrahydro-2h-pyran-4-yl)methyl]amino]phenyl}sulfonyl)-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide\",\n",
    "    \"4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzene-1-sulfonyl)-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide\",\n",
    "    \"Venetoclax [USAN:INN]\",\n",
    "    \"Venclexta (TN)\",\n",
    "    \"Benzamide, 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-\",\n",
    "    \"VENETOCLAX [MI]\",\n",
    "    \"VENETOCLAX [INN]\",\n",
    "    \"VENETOCLAX [JAN]\",\n",
    "    \"VENETOCLAX [USAN]\",\n",
    "    \"VENETOCLAX [WHO-DD]\",\n",
    "    \"4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide\",\n",
    "    \"MLS006010298\",\n",
    "    \"SCHEMBL523816\",\n",
    "    \"Venetoclax (JAN/USAN/INN)\",\n",
    "    \"AMY343\",\n",
    "    \"GTPL8318\",\n",
    "    \"CHEMBL3137309\",\n",
    "    \"SCHEMBL19236295\",\n",
    "    \"VENETOCLAX [ORANGE BOOK]\",\n",
    "    \"BDBM60828\",\n",
    "    \"DTXSID30154863\",\n",
    "    \"EX-A168\",\n",
    "    \"CHEBI:133021\",\n",
    "    \"HMS3653J06\",\n",
    "    \"HMS3745E07\",\n",
    "    \"BCP06811\",\n",
    "    \"BDBM50162774\",\n",
    "    \"MFCD23160052\",\n",
    "    \"NSC766270\",\n",
    "    \"AKOS025289539\",\n",
    "    \"CCG-270543\",\n",
    "    \"CS-1155\",\n",
    "    \"DB11581\",\n",
    "    \"KS-1470\",\n",
    "    \"NSC-766270\",\n",
    "    \"SB16499\",\n",
    "    \"NCGC00345789-01\",\n",
    "    \"NCGC00345789-05\",\n",
    "    \"NCGC00345789-10\",\n",
    "    \"NCGC00345789-11\",\n",
    "    \"AC-28754\",\n",
    "    \"DA-35360\",\n",
    "    \"HY-15531\",\n",
    "    \"SMR004701366\",\n",
    "    \"FT-0699586\",\n",
    "    \"S8048\",\n",
    "    \"SW219672-1\",\n",
    "    \"J3.516.625D\",\n",
    "    \"D10679\",\n",
    "    \"US9174982, 5\",\n",
    "    \"EN300-7399830\",\n",
    "    \"A850921\",\n",
    "    \"US9174982, 369\",\n",
    "    \"J-005269\",\n",
    "    \"Q23671272\",\n",
    "    \"Z2037279542\",\n",
    "    \"2-((1H-Pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide\",\n",
    "    \"4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2HPYRAN-4-YLMETHYL) AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE\",\n",
    "    \"4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-(3-nitro-4-{[(oxan-4-yl)methyl]amino}benzenesulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide\",\n",
    "    \"4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-cyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(tetrahydropyran-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2053</th>\n",
       "      <td>40904268</td>\n",
       "      <td>NCT04450173</td>\n",
       "      <td>Drug</td>\n",
       "      <td>venetoclax</td>\n",
       "      <td>Given PO</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2518</th>\n",
       "      <td>41204387</td>\n",
       "      <td>NCT01594229</td>\n",
       "      <td>Drug</td>\n",
       "      <td>abt-199</td>\n",
       "      <td>ABT-199 is taken orally once daily for 3 days ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5557</th>\n",
       "      <td>40905606</td>\n",
       "      <td>NCT04266795</td>\n",
       "      <td>Drug</td>\n",
       "      <td>venetoclax</td>\n",
       "      <td>Venetoclax tablets.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5808</th>\n",
       "      <td>40905795</td>\n",
       "      <td>NCT05053659</td>\n",
       "      <td>Drug</td>\n",
       "      <td>venetoclax</td>\n",
       "      <td>Participants will receive venetoclax at target...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7976</th>\n",
       "      <td>41062682</td>\n",
       "      <td>NCT03379051</td>\n",
       "      <td>Drug</td>\n",
       "      <td>venetoclax</td>\n",
       "      <td>BCL-2 Inhibitor</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "            id       nct_id intervention_type        name  \\\n",
       "2053  40904268  NCT04450173              Drug  venetoclax   \n",
       "2518  41204387  NCT01594229              Drug     abt-199   \n",
       "5557  40905606  NCT04266795              Drug  venetoclax   \n",
       "5808  40905795  NCT05053659              Drug  venetoclax   \n",
       "7976  41062682  NCT03379051              Drug  venetoclax   \n",
       "\n",
       "                                            description  \n",
       "2053                                           Given PO  \n",
       "2518  ABT-199 is taken orally once daily for 3 days ...  \n",
       "5557                                Venetoclax tablets.  \n",
       "5808  Participants will receive venetoclax at target...  \n",
       "7976                                    BCL-2 Inhibitor  "
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "325"
      ]
     },
     "execution_count": 56,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {},
   "outputs": [],
   "source": [
    "venetoclax_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "325"
      ]
     },
     "execution_count": 58,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "venetoclax_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT04493099</td>\n",
       "      <td>2020-10-31</td>\n",
       "      <td>Alvocidib in Combination With Decitabine and V...</td>\n",
       "      <td>A Phase 1/2 Study of Alvocidib in Combination ...</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>0.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40962516</td>\n",
       "      <td>Drug</td>\n",
       "      <td>venetoclax</td>\n",
       "      <td>Given PO</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT03312530</td>\n",
       "      <td>2017-11-13</td>\n",
       "      <td>A Study of Cobimetinib Administered as Single ...</td>\n",
       "      <td>A Phase Ib/II Study of Cobimetinib Administere...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>49.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>5.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41128985</td>\n",
       "      <td>Drug</td>\n",
       "      <td>venetoclax</td>\n",
       "      <td>Venetoclax will be administered as per the sch...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT04447768</td>\n",
       "      <td>2020-12-03</td>\n",
       "      <td>The Combination of Venetoclax and Obinutuzumab...</td>\n",
       "      <td>A Phase II: Venetoclax-Based Therapy for the T...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>100.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41130503</td>\n",
       "      <td>Drug</td>\n",
       "      <td>venetoclax</td>\n",
       "      <td>Cycle 1, Day 22 to 28 -20 mg daily\\n\\nCycle 2,...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT03801525</td>\n",
       "      <td>2019-05-16</td>\n",
       "      <td>Study to Assess the Efficacy and Safety of Ubl...</td>\n",
       "      <td>Phase 2/3 Randomized Study to Assess the Effic...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 2/Phase 3</td>\n",
       "      <td>271.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>7.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41130599</td>\n",
       "      <td>Drug</td>\n",
       "      <td>venetoclax</td>\n",
       "      <td>B-cell lymphoma 2 (BCL-2) inhibitor\\nTablet fo...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT02756611</td>\n",
       "      <td>2016-06-22</td>\n",
       "      <td>A Study to Evaluate the Efficacy of Venetoclax...</td>\n",
       "      <td>Open-Label, Single Arm, Phase 3b, Multi-Center...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>258.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41130696</td>\n",
       "      <td>Drug</td>\n",
       "      <td>venetoclax</td>\n",
       "      <td>Tablets for oral administration</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT04493099  2020-10-31  Alvocidib in Combination With Decitabine and V...   \n",
       "1  NCT03312530  2017-11-13  A Study of Cobimetinib Administered as Single ...   \n",
       "2  NCT04447768  2020-12-03  The Combination of Venetoclax and Obinutuzumab...   \n",
       "3  NCT03801525  2019-05-16  Study to Assess the Efficacy and Safety of Ubl...   \n",
       "4  NCT02756611  2016-06-22  A Study to Evaluate the Efficacy of Venetoclax...   \n",
       "\n",
       "                                      official_title overall_status  \\\n",
       "0  A Phase 1/2 Study of Alvocidib in Combination ...      Withdrawn   \n",
       "1  A Phase Ib/II Study of Cobimetinib Administere...      Completed   \n",
       "2  A Phase II: Venetoclax-Based Therapy for the T...     Recruiting   \n",
       "3  Phase 2/3 Randomized Study to Assess the Effic...     Terminated   \n",
       "4  Open-Label, Single Arm, Phase 3b, Multi-Center...      Completed   \n",
       "\n",
       "             phase  enrollment enrollment_type  number_of_arms  results  \\\n",
       "0  Phase 1/Phase 2         0.0          Actual             1.0        0   \n",
       "1  Phase 1/Phase 2        49.0          Actual             5.0        1   \n",
       "2          Phase 2       100.0     Anticipated             1.0        0   \n",
       "3  Phase 2/Phase 3       271.0          Actual             7.0        0   \n",
       "4          Phase 3       258.0          Actual             1.0        1   \n",
       "\n",
       "         id intervention_type        name  \\\n",
       "0  40962516              Drug  venetoclax   \n",
       "1  41128985              Drug  venetoclax   \n",
       "2  41130503              Drug  venetoclax   \n",
       "3  41130599              Drug  venetoclax   \n",
       "4  41130696              Drug  venetoclax   \n",
       "\n",
       "                                         description  \n",
       "0                                           Given PO  \n",
       "1  Venetoclax will be administered as per the sch...  \n",
       "2  Cycle 1, Day 22 to 28 -20 mg daily\\n\\nCycle 2,...  \n",
       "3  B-cell lymphoma 2 (BCL-2) inhibitor\\nTablet fo...  \n",
       "4                    Tablets for oral administration  "
      ]
     },
     "execution_count": 59,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "venetoclax_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    302\n",
       "1     26\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "venetoclax_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Durvalumab\n",
    "### Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "durvalumab\n",
      "medi4736\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    'Durvalumab',\n",
    "    \"1428935-60-7\",\n",
    "    'Imfinzi',\n",
    "    'MEDI4736',\n",
    "    '28X28X9OKV',\n",
    "    \"IMMUNOGLOBULIN G1, ANTI-(HUMAN PROTEIN B7-H1) (HUMAN MONOCLONAL MEDI4736 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL MEDI4736 kappa-CHAIN, DIMER\",\n",
    "    \"Immunoglobulin G1, anti-(human cd antigen cd274) (human monoclonal MEDI4736 heavy chain), disulfide with human monoclonal MEDI4736 kappa-chain, dimer\",\n",
    "    \"DURVALUMAB (PURPLE BOOK CDER)\",\n",
    "    \"L01XC28\",\n",
    "    \"MEDI 4736\",\n",
    "    \"UNII-28X28X9OKV\",\n",
    "    \"anti-B7H1 monoclonal antibody\",\n",
    "    \"durvalumabum\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2480</th>\n",
       "      <td>40904413</td>\n",
       "      <td>NCT02899195</td>\n",
       "      <td>Drug</td>\n",
       "      <td>durvalumab</td>\n",
       "      <td>On Day 1 of each 21 day cycle: Durvalumab 1120...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5167</th>\n",
       "      <td>40905354</td>\n",
       "      <td>NCT03446547</td>\n",
       "      <td>Drug</td>\n",
       "      <td>durvalumab</td>\n",
       "      <td>durvalumab 1500 mg i.v. every fourth week for ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6172</th>\n",
       "      <td>40906082</td>\n",
       "      <td>NCT03419559</td>\n",
       "      <td>Drug</td>\n",
       "      <td>durvalumab</td>\n",
       "      <td>PD-L1 antagonist monoclonal antibody</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7823</th>\n",
       "      <td>40782951</td>\n",
       "      <td>NCT03872505</td>\n",
       "      <td>Drug</td>\n",
       "      <td>durvalumab</td>\n",
       "      <td>IV administration of 5 treatments;every 2 week...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9845</th>\n",
       "      <td>40907707</td>\n",
       "      <td>NCT02520453</td>\n",
       "      <td>Drug</td>\n",
       "      <td>durvalumab</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "            id       nct_id intervention_type        name  \\\n",
       "2480  40904413  NCT02899195              Drug  durvalumab   \n",
       "5167  40905354  NCT03446547              Drug  durvalumab   \n",
       "6172  40906082  NCT03419559              Drug  durvalumab   \n",
       "7823  40782951  NCT03872505              Drug  durvalumab   \n",
       "9845  40907707  NCT02520453              Drug  durvalumab   \n",
       "\n",
       "                                            description  \n",
       "2480  On Day 1 of each 21 day cycle: Durvalumab 1120...  \n",
       "5167  durvalumab 1500 mg i.v. every fourth week for ...  \n",
       "6172               PD-L1 antagonist monoclonal antibody  \n",
       "7823  IV administration of 5 treatments;every 2 week...  \n",
       "9845                                                NaN  "
      ]
     },
     "execution_count": 63,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "467"
      ]
     },
     "execution_count": 64,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [],
   "source": [
    "durvalumab_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "467"
      ]
     },
     "execution_count": 66,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "durvalumab_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03141359</td>\n",
       "      <td>2017-05-12</td>\n",
       "      <td>Use of High Dose Radiation Followed by Chemoth...</td>\n",
       "      <td>LCI-LUN-NSC-SBRT-001: Phase II Prospective Tri...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>61.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41125820</td>\n",
       "      <td>Drug</td>\n",
       "      <td>durvalumab</td>\n",
       "      <td>adjuvant immunotherapy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04866017</td>\n",
       "      <td>2021-06-17</td>\n",
       "      <td>A Study to Compare Ociperlimab Plus Tislelizum...</td>\n",
       "      <td>A Phase 3, Randomized, Open-Label Study to Com...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>700.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41416014</td>\n",
       "      <td>Drug</td>\n",
       "      <td>durvalumab</td>\n",
       "      <td>administered by intravenous infusion</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT05327582</td>\n",
       "      <td>2022-04-12</td>\n",
       "      <td>An Open-label, Phase I/II Study of PLENA Regim...</td>\n",
       "      <td>A Phase I/II, Open-label, One-arm, Single-cent...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>65.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41127677</td>\n",
       "      <td>Drug</td>\n",
       "      <td>durvalumab</td>\n",
       "      <td>Administered intravenously, 1000 mg on day 1 i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT03004105</td>\n",
       "      <td>2018-05-31</td>\n",
       "      <td>MEDI4736 With Selumetinib for KRAS Mutant Non-...</td>\n",
       "      <td>Phase II Trial of Immunotherapy With Durvaluma...</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>0.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41128975</td>\n",
       "      <td>Drug</td>\n",
       "      <td>durvalumab</td>\n",
       "      <td>Safety Run-In, Intermittent Arm, Continuous Ar...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT03732677</td>\n",
       "      <td>2018-11-16</td>\n",
       "      <td>Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant...</td>\n",
       "      <td>A Phase III, Randomized, Open-Label, Multi-Cen...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1063.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40964454</td>\n",
       "      <td>Drug</td>\n",
       "      <td>durvalumab</td>\n",
       "      <td>Anti- PD-L1 Antibody</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT03141359  2017-05-12  Use of High Dose Radiation Followed by Chemoth...   \n",
       "1  NCT04866017  2021-06-17  A Study to Compare Ociperlimab Plus Tislelizum...   \n",
       "2  NCT05327582  2022-04-12  An Open-label, Phase I/II Study of PLENA Regim...   \n",
       "3  NCT03004105  2018-05-31  MEDI4736 With Selumetinib for KRAS Mutant Non-...   \n",
       "4  NCT03732677  2018-11-16  Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  LCI-LUN-NSC-SBRT-001: Phase II Prospective Tri...  Active, not recruiting   \n",
       "1  A Phase 3, Randomized, Open-Label Study to Com...              Recruiting   \n",
       "2  A Phase I/II, Open-label, One-arm, Single-cent...              Recruiting   \n",
       "3  Phase II Trial of Immunotherapy With Durvaluma...               Withdrawn   \n",
       "4  A Phase III, Randomized, Open-Label, Multi-Cen...  Active, not recruiting   \n",
       "\n",
       "             phase  enrollment enrollment_type  number_of_arms  results  \\\n",
       "0          Phase 2        61.0          Actual             1.0        0   \n",
       "1          Phase 3       700.0     Anticipated             3.0        0   \n",
       "2  Phase 1/Phase 2        65.0     Anticipated             1.0        0   \n",
       "3          Phase 2         0.0          Actual             3.0        0   \n",
       "4          Phase 3      1063.0          Actual             2.0        0   \n",
       "\n",
       "         id intervention_type        name  \\\n",
       "0  41125820              Drug  durvalumab   \n",
       "1  41416014              Drug  durvalumab   \n",
       "2  41127677              Drug  durvalumab   \n",
       "3  41128975              Drug  durvalumab   \n",
       "4  40964454              Drug  durvalumab   \n",
       "\n",
       "                                         description  \n",
       "0                             adjuvant immunotherapy  \n",
       "1               administered by intravenous infusion  \n",
       "2  Administered intravenously, 1000 mg on day 1 i...  \n",
       "3  Safety Run-In, Intermittent Arm, Continuous Ar...  \n",
       "4                               Anti- PD-L1 Antibody  "
      ]
     },
     "execution_count": 67,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "durvalumab_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    393\n",
       "1     75\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 68,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "durvalumab_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Cemiplimab\n",
    "### Advanced cutaneous squamous cell carcinoma"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "cemiplimab\n",
      "regn2810\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    'Cemiplomab',\n",
    "    'CEMIPLIMAB',\n",
    "    \"1801342-60-8\",\n",
    "    \"CEMIPLIMAB [JAN]\",\n",
    "    \"CEMIPLIMAB [MI]\",\n",
    "    \"CEMIPLIMAB [USAN]\",\n",
    "    \"Cemiplimab [WHO-DD]\",\n",
    "    \"IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER\",\n",
    "    \"REGN-2810\",\n",
    "    \"REGN2810\",\n",
    "    \"cemiplimab [INN]\",\n",
    "    \"6QVL057INT\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>16956</th>\n",
       "      <td>41404715</td>\n",
       "      <td>NCT04526899</td>\n",
       "      <td>Biological</td>\n",
       "      <td>cemiplimab</td>\n",
       "      <td>IV infusion</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19319</th>\n",
       "      <td>40910142</td>\n",
       "      <td>NCT04465487</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cemiplimab</td>\n",
       "      <td>Administered by IV infusion</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20120</th>\n",
       "      <td>40910307</td>\n",
       "      <td>NCT03969004</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cemiplimab</td>\n",
       "      <td>Intravenous (IV) infusion over 30 minutes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25922</th>\n",
       "      <td>41211409</td>\n",
       "      <td>NCT03294083</td>\n",
       "      <td>Biological</td>\n",
       "      <td>cemiplimab</td>\n",
       "      <td>Cemiplimab is a monoclonal antibody to Program...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28907</th>\n",
       "      <td>41068027</td>\n",
       "      <td>NCT04913220</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cemiplimab</td>\n",
       "      <td>Solution for infusion: intravenous infusion</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id       nct_id intervention_type        name  \\\n",
       "16956  41404715  NCT04526899        Biological  cemiplimab   \n",
       "19319  40910142  NCT04465487              Drug  cemiplimab   \n",
       "20120  40910307  NCT03969004              Drug  cemiplimab   \n",
       "25922  41211409  NCT03294083        Biological  cemiplimab   \n",
       "28907  41068027  NCT04913220              Drug  cemiplimab   \n",
       "\n",
       "                                             description  \n",
       "16956                                        IV infusion  \n",
       "19319                        Administered by IV infusion  \n",
       "20120          Intravenous (IV) infusion over 30 minutes  \n",
       "25922  Cemiplimab is a monoclonal antibody to Program...  \n",
       "28907        Solution for infusion: intravenous infusion  "
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "67"
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [],
   "source": [
    "cemiplimab_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "67"
      ]
     },
     "execution_count": 74,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cemiplimab_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05125016</td>\n",
       "      <td>2021-11-30</td>\n",
       "      <td>A Trial to Find Out if REGN4336 is Safe and Ho...</td>\n",
       "      <td>Phase 1/2 Study of REGN4336 (a PSMAXCD3 Bispec...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>199.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41415907</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cemiplimab</td>\n",
       "      <td>Administered concomitantly every 3 weeks (Q3W)...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04339062</td>\n",
       "      <td>2020-07-15</td>\n",
       "      <td>Cemiplimab in AlloSCT/SOT Recipients With CSCC</td>\n",
       "      <td>Safety and Efficacy of Cemiplimab (PD-1 Blocka...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>12.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41416173</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cemiplimab</td>\n",
       "      <td>Cemiplimab: via IV, flat predetermined dosage ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT04706715</td>\n",
       "      <td>2022-01-18</td>\n",
       "      <td>LAG3 PET Imaging in Advanced Solid Tumors</td>\n",
       "      <td>ImmunoPET Imaging With 89Zr-DFO-REGN3767 in Pa...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>38.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40964547</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cemiplimab</td>\n",
       "      <td>Cemiplimab 350 mg every 3 weeks with or withou...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04543071</td>\n",
       "      <td>2020-11-09</td>\n",
       "      <td>Chemo4METPANC Combination Chemokine Inhibitor,...</td>\n",
       "      <td>A Phase 2 Study With Combination Chemotherapy ...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>10.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40972466</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cemiplimab</td>\n",
       "      <td>350 mg intravenous (IV) once every 21 days</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT04243616</td>\n",
       "      <td>2020-03-05</td>\n",
       "      <td>Cemiplimab in High Risk or Locally Advanced Ho...</td>\n",
       "      <td>Phase II Study of PD-1 Inhibition With Cemipli...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>36.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41139167</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cemiplimab</td>\n",
       "      <td>350 mg, IV, Day 1 of Cycle 1-2 (3-week cycle)</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT05125016  2021-11-30  A Trial to Find Out if REGN4336 is Safe and Ho...   \n",
       "1  NCT04339062  2020-07-15     Cemiplimab in AlloSCT/SOT Recipients With CSCC   \n",
       "2  NCT04706715  2022-01-18          LAG3 PET Imaging in Advanced Solid Tumors   \n",
       "3  NCT04543071  2020-11-09  Chemo4METPANC Combination Chemokine Inhibitor,...   \n",
       "4  NCT04243616  2020-03-05  Cemiplimab in High Risk or Locally Advanced Ho...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  Phase 1/2 Study of REGN4336 (a PSMAXCD3 Bispec...              Recruiting   \n",
       "1  Safety and Efficacy of Cemiplimab (PD-1 Blocka...  Active, not recruiting   \n",
       "2  ImmunoPET Imaging With 89Zr-DFO-REGN3767 in Pa...              Recruiting   \n",
       "3  A Phase 2 Study With Combination Chemotherapy ...              Recruiting   \n",
       "4  Phase II Study of PD-1 Inhibition With Cemipli...              Recruiting   \n",
       "\n",
       "             phase  enrollment enrollment_type  number_of_arms  results  \\\n",
       "0  Phase 1/Phase 2       199.0     Anticipated             2.0        0   \n",
       "1          Phase 1        12.0     Anticipated             2.0        0   \n",
       "2  Phase 1/Phase 2        38.0     Anticipated             2.0        0   \n",
       "3          Phase 2        10.0     Anticipated             1.0        0   \n",
       "4          Phase 2        36.0     Anticipated             1.0        0   \n",
       "\n",
       "         id intervention_type        name  \\\n",
       "0  41415907              Drug  cemiplimab   \n",
       "1  41416173              Drug  cemiplimab   \n",
       "2  40964547              Drug  cemiplimab   \n",
       "3  40972466              Drug  cemiplimab   \n",
       "4  41139167              Drug  cemiplimab   \n",
       "\n",
       "                                         description  \n",
       "0  Administered concomitantly every 3 weeks (Q3W)...  \n",
       "1  Cemiplimab: via IV, flat predetermined dosage ...  \n",
       "2  Cemiplimab 350 mg every 3 weeks with or withou...  \n",
       "3         350 mg intravenous (IV) once every 21 days  \n",
       "4      350 mg, IV, Day 1 of Cycle 1-2 (3-week cycle)  "
      ]
     },
     "execution_count": 75,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cemiplimab_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    63\n",
       "1     4\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 76,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cemiplimab_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Asciminib\n",
    "### Chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "abl001\n",
      "asciminib\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    \"(R)-N- (4-(chlorodifluoromethoxy)phenyl)- 6-(3- hydroxypyrrolidin-1- yl)-5- (1H-pyrazol- 5-yl)nicotinamide\",\n",
    "    \"(R)-N-(4-(Chloro difluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide\",\n",
    "    \"(R)-N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-3-yl)nicotinamide\",\n",
    "    \"(R)-N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide\",\n",
    "    \"1492952-76-7\",\n",
    "    \"1492952-76-7 (free base)\",\n",
    "    \"3-Pyridinecarboxamide, N-(4-(chlorodifluoromethoxy)phenyl)-6-((3R)-3-hydroxy-1-pyrrolidinyl)-5-(1H-pyrazol-3-yl)-\",\n",
    "    \"3-Pyridinecarboxamide, N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxy-1-pyrrolidinyl]-5-(1H-pyrazol-3-yl)-\",\n",
    "    \"A910986\",\n",
    "    \"ABL-001\",\n",
    "    \"ABL-001-NX\",\n",
    "    \"ABL001\",\n",
    "    \"ABL001-NX\",\n",
    "    \"Asciminib\",\n",
    "    \"Asciminib (ABL001)\",\n",
    "    \"Asciminib (USAN/INN)\",\n",
    "    \"ASCIMINIB [INN]\",\n",
    "    \"Asciminib [USAN]\",\n",
    "    \"ASCIMINIB [WHO-DD]\",\n",
    "    \"Asciminib free base\",\n",
    "    \"AT30330\",\n",
    "    \"AY7\",\n",
    "    \"BA166957\",\n",
    "    \"BDBM50459091\",\n",
    "    \"BS-15538\",\n",
    "    \"CCG-269232\",\n",
    "    \"CHEMBL4208229\",\n",
    "    \"compound 1 [PMID: 30137981]\",\n",
    "    \"CS-7655\",\n",
    "    \"D11403\",\n",
    "    \"DB12597\",\n",
    "    \"EX-A3030\",\n",
    "    \"Example 9\",\n",
    "    \"GTPL8962\",\n",
    "    \"HY-104010\",\n",
    "    \"L1F3R18W77\",\n",
    "    \"N-(4-(CHLORODIFLUOROMETHOXY)PHENYL)-6-((3R)-3- HYDROXYPYRROLIDIN-1-YL)-5-(1H-PYRAZOL-3-YL)PYRIDINE- 3-CARBOXAMIDE\",\n",
    "    \"N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-3-yl)pyridine-3-carboxamide\",\n",
    "    \"N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide\",\n",
    "    \"NSC-789925\",\n",
    "    \"NSC789925\",\n",
    "    \"NVP-ABL001\",\n",
    "    \"Q27074535\",\n",
    "    \"s8555\",\n",
    "    \"Scemblix\",\n",
    "    \"SCHEMBL15388306\",\n",
    "    \"TQP0925\",\n",
    "    \"UNII-L1F3R18W77\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>11835</th>\n",
       "      <td>41205813</td>\n",
       "      <td>NCT04877522</td>\n",
       "      <td>Drug</td>\n",
       "      <td>asciminib</td>\n",
       "      <td>Taken orally, once daily, in the morning with ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56261</th>\n",
       "      <td>41074336</td>\n",
       "      <td>NCT03874858</td>\n",
       "      <td>Drug</td>\n",
       "      <td>asciminib</td>\n",
       "      <td>Asciminib orally at a dose of 40 mg BID film-c...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60108</th>\n",
       "      <td>41077264</td>\n",
       "      <td>NCT03106779</td>\n",
       "      <td>Drug</td>\n",
       "      <td>asciminib</td>\n",
       "      <td>40 mg tablets was taken orally twice a day (BID)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60132</th>\n",
       "      <td>40920629</td>\n",
       "      <td>NCT03605277</td>\n",
       "      <td>Drug</td>\n",
       "      <td>asciminib</td>\n",
       "      <td>40 mg single dose</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>119945</th>\n",
       "      <td>41087929</td>\n",
       "      <td>NCT04838041</td>\n",
       "      <td>Drug</td>\n",
       "      <td>asciminib</td>\n",
       "      <td>40 mg by mouth (PO) twice a day (BID).</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              id       nct_id intervention_type       name  \\\n",
       "11835   41205813  NCT04877522              Drug  asciminib   \n",
       "56261   41074336  NCT03874858              Drug  asciminib   \n",
       "60108   41077264  NCT03106779              Drug  asciminib   \n",
       "60132   40920629  NCT03605277              Drug  asciminib   \n",
       "119945  41087929  NCT04838041              Drug  asciminib   \n",
       "\n",
       "                                              description  \n",
       "11835   Taken orally, once daily, in the morning with ...  \n",
       "56261   Asciminib orally at a dose of 40 mg BID film-c...  \n",
       "60108    40 mg tablets was taken orally twice a day (BID)  \n",
       "60132                                   40 mg single dose  \n",
       "119945             40 mg by mouth (PO) twice a day (BID).  "
      ]
     },
     "execution_count": 79,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "16"
      ]
     },
     "execution_count": 80,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [],
   "source": [
    "asciminib_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "16"
      ]
     },
     "execution_count": 82,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "asciminib_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05384587</td>\n",
       "      <td>2022-08-29</td>\n",
       "      <td>Asciminib Monotherapy, With Dose Escalation, f...</td>\n",
       "      <td>A Phase II Multicenter, Open-label, Single-arm...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>92.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41138112</td>\n",
       "      <td>Drug</td>\n",
       "      <td>asciminib</td>\n",
       "      <td>Supplied in 20 mg and 40 mg tablets for oral u...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04971226</td>\n",
       "      <td>2021-10-06</td>\n",
       "      <td>A Study of Oral Asciminib Versus Other TKIs in...</td>\n",
       "      <td>A Phase III, Multi-center, Open-label, Randomi...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>404.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41171111</td>\n",
       "      <td>Drug</td>\n",
       "      <td>asciminib</td>\n",
       "      <td>Comes in 40 mg tablets and taken orally</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT04666259</td>\n",
       "      <td>2021-05-19</td>\n",
       "      <td>Asciminib in Monotherapy for Chronic Myeloid L...</td>\n",
       "      <td>An Open Label, Multi-center Phase IIIb Study o...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>115.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40992513</td>\n",
       "      <td>Drug</td>\n",
       "      <td>abl001</td>\n",
       "      <td>Asciminib will be supplied as 20 mg or 40 mg s...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT05143840</td>\n",
       "      <td>2022-04-22</td>\n",
       "      <td>Asciminib as Initial Therapy for Patients With...</td>\n",
       "      <td>Asciminib as Initial Therapy for Patients With...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>8.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41287377</td>\n",
       "      <td>Drug</td>\n",
       "      <td>asciminib</td>\n",
       "      <td>Potent tyrosine kinase inhibitor that displays...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT02081378</td>\n",
       "      <td>2014-04-24</td>\n",
       "      <td>A Phase I Study of Oral ABL001 in Patients Wit...</td>\n",
       "      <td>A Phase I, Multicenter, Open-label Study of Or...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>326.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>5.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41290029</td>\n",
       "      <td>Drug</td>\n",
       "      <td>abl001</td>\n",
       "      <td>ABL001 will be administered orally in a dose e...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT05384587  2022-08-29  Asciminib Monotherapy, With Dose Escalation, f...   \n",
       "1  NCT04971226  2021-10-06  A Study of Oral Asciminib Versus Other TKIs in...   \n",
       "2  NCT04666259  2021-05-19  Asciminib in Monotherapy for Chronic Myeloid L...   \n",
       "3  NCT05143840  2022-04-22  Asciminib as Initial Therapy for Patients With...   \n",
       "4  NCT02081378  2014-04-24  A Phase I Study of Oral ABL001 in Patients Wit...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  A Phase II Multicenter, Open-label, Single-arm...              Recruiting   \n",
       "1  A Phase III, Multi-center, Open-label, Randomi...  Active, not recruiting   \n",
       "2  An Open Label, Multi-center Phase IIIb Study o...  Active, not recruiting   \n",
       "3  Asciminib as Initial Therapy for Patients With...              Recruiting   \n",
       "4  A Phase I, Multicenter, Open-label Study of Or...               Completed   \n",
       "\n",
       "     phase  enrollment enrollment_type  number_of_arms  results        id  \\\n",
       "0  Phase 2        92.0     Anticipated             1.0        0  41138112   \n",
       "1  Phase 3       404.0          Actual             2.0        0  41171111   \n",
       "2  Phase 3       115.0     Anticipated             3.0        0  40992513   \n",
       "3  Phase 2         8.0     Anticipated             1.0        0  41287377   \n",
       "4  Phase 1       326.0          Actual             5.0        0  41290029   \n",
       "\n",
       "  intervention_type       name  \\\n",
       "0              Drug  asciminib   \n",
       "1              Drug  asciminib   \n",
       "2              Drug     abl001   \n",
       "3              Drug  asciminib   \n",
       "4              Drug     abl001   \n",
       "\n",
       "                                         description  \n",
       "0  Supplied in 20 mg and 40 mg tablets for oral u...  \n",
       "1            Comes in 40 mg tablets and taken orally  \n",
       "2  Asciminib will be supplied as 20 mg or 40 mg s...  \n",
       "3  Potent tyrosine kinase inhibitor that displays...  \n",
       "4  ABL001 will be administered orally in a dose e...  "
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "asciminib_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    16\n",
       "1     1\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 84,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "asciminib_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Nivolumab\n",
    "### Invasive urothelial cancer at high risk of recurrence"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "nivolumab\n",
      "opdivo\n",
      "bms-936558\n",
      "mdx-1106\n",
      "ono-4538\n",
      "cmab819\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    'Nivolumab',\n",
    "    'Opdivo',\n",
    "    '946414-94-4',\n",
    "    'BMS-936558',\n",
    "    'MDX-1106',\n",
    "    'ONO-4538',\n",
    "    '31YO63LBSN',\n",
    "    'UNII-31YO63LBSN',\n",
    "    'Anti-PD-1 human monoclonal antibody MDX-1106',\n",
    "    'Anti-PD-1 human monoclonal antibody MDX-1106.',\n",
    "    'BMS-986213 COMPONENT NIVOLUMAB',\n",
    "    'BMS-986298',\n",
    "    'CMAB819',\n",
    "    'HSDB 8256',\n",
    "    'L01XC17',\n",
    "    'NIVO',\n",
    "    'NIVOLUMAB (PURPLE BOOK CDER)',\n",
    "    'NIVOLUMAB COMPONENT OF OPDUALAG',\n",
    "    'Nivolumab Biosimilar CMAB819',\n",
    "    'OPDUALAG COMPONENT NIVOLUMAB',\n",
    "    'nivolumabum'\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>259</th>\n",
       "      <td>40781620</td>\n",
       "      <td>NCT05116917</td>\n",
       "      <td>Drug</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>3 mg/kg (up to 240 mg maximum) will be given o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3978</th>\n",
       "      <td>41061958</td>\n",
       "      <td>NCT05130684</td>\n",
       "      <td>Drug</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>adding nivolumab to conventional neoadjuvant CRT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4510</th>\n",
       "      <td>40782405</td>\n",
       "      <td>NCT05498480</td>\n",
       "      <td>Biological</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>Specified dose on specified days</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6624</th>\n",
       "      <td>40906392</td>\n",
       "      <td>NCT02357732</td>\n",
       "      <td>Drug</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7810</th>\n",
       "      <td>40907104</td>\n",
       "      <td>NCT03149120</td>\n",
       "      <td>Biological</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>Nivolumab will be given as an intravenous infu...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "            id       nct_id intervention_type       name  \\\n",
       "259   40781620  NCT05116917              Drug  nivolumab   \n",
       "3978  41061958  NCT05130684              Drug  nivolumab   \n",
       "4510  40782405  NCT05498480        Biological  nivolumab   \n",
       "6624  40906392  NCT02357732              Drug  nivolumab   \n",
       "7810  40907104  NCT03149120        Biological  nivolumab   \n",
       "\n",
       "                                            description  \n",
       "259   3 mg/kg (up to 240 mg maximum) will be given o...  \n",
       "3978   adding nivolumab to conventional neoadjuvant CRT  \n",
       "4510                   Specified dose on specified days  \n",
       "6624                                                NaN  \n",
       "7810  Nivolumab will be given as an intravenous infu...  "
      ]
     },
     "execution_count": 87,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1108"
      ]
     },
     "execution_count": 88,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "metadata": {},
   "outputs": [],
   "source": [
    "nivolumab_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1108"
      ]
     },
     "execution_count": 90,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "nivolumab_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05327686</td>\n",
       "      <td>2022-06-30</td>\n",
       "      <td>Testing the Addition of Stereotactic Radiation...</td>\n",
       "      <td>Randomized Phase II Stereotactic Ablative Radi...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>240.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41415847</td>\n",
       "      <td>Biological</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>Given IV</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT03317327</td>\n",
       "      <td>2017-09-09</td>\n",
       "      <td>REirradiation and Programmed Cell Death Protei...</td>\n",
       "      <td>REPORT; REirradiation and PD-1 Blockade On Rec...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>20.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40962687</td>\n",
       "      <td>Drug</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>Nivolumab is a humanized antibody used in canc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03220009</td>\n",
       "      <td>2017-11-03</td>\n",
       "      <td>Nivolumab or Expectant Observation Following I...</td>\n",
       "      <td>A Randomized Phase II Trial of Adjuvant Nivolu...</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>0.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40962798</td>\n",
       "      <td>Biological</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>Given IV</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT03711188</td>\n",
       "      <td>2018-10-04</td>\n",
       "      <td>A Study of IMM-101 in Combination With Checkpo...</td>\n",
       "      <td>A Study of the Safety and Efficacy of IMM-101 ...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>16.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41126967</td>\n",
       "      <td>Drug</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>Nivolumab is to be administered as a 3 mg/kg I...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT03161756</td>\n",
       "      <td>2017-12-07</td>\n",
       "      <td>Evaluation of Denosumab in Combination With Im...</td>\n",
       "      <td>A Phase Ib/II Trial of Ipilimumab-Nivolumab-De...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>72.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41127051</td>\n",
       "      <td>Drug</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>Nivolumab is a human monoclonal antibody that ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT05327686  2022-06-30  Testing the Addition of Stereotactic Radiation...   \n",
       "1  NCT03317327  2017-09-09  REirradiation and Programmed Cell Death Protei...   \n",
       "2  NCT03220009  2017-11-03  Nivolumab or Expectant Observation Following I...   \n",
       "3  NCT03711188  2018-10-04  A Study of IMM-101 in Combination With Checkpo...   \n",
       "4  NCT03161756  2017-12-07  Evaluation of Denosumab in Combination With Im...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  Randomized Phase II Stereotactic Ablative Radi...              Recruiting   \n",
       "1  REPORT; REirradiation and PD-1 Blockade On Rec...              Recruiting   \n",
       "2  A Randomized Phase II Trial of Adjuvant Nivolu...               Withdrawn   \n",
       "3  A Study of the Safety and Efficacy of IMM-101 ...               Completed   \n",
       "4  A Phase Ib/II Trial of Ipilimumab-Nivolumab-De...  Active, not recruiting   \n",
       "\n",
       "             phase  enrollment enrollment_type  number_of_arms  results  \\\n",
       "0          Phase 2       240.0     Anticipated             2.0        0   \n",
       "1  Phase 1/Phase 2        20.0     Anticipated             1.0        0   \n",
       "2          Phase 2         0.0          Actual             2.0        0   \n",
       "3          Phase 2        16.0          Actual             1.0        0   \n",
       "4  Phase 1/Phase 2        72.0     Anticipated             2.0        0   \n",
       "\n",
       "         id intervention_type       name  \\\n",
       "0  41415847        Biological  nivolumab   \n",
       "1  40962687              Drug  nivolumab   \n",
       "2  40962798        Biological  nivolumab   \n",
       "3  41126967              Drug  nivolumab   \n",
       "4  41127051              Drug  nivolumab   \n",
       "\n",
       "                                         description  \n",
       "0                                           Given IV  \n",
       "1  Nivolumab is a humanized antibody used in canc...  \n",
       "2                                           Given IV  \n",
       "3  Nivolumab is to be administered as a 3 mg/kg I...  \n",
       "4  Nivolumab is a human monoclonal antibody that ...  "
      ]
     },
     "execution_count": 91,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "nivolumab_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    898\n",
       "1    228\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 92,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "nivolumab_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Sacituzumab govitecan\n",
    "### Unresectable triple-negative advanced breast cancer after 2 or more therapies"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "immu-132\n",
      "sacituzumab govitecan\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    '1491917-83-9'\n",
    "    'CYSTEINYL CL2A-SN-38',\n",
    "    'DA64T2C2IO',\n",
    "    'DTXSID401335985',\n",
    "    'EX-A4354',\n",
    "    'F82944',\n",
    "    'GOVITECAN CYSTEINYL CONJUGATE',\n",
    "    'hRS 7SN38',\n",
    "    'hRS7-SN38',\n",
    "    'IMMU 132',\n",
    "    'IMMU-132',\n",
    "    'M9BYU8XDQ6',\n",
    "    'Sacituzumab govitecan',\n",
    "    'Sacituzumab govitecan [USAN]',\n",
    "    'sacituzumab-govitecan',\n",
    "    'Satralizumab linker',\n",
    "    'SN-38 CYSTEINYL CONJUGATE',\n",
    "    'UNII-M9BYU8XDQ6'\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>18002</th>\n",
       "      <td>40909851</td>\n",
       "      <td>NCT05143229</td>\n",
       "      <td>Drug</td>\n",
       "      <td>sacituzumab govitecan</td>\n",
       "      <td>Trop-2-directed antibody and topoisomerase inh...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34486</th>\n",
       "      <td>41214959</td>\n",
       "      <td>NCT04559230</td>\n",
       "      <td>Drug</td>\n",
       "      <td>sacituzumab govitecan</td>\n",
       "      <td>Sacituzumab Govitecan will be administered by ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41434</th>\n",
       "      <td>40915497</td>\n",
       "      <td>NCT04986579</td>\n",
       "      <td>Drug</td>\n",
       "      <td>sacituzumab govitecan</td>\n",
       "      <td>Intravenous Infusion</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79019</th>\n",
       "      <td>41238295</td>\n",
       "      <td>NCT05327530</td>\n",
       "      <td>Drug</td>\n",
       "      <td>sacituzumab govitecan</td>\n",
       "      <td>Participants will receive sacituzumab goviteca...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>140850</th>\n",
       "      <td>40937703</td>\n",
       "      <td>NCT03725761</td>\n",
       "      <td>Drug</td>\n",
       "      <td>immu-132</td>\n",
       "      <td>IMMU-132 is a novel Antibody Drug Conjugate (A...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              id       nct_id intervention_type                   name  \\\n",
       "18002   40909851  NCT05143229              Drug  sacituzumab govitecan   \n",
       "34486   41214959  NCT04559230              Drug  sacituzumab govitecan   \n",
       "41434   40915497  NCT04986579              Drug  sacituzumab govitecan   \n",
       "79019   41238295  NCT05327530              Drug  sacituzumab govitecan   \n",
       "140850  40937703  NCT03725761              Drug               immu-132   \n",
       "\n",
       "                                              description  \n",
       "18002   Trop-2-directed antibody and topoisomerase inh...  \n",
       "34486   Sacituzumab Govitecan will be administered by ...  \n",
       "41434                                Intravenous Infusion  \n",
       "79019   Participants will receive sacituzumab goviteca...  \n",
       "140850  IMMU-132 is a novel Antibody Drug Conjugate (A...  "
      ]
     },
     "execution_count": 95,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "24"
      ]
     },
     "execution_count": 96,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "metadata": {},
   "outputs": [],
   "source": [
    "sacituzumab_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "24"
      ]
     },
     "execution_count": 98,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sacituzumab_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT04595565</td>\n",
       "      <td>2020-10-28</td>\n",
       "      <td>Sacituzumab Govitecan in Primary HER2-negative...</td>\n",
       "      <td>Phase III Postneoadjuvant Study Evaluating Sac...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>1332.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41132039</td>\n",
       "      <td>Drug</td>\n",
       "      <td>sacituzumab govitecan</td>\n",
       "      <td>10 mg/kg body weight on days 1, 8 q3w</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04448886</td>\n",
       "      <td>2020-09-23</td>\n",
       "      <td>Sacituzumab Govitecan +/- Pembrolizumab In HR+...</td>\n",
       "      <td>Saci-IO HR+: Randomized Phase II Study of Saci...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>110.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41140622</td>\n",
       "      <td>Drug</td>\n",
       "      <td>sacituzumab govitecan</td>\n",
       "      <td>(iv) fixed dose, administered twice per cycle</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03869190</td>\n",
       "      <td>2019-06-01</td>\n",
       "      <td>Study Evaluating the Efficacy and Safety of Mu...</td>\n",
       "      <td>A Phase Ib/II, Open-Label, Multicenter, Random...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>645.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>16.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41146893</td>\n",
       "      <td>Drug</td>\n",
       "      <td>sacituzumab govitecan</td>\n",
       "      <td>Sacituzumab Govitecan will be administered at ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04230109</td>\n",
       "      <td>2020-07-07</td>\n",
       "      <td>Sacituzumab Govitecan In TNBC</td>\n",
       "      <td>A Phase 2 Study of Response-guided Neoadjuvant...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>51.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40979708</td>\n",
       "      <td>Drug</td>\n",
       "      <td>sacituzumab govitecan</td>\n",
       "      <td>Sacituzumab Govitecan via iv, predetermined do...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT05097599</td>\n",
       "      <td>2021-11-19</td>\n",
       "      <td>Strata PATH™ (Precision Indications for Approv...</td>\n",
       "      <td>Strata PATH™ (Precision Indications for Approv...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>700.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>8.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40995191</td>\n",
       "      <td>Drug</td>\n",
       "      <td>sacituzumab govitecan</td>\n",
       "      <td>This arm of the Strata PATH trial will assess ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT04595565  2020-10-28  Sacituzumab Govitecan in Primary HER2-negative...   \n",
       "1  NCT04448886  2020-09-23  Sacituzumab Govitecan +/- Pembrolizumab In HR+...   \n",
       "2  NCT03869190  2019-06-01  Study Evaluating the Efficacy and Safety of Mu...   \n",
       "3  NCT04230109  2020-07-07                      Sacituzumab Govitecan In TNBC   \n",
       "4  NCT05097599  2021-11-19  Strata PATH™ (Precision Indications for Approv...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  Phase III Postneoadjuvant Study Evaluating Sac...              Recruiting   \n",
       "1  Saci-IO HR+: Randomized Phase II Study of Saci...              Recruiting   \n",
       "2  A Phase Ib/II, Open-Label, Multicenter, Random...              Recruiting   \n",
       "3  A Phase 2 Study of Response-guided Neoadjuvant...  Active, not recruiting   \n",
       "4  Strata PATH™ (Precision Indications for Approv...              Recruiting   \n",
       "\n",
       "             phase  enrollment enrollment_type  number_of_arms  results  \\\n",
       "0          Phase 3      1332.0     Anticipated             2.0        0   \n",
       "1          Phase 2       110.0     Anticipated             3.0        0   \n",
       "2  Phase 1/Phase 2       645.0     Anticipated            16.0        0   \n",
       "3          Phase 2        51.0          Actual             2.0        0   \n",
       "4          Phase 2       700.0     Anticipated             8.0        0   \n",
       "\n",
       "         id intervention_type                   name  \\\n",
       "0  41132039              Drug  sacituzumab govitecan   \n",
       "1  41140622              Drug  sacituzumab govitecan   \n",
       "2  41146893              Drug  sacituzumab govitecan   \n",
       "3  40979708              Drug  sacituzumab govitecan   \n",
       "4  40995191              Drug  sacituzumab govitecan   \n",
       "\n",
       "                                         description  \n",
       "0              10 mg/kg body weight on days 1, 8 q3w  \n",
       "1      (iv) fixed dose, administered twice per cycle  \n",
       "2  Sacituzumab Govitecan will be administered at ...  \n",
       "3  Sacituzumab Govitecan via iv, predetermined do...  \n",
       "4  This arm of the Strata PATH trial will assess ...  "
      ]
     },
     "execution_count": 99,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sacituzumab_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 100,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    23\n",
       "1     1\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 100,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sacituzumab_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Atezolizumab\n",
    "### Adjuvant treatment of resected non-small-cell lung cancer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 101,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "atezolizumab\n",
      "mpdl3280a\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    'ATEZOLIZUMAB',\n",
    "    '1380723-44-3',\n",
    "    '0INE2SFD9E',\n",
    "    'AN ANTIBODY TO PROGRAMMED DEATH LIGAND 1 FOR CANCER THERAPY',\n",
    "    \"ATEZOLIZUMAB [JAN]\",\n",
    "    'ATEZOLIZUMAB [MI]',\n",
    "    'ATEZOLIZUMAB [PURPLE BOOK CDER]',\n",
    "    'ATEZOLIZUMAB [USAN]',\n",
    "    'Atezolizumab [WHO-DD]',\n",
    "    'IMMUNOGLOBULIN G1, ANTI-(HUMAN CD ANTIGEN CD274) (HUMAN MONOCLONAL MPDL3280A HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL MPDL3280A .KAPPA.-CHAIN, DIMER',\n",
    "    'MPDL-3280A',\n",
    "    'MPDL3280A',\n",
    "    'RG-7446',\n",
    "    'RG7446',\n",
    "    'TECENTRIQ',\n",
    "    'atezolizumab [INN]',\n",
    "    '52CMI0WC3Y'\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 103,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>702</th>\n",
       "      <td>40903800</td>\n",
       "      <td>NCT04471415</td>\n",
       "      <td>Biological</td>\n",
       "      <td>atezolizumab</td>\n",
       "      <td>atezolizumab administered intravenously over 1...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5993</th>\n",
       "      <td>40905953</td>\n",
       "      <td>NCT02451423</td>\n",
       "      <td>Drug</td>\n",
       "      <td>atezolizumab</td>\n",
       "      <td>1200 mg Given IV</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7149</th>\n",
       "      <td>40906763</td>\n",
       "      <td>NCT03618953</td>\n",
       "      <td>Biological</td>\n",
       "      <td>atezolizumab</td>\n",
       "      <td>monoclonal antibody; checkpoint inhibitor</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7658</th>\n",
       "      <td>41062540</td>\n",
       "      <td>NCT03395899</td>\n",
       "      <td>Drug</td>\n",
       "      <td>atezolizumab</td>\n",
       "      <td>PD-L1 antibody</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7697</th>\n",
       "      <td>40907057</td>\n",
       "      <td>NCT03616691</td>\n",
       "      <td>Drug</td>\n",
       "      <td>atezolizumab</td>\n",
       "      <td>Stage I: The dose level of atezolizumab propos...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "            id       nct_id intervention_type          name  \\\n",
       "702   40903800  NCT04471415        Biological  atezolizumab   \n",
       "5993  40905953  NCT02451423              Drug  atezolizumab   \n",
       "7149  40906763  NCT03618953        Biological  atezolizumab   \n",
       "7658  41062540  NCT03395899              Drug  atezolizumab   \n",
       "7697  40907057  NCT03616691              Drug  atezolizumab   \n",
       "\n",
       "                                            description  \n",
       "702   atezolizumab administered intravenously over 1...  \n",
       "5993                                   1200 mg Given IV  \n",
       "7149          monoclonal antibody; checkpoint inhibitor  \n",
       "7658                                     PD-L1 antibody  \n",
       "7697  Stage I: The dose level of atezolizumab propos...  "
      ]
     },
     "execution_count": 103,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "454"
      ]
     },
     "execution_count": 104,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "metadata": {},
   "outputs": [],
   "source": [
    "atezolizumab_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 106,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "454"
      ]
     },
     "execution_count": 106,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "atezolizumab_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT04923776</td>\n",
       "      <td>2021-09-20</td>\n",
       "      <td>Liver Directed RT + Chemo-immunotherapy for ES...</td>\n",
       "      <td>A Phase II Trial of Atezolizumab + Carboplatin...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>18.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41127752</td>\n",
       "      <td>Drug</td>\n",
       "      <td>atezolizumab</td>\n",
       "      <td>The dosage for this drug is 1200 mg Intravenou...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT03312530</td>\n",
       "      <td>2017-11-13</td>\n",
       "      <td>A Study of Cobimetinib Administered as Single ...</td>\n",
       "      <td>A Phase Ib/II Study of Cobimetinib Administere...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>49.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>5.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41128986</td>\n",
       "      <td>Drug</td>\n",
       "      <td>atezolizumab</td>\n",
       "      <td>Atezolizumab will be administered as per the s...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03059667</td>\n",
       "      <td>2017-03-13</td>\n",
       "      <td>Immunotherapy as Second-line in Patient With S...</td>\n",
       "      <td>A Randomized Non-comparative Phase II Study of...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>73.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40965825</td>\n",
       "      <td>Drug</td>\n",
       "      <td>atezolizumab</td>\n",
       "      <td>Atezolizumab at 1200 mg IV every 3 weeks</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04356729</td>\n",
       "      <td>2020-08-06</td>\n",
       "      <td>A Phase II Trial of PD-L1 Therapy Combined Wit...</td>\n",
       "      <td>A Phase II Trial of PD-L1 Therapy Combined Wit...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>30.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40968341</td>\n",
       "      <td>Drug</td>\n",
       "      <td>atezolizumab</td>\n",
       "      <td>Atezolizumab will be administered intravenousl...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT02596971</td>\n",
       "      <td>2015-12-22</td>\n",
       "      <td>A Study of Atezolizumab in Combination With Ei...</td>\n",
       "      <td>A Phase IB/II Study Evaluating the Safety and ...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>91.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>3.0</td>\n",
       "      <td>1</td>\n",
       "      <td>40968537</td>\n",
       "      <td>Drug</td>\n",
       "      <td>atezolizumab</td>\n",
       "      <td>Atezo-G-Benda: Atezolizumab 840 milligrams (mg...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT04923776  2021-09-20  Liver Directed RT + Chemo-immunotherapy for ES...   \n",
       "1  NCT03312530  2017-11-13  A Study of Cobimetinib Administered as Single ...   \n",
       "2  NCT03059667  2017-03-13  Immunotherapy as Second-line in Patient With S...   \n",
       "3  NCT04356729  2020-08-06  A Phase II Trial of PD-L1 Therapy Combined Wit...   \n",
       "4  NCT02596971  2015-12-22  A Study of Atezolizumab in Combination With Ei...   \n",
       "\n",
       "                                      official_title overall_status  \\\n",
       "0  A Phase II Trial of Atezolizumab + Carboplatin...     Recruiting   \n",
       "1  A Phase Ib/II Study of Cobimetinib Administere...      Completed   \n",
       "2  A Randomized Non-comparative Phase II Study of...      Completed   \n",
       "3  A Phase II Trial of PD-L1 Therapy Combined Wit...     Recruiting   \n",
       "4  A Phase IB/II Study Evaluating the Safety and ...      Completed   \n",
       "\n",
       "             phase  enrollment enrollment_type  number_of_arms  results  \\\n",
       "0          Phase 2        18.0     Anticipated             1.0        0   \n",
       "1  Phase 1/Phase 2        49.0          Actual             5.0        1   \n",
       "2          Phase 2        73.0          Actual             2.0        0   \n",
       "3          Phase 2        30.0     Anticipated             1.0        0   \n",
       "4  Phase 1/Phase 2        91.0          Actual             3.0        1   \n",
       "\n",
       "         id intervention_type          name  \\\n",
       "0  41127752              Drug  atezolizumab   \n",
       "1  41128986              Drug  atezolizumab   \n",
       "2  40965825              Drug  atezolizumab   \n",
       "3  40968341              Drug  atezolizumab   \n",
       "4  40968537              Drug  atezolizumab   \n",
       "\n",
       "                                         description  \n",
       "0  The dosage for this drug is 1200 mg Intravenou...  \n",
       "1  Atezolizumab will be administered as per the s...  \n",
       "2           Atezolizumab at 1200 mg IV every 3 weeks  \n",
       "3  Atezolizumab will be administered intravenousl...  \n",
       "4  Atezo-G-Benda: Atezolizumab 840 milligrams (mg...  "
      ]
     },
     "execution_count": 107,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "atezolizumab_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    406\n",
       "1     55\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 108,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "atezolizumab_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Pembrolizumab \n",
    "### Adjuvant treatment of renal cell carcinoma\n",
    "### Adjuvant treatment of resected stage 2B or 2C melanoma\n",
    "### Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 109,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "pembrolizumab\n",
      "keytruda\n",
      "mk-3475\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    'Pembrolizumab',\n",
    "    '1374853-91-4',\n",
    "    'Keytruda',\n",
    "    'DPT0O3T46P',\n",
    "    'MK-3475',\n",
    "    \"Immunoglobulin G4, anti-(human programmed cell death 1); humanized mouse monoclonal (228-L-proline(H10-S>P))gamma 4 heavy chain (134-218')-disulfide with humanized mouse monoclonal kappa light chain dimer (226-226'':229-229'')-bisdisulfide\",\n",
    "    \"Immunoglobulin G4, anti-(human protein PDCD1 (programmed cell death 1)) (human-Mus musculus monoclonal heavy chain), disulfide with human-Mus musculus monoclonal light chain, dimer\",\n",
    "    'MK 3475',\n",
    "    'SCH-900475',\n",
    "    'Sch 900475',\n",
    "    'UNII-DPT0O3T46P',\n",
    "    'HSDB 8257',\n",
    "    'KEYLYNK-010 COMPONENT PEMBROLIZUMAB',\n",
    "    'L01XC18',\n",
    "    'MK 7684A COMPONENT PEMBROLIZUMAB',\n",
    "    'MK-1308A COMPONENT PEMBROLIZUMAB',\n",
    "    'Merck 3475',\n",
    "    'PEMBROLIZUMAB (PURPLE BOOK CDER)',\n",
    "    'PEMBROLIZUMAB COMPONENT OF KEYLYNK-010',\n",
    "    'pembrolizumabum'\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2315</th>\n",
       "      <td>41061577</td>\n",
       "      <td>NCT05547321</td>\n",
       "      <td>Drug</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>The investigational product is OMTX705 adminis...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3246</th>\n",
       "      <td>40904716</td>\n",
       "      <td>NCT04373265</td>\n",
       "      <td>Drug</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Pembrolizumab 400 mg infusion every 6 weeks</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4533</th>\n",
       "      <td>40905139</td>\n",
       "      <td>NCT02499952</td>\n",
       "      <td>Drug</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>200mg IV every 3 weeks until progressive disea...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6308</th>\n",
       "      <td>41404554</td>\n",
       "      <td>NCT05174832</td>\n",
       "      <td>Drug</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>200 mg IV every 21 days</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8753</th>\n",
       "      <td>41063072</td>\n",
       "      <td>NCT03836352</td>\n",
       "      <td>Drug</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>IV Infusion (q3w)</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "            id       nct_id intervention_type           name  \\\n",
       "2315  41061577  NCT05547321              Drug  pembrolizumab   \n",
       "3246  40904716  NCT04373265              Drug  pembrolizumab   \n",
       "4533  40905139  NCT02499952              Drug  pembrolizumab   \n",
       "6308  41404554  NCT05174832              Drug  pembrolizumab   \n",
       "8753  41063072  NCT03836352              Drug  pembrolizumab   \n",
       "\n",
       "                                            description  \n",
       "2315  The investigational product is OMTX705 adminis...  \n",
       "3246        Pembrolizumab 400 mg infusion every 6 weeks  \n",
       "4533  200mg IV every 3 weeks until progressive disea...  \n",
       "6308                            200 mg IV every 21 days  \n",
       "8753                                  IV Infusion (q3w)  "
      ]
     },
     "execution_count": 111,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1407"
      ]
     },
     "execution_count": 112,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "metadata": {},
   "outputs": [],
   "source": [
    "pembrolizumab_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1407"
      ]
     },
     "execution_count": 114,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pembrolizumab_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05327686</td>\n",
       "      <td>2022-06-30</td>\n",
       "      <td>Testing the Addition of Stereotactic Radiation...</td>\n",
       "      <td>Randomized Phase II Stereotactic Ablative Radi...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>240.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41415848</td>\n",
       "      <td>Biological</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Given IV</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT03534635</td>\n",
       "      <td>2018-06-01</td>\n",
       "      <td>Analysis of the Modulation of the Tumor Microe...</td>\n",
       "      <td>An Interventional Phase II Study to Analyze th...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>30.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41126476</td>\n",
       "      <td>Drug</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Pembrolizumab monotherapy at 200 mg every 3 we...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03463161</td>\n",
       "      <td>2018-03-23</td>\n",
       "      <td>Epacadostat and Pembrolizumab in Patients With...</td>\n",
       "      <td>A Phase II Study of Epacadostat + Pembrolizuma...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41126548</td>\n",
       "      <td>Drug</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Pembrolizumab (200mg/kg) given by intravenous ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04746924</td>\n",
       "      <td>2021-06-08</td>\n",
       "      <td>A Study of Ociperlimab With Tislelizumab Compa...</td>\n",
       "      <td>A Phase 3, Randomized, Double-Blind Study of O...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>660.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41416073</td>\n",
       "      <td>Drug</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Pembrolizumab is a monoclonal antibody formula...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT04432857</td>\n",
       "      <td>2020-08-20</td>\n",
       "      <td>AN0025 and Pembrolizumab Combination in Advanc...</td>\n",
       "      <td>An Open-Label Multicenter Phase Ib Study of AN...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>84.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>6.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41416148</td>\n",
       "      <td>Drug</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Infusion</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT05327686  2022-06-30  Testing the Addition of Stereotactic Radiation...   \n",
       "1  NCT03534635  2018-06-01  Analysis of the Modulation of the Tumor Microe...   \n",
       "2  NCT03463161  2018-03-23  Epacadostat and Pembrolizumab in Patients With...   \n",
       "3  NCT04746924  2021-06-08  A Study of Ociperlimab With Tislelizumab Compa...   \n",
       "4  NCT04432857  2020-08-20  AN0025 and Pembrolizumab Combination in Advanc...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  Randomized Phase II Stereotactic Ablative Radi...              Recruiting   \n",
       "1  An Interventional Phase II Study to Analyze th...  Active, not recruiting   \n",
       "2  A Phase II Study of Epacadostat + Pembrolizuma...              Terminated   \n",
       "3  A Phase 3, Randomized, Double-Blind Study of O...              Recruiting   \n",
       "4  An Open-Label Multicenter Phase Ib Study of AN...              Recruiting   \n",
       "\n",
       "     phase  enrollment enrollment_type  number_of_arms  results        id  \\\n",
       "0  Phase 2       240.0     Anticipated             2.0        0  41415848   \n",
       "1  Phase 2        30.0     Anticipated             1.0        0  41126476   \n",
       "2  Phase 2         2.0          Actual             2.0        1  41126548   \n",
       "3  Phase 3       660.0     Anticipated             3.0        0  41416073   \n",
       "4  Phase 1        84.0     Anticipated             6.0        0  41416148   \n",
       "\n",
       "  intervention_type           name  \\\n",
       "0        Biological  pembrolizumab   \n",
       "1              Drug  pembrolizumab   \n",
       "2              Drug  pembrolizumab   \n",
       "3              Drug  pembrolizumab   \n",
       "4              Drug  pembrolizumab   \n",
       "\n",
       "                                         description  \n",
       "0                                           Given IV  \n",
       "1  Pembrolizumab monotherapy at 200 mg every 3 we...  \n",
       "2  Pembrolizumab (200mg/kg) given by intravenous ...  \n",
       "3  Pembrolizumab is a monoclonal antibody formula...  \n",
       "4                                           Infusion  "
      ]
     },
     "execution_count": 115,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pembrolizumab_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    1123\n",
       "1     292\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 116,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pembrolizumab_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Cabozantinib \n",
    "### Adjuvant treatment of resected stage 2B or 2C melanoma"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 117,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "cabozantinib\n",
      "xl184\n",
      "cabometyx\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    'Cabozantinib',\n",
    "    '849217-68-1',\n",
    "    'Cometriq',\n",
    "    'XL184',\n",
    "    'XL-184',\n",
    "    'BMS-907351',\n",
    "    'XL 184',\n",
    "    'BMS 907351',\n",
    "    'XL-184 free base',\n",
    "    'Cabometyx',\n",
    "    \"Cabozantinib (XL184, BMS-907351)\",\n",
    "    \"Cabozantinib [USAN]\",\n",
    "    \"CHEBI:72317\",\n",
    "    \"Cabozantinib [USAN:INN]\",\n",
    "    'UNII-1C39JW444G',\n",
    "    \"1C39JW444G\",\n",
    "    \"BMS-907351 FREE BASE\",\n",
    "    'MFCD20926324',\n",
    "    \"Cabozantinib (USAN)\",\n",
    "    \"N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE\",\n",
    "    \"XL-184 (Cabozantinib,BMS907351)\",\n",
    "    'Cabometyx (TN)',\n",
    "    \"Cometriq (TN)\",\n",
    "    \"1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide\",\n",
    "    \"n-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide\",\n",
    "    \"1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-\",\n",
    "    \"N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide\",\n",
    "    'XL184 cpd',\n",
    "    'Carbozantinib',\n",
    "    \"1,1-CYCLOPROPANEDICARBOXAMIDE, N'-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N-(4-FLUOROPHENYL)-\",\n",
    "    'XL184 free base',\n",
    "    'Cabozantinib (free base)',\n",
    "    'CABOZANTINIB [MI]',\n",
    "    'CABOZANTINIB [INN]',\n",
    "    'D0IQ6P',\n",
    "    'CABOZANTINIB [VANDF]',\n",
    "    'CABOZANTINIB [WHO-DD]',\n",
    "    'SCHEMBL360795',\n",
    "    'GTPL5887',\n",
    "    'Cabozantinib (BMS-907351)',\n",
    "    'CHEMBL2105717',\n",
    "    'DTXSID10233968',\n",
    "    'EX-A075',\n",
    "    'XL184 free base - Cabozantinib',\n",
    "    'BCPP000308',\n",
    "    'HMS3654G06',\n",
    "    'XL-184 free base (Cabozantinib)',\n",
    "    'BCP02591',\n",
    "    '849217-68-1 (free base)',\n",
    "    'BDBM50021574',\n",
    "    'NSC761068',\n",
    "    'NSC800066',\n",
    "    's1119',\n",
    "    'AKOS025142112',\n",
    "    'BCP9000470',\n",
    "    'CCG-264678',\n",
    "    'CS-0278',\n",
    "    'DB08875',\n",
    "    'NSC-761068',\n",
    "    'NSC-800066',\n",
    "    'SB20062',\n",
    "    'XL-184,Cabozantinib, BMS-907351',\n",
    "    'NCGC00263164-01',\n",
    "    'NCGC00263164-14',\n",
    "    'NCGC00263164-17',\n",
    "    \"1,1-Cyclopropanedicarboxamide,N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-\",\n",
    "    'AC-25082',\n",
    "    'AS-16277',\n",
    "    \"HY-13016\",\n",
    "    \"N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide\",\n",
    "    'SY097158',\n",
    "    'FT-0664184',\n",
    "    'SW218093-3',\n",
    "    'D10062',\n",
    "    'AB01565831_02',\n",
    "    'Q795057',\n",
    "    'SR-01000941569',\n",
    "    'J-523016',\n",
    "    'SR-01000941569-1',\n",
    "    'BRD-K51544265-001-01-8',\n",
    "    \"1,1-Cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-\",\n",
    "    \"1,1-CYCLOPROPANEDICARBOXAMIDE, N-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N'-(4-FLUOROPHENYL)-\",\n",
    "    \"cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide\",\n",
    "    \"cyclopropane-1,1-dicarboxylic acid[4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide\",\n",
    "    \"N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4 fluorophenyl)cyclopropane-1,1-dicarboxamide\",\n",
    "    \"N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide\",\n",
    "    \"N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide\",\n",
    "    \"N-[4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl]-N inverted exclamation mark -(4-fluorophenyl)cyclopropane-1,1-dicarboxamide\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>19470</th>\n",
       "      <td>41065798</td>\n",
       "      <td>NCT03957551</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cabozantinib</td>\n",
       "      <td>Cabozantinib is an oral small molecule potent ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20979</th>\n",
       "      <td>40910482</td>\n",
       "      <td>NCT03468218</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cabozantinib</td>\n",
       "      <td>Given PO</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21865</th>\n",
       "      <td>41209854</td>\n",
       "      <td>NCT01658878</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cabozantinib</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22050</th>\n",
       "      <td>40910651</td>\n",
       "      <td>NCT02036476</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cabozantinib</td>\n",
       "      <td>oral administration</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22715</th>\n",
       "      <td>41066414</td>\n",
       "      <td>NCT04149275</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cabozantinib</td>\n",
       "      <td>Treatment with oral Cabozantinib once daily</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id       nct_id intervention_type          name  \\\n",
       "19470  41065798  NCT03957551              Drug  cabozantinib   \n",
       "20979  40910482  NCT03468218              Drug  cabozantinib   \n",
       "21865  41209854  NCT01658878              Drug  cabozantinib   \n",
       "22050  40910651  NCT02036476              Drug  cabozantinib   \n",
       "22715  41066414  NCT04149275              Drug  cabozantinib   \n",
       "\n",
       "                                             description  \n",
       "19470  Cabozantinib is an oral small molecule potent ...  \n",
       "20979                                           Given PO  \n",
       "21865                                                NaN  \n",
       "22050                                oral administration  \n",
       "22715        Treatment with oral Cabozantinib once daily  "
      ]
     },
     "execution_count": 119,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "144"
      ]
     },
     "execution_count": 120,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "metadata": {},
   "outputs": [],
   "source": [
    "cabozantinib_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "144"
      ]
     },
     "execution_count": 122,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cabozantinib_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 123,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05327686</td>\n",
       "      <td>2022-06-30</td>\n",
       "      <td>Testing the Addition of Stereotactic Radiation...</td>\n",
       "      <td>Randomized Phase II Stereotactic Ablative Radi...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>240.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41415844</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cabozantinib</td>\n",
       "      <td>Given PO</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04413123</td>\n",
       "      <td>2020-11-05</td>\n",
       "      <td>Cabozantinib In Combo With NIVO + IPI In Advan...</td>\n",
       "      <td>A Phase 2 Study of Cabozantinib in Combination...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>60.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40966031</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cabozantinib</td>\n",
       "      <td>Cabozantinib predetermined protocol dosage po ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT02260531</td>\n",
       "      <td>2014-11-30</td>\n",
       "      <td>Cabozantinib +/- Trastuzumab In Breast Cancer ...</td>\n",
       "      <td>A Phase II Study of Cabozantinib Alone or in C...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>36.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>3.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41132989</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cabozantinib</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01834651</td>\n",
       "      <td>2013-04-30</td>\n",
       "      <td>A Phase II Study of Cabozantinib (XL184) Thera...</td>\n",
       "      <td>A Phase II Study of Cabozantinib (XL184) Thera...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>17.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41133525</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cabozantinib</td>\n",
       "      <td>Cabozantinib 60 mg daily (oral). Subjects may ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT04427787</td>\n",
       "      <td>2020-06-20</td>\n",
       "      <td>A Trial Aiming to Assess the Safety and Activi...</td>\n",
       "      <td>A Phase II Trial Aiming to Assess the Safety a...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>69.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40968165</td>\n",
       "      <td>Drug</td>\n",
       "      <td>cabozantinib</td>\n",
       "      <td>Cabozantinib will be administered orally at a ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT05327686  2022-06-30  Testing the Addition of Stereotactic Radiation...   \n",
       "1  NCT04413123  2020-11-05  Cabozantinib In Combo With NIVO + IPI In Advan...   \n",
       "2  NCT02260531  2014-11-30  Cabozantinib +/- Trastuzumab In Breast Cancer ...   \n",
       "3  NCT01834651  2013-04-30  A Phase II Study of Cabozantinib (XL184) Thera...   \n",
       "4  NCT04427787  2020-06-20  A Trial Aiming to Assess the Safety and Activi...   \n",
       "\n",
       "                                      official_title overall_status    phase  \\\n",
       "0  Randomized Phase II Stereotactic Ablative Radi...     Recruiting  Phase 2   \n",
       "1  A Phase 2 Study of Cabozantinib in Combination...     Recruiting  Phase 2   \n",
       "2  A Phase II Study of Cabozantinib Alone or in C...      Completed  Phase 2   \n",
       "3  A Phase II Study of Cabozantinib (XL184) Thera...      Completed  Phase 2   \n",
       "4  A Phase II Trial Aiming to Assess the Safety a...     Recruiting  Phase 2   \n",
       "\n",
       "   enrollment enrollment_type  number_of_arms  results        id  \\\n",
       "0       240.0     Anticipated             2.0        0  41415844   \n",
       "1        60.0     Anticipated             1.0        0  40966031   \n",
       "2        36.0          Actual             3.0        1  41132989   \n",
       "3        17.0          Actual             1.0        1  41133525   \n",
       "4        69.0     Anticipated             1.0        0  40968165   \n",
       "\n",
       "  intervention_type          name  \\\n",
       "0              Drug  cabozantinib   \n",
       "1              Drug  cabozantinib   \n",
       "2              Drug  cabozantinib   \n",
       "3              Drug  cabozantinib   \n",
       "4              Drug  cabozantinib   \n",
       "\n",
       "                                         description  \n",
       "0                                           Given PO  \n",
       "1  Cabozantinib predetermined protocol dosage po ...  \n",
       "2                                                NaN  \n",
       "3  Cabozantinib 60 mg daily (oral). Subjects may ...  \n",
       "4  Cabozantinib will be administered orally at a ...  "
      ]
     },
     "execution_count": 123,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cabozantinib_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    116\n",
       "1     33\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 124,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cabozantinib_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Trifluridine \n",
    "### Metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 125,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "trifluridine\n",
      "trifluridine\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    \"Trifluridine\",\n",
    "    \"TRIFLUOROTHYMIDINE\",\n",
    "    \"70-00-8\",\n",
    "    \"Viroptic\",\n",
    "    \"5-Trifluorothymidine\",\n",
    "    \"Trifluoromethyldeoxyuridine\",\n",
    "    \"F3DThd\",\n",
    "    \"Trifluridina\",\n",
    "    \"Virophta\",\n",
    "    \"5-(Trifluoromethyl)deoxyuridine\",\n",
    "    \"F3TDR\",\n",
    "    \"Trifluridinum\",\n",
    "    \"TFDU\",\n",
    "    \"5-Trifluoromethyl-2-deoxyuridine\",\n",
    "    \"Trifluorothymine deoxyriboside\",\n",
    "    \"2'-Deoxy-5-(trifluoromethyl)uridine\",\n",
    "    \"Trifluoridine\",\n",
    "    \"Fluridine\",\n",
    "    \"Trifluridinum [INN-Latin]\",\n",
    "    \"Trifluridina [INN-Spanish]\",\n",
    "    \"5-Trifluoromethyl-2'-deoxyuridine\",\n",
    "    \"1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione\",\n",
    "    \"Trifluridine [USAN:INN]\",\n",
    "    \"2'-Deoxy-5-trifluoromethyluridine\",\n",
    "    \"5-Trifluoro-2'-deoxythymidine\",\n",
    "    \"Trifluridine (Viroptic)\",\n",
    "    \"alpha,alpha,alpha-Trifluorothymidine\",\n",
    "    \"CF3dUrd\",\n",
    "    \"NSC 75520\",\n",
    "    \"Viroptic (TN)\",\n",
    "    \"NSC 529182\",\n",
    "    \"Thymidine, alpha,alpha,alpha-trifluoro-\",\n",
    "    \"CCRIS 2348\",\n",
    "    \"F3T\",\n",
    "    \"Uridine, 2'-deoxy-5-(trifluoromethyl)-\",\n",
    "    \"C10H11F3N2O5\",\n",
    "    \"EINECS 200-722-8\",\n",
    "    \"UNII-RMW9V5RW38\",\n",
    "    \"BRN 0568095\",\n",
    "    \"CHEMBL1129\",\n",
    "    \"RMW9V5RW38\",\n",
    "    \"MLS000028361\",\n",
    "    \"Trifluridine [USAN:USP:INN]\",\n",
    "    \"DTXSID4046602\",\n",
    "    \"CHEBI:75179\",\n",
    "    \"HSDB 8126\",\n",
    "    \"5-(Trifluoromethyl)-2'-deoxyuridine\",\n",
    "    \"NSC-75520\",\n",
    "    \"1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione\",\n",
    "    \"NSC-529182\",\n",
    "    \"HS-0007\",\n",
    "    \"SMR000058583\",\n",
    "    \"2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-5-(trifluoromethyl)-\",\n",
    "    \"1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)-1,2,3,4-tetrahydropyrimidine-2,4-dione\",\n",
    "    \"DTXCID2026602\",\n",
    "    \"MFCD00006534\",\n",
    "    \"trifluridin-\",\n",
    "    \"NSC75520\",\n",
    "    \"NSC529182\",\n",
    "    \"CAS-70-00-8\",\n",
    "    \"NCGC00166323-01\",\n",
    "    \"Opera_ID_1810\",\n",
    "    \"5-Trifluoromethylthymidine\",\n",
    "    \"Trifluridine (USP/INN)\",\n",
    "    \"TRIFLURIDINE [MI]\",\n",
    "    \"TRIFLURIDINE [INN]\",\n",
    "    \"TRIFLURIDINE [JAN]\",\n",
    "    \"D05RHI\",\n",
    "    \"Trifluoromethyl Deoxyuridine\",\n",
    "    \"TRIFLURIDINE [USAN]\",\n",
    "    \"cid_6256\",\n",
    "    \"SCHEMBL3479\",\n",
    "    \"TRIFLURIDINE [VANDF]\",\n",
    "    \"TRIFLURIDINE [MART.]\",\n",
    "    \"MLS001148248\",\n",
    "    \"MLS006010219\",\n",
    "    \"TRIFLURIDINE [USP-RS]\",\n",
    "    \"TRIFLURIDINE [WHO-DD]\",\n",
    "    \"Trifluridine (JAN/USP/INN)\",\n",
    "    \"GTPL8697\",\n",
    "    \"cid_6708818\",\n",
    "    \"HMS2233N19\",\n",
    "    \"HMS3715C14\",\n",
    "    \"TRIFLURIDINE [ORANGE BOOK]\",\n",
    "    \"TRIFLURIDINE [EP MONOGRAPH]\",\n",
    "    \"5-trifluoromethyl-2''-deoxyuridine\",\n",
    "    \"BCP09147\",\n",
    "    \"DRG-0120\",\n",
    "    \"HY-A0061\",\n",
    "    \"Tox21_112411\",\n",
    "    \"TRIFLURIDINE [USP MONOGRAPH]\",\n",
    "    \"BDBM50132298\",\n",
    "    \"Trifluorothymidine\",\n",
    "    \"AKOS015919482\",\n",
    "    \"Tox21_112411_1\",\n",
    "    \"C10-H11-F3-N2-O5\",\n",
    "    \"CCG-221056\",\n",
    "    \"CS-1602\",\n",
    "    \"DB00432\",\n",
    "    \"TAS-102 COMPONENT TRIFLURIDINE\",\n",
    "    \"TRIFLURIDINE COMPONENT OF LONSURF\",\n",
    "    \"NCGC00166323-02\",\n",
    "    \"NCGC00166323-16\",\n",
    "    \"S-95005 COMPONENT TRIFLURIDINE\",\n",
    "    \"1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione\",\n",
    "    \"BP-58659\",\n",
    "    \"SRI-10817-12\",\n",
    "    \"SRI-10817_14\",\n",
    "    \"Viroptic\",\n",
    "    \"Trifluorothymidine\",\n",
    "    \"Trifluridine\",\n",
    "    \"LS-153788\",\n",
    "    \"AM20100660\",\n",
    "    \"S1778\",\n",
    "    \"SW199522-2\",\n",
    "    \"T2511\",\n",
    "    \"D00391\",\n",
    "    \"Thymidine, .alpha.,.alpha.,.alpha.-trifluoro-\",\n",
    "    \"A836733\",\n",
    "    \"EN300-24409722\",\n",
    "    \"SR-01000721911\",\n",
    "    \"J-700255\",\n",
    "    \"J-700357\",\n",
    "    \"Q2359590\",\n",
    "    \"SR-01000721911-2\",\n",
    "    \"BRD-K03243820-001-12-1\",\n",
    "    \"BRD-K03243820-001-25-3\",\n",
    "    \"Trifluridine, British Pharmacopoeia (BP) Reference Standard\",\n",
    "    \"Trifluridine;FTD;5-Trifluorothymidine;NSC 529182;NSC 75520\",\n",
    "    \"Trifluridine, United States Pharmacopeia (USP) Reference Standard\",\n",
    "    \"1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione\",\n",
    "    \"1-((2R,5R)-4-Hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-5-trifluoromethyl-1H-pyrimidine-2,4-dione\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 126,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>66045</th>\n",
       "      <td>41228691</td>\n",
       "      <td>NCT01867866</td>\n",
       "      <td>Drug</td>\n",
       "      <td>trifluridine</td>\n",
       "      <td>35 mg/m2, orally, single dose</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>701676</th>\n",
       "      <td>40872087</td>\n",
       "      <td>NCT04854434</td>\n",
       "      <td>Drug</td>\n",
       "      <td>trifluridine</td>\n",
       "      <td>Participants will receive trifluridine oral ta...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              id       nct_id intervention_type          name  \\\n",
       "66045   41228691  NCT01867866              Drug  trifluridine   \n",
       "701676  40872087  NCT04854434              Drug  trifluridine   \n",
       "\n",
       "                                              description  \n",
       "66045                       35 mg/m2, orally, single dose  \n",
       "701676  Participants will receive trifluridine oral ta...  "
      ]
     },
     "execution_count": 127,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 128,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2"
      ]
     },
     "execution_count": 128,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 129,
   "metadata": {},
   "outputs": [],
   "source": [
    "trifluridine_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 130,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2"
      ]
     },
     "execution_count": 130,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trifluridine_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT04854434</td>\n",
       "      <td>2021-06-29</td>\n",
       "      <td>A Study to Evaluate the Safety and Efficacy of...</td>\n",
       "      <td>A Phase 2 Open-Label Multicenter Study to Eval...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>78.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40872087</td>\n",
       "      <td>Drug</td>\n",
       "      <td>trifluridine</td>\n",
       "      <td>Participants will receive trifluridine oral ta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01867866</td>\n",
       "      <td>2013-05-31</td>\n",
       "      <td>Study Comparing the Pharmacokinetics of FTD as...</td>\n",
       "      <td>A Phase 1, Open-Label, Randomized, Parallel Gr...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>44.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41228691</td>\n",
       "      <td>Drug</td>\n",
       "      <td>trifluridine</td>\n",
       "      <td>35 mg/m2, orally, single dose</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT04854434  2021-06-29  A Study to Evaluate the Safety and Efficacy of...   \n",
       "1  NCT01867866  2013-05-31  Study Comparing the Pharmacokinetics of FTD as...   \n",
       "\n",
       "                                      official_title overall_status    phase  \\\n",
       "0  A Phase 2 Open-Label Multicenter Study to Eval...     Terminated  Phase 2   \n",
       "1  A Phase 1, Open-Label, Randomized, Parallel Gr...      Completed  Phase 1   \n",
       "\n",
       "   enrollment enrollment_type  number_of_arms  results        id  \\\n",
       "0        78.0          Actual             3.0        0  40872087   \n",
       "1        44.0          Actual             2.0        0  41228691   \n",
       "\n",
       "  intervention_type          name  \\\n",
       "0              Drug  trifluridine   \n",
       "1              Drug  trifluridine   \n",
       "\n",
       "                                         description  \n",
       "0  Participants will receive trifluridine oral ta...  \n",
       "1                      35 mg/m2, orally, single dose  "
      ]
     },
     "execution_count": 131,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trifluridine_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 132,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    2\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 132,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trifluridine_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Mobocertinib \n",
    "### EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 133,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "mobocertinib\n",
      "tak-788\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    'Mobocertinib',\n",
    "    \"1847461-43-1\",\n",
    "    \"TAK-788\",\n",
    "    \"AP32788\",\n",
    "    \"Exkivity\",\n",
    "    \"TAK788\",\n",
    "    \"Mobocertinib [INN]\",\n",
    "    \"AP-32788\",\n",
    "    \"Mobocertinib [USAN]\",\n",
    "    \"Mobocertinib(TAK-788)\",\n",
    "    \"propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate\",\n",
    "    \"39HBQ4A67L\",\n",
    "    \"Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate\",\n",
    "    \"1-Methylethyl 2-[[4-[[2-(dimethylamino)ethyl]methylamino]-2-methoxy-5-[(1-oxo-2-propen-1-yl)amino]phenyl]amino]-4-(1-methyl-1H-indol-3-yl)-5-pyrimidinecarboxylate\",\n",
    "    \"5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester\",\n",
    "    \"Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate\",\n",
    "    \"Mobocertinib (TAK788)\",\n",
    "    \"Mobocertinib [USAN:INN]\",\n",
    "    \"UNII-39HBQ4A67L\",\n",
    "    \"MOBOCERTINIB [WHO-DD]\",\n",
    "    \"CHEMBL4650319\",\n",
    "    \"SCHEMBL17373133\",\n",
    "    \"GTPL10468\",\n",
    "    \"BDBM368374\",\n",
    "    \"DTXSID201336749\",\n",
    "    \"BCP31045\",\n",
    "    \"EX-A3392\",\n",
    "    \"US10227342\", \n",
    "    \"Example 10\",\n",
    "    \"XYC46143\",\n",
    "    \"MFCD32669806\",\n",
    "    \"NSC825519\",\n",
    "    \"s6813\",\n",
    "    \"TAK-788;AP32788\",\n",
    "    \"WHO 11183\",\n",
    "    \"AKOS040759315\",\n",
    "    \"AT30193\",\n",
    "    \"NSC-825519\",\n",
    "    \"AC-36436\",\n",
    "    \"example 94 [WO2015195228A1]\",\n",
    "    \"MS-30474\",\n",
    "    \"HY-135815\",\n",
    "    \"CS-0114256\",\n",
    "    \"D81621\",\n",
    "    \"A934607\",\n",
    "    \"TAK-788;TAK 788; TAK788; AP32788; AP-32788; AP 32788\",\n",
    "    \"Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate\",\n",
    "    \"propan-2-yl 2-[(4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)phenyl)amino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 134,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 135,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>281722</th>\n",
       "      <td>41277386</td>\n",
       "      <td>NCT03807778</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tak-788</td>\n",
       "      <td>TAK-788 capsule</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>286536</th>\n",
       "      <td>41149532</td>\n",
       "      <td>NCT04441255</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tak-788</td>\n",
       "      <td>TAK-788 Capsule.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>287205</th>\n",
       "      <td>41149716</td>\n",
       "      <td>NCT03928327</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tak-788</td>\n",
       "      <td>TAK-788 Capsules</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>396316</th>\n",
       "      <td>41423582</td>\n",
       "      <td>NCT04056468</td>\n",
       "      <td>Drug</td>\n",
       "      <td>mobocertinib</td>\n",
       "      <td>Mobocertinib capsule.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>418378</th>\n",
       "      <td>41343435</td>\n",
       "      <td>NCT04576208</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tak-788</td>\n",
       "      <td>TAK-788 capsules</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              id       nct_id intervention_type          name  \\\n",
       "281722  41277386  NCT03807778              Drug       tak-788   \n",
       "286536  41149532  NCT04441255              Drug       tak-788   \n",
       "287205  41149716  NCT03928327              Drug       tak-788   \n",
       "396316  41423582  NCT04056468              Drug  mobocertinib   \n",
       "418378  41343435  NCT04576208              Drug       tak-788   \n",
       "\n",
       "                  description  \n",
       "281722        TAK-788 capsule  \n",
       "286536       TAK-788 Capsule.  \n",
       "287205       TAK-788 Capsules  \n",
       "396316  Mobocertinib capsule.  \n",
       "418378       TAK-788 capsules  "
      ]
     },
     "execution_count": 135,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "11"
      ]
     },
     "execution_count": 136,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 137,
   "metadata": {},
   "outputs": [],
   "source": [
    "mobocertinib_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 138,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "11"
      ]
     },
     "execution_count": 138,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "mobocertinib_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 139,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT04441255</td>\n",
       "      <td>2020-07-01</td>\n",
       "      <td>A Study to Evaluate the Effect of High-Fat Mea...</td>\n",
       "      <td>A Phase 1, Randomized, 2-Period, 2-Sequence, C...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>14.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41149532</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tak-788</td>\n",
       "      <td>TAK-788 Capsule.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT03928327</td>\n",
       "      <td>2019-05-02</td>\n",
       "      <td>A Study to Evaluate Drug-Drug Interaction of T...</td>\n",
       "      <td>A Phase 1 Study of Oral TAK-788 to Evaluate th...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>24.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41149716</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tak-788</td>\n",
       "      <td>TAK-788 Capsules</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT04056468</td>\n",
       "      <td>2019-08-23</td>\n",
       "      <td>A Study to Evaluate Pharmacokinetics (PK) and ...</td>\n",
       "      <td>Phase 1 Pharmacokinetics and Safety Study of O...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>24.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41423582</td>\n",
       "      <td>Drug</td>\n",
       "      <td>mobocertinib</td>\n",
       "      <td>Mobocertinib capsule.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT03807778</td>\n",
       "      <td>2019-02-04</td>\n",
       "      <td>A Study of TAK-788 in Japanese Adults With Non...</td>\n",
       "      <td>A Phase 1/2 Study of the Oral EGFR/HER2 Inhibi...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>33.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41277386</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tak-788</td>\n",
       "      <td>TAK-788 capsule</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT04576208</td>\n",
       "      <td>2020-11-30</td>\n",
       "      <td>A Study to Evaluate the Impact of Management S...</td>\n",
       "      <td>A Randomized Open-label Phase 2 Multicenter St...</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>0.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41343435</td>\n",
       "      <td>Drug</td>\n",
       "      <td>tak-788</td>\n",
       "      <td>TAK-788 capsules</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT04441255  2020-07-01  A Study to Evaluate the Effect of High-Fat Mea...   \n",
       "1  NCT03928327  2019-05-02  A Study to Evaluate Drug-Drug Interaction of T...   \n",
       "2  NCT04056468  2019-08-23  A Study to Evaluate Pharmacokinetics (PK) and ...   \n",
       "3  NCT03807778  2019-02-04  A Study of TAK-788 in Japanese Adults With Non...   \n",
       "4  NCT04576208  2020-11-30  A Study to Evaluate the Impact of Management S...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  A Phase 1, Randomized, 2-Period, 2-Sequence, C...               Completed   \n",
       "1  A Phase 1 Study of Oral TAK-788 to Evaluate th...               Completed   \n",
       "2  Phase 1 Pharmacokinetics and Safety Study of O...               Completed   \n",
       "3  A Phase 1/2 Study of the Oral EGFR/HER2 Inhibi...  Active, not recruiting   \n",
       "4  A Randomized Open-label Phase 2 Multicenter St...               Withdrawn   \n",
       "\n",
       "     phase  enrollment enrollment_type  number_of_arms  results        id  \\\n",
       "0  Phase 1        14.0          Actual             2.0        1  41149532   \n",
       "1  Phase 1        24.0          Actual             2.0        1  41149716   \n",
       "2  Phase 1        24.0          Actual             3.0        0  41423582   \n",
       "3  Phase 1        33.0          Actual             2.0        0  41277386   \n",
       "4  Phase 2         0.0          Actual             2.0        0  41343435   \n",
       "\n",
       "  intervention_type          name            description  \n",
       "0              Drug       tak-788       TAK-788 Capsule.  \n",
       "1              Drug       tak-788       TAK-788 Capsules  \n",
       "2              Drug  mobocertinib  Mobocertinib capsule.  \n",
       "3              Drug       tak-788        TAK-788 capsule  \n",
       "4              Drug       tak-788       TAK-788 capsules  "
      ]
     },
     "execution_count": 139,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "mobocertinib_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 140,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    7\n",
       "1    5\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 140,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "mobocertinib_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Lenvatinib \n",
    "###  Untreated advanced renal cell carcinoma"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 141,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "lenvatinib\n",
      "e7080\n",
      "lev\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    \"Lenvatinib\",\n",
    "    \"417716-92-8\",\n",
    "    \"E7080\",\n",
    "    \"Lenvima\",\n",
    "    \"E7080 (Lenvatinib)\",\n",
    "    \"4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide\",\n",
    "    \"Lenvatinib (E7080)\",\n",
    "    \"E-7080\",\n",
    "    \"E 7080\",\n",
    "    \"ER-203492-00\",\n",
    "    \"Lenvatinib free base\",\n",
    "    \"Lenvatinib [USAN]\",\n",
    "    \"4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide\",\n",
    "    \"4-{3-Chloro-4-[(Cyclopropylcarbamoyl)amino]phenoxy}-7-Methoxyquinoline-6-Carboxamide\",\n",
    "    \"UNII-EE083865G2\",\n",
    "    \"Lenvatinib [USAN:INN]\",\n",
    "    \"C21H19ClN4O4\",\n",
    "    \"4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide\",\n",
    "    \"CHEMBL1289601\",\n",
    "    \"CHEBI:85994\",\n",
    "    \"417716-92-8 (free base)\",\n",
    "    \"EE083865G2\",\n",
    "    \"4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide\",\n",
    "    \"4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide\",\n",
    "    \"4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide\",\n",
    "    \"Kisplyx\",\n",
    "    \"4-(3-CHLORO-4-((CYCLOPROPYLCARBAMOYL)AMINO)PHENOXY)-7-METHOXYQUINOLINE-6-CARBOXAMIDE\",\n",
    "    \"4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide\",\n",
    "    \"LEV\",\n",
    "    \"Lenvatinib; E7080\",\n",
    "    \"LENVATINIB [MI]\",\n",
    "    \"Lenvatinib base- Bio-X\",\n",
    "    \"LENVATINIB [INN]\",\n",
    "    \"Lenvatinib (USAN/INN)\",\n",
    "    \"D0R0FO\",\n",
    "    \"4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide\",\n",
    "    \"LENVATINIB [WHO-DD]\",\n",
    "    \"MLS006011239\",\n",
    "    \"SCHEMBL864638\",\n",
    "    \"GTPL7426\",\n",
    "    \"AMY9240\",\n",
    "    \"DTXSID50194605\",\n",
    "    \"EX-A249\",\n",
    "    \"BCPP000247\",\n",
    "    \"HMS3244A07\",\n",
    "    \"HMS3244A08\",\n",
    "    \"HMS3244B07\",\n",
    "    \"HMS3654A14\",\n",
    "    \"BCP01799\",\n",
    "    \"BDBM50331094\",\n",
    "    \"MFCD16038644\",\n",
    "    \"NSC755980\",\n",
    "    \"NSC800781\",\n",
    "    \"s1164\",\n",
    "    \"AKOS025401742\",\n",
    "    \"BCP9000633\",\n",
    "    \"CCG-264842\",\n",
    "    \"CS-0109\",\n",
    "    \"DB09078\",\n",
    "    \"NSC-755980\",\n",
    "    \"NSC-800781\",\n",
    "    \"SB16580\",\n",
    "    \"NCGC00263198-01\",\n",
    "    \"NCGC00263198-04\",\n",
    "    \"NCGC00263198-07\",\n",
    "    \"AC-25047\",\n",
    "    \"AS-16203\",\n",
    "    \"BL164616\",\n",
    "    \"HY-10981\",\n",
    "    \"SMR004702999\",\n",
    "    \"FT-0700727\",\n",
    "    \"SW219259-1\",\n",
    "    \"D09919\",\n",
    "    \"E-7080, E7080\",\n",
    "    \"EN300-7418350\",\n",
    "    \"A825653\",\n",
    "    \"J-513372\",\n",
    "    \"Q6523413\",\n",
    "    \"BRD-K39974922-001-02-7\",\n",
    "    \"Z2235801899\",\n",
    "    \"4-[3-chloranyl-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide\",\n",
    "    \"N-(4-((6-CARBAMOYL-7-METHOXYQUINOLIN-4-YL)OXY)-2-CHLOROPHENYL)-N'-CYCLOPROPYLUREA\",\n",
    "    \"4-[3-chloro-4-[[(cyclopropylamino)-oxomethyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide\",\n",
    "    \"6-Quinolinecarboxamide, 4-(3-chloro-4- (((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-\",\n",
    "    \"6-QUINOLINECARBOXAMIDE, 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)- 7-METHOXY-\",\n",
    "    \"6-QUINOLINECARBOXAMIDE, 4-(3-CHLORO-4-(((CYCLOPROPYLAMINO)CARBONYL)AMINO)PHENOXY)-7-METHOXY-\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 142,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 143,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1778</th>\n",
       "      <td>40904156</td>\n",
       "      <td>NCT04053985</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>lenvatinib only</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10864</th>\n",
       "      <td>40908049</td>\n",
       "      <td>NCT03609359</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>Lenvatinib will be administered with water ora...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11788</th>\n",
       "      <td>41205786</td>\n",
       "      <td>NCT05030506</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>10 mg capsule administered orally at a dose of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12273</th>\n",
       "      <td>41206019</td>\n",
       "      <td>NCT03245151</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>oral hard capsules containing 1 mg, 4 mg, or 1...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14030</th>\n",
       "      <td>41064153</td>\n",
       "      <td>NCT04287829</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>Capsule</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id       nct_id intervention_type        name  \\\n",
       "1778   40904156  NCT04053985              Drug  lenvatinib   \n",
       "10864  40908049  NCT03609359              Drug  lenvatinib   \n",
       "11788  41205786  NCT05030506              Drug  lenvatinib   \n",
       "12273  41206019  NCT03245151              Drug  lenvatinib   \n",
       "14030  41064153  NCT04287829              Drug  lenvatinib   \n",
       "\n",
       "                                             description  \n",
       "1778                                     lenvatinib only  \n",
       "10864  Lenvatinib will be administered with water ora...  \n",
       "11788  10 mg capsule administered orally at a dose of...  \n",
       "12273  oral hard capsules containing 1 mg, 4 mg, or 1...  \n",
       "14030                                            Capsule  "
      ]
     },
     "execution_count": 143,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 144,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "220"
      ]
     },
     "execution_count": 144,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 145,
   "metadata": {},
   "outputs": [],
   "source": [
    "lenvatinib_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 146,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "220"
      ]
     },
     "execution_count": 146,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "lenvatinib_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 147,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT05327686</td>\n",
       "      <td>2022-06-30</td>\n",
       "      <td>Testing the Addition of Stereotactic Radiation...</td>\n",
       "      <td>Randomized Phase II Stereotactic Ablative Radi...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>240.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41415846</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>Given PO</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT05327582</td>\n",
       "      <td>2022-04-12</td>\n",
       "      <td>An Open-label, Phase I/II Study of PLENA Regim...</td>\n",
       "      <td>A Phase I/II, Open-label, One-arm, Single-cent...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>65.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41127678</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>Administered orally, 8mg/d once daily in a 3-w...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT04911959</td>\n",
       "      <td>2022-07-01</td>\n",
       "      <td>Study of TACE Combined With Lenvatinib to Prev...</td>\n",
       "      <td>Study on the Safety and Effectiveness of Trans...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>50.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40963438</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>Lenvatinib is taken orally.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04924101</td>\n",
       "      <td>2021-07-15</td>\n",
       "      <td>Efficacy and Safety of Pembrolizumab Plus Inve...</td>\n",
       "      <td>A Phase 2 Study to Evaluate the Efficacy and S...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>120.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41130392</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>Oral capsule</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT04246177</td>\n",
       "      <td>2020-05-22</td>\n",
       "      <td>Safety and Efficacy of Lenvatinib (E7080/MK-79...</td>\n",
       "      <td>A Phase 3 Multicenter, Randomized, Double-blin...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>450.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41132559</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>Administered at a dose of 12 mg (for participa...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT05327686  2022-06-30  Testing the Addition of Stereotactic Radiation...   \n",
       "1  NCT05327582  2022-04-12  An Open-label, Phase I/II Study of PLENA Regim...   \n",
       "2  NCT04911959  2022-07-01  Study of TACE Combined With Lenvatinib to Prev...   \n",
       "3  NCT04924101  2021-07-15  Efficacy and Safety of Pembrolizumab Plus Inve...   \n",
       "4  NCT04246177  2020-05-22  Safety and Efficacy of Lenvatinib (E7080/MK-79...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  Randomized Phase II Stereotactic Ablative Radi...              Recruiting   \n",
       "1  A Phase I/II, Open-label, One-arm, Single-cent...              Recruiting   \n",
       "2  Study on the Safety and Effectiveness of Trans...              Recruiting   \n",
       "3  A Phase 2 Study to Evaluate the Efficacy and S...  Active, not recruiting   \n",
       "4  A Phase 3 Multicenter, Randomized, Double-blin...  Active, not recruiting   \n",
       "\n",
       "             phase  enrollment enrollment_type  number_of_arms  results  \\\n",
       "0          Phase 2       240.0     Anticipated             2.0        0   \n",
       "1  Phase 1/Phase 2        65.0     Anticipated             1.0        0   \n",
       "2  Phase 1/Phase 2        50.0     Anticipated             2.0        0   \n",
       "3          Phase 2       120.0     Anticipated             3.0        0   \n",
       "4          Phase 3       450.0     Anticipated             2.0        0   \n",
       "\n",
       "         id intervention_type        name  \\\n",
       "0  41415846              Drug  lenvatinib   \n",
       "1  41127678              Drug  lenvatinib   \n",
       "2  40963438              Drug  lenvatinib   \n",
       "3  41130392              Drug  lenvatinib   \n",
       "4  41132559              Drug  lenvatinib   \n",
       "\n",
       "                                         description  \n",
       "0                                           Given PO  \n",
       "1  Administered orally, 8mg/d once daily in a 3-w...  \n",
       "2                        Lenvatinib is taken orally.  \n",
       "3                                       Oral capsule  \n",
       "4  Administered at a dose of 12 mg (for participa...  "
      ]
     },
     "execution_count": 147,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "lenvatinib_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 148,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    187\n",
       "1     43\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 148,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "lenvatinib_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Trastuzumab deruxtecan  \n",
    "### HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 149,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "trastuzumab deruxtecan\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    \"Trastuzumab deruxtecan\",\n",
    "    \"BCP32858\",\n",
    "    \"FT-0777984\",\n",
    "    \"Exatecan derivative for ADC;Exatecan derivative; DX-8951 derivative; DX-8951; DX8951; Trastuzumab Deruxtecan (DS-8201a)\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 150,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 151,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>28325</th>\n",
       "      <td>41212364</td>\n",
       "      <td>NCT03742102</td>\n",
       "      <td>Drug</td>\n",
       "      <td>trastuzumab deruxtecan</td>\n",
       "      <td>Trastuzumab deruxtecan iv 3-week cycles (once ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41435</th>\n",
       "      <td>40915498</td>\n",
       "      <td>NCT04986579</td>\n",
       "      <td>Drug</td>\n",
       "      <td>trastuzumab deruxtecan</td>\n",
       "      <td>Intravenous Infusion</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41911</th>\n",
       "      <td>40915606</td>\n",
       "      <td>NCT04704934</td>\n",
       "      <td>Drug</td>\n",
       "      <td>trastuzumab deruxtecan</td>\n",
       "      <td>6.4 mg/kg IV infusion every 3 weeks on Day 1 o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76832</th>\n",
       "      <td>40922648</td>\n",
       "      <td>NCT05376878</td>\n",
       "      <td>Biological</td>\n",
       "      <td>trastuzumab deruxtecan</td>\n",
       "      <td>Given IV</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96378</th>\n",
       "      <td>41408105</td>\n",
       "      <td>NCT05372614</td>\n",
       "      <td>Biological</td>\n",
       "      <td>trastuzumab deruxtecan</td>\n",
       "      <td>Given IV</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id       nct_id intervention_type                    name  \\\n",
       "28325  41212364  NCT03742102              Drug  trastuzumab deruxtecan   \n",
       "41435  40915498  NCT04986579              Drug  trastuzumab deruxtecan   \n",
       "41911  40915606  NCT04704934              Drug  trastuzumab deruxtecan   \n",
       "76832  40922648  NCT05376878        Biological  trastuzumab deruxtecan   \n",
       "96378  41408105  NCT05372614        Biological  trastuzumab deruxtecan   \n",
       "\n",
       "                                             description  \n",
       "28325  Trastuzumab deruxtecan iv 3-week cycles (once ...  \n",
       "41435                               Intravenous Infusion  \n",
       "41911  6.4 mg/kg IV infusion every 3 weeks on Day 1 o...  \n",
       "76832                                           Given IV  \n",
       "96378                                           Given IV  "
      ]
     },
     "execution_count": 151,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 152,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "33"
      ]
     },
     "execution_count": 152,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 153,
   "metadata": {},
   "outputs": [],
   "source": [
    "trastuzumab_deruxtecan_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 154,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "33"
      ]
     },
     "execution_count": 154,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trastuzumab_deruxtecan_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 155,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT04585958</td>\n",
       "      <td>2021-01-04</td>\n",
       "      <td>Testing the Combination of DS-8201a and Olapar...</td>\n",
       "      <td>A Phase I Study of DS-8201a in Combination Wit...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>55.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41132371</td>\n",
       "      <td>Biological</td>\n",
       "      <td>trastuzumab deruxtecan</td>\n",
       "      <td>Given IV</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT03523585</td>\n",
       "      <td>2018-08-01</td>\n",
       "      <td>DS-8201a in Pre-treated HER2 Breast Cancer Tha...</td>\n",
       "      <td>A Phase 3, Multicenter, Randomized, Open-label...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>600.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41167574</td>\n",
       "      <td>Drug</td>\n",
       "      <td>trastuzumab deruxtecan</td>\n",
       "      <td>DS-8201a is sterile lyophilized powder reconst...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT04538742</td>\n",
       "      <td>2020-12-28</td>\n",
       "      <td>A Phase 1b/2 Study of T-DXd Combinations in HE...</td>\n",
       "      <td>A Phase 1b/2 Multicentre, Open-label, Modular,...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>245.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>8.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41174132</td>\n",
       "      <td>Drug</td>\n",
       "      <td>trastuzumab deruxtecan</td>\n",
       "      <td>T-DXd: administered as an IV infusion</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04616560</td>\n",
       "      <td>2021-02-01</td>\n",
       "      <td>Trastuzumab Deruxtecan for the Treatment of HE...</td>\n",
       "      <td>A Phase 2 Study of DS-8201a (NSC# 807708) in A...</td>\n",
       "      <td>Suspended</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>27.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41279290</td>\n",
       "      <td>Biological</td>\n",
       "      <td>trastuzumab deruxtecan</td>\n",
       "      <td>Given IV</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT04294628</td>\n",
       "      <td>2020-07-14</td>\n",
       "      <td>Testing the Biological Effects of DS-8201a on ...</td>\n",
       "      <td>Pilot Study of DS-8201a Pharmacodynamics in Pa...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>55.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41279426</td>\n",
       "      <td>Biological</td>\n",
       "      <td>trastuzumab deruxtecan</td>\n",
       "      <td>Given IV</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT04585958  2021-01-04  Testing the Combination of DS-8201a and Olapar...   \n",
       "1  NCT03523585  2018-08-01  DS-8201a in Pre-treated HER2 Breast Cancer Tha...   \n",
       "2  NCT04538742  2020-12-28  A Phase 1b/2 Study of T-DXd Combinations in HE...   \n",
       "3  NCT04616560  2021-02-01  Trastuzumab Deruxtecan for the Treatment of HE...   \n",
       "4  NCT04294628  2020-07-14  Testing the Biological Effects of DS-8201a on ...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  A Phase I Study of DS-8201a in Combination Wit...              Recruiting   \n",
       "1  A Phase 3, Multicenter, Randomized, Open-label...  Active, not recruiting   \n",
       "2  A Phase 1b/2 Multicentre, Open-label, Modular,...              Recruiting   \n",
       "3  A Phase 2 Study of DS-8201a (NSC# 807708) in A...               Suspended   \n",
       "4  Pilot Study of DS-8201a Pharmacodynamics in Pa...              Recruiting   \n",
       "\n",
       "             phase  enrollment enrollment_type  number_of_arms  results  \\\n",
       "0          Phase 1        55.0     Anticipated             1.0        0   \n",
       "1          Phase 3       600.0     Anticipated             3.0        0   \n",
       "2  Phase 1/Phase 2       245.0     Anticipated             8.0        0   \n",
       "3          Phase 2        27.0     Anticipated             1.0        0   \n",
       "4          Phase 1        55.0     Anticipated             1.0        0   \n",
       "\n",
       "         id intervention_type                    name  \\\n",
       "0  41132371        Biological  trastuzumab deruxtecan   \n",
       "1  41167574              Drug  trastuzumab deruxtecan   \n",
       "2  41174132              Drug  trastuzumab deruxtecan   \n",
       "3  41279290        Biological  trastuzumab deruxtecan   \n",
       "4  41279426        Biological  trastuzumab deruxtecan   \n",
       "\n",
       "                                         description  \n",
       "0                                           Given IV  \n",
       "1  DS-8201a is sterile lyophilized powder reconst...  \n",
       "2              T-DXd: administered as an IV infusion  \n",
       "3                                           Given IV  \n",
       "4                                           Given IV  "
      ]
     },
     "execution_count": 155,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trastuzumab_deruxtecan_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 156,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    30\n",
       "1     4\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 156,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trastuzumab_deruxtecan_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Regorafenib  \n",
    "### Previously treated metastatic colorectal cancer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 157,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "regorafenib\n",
      "regorafenib (bay 73-4506)\n",
      "bay73-4506\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    \"Regorafenib\",\n",
    "    \"755037-03-7\",\n",
    "    \"BAY 73-4506\",\n",
    "    \"Stivarga\",\n",
    "    \"4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide\",\n",
    "    \"Regorafenibum\",\n",
    "    \"Regorafenib (BAY 73-4506)\",\n",
    "    \"BAY73-4506\",\n",
    "    \"4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide\",\n",
    "    \"BAY-73-4506\",\n",
    "    \"Regorafenib [INN]\",\n",
    "    \"Regorafenib [USAN:INN]\",\n",
    "    \"4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide\",\n",
    "    \"UNII-24T2A1DOYB\",\n",
    "    \"REGORAFENIB ANHYDROUS\",\n",
    "    \"24T2A1DOYB\",\n",
    "    \"CHEMBL1946170\",\n",
    "    \"CHEBI:68647\",\n",
    "    \"Bay-734506\",\n",
    "    \"anhydrous regorafenib\",\n",
    "    \"Stivarga (TN)\",\n",
    "    \"Regorafenib (BAY73-4506,Fluoro-Sorafenib)\",\n",
    "    \"4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide\",\n",
    "    \"C21H15ClF4N4O3\",\n",
    "    \"Fluoro-Sorafenib\",\n",
    "    \"4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl}amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide\",\n",
    "    \"Regorafenib-13C-d3\",\n",
    "    \"REGORAFENIB [MI]\",\n",
    "    \"Regorafenib (USAN/INN)\",\n",
    "    \"D09GDD\",\n",
    "    \"REGORAFENIB [VANDF]\",\n",
    "    \"REGORAFENIB [WHO-DD]\",\n",
    "    \"MLS006010303\",\n",
    "    \"Regorafenib crystalline form I\",\n",
    "    \"SCHEMBL432230\",\n",
    "    \"Regorafenib,BAY 73-4506\",\n",
    "    \"GTPL5891\",\n",
    "    \"DTXSID60226441\",\n",
    "    \"EX-A058\",\n",
    "    \"Regorafenib - BAY 73-4506\",\n",
    "    \"BCPP000352\",\n",
    "    \"HMS3654K16\",\n",
    "    \"HMS3672E15\",\n",
    "    \"BCP02105\",\n",
    "    \"BKD17855\",\n",
    "    \"BDBM50363397\",\n",
    "    \"MFCD16038047\",\n",
    "    \"NSC763932\",\n",
    "    \"NSC800865\",\n",
    "    \"s1178\",\n",
    "    \"AKOS015951107\",\n",
    "    \"AM81251\",\n",
    "    \"BAY 734506\",\n",
    "    \"BCP9000384\",\n",
    "    \"CCG-269571\",\n",
    "    \"CS-0170\",\n",
    "    \"DB08896\",\n",
    "    \"NSC-763932\",\n",
    "    \"NSC-800865\",\n",
    "    \"SB16819\",\n",
    "    \"NCGC00263138-01\",\n",
    "    \"NCGC00263138-13\",\n",
    "    \"NCGC00263138-19\",\n",
    "    \"2-Pyridinecarboxamide,4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-\",\n",
    "    \"835621-08-4\",\n",
    "    \"AC-25075\",\n",
    "    \"AC-31116\",\n",
    "    \"AS-16304\",\n",
    "    \"HY-10331\",\n",
    "    \"SMR004701370\",\n",
    "    \"FT-0674338\",\n",
    "    \"R0142\",\n",
    "    \"SW218097-2\",\n",
    "    \"cas:835621-07-3;Regorafenib hydrochloride\",\n",
    "    \"A25020\",\n",
    "    \"D10138\",\n",
    "    \"AB01565826_02\",\n",
    "    \"SR-01000941571\",\n",
    "    \"Q3891664\",\n",
    "    \"SR-01000941571-1\",\n",
    "    \"BRD-K16730910-001-02-4\",\n",
    "    \"Z2235801830\",\n",
    "    \"2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-\",\n",
    "    \"4-[4-({[4-Chloro-3-(trifluoromethy)phenyl]carbamoyl}amino)-3-fluorophenoxy]-1-methylpyridine-2-carboxamide\",\n",
    "    \"4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide\",\n",
    "    \"Regorafenib;1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 158,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 159,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1858</th>\n",
       "      <td>41061479</td>\n",
       "      <td>NCT05057052</td>\n",
       "      <td>Drug</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>Regorafenib will be initiated on day 14 after ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5560</th>\n",
       "      <td>40782605</td>\n",
       "      <td>NCT02389244</td>\n",
       "      <td>Drug</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>For adults patients and children with BSA ≥1.7...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35817</th>\n",
       "      <td>40914105</td>\n",
       "      <td>NCT02096354</td>\n",
       "      <td>Drug</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36049</th>\n",
       "      <td>41215725</td>\n",
       "      <td>NCT05426811</td>\n",
       "      <td>Drug</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>Regorafenib:120mg/d，Po，qd,d1-d21，Every 4 weeks</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37798</th>\n",
       "      <td>41070119</td>\n",
       "      <td>NCT04625907</td>\n",
       "      <td>Drug</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>Oral multi-kinase inhibitor that targets a bro...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id       nct_id intervention_type         name  \\\n",
       "1858   41061479  NCT05057052              Drug  regorafenib   \n",
       "5560   40782605  NCT02389244              Drug  regorafenib   \n",
       "35817  40914105  NCT02096354              Drug  regorafenib   \n",
       "36049  41215725  NCT05426811              Drug  regorafenib   \n",
       "37798  41070119  NCT04625907              Drug  regorafenib   \n",
       "\n",
       "                                             description  \n",
       "1858   Regorafenib will be initiated on day 14 after ...  \n",
       "5560   For adults patients and children with BSA ≥1.7...  \n",
       "35817                                                NaN  \n",
       "36049     Regorafenib:120mg/d，Po，qd,d1-d21，Every 4 weeks  \n",
       "37798  Oral multi-kinase inhibitor that targets a bro...  "
      ]
     },
     "execution_count": 159,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 160,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "133"
      ]
     },
     "execution_count": 160,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 161,
   "metadata": {},
   "outputs": [],
   "source": [
    "regorafenib_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 162,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "133"
      ]
     },
     "execution_count": 162,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "regorafenib_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 163,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT02234180</td>\n",
       "      <td>2014-09-30</td>\n",
       "      <td>Regorafenib in Treating Patients With Locally ...</td>\n",
       "      <td>Randomized Phase II Double Blind Study of Adju...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>3.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41125938</td>\n",
       "      <td>Drug</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>Given PO</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT03042689</td>\n",
       "      <td>2017-04-17</td>\n",
       "      <td>Study of Regorafenib in Patients With Advanced...</td>\n",
       "      <td>Phase I Study of Regorafenib in Patients With ...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>16.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41416446</td>\n",
       "      <td>Drug</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>Regorafenib will be administered on a 28 day c...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT02278783</td>\n",
       "      <td>2015-03-31</td>\n",
       "      <td>Phase 2 Trial of Regorafenib in Patients With ...</td>\n",
       "      <td>Phase 2 Trial of Regorafenib in Patients With ...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>1.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41133976</td>\n",
       "      <td>Drug</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>Patients will be treated with Regorafenib 160 ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT02910843</td>\n",
       "      <td>2017-02-22</td>\n",
       "      <td>Neoadjuvant Treatment With Regorafenib and Cap...</td>\n",
       "      <td>Neoadjuvant Treatment With Regorafenib and Cap...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>25.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40969820</td>\n",
       "      <td>Drug</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>Regorafenib dosel level 1-3: day 1 to 14 and d...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT02053376</td>\n",
       "      <td>2014-01-31</td>\n",
       "      <td>A Phase 2 Trial of Regorafenib as A Single Age...</td>\n",
       "      <td>A Phase 2 Trial of Regorafenib as A Single Age...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>43.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41136960</td>\n",
       "      <td>Drug</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>regorafenib (120 mg) (160 mg for second and su...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT02234180  2014-09-30  Regorafenib in Treating Patients With Locally ...   \n",
       "1  NCT03042689  2017-04-17  Study of Regorafenib in Patients With Advanced...   \n",
       "2  NCT02278783  2015-03-31  Phase 2 Trial of Regorafenib in Patients With ...   \n",
       "3  NCT02910843  2017-02-22  Neoadjuvant Treatment With Regorafenib and Cap...   \n",
       "4  NCT02053376  2014-01-31  A Phase 2 Trial of Regorafenib as A Single Age...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  Randomized Phase II Double Blind Study of Adju...              Terminated   \n",
       "1  Phase I Study of Regorafenib in Patients With ...  Active, not recruiting   \n",
       "2  Phase 2 Trial of Regorafenib in Patients With ...              Terminated   \n",
       "3  Neoadjuvant Treatment With Regorafenib and Cap...              Terminated   \n",
       "4  A Phase 2 Trial of Regorafenib as A Single Age...               Completed   \n",
       "\n",
       "     phase  enrollment enrollment_type  number_of_arms  results        id  \\\n",
       "0  Phase 2         3.0          Actual             2.0        1  41125938   \n",
       "1  Phase 1        16.0          Actual             1.0        0  41416446   \n",
       "2  Phase 2         1.0          Actual             1.0        1  41133976   \n",
       "3  Phase 1        25.0          Actual             1.0        0  40969820   \n",
       "4  Phase 2        43.0          Actual             1.0        1  41136960   \n",
       "\n",
       "  intervention_type         name  \\\n",
       "0              Drug  regorafenib   \n",
       "1              Drug  regorafenib   \n",
       "2              Drug  regorafenib   \n",
       "3              Drug  regorafenib   \n",
       "4              Drug  regorafenib   \n",
       "\n",
       "                                         description  \n",
       "0                                           Given PO  \n",
       "1  Regorafenib will be administered on a 28 day c...  \n",
       "2  Patients will be treated with Regorafenib 160 ...  \n",
       "3  Regorafenib dosel level 1-3: day 1 to 14 and d...  \n",
       "4  regorafenib (120 mg) (160 mg for second and su...  "
      ]
     },
     "execution_count": 163,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "regorafenib_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 164,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    108\n",
       "1     26\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 164,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "regorafenib_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Axicabtagene ciloleucel  \n",
    "### Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 165,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "axicabtagene ciloleucel\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    \"axicabtagene ciloleucel\",\n",
    "    \"U2I8T43Y7R\",\n",
    "    \"C120309\",\n",
    "    \"1987398\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 166,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 167,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>3115</th>\n",
       "      <td>41404475</td>\n",
       "      <td>NCT05371093</td>\n",
       "      <td>Biological</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>A single infusion of chimeric antigen receptor...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16771</th>\n",
       "      <td>40909593</td>\n",
       "      <td>NCT05459571</td>\n",
       "      <td>Biological</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>Administered intravenously</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25302</th>\n",
       "      <td>41211251</td>\n",
       "      <td>NCT04432506</td>\n",
       "      <td>Biological</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>Given IV</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79175</th>\n",
       "      <td>41238438</td>\n",
       "      <td>NCT05041309</td>\n",
       "      <td>Biological</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>No investigational product will be administered</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>150190</th>\n",
       "      <td>40947047</td>\n",
       "      <td>NCT04002401</td>\n",
       "      <td>Biological</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>A single infusion of chimeric antigen receptor...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              id       nct_id intervention_type                     name  \\\n",
       "3115    41404475  NCT05371093        Biological  axicabtagene ciloleucel   \n",
       "16771   40909593  NCT05459571        Biological  axicabtagene ciloleucel   \n",
       "25302   41211251  NCT04432506        Biological  axicabtagene ciloleucel   \n",
       "79175   41238438  NCT05041309        Biological  axicabtagene ciloleucel   \n",
       "150190  40947047  NCT04002401        Biological  axicabtagene ciloleucel   \n",
       "\n",
       "                                              description  \n",
       "3115    A single infusion of chimeric antigen receptor...  \n",
       "16771                          Administered intravenously  \n",
       "25302                                            Given IV  \n",
       "79175     No investigational product will be administered  \n",
       "150190  A single infusion of chimeric antigen receptor...  "
      ]
     },
     "execution_count": 167,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 168,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "18"
      ]
     },
     "execution_count": 168,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 169,
   "metadata": {},
   "outputs": [],
   "source": [
    "axicabtagene_ciloleucel_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 170,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "18"
      ]
     },
     "execution_count": 170,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "axicabtagene_ciloleucel_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 171,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT04314843</td>\n",
       "      <td>2020-05-26</td>\n",
       "      <td>Study of Lenzilumab and Axicabtagene Ciloleuce...</td>\n",
       "      <td>A Phase 1/2 Open-label, Multicenter Study of L...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>6.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40969950</td>\n",
       "      <td>Biological</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>A single infusion of chimeric antigen receptor...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04257578</td>\n",
       "      <td>2020-12-02</td>\n",
       "      <td>Acalabrutinib and Anti-CD19 CAR T-cell Therapy...</td>\n",
       "      <td>Acalabrutinib in Combination With Anti-CD19 Ch...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>50.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41171262</td>\n",
       "      <td>Biological</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>Given IV</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03105336</td>\n",
       "      <td>2017-06-20</td>\n",
       "      <td>A Phase 2 Multicenter Study of Axicabtagene Ci...</td>\n",
       "      <td>A Phase 2 Multicenter Study of Axicabtagene Ci...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>159.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41171420</td>\n",
       "      <td>Biological</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>A single infusion of axicabtagene ciloleucel C...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04205838</td>\n",
       "      <td>2020-03-04</td>\n",
       "      <td>Anakinra in Preventing Severe Chimeric Antigen...</td>\n",
       "      <td>IL-1 Receptor Antagonist to Prevent Severe Chi...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>36.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41173786</td>\n",
       "      <td>Biological</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>Given via infusion</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT03704298</td>\n",
       "      <td>2018-11-20</td>\n",
       "      <td>Safety and Efficacy of Axicabtagene Ciloleucel...</td>\n",
       "      <td>A Phase 1/2 Multi-center Study Evaluating the ...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>15.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41423738</td>\n",
       "      <td>Biological</td>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>A single infusion of chimeric antigen receptor...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT04314843  2020-05-26  Study of Lenzilumab and Axicabtagene Ciloleuce...   \n",
       "1  NCT04257578  2020-12-02  Acalabrutinib and Anti-CD19 CAR T-cell Therapy...   \n",
       "2  NCT03105336  2017-06-20  A Phase 2 Multicenter Study of Axicabtagene Ci...   \n",
       "3  NCT04205838  2020-03-04  Anakinra in Preventing Severe Chimeric Antigen...   \n",
       "4  NCT03704298  2018-11-20  Safety and Efficacy of Axicabtagene Ciloleucel...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  A Phase 1/2 Open-label, Multicenter Study of L...              Terminated   \n",
       "1  Acalabrutinib in Combination With Anti-CD19 Ch...              Recruiting   \n",
       "2  A Phase 2 Multicenter Study of Axicabtagene Ci...  Active, not recruiting   \n",
       "3  IL-1 Receptor Antagonist to Prevent Severe Chi...              Recruiting   \n",
       "4  A Phase 1/2 Multi-center Study Evaluating the ...              Terminated   \n",
       "\n",
       "             phase  enrollment enrollment_type  number_of_arms  results  \\\n",
       "0          Phase 1         6.0          Actual             1.0        0   \n",
       "1  Phase 1/Phase 2        50.0     Anticipated             1.0        0   \n",
       "2          Phase 2       159.0          Actual             1.0        0   \n",
       "3          Phase 2        36.0     Anticipated             1.0        0   \n",
       "4          Phase 1        15.0          Actual             1.0        0   \n",
       "\n",
       "         id intervention_type                     name  \\\n",
       "0  40969950        Biological  axicabtagene ciloleucel   \n",
       "1  41171262        Biological  axicabtagene ciloleucel   \n",
       "2  41171420        Biological  axicabtagene ciloleucel   \n",
       "3  41173786        Biological  axicabtagene ciloleucel   \n",
       "4  41423738        Biological  axicabtagene ciloleucel   \n",
       "\n",
       "                                         description  \n",
       "0  A single infusion of chimeric antigen receptor...  \n",
       "1                                           Given IV  \n",
       "2  A single infusion of axicabtagene ciloleucel C...  \n",
       "3                                 Given via infusion  \n",
       "4  A single infusion of chimeric antigen receptor...  "
      ]
     },
     "execution_count": 171,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "axicabtagene_ciloleucel_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 172,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    15\n",
       "1     3\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 172,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "axicabtagene_ciloleucel_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Daratumumab\n",
    "### Relapsed and refractory multiple myeloma"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 173,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Trials found with the following drug names:\n",
      "daratumumab\n"
     ]
    }
   ],
   "source": [
    "# Define the drug names you want to search for\n",
    "drug_names = [\n",
    "    \"DARATUMUMAB\",\n",
    "    \"945721-28-8\",\n",
    "    \"DARATUMUMAB COMPONENT OF DARZALEX FASPRO TM\",\n",
    "    \"DARATUMUMAB [JAN]\",\n",
    "    \"DARATUMUMAB [MI]\",\n",
    "    \"DARATUMUMAB [PURPLE BOOK CDER]\",\n",
    "    \"DARATUMUMAB [USAN]\",\n",
    "    \"DARZALEX\",\n",
    "    \"DARZALEX FASPRO TM COMPONENT DARATUMUMAB\",\n",
    "    \"Daratumumab [WHO-DD]\",\n",
    "    \"HUMAX-CD 38\",\n",
    "    \"HUMAX-CD38\",\n",
    "    \"IMMUNOGLOBULIN G1, ANTI-(HUMAN CD38 (ANTIGEN)) (HUMAN MONOCLONAL 3003-005 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL 3003-005 .KAPPA.-CHAIN, DIMER\",\n",
    "    \"daratumumab [INN]\",\n",
    "    \"4Z63YK6E0E\"\n",
    "]\n",
    "\n",
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "trial_drug_names = filtered_interventions[\"name\"].tolist()\n",
    "\n",
    "# Check if any trial drug names match the given drug names\n",
    "matching_trials = [name for name in drug_names if name in trial_drug_names]\n",
    "\n",
    "if matching_trials:\n",
    "    print(\"Trials found with the following drug names:\")\n",
    "    for name in matching_trials:\n",
    "        print(name)\n",
    "else:\n",
    "    print(\"No trials found with the given drug names.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 174,
   "metadata": {},
   "outputs": [],
   "source": [
    "drug_names = [name.lower() for name in drug_names]\n",
    "\n",
    "matching_trials = filtered_interventions[filtered_interventions[\"name\"].isin(drug_names)].copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 175,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>16199</th>\n",
       "      <td>41064765</td>\n",
       "      <td>NCT05054478</td>\n",
       "      <td>Drug</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>Daratumumab added to induction, first consolid...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17705</th>\n",
       "      <td>40909777</td>\n",
       "      <td>NCT05259839</td>\n",
       "      <td>Drug</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>Subcutaneous Injection (SC)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18397</th>\n",
       "      <td>40909944</td>\n",
       "      <td>NCT04910568</td>\n",
       "      <td>Drug</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>Daratumumab will be administered subcutaneousl...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22374</th>\n",
       "      <td>40910768</td>\n",
       "      <td>NCT03606577</td>\n",
       "      <td>Drug</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>induction: 6 cycles Daratumumab 8/16mg/kg IV o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27991</th>\n",
       "      <td>41212225</td>\n",
       "      <td>NCT04614636</td>\n",
       "      <td>Drug</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>Monoclonal Antibody, CD38, Anti-CD38</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             id       nct_id intervention_type         name  \\\n",
       "16199  41064765  NCT05054478              Drug  daratumumab   \n",
       "17705  40909777  NCT05259839              Drug  daratumumab   \n",
       "18397  40909944  NCT04910568              Drug  daratumumab   \n",
       "22374  40910768  NCT03606577              Drug  daratumumab   \n",
       "27991  41212225  NCT04614636              Drug  daratumumab   \n",
       "\n",
       "                                             description  \n",
       "16199  Daratumumab added to induction, first consolid...  \n",
       "17705                        Subcutaneous Injection (SC)  \n",
       "18397  Daratumumab will be administered subcutaneousl...  \n",
       "22374  induction: 6 cycles Daratumumab 8/16mg/kg IV o...  \n",
       "27991               Monoclonal Antibody, CD38, Anti-CD38  "
      ]
     },
     "execution_count": 175,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 176,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "172"
      ]
     },
     "execution_count": 176,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_trials.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 177,
   "metadata": {},
   "outputs": [],
   "source": [
    "daratumumab_uk = pd.merge(world_trials_results_dummy,matching_trials,on='nct_id',how='inner')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 178,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "172"
      ]
     },
     "execution_count": 178,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "daratumumab_uk.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 179,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT04782687</td>\n",
       "      <td>2021-09-10</td>\n",
       "      <td>Study of Selinexor Plus DRd for Newly Diagnose...</td>\n",
       "      <td>A Phase II Trial of Daratumumab, Lenalidomide ...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>100.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40964136</td>\n",
       "      <td>Drug</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>Patients will receive daratumumab subcutaneous...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04868838</td>\n",
       "      <td>2021-04-20</td>\n",
       "      <td>Daratumumab to Treat Active Lupus Nephritis</td>\n",
       "      <td>A Phase 2 Open-label Trial Evaluating the Effi...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>12.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41134551</td>\n",
       "      <td>Drug</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>1800 mg administered by subcutaneous injection...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT02944565</td>\n",
       "      <td>2017-02-22</td>\n",
       "      <td>Daratumumab in Treating Patients With Multiple...</td>\n",
       "      <td>Daratumumab Infusion Acceleration</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>28.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41136520</td>\n",
       "      <td>Biological</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>Given IV</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT02807558</td>\n",
       "      <td>2016-08-31</td>\n",
       "      <td>A Biomarker-Directed Phase 2 Trial of SY-1425 ...</td>\n",
       "      <td>A Biomarker-Directed Phase 2 Trial of SY-1425,...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>155.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41147841</td>\n",
       "      <td>Drug</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>16 mg/kg/day IV starting on Cycle 1 Day 1 week...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT03591744</td>\n",
       "      <td>2018-10-25</td>\n",
       "      <td>Daratumumab, Bortezomib, Dexamethasone, Pegyla...</td>\n",
       "      <td>Phase 1 Study of Daratumumab When Given in Com...</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>0.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41160552</td>\n",
       "      <td>Biological</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>Given IV</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT04782687  2021-09-10  Study of Selinexor Plus DRd for Newly Diagnose...   \n",
       "1  NCT04868838  2021-04-20        Daratumumab to Treat Active Lupus Nephritis   \n",
       "2  NCT02944565  2017-02-22  Daratumumab in Treating Patients With Multiple...   \n",
       "3  NCT02807558  2016-08-31  A Biomarker-Directed Phase 2 Trial of SY-1425 ...   \n",
       "4  NCT03591744  2018-10-25  Daratumumab, Bortezomib, Dexamethasone, Pegyla...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  A Phase II Trial of Daratumumab, Lenalidomide ...              Recruiting   \n",
       "1  A Phase 2 Open-label Trial Evaluating the Effi...              Recruiting   \n",
       "2                  Daratumumab Infusion Acceleration               Completed   \n",
       "3  A Biomarker-Directed Phase 2 Trial of SY-1425,...  Active, not recruiting   \n",
       "4  Phase 1 Study of Daratumumab When Given in Com...               Withdrawn   \n",
       "\n",
       "     phase  enrollment enrollment_type  number_of_arms  results        id  \\\n",
       "0  Phase 2       100.0     Anticipated             1.0        0  40964136   \n",
       "1  Phase 2        12.0     Anticipated             1.0        0  41134551   \n",
       "2  Phase 2        28.0          Actual             1.0        1  41136520   \n",
       "3  Phase 2       155.0          Actual             3.0        0  41147841   \n",
       "4  Phase 1         0.0          Actual             1.0        0  41160552   \n",
       "\n",
       "  intervention_type         name  \\\n",
       "0              Drug  daratumumab   \n",
       "1              Drug  daratumumab   \n",
       "2        Biological  daratumumab   \n",
       "3              Drug  daratumumab   \n",
       "4        Biological  daratumumab   \n",
       "\n",
       "                                         description  \n",
       "0  Patients will receive daratumumab subcutaneous...  \n",
       "1  1800 mg administered by subcutaneous injection...  \n",
       "2                                           Given IV  \n",
       "3  16 mg/kg/day IV starting on Cycle 1 Day 1 week...  \n",
       "4                                           Given IV  "
      ]
     },
     "execution_count": 179,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "daratumumab_uk.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 180,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    150\n",
       "1     24\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 180,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "daratumumab_uk.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# merging all together"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 181,
   "metadata": {},
   "outputs": [],
   "source": [
    "trials_drugs = pd.concat([daratumumab_uk,\n",
    "                         niraparib_uk,\n",
    "                         avelumab_uk,\n",
    "                         tepotinib_uk,\n",
    "                         venetoclax_uk,\n",
    "                         durvalumab_uk,\n",
    "                         cemiplimab_uk,\n",
    "                         asciminib_uk,\n",
    "                         nivolumab_uk,\n",
    "                         sacituzumab_uk,\n",
    "                         atezolizumab_uk,\n",
    "                         pembrolizumab_uk,\n",
    "                         cabozantinib_uk,\n",
    "                         trifluridine_uk,\n",
    "                         mobocertinib_uk,\n",
    "                         lenvatinib_uk,\n",
    "                         regorafenib_uk,\n",
    "                         axicabtagene_ciloleucel_uk], ignore_index=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 182,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 4971 entries, 0 to 4970\n",
      "Data columns (total 14 columns):\n",
      " #   Column             Non-Null Count  Dtype  \n",
      "---  ------             --------------  -----  \n",
      " 0   nct_id             4971 non-null   object \n",
      " 1   start_date         4971 non-null   object \n",
      " 2   brief_title        4971 non-null   object \n",
      " 3   official_title     4967 non-null   object \n",
      " 4   overall_status     4971 non-null   object \n",
      " 5   phase              4971 non-null   object \n",
      " 6   enrollment         4970 non-null   float64\n",
      " 7   enrollment_type    4970 non-null   object \n",
      " 8   number_of_arms     4969 non-null   float64\n",
      " 9   results            4971 non-null   int64  \n",
      " 10  id                 4971 non-null   int64  \n",
      " 11  intervention_type  4971 non-null   object \n",
      " 12  name               4971 non-null   object \n",
      " 13  description        4761 non-null   object \n",
      "dtypes: float64(2), int64(2), object(10)\n",
      "memory usage: 543.8+ KB\n"
     ]
    }
   ],
   "source": [
    "trials_drugs.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 183,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "4586"
      ]
     },
     "execution_count": 183,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials_drugs.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 184,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>NCT02316106</td>\n",
       "      <td>2015-05-31</td>\n",
       "      <td>A Study to Evaluate 3 Dose Schedules of Daratu...</td>\n",
       "      <td>A Randomized Phase 2 Trial to Evaluate Three D...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>123.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41497114</td>\n",
       "      <td>Drug</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>16 mg/kg administered by IV infusion once ever...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>NCT02316106</td>\n",
       "      <td>2015-05-31</td>\n",
       "      <td>A Study to Evaluate 3 Dose Schedules of Daratu...</td>\n",
       "      <td>A Randomized Phase 2 Trial to Evaluate Three D...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>123.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41497115</td>\n",
       "      <td>Drug</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>16 mg/kg administered by IV infusion once ever...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>208</th>\n",
       "      <td>NCT04655183</td>\n",
       "      <td>2020-12-01</td>\n",
       "      <td>Study of M4344 in Combination With Niraparib</td>\n",
       "      <td>A Phase I Dose Escalation Study of ATR Inhibit...</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>0.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>5.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41332798</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Niraparib will be administered orally once dai...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>209</th>\n",
       "      <td>NCT04655183</td>\n",
       "      <td>2020-12-01</td>\n",
       "      <td>Study of M4344 in Combination With Niraparib</td>\n",
       "      <td>A Phase I Dose Escalation Study of ATR Inhibit...</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>0.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>5.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41332800</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Niraparib will be administered orally, once da...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>210</th>\n",
       "      <td>NCT04655183</td>\n",
       "      <td>2020-12-01</td>\n",
       "      <td>Study of M4344 in Combination With Niraparib</td>\n",
       "      <td>A Phase I Dose Escalation Study of ATR Inhibit...</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>0.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>5.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41332801</td>\n",
       "      <td>Drug</td>\n",
       "      <td>niraparib</td>\n",
       "      <td>Niraparib will be administered as single agent...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4912</th>\n",
       "      <td>NCT04170556</td>\n",
       "      <td>2020-03-16</td>\n",
       "      <td>Regorafenib Followed by Nivolumab in Patients ...</td>\n",
       "      <td>The GOING Study: Regorafenib Followed by Nivol...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>78.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40770834</td>\n",
       "      <td>Drug</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>Regorafenib 160 mg/day 3 weeks on and 1 week off</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4926</th>\n",
       "      <td>NCT03899428</td>\n",
       "      <td>2019-05-02</td>\n",
       "      <td>Immune Checkpoint Therapy vs Target Therapy in...</td>\n",
       "      <td>A Randomized, Open-label Trial Comparing Immun...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>30.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40780665</td>\n",
       "      <td>Drug</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>Prescribed by physician.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4936</th>\n",
       "      <td>NCT03555149</td>\n",
       "      <td>2018-09-27</td>\n",
       "      <td>A Study Evaluating the Efficacy and Safety of ...</td>\n",
       "      <td>A Phase Ib/II, Open-Label, Multicenter, Random...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>94.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>8.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41259680</td>\n",
       "      <td>Drug</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>Regorafenib will be administered orally on Day...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4942</th>\n",
       "      <td>NCT04757363</td>\n",
       "      <td>2021-02-11</td>\n",
       "      <td>A Study of Nivolumab Combined With FOLFOX and ...</td>\n",
       "      <td>A Phase II Study of Nivolumab in Combination W...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>39.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40944113</td>\n",
       "      <td>Drug</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>regorafenib (80 mg on days 1-21 of the 28-day ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4943</th>\n",
       "      <td>NCT03406871</td>\n",
       "      <td>2018-01-25</td>\n",
       "      <td>Regorafenib and Nivolumab Simultaneous Combina...</td>\n",
       "      <td>Regorafenib and Nivolumab Simultaneous Combina...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>50.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41098020</td>\n",
       "      <td>Drug</td>\n",
       "      <td>regorafenib</td>\n",
       "      <td>One course will last 28 days. Oral administrat...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>385 rows × 14 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "           nct_id  start_date  \\\n",
       "91    NCT02316106  2015-05-31   \n",
       "92    NCT02316106  2015-05-31   \n",
       "208   NCT04655183  2020-12-01   \n",
       "209   NCT04655183  2020-12-01   \n",
       "210   NCT04655183  2020-12-01   \n",
       "...           ...         ...   \n",
       "4912  NCT04170556  2020-03-16   \n",
       "4926  NCT03899428  2019-05-02   \n",
       "4936  NCT03555149  2018-09-27   \n",
       "4942  NCT04757363  2021-02-11   \n",
       "4943  NCT03406871  2018-01-25   \n",
       "\n",
       "                                            brief_title  \\\n",
       "91    A Study to Evaluate 3 Dose Schedules of Daratu...   \n",
       "92    A Study to Evaluate 3 Dose Schedules of Daratu...   \n",
       "208        Study of M4344 in Combination With Niraparib   \n",
       "209        Study of M4344 in Combination With Niraparib   \n",
       "210        Study of M4344 in Combination With Niraparib   \n",
       "...                                                 ...   \n",
       "4912  Regorafenib Followed by Nivolumab in Patients ...   \n",
       "4926  Immune Checkpoint Therapy vs Target Therapy in...   \n",
       "4936  A Study Evaluating the Efficacy and Safety of ...   \n",
       "4942  A Study of Nivolumab Combined With FOLFOX and ...   \n",
       "4943  Regorafenib and Nivolumab Simultaneous Combina...   \n",
       "\n",
       "                                         official_title  \\\n",
       "91    A Randomized Phase 2 Trial to Evaluate Three D...   \n",
       "92    A Randomized Phase 2 Trial to Evaluate Three D...   \n",
       "208   A Phase I Dose Escalation Study of ATR Inhibit...   \n",
       "209   A Phase I Dose Escalation Study of ATR Inhibit...   \n",
       "210   A Phase I Dose Escalation Study of ATR Inhibit...   \n",
       "...                                                 ...   \n",
       "4912  The GOING Study: Regorafenib Followed by Nivol...   \n",
       "4926  A Randomized, Open-label Trial Comparing Immun...   \n",
       "4936  A Phase Ib/II, Open-Label, Multicenter, Random...   \n",
       "4942  A Phase II Study of Nivolumab in Combination W...   \n",
       "4943  Regorafenib and Nivolumab Simultaneous Combina...   \n",
       "\n",
       "              overall_status            phase  enrollment enrollment_type  \\\n",
       "91    Active, not recruiting          Phase 2       123.0          Actual   \n",
       "92    Active, not recruiting          Phase 2       123.0          Actual   \n",
       "208                Withdrawn  Phase 1/Phase 2         0.0          Actual   \n",
       "209                Withdrawn  Phase 1/Phase 2         0.0          Actual   \n",
       "210                Withdrawn  Phase 1/Phase 2         0.0          Actual   \n",
       "...                      ...              ...         ...             ...   \n",
       "4912  Active, not recruiting  Phase 1/Phase 2        78.0     Anticipated   \n",
       "4926              Recruiting          Phase 2        30.0     Anticipated   \n",
       "4936              Terminated  Phase 1/Phase 2        94.0          Actual   \n",
       "4942  Active, not recruiting          Phase 2        39.0          Actual   \n",
       "4943               Completed  Phase 1/Phase 2        50.0          Actual   \n",
       "\n",
       "      number_of_arms  results        id intervention_type         name  \\\n",
       "91               3.0        0  41497114              Drug  daratumumab   \n",
       "92               3.0        0  41497115              Drug  daratumumab   \n",
       "208              5.0        0  41332798              Drug    niraparib   \n",
       "209              5.0        0  41332800              Drug    niraparib   \n",
       "210              5.0        0  41332801              Drug    niraparib   \n",
       "...              ...      ...       ...               ...          ...   \n",
       "4912             1.0        0  40770834              Drug  regorafenib   \n",
       "4926             2.0        0  40780665              Drug  regorafenib   \n",
       "4936             8.0        0  41259680              Drug  regorafenib   \n",
       "4942             1.0        0  40944113              Drug  regorafenib   \n",
       "4943             1.0        0  41098020              Drug  regorafenib   \n",
       "\n",
       "                                            description  \n",
       "91    16 mg/kg administered by IV infusion once ever...  \n",
       "92    16 mg/kg administered by IV infusion once ever...  \n",
       "208   Niraparib will be administered orally once dai...  \n",
       "209   Niraparib will be administered orally, once da...  \n",
       "210   Niraparib will be administered as single agent...  \n",
       "...                                                 ...  \n",
       "4912   Regorafenib 160 mg/day 3 weeks on and 1 week off  \n",
       "4926                           Prescribed by physician.  \n",
       "4936  Regorafenib will be administered orally on Day...  \n",
       "4942  regorafenib (80 mg on days 1-21 of the 28-day ...  \n",
       "4943  One course will last 28 days. Oral administrat...  \n",
       "\n",
       "[385 rows x 14 columns]"
      ]
     },
     "execution_count": 184,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Find duplicate 'nct_id' values in 'trials_drugs'\n",
    "duplicate_nct_id = trials_drugs.duplicated(subset=['nct_id'])\n",
    "\n",
    "# Filter the DataFrame to show only the duplicate 'nct_id' rows\n",
    "duplicate_nct_id_df = trials_drugs[duplicate_nct_id]\n",
    "\n",
    "duplicate_nct_id_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 185,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Filter the DataFrame to keep only the first instance of each duplicated 'nct_id'\n",
    "trials_drugs = trials_drugs[~duplicate_nct_id]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 186,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    3756\n",
       "1     830\n",
       "Name: results, dtype: int64"
      ]
     },
     "execution_count": 186,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials_drugs.results.value_counts()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "From the 4586 trials, 830 have released results."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 187,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "([<matplotlib.patches.Wedge at 0x7efe8e16c3a0>,\n",
       "  <matplotlib.patches.Wedge at 0x7efe8e15f340>],\n",
       " [Text(-0.5922824588165858, 0.9269312212770587, ''),\n",
       "  Text(0.592282415423803, -0.9269312490038006, '')])"
      ]
     },
     "execution_count": 187,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'Proportion of Trials with any Reported Results \\n- Studies with drugs approved in the UK 2022')"
      ]
     },
     "execution_count": 187,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.patches.Circle at 0x7efe8e1a1d90>"
      ]
     },
     "execution_count": 187,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0, '18.1%')"
      ]
     },
     "execution_count": 187,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "(-1.1061953877807993,\n",
       " 1.1037662232448247,\n",
       " -1.1054899300839367,\n",
       " 1.1002614252420921)"
      ]
     },
     "execution_count": 187,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Calculate the counts\n",
    "count_results = trials_drugs['results'].sum()\n",
    "count_no_results = len(trials_drugs) - count_results\n",
    "\n",
    "# Calculate the proportions\n",
    "total_trials = len(trials_drugs)\n",
    "proportion_results = count_results / total_trials\n",
    "proportion_no_results = count_no_results / total_trials\n",
    "\n",
    "# Create the donut chart\n",
    "labels = ['Results Reported', 'Results Not Reported']\n",
    "sizes = [proportion_results, proportion_no_results]\n",
    "colors = ['#fefe06', '#262626']\n",
    "outline_color = '#000000'  # Outline color\n",
    "\n",
    "plt.pie(sizes, labels=None, colors=colors, startangle=90, wedgeprops={'edgecolor': outline_color, 'linewidth': 2})\n",
    "plt.title('Proportion of Trials with any Reported Results \\n- Studies with drugs approved in the UK 2022', fontsize=15)\n",
    "\n",
    "# Draw a white circle at the center to create the donut shape\n",
    "centre_circle = plt.Circle((0, 0), 0.70, fc='white', ec=outline_color, lw=2)  # Add outline to the center circle\n",
    "fig = plt.gcf()\n",
    "fig.gca().add_artist(centre_circle)\n",
    "\n",
    "# Display the value of \"Results Reported\" in the middle of the donut chart\n",
    "plt.text(0, 0, f'{proportion_results*100:.1f}%', horizontalalignment='center', verticalalignment='center', fontsize=30, color='black')\n",
    "\n",
    "# Set aspect ratio to be equal so that the pie is drawn as a circle\n",
    "plt.axis('equal')\n",
    "\n",
    "# Save the chart as an image file\n",
    "plt.savefig('/project/approved_drugs_charts_data/donut_chart.png', dpi=300)\n",
    "\n",
    "# Display the chart\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 188,
   "metadata": {},
   "outputs": [],
   "source": [
    "trials_drugs.to_csv(r'/project/approved_drugs_charts_data/trials_drugs.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 189,
   "metadata": {},
   "outputs": [],
   "source": [
    "trials_results = trials_drugs[trials_drugs['results']==1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 190,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "830"
      ]
     },
     "execution_count": 190,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials_results.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 191,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT02944565</td>\n",
       "      <td>2017-02-22</td>\n",
       "      <td>Daratumumab in Treating Patients With Multiple...</td>\n",
       "      <td>Daratumumab Infusion Acceleration</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>28.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41136520</td>\n",
       "      <td>Biological</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>Given IV</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>NCT03481556</td>\n",
       "      <td>2018-04-12</td>\n",
       "      <td>Study of Melphalan Flufenamide (Melflufen) + D...</td>\n",
       "      <td>An Open-Label Phase 1/2a Study of the Safety a...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>56.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41422537</td>\n",
       "      <td>Drug</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>Intravenous infusion</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>NCT03439293</td>\n",
       "      <td>2018-03-13</td>\n",
       "      <td>A Study of Ixazomib+Daratumumab+Dexamethasone ...</td>\n",
       "      <td>A Phase 2, Open-Label Study of Ixazomib+Daratu...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>61.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41289776</td>\n",
       "      <td>Drug</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>Daratumumab IV infusion.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>NCT02413489</td>\n",
       "      <td>2015-09-02</td>\n",
       "      <td>An Efficacy and Safety Proof of Concept Study ...</td>\n",
       "      <td>An Open Label, Phase 2 Study to Evaluate Effic...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>36.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1</td>\n",
       "      <td>40999634</td>\n",
       "      <td>Drug</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>Daratumumab 16 mg/kg will be administered as i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>NCT02488759</td>\n",
       "      <td>2015-10-13</td>\n",
       "      <td>An Investigational Immuno-therapy Study to Inv...</td>\n",
       "      <td>Non-Comparative, Open-Label, Multiple Cohort, ...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>578.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>5.0</td>\n",
       "      <td>1</td>\n",
       "      <td>41006716</td>\n",
       "      <td>Drug</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         nct_id  start_date  \\\n",
       "2   NCT02944565  2017-02-22   \n",
       "10  NCT03481556  2018-04-12   \n",
       "20  NCT03439293  2018-03-13   \n",
       "21  NCT02413489  2015-09-02   \n",
       "25  NCT02488759  2015-10-13   \n",
       "\n",
       "                                          brief_title  \\\n",
       "2   Daratumumab in Treating Patients With Multiple...   \n",
       "10  Study of Melphalan Flufenamide (Melflufen) + D...   \n",
       "20  A Study of Ixazomib+Daratumumab+Dexamethasone ...   \n",
       "21  An Efficacy and Safety Proof of Concept Study ...   \n",
       "25  An Investigational Immuno-therapy Study to Inv...   \n",
       "\n",
       "                                       official_title          overall_status  \\\n",
       "2                   Daratumumab Infusion Acceleration               Completed   \n",
       "10  An Open-Label Phase 1/2a Study of the Safety a...              Terminated   \n",
       "20  A Phase 2, Open-Label Study of Ixazomib+Daratu...  Active, not recruiting   \n",
       "21  An Open Label, Phase 2 Study to Evaluate Effic...              Terminated   \n",
       "25  Non-Comparative, Open-Label, Multiple Cohort, ...               Completed   \n",
       "\n",
       "              phase  enrollment enrollment_type  number_of_arms  results  \\\n",
       "2           Phase 2        28.0          Actual             1.0        1   \n",
       "10  Phase 1/Phase 2        56.0          Actual             2.0        1   \n",
       "20          Phase 2        61.0          Actual             1.0        1   \n",
       "21          Phase 2        36.0          Actual             1.0        1   \n",
       "25  Phase 1/Phase 2       578.0          Actual             5.0        1   \n",
       "\n",
       "          id intervention_type         name  \\\n",
       "2   41136520        Biological  daratumumab   \n",
       "10  41422537              Drug  daratumumab   \n",
       "20  41289776              Drug  daratumumab   \n",
       "21  40999634              Drug  daratumumab   \n",
       "25  41006716              Drug  daratumumab   \n",
       "\n",
       "                                          description  \n",
       "2                                            Given IV  \n",
       "10                               Intravenous infusion  \n",
       "20                           Daratumumab IV infusion.  \n",
       "21  Daratumumab 16 mg/kg will be administered as i...  \n",
       "25                                                NaN  "
      ]
     },
     "execution_count": 191,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials_results.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 192,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_268/3339586755.py:2: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  trials_results['race_dum'] = trials_results['nct_id'].isin(race_df['nct_id']).astype(int)\n"
     ]
    }
   ],
   "source": [
    "# Create the 'race_dum' column in 'trials_results'\n",
    "trials_results['race_dum'] = trials_results['nct_id'].isin(race_df['nct_id']).astype(int)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 193,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "830"
      ]
     },
     "execution_count": 193,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials_results.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 194,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1    704\n",
       "0    126\n",
       "Name: race_dum, dtype: int64"
      ]
     },
     "execution_count": 194,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials_results.race_dum.value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 195,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "([<matplotlib.patches.Wedge at 0x7efe8d838880>,\n",
       "  <matplotlib.patches.Wedge at 0x7efe8d838d60>],\n",
       " [Text(-0.5049461654146222, -0.9772560411852511, ''),\n",
       "  Text(0.5049462111632783, 0.9772560175470143, '')])"
      ]
     },
     "execution_count": 195,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'Proportion of Trials with Race Results of those that reported results \\n- Studies with drugs approved in the UK 2022')"
      ]
     },
     "execution_count": 195,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.patches.Circle at 0x7efe8d90e850>"
      ]
     },
     "execution_count": 195,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0, '84.8%')"
      ]
     },
     "execution_count": 195,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "(-1.1065561825637125,\n",
       " 1.1047784656704585,\n",
       " -1.1059063445063606,\n",
       " 1.100281254500303)"
      ]
     },
     "execution_count": 195,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Calculate the counts\n",
    "count_results = trials_results['race_dum'].sum()\n",
    "count_no_results = len(trials_results) - count_results\n",
    "\n",
    "# Calculate the proportions\n",
    "total_trials = len(trials_results)\n",
    "proportion_results = count_results / total_trials\n",
    "proportion_no_results = count_no_results / total_trials\n",
    "\n",
    "# Create the donut chart\n",
    "labels = ['Race Results Reported', 'Race Results Not Reported']\n",
    "sizes = [proportion_results, proportion_no_results]\n",
    "colors = ['#fefe06', '#262626']\n",
    "outline_color = '#000000'  # Outline color\n",
    "\n",
    "plt.pie(sizes, labels=None, colors=colors, startangle=90, wedgeprops={'edgecolor': outline_color, 'linewidth': 2})\n",
    "plt.title('Proportion of Trials with Race Results of those that reported results \\n- Studies with drugs approved in the UK 2022', fontsize=15)\n",
    "\n",
    "# Draw a white circle at the center to create the donut shape\n",
    "centre_circle = plt.Circle((0, 0), 0.70, fc='white', ec=outline_color, lw=2)  # Add outline to the center circle\n",
    "fig = plt.gcf()\n",
    "fig.gca().add_artist(centre_circle)\n",
    "\n",
    "# Display the value of \"Results Reported\" in the middle of the donut chart\n",
    "plt.text(0, 0, f'{proportion_results*100:.1f}%', horizontalalignment='center', verticalalignment='center', fontsize=30, color='black')\n",
    "\n",
    "# Set aspect ratio to be equal so that the pie is drawn as a circle\n",
    "plt.axis('equal')\n",
    "\n",
    "# Save the chart as an image file\n",
    "plt.savefig('/project/approved_drugs_charts_data/donut_chart_race.png', dpi=300)\n",
    "\n",
    "# Display the chart\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 196,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Merge the two DataFrames on 'nct_id'\n",
    "trials_drugs_race = pd.merge(race_df, trials_results, on='nct_id')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 197,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>category</th>\n",
       "      <th>title</th>\n",
       "      <th>units</th>\n",
       "      <th>param_type</th>\n",
       "      <th>param_value</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "      <th>race_dum</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT04099277</td>\n",
       "      <td>Hispanic or Latino</td>\n",
       "      <td>Ethnicity (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>1.0</td>\n",
       "      <td>2019-10-28</td>\n",
       "      <td>A Study of LY3435151 in Participants With Soli...</td>\n",
       "      <td>A Phase 1a/1b Study of LY3435151 Administered ...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>4.0</td>\n",
       "      <td>1</td>\n",
       "      <td>40828836</td>\n",
       "      <td>Drug</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Administered IV</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04099277</td>\n",
       "      <td>Not Hispanic or Latino</td>\n",
       "      <td>Ethnicity (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2019-10-28</td>\n",
       "      <td>A Study of LY3435151 in Participants With Soli...</td>\n",
       "      <td>A Phase 1a/1b Study of LY3435151 Administered ...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>4.0</td>\n",
       "      <td>1</td>\n",
       "      <td>40828836</td>\n",
       "      <td>Drug</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Administered IV</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT04099277</td>\n",
       "      <td>Unknown or Not Reported</td>\n",
       "      <td>Ethnicity (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>1.0</td>\n",
       "      <td>2019-10-28</td>\n",
       "      <td>A Study of LY3435151 in Participants With Soli...</td>\n",
       "      <td>A Phase 1a/1b Study of LY3435151 Administered ...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>4.0</td>\n",
       "      <td>1</td>\n",
       "      <td>40828836</td>\n",
       "      <td>Drug</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Administered IV</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04099277</td>\n",
       "      <td>American Indian or Alaska Native</td>\n",
       "      <td>Race (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2019-10-28</td>\n",
       "      <td>A Study of LY3435151 in Participants With Soli...</td>\n",
       "      <td>A Phase 1a/1b Study of LY3435151 Administered ...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>4.0</td>\n",
       "      <td>1</td>\n",
       "      <td>40828836</td>\n",
       "      <td>Drug</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Administered IV</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT04099277</td>\n",
       "      <td>Asian</td>\n",
       "      <td>Race (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>1.0</td>\n",
       "      <td>2019-10-28</td>\n",
       "      <td>A Study of LY3435151 in Participants With Soli...</td>\n",
       "      <td>A Phase 1a/1b Study of LY3435151 Administered ...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>4.0</td>\n",
       "      <td>1</td>\n",
       "      <td>40828836</td>\n",
       "      <td>Drug</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Administered IV</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id                          category                title  \\\n",
       "0  NCT04099277                Hispanic or Latino  Ethnicity (NIH/OMB)   \n",
       "1  NCT04099277            Not Hispanic or Latino  Ethnicity (NIH/OMB)   \n",
       "2  NCT04099277           Unknown or Not Reported  Ethnicity (NIH/OMB)   \n",
       "3  NCT04099277  American Indian or Alaska Native       Race (NIH/OMB)   \n",
       "4  NCT04099277                             Asian       Race (NIH/OMB)   \n",
       "\n",
       "          units             param_type param_value  start_date  \\\n",
       "0  Participants  Count of Participants         1.0  2019-10-28   \n",
       "1  Participants  Count of Participants         0.0  2019-10-28   \n",
       "2  Participants  Count of Participants         1.0  2019-10-28   \n",
       "3  Participants  Count of Participants         0.0  2019-10-28   \n",
       "4  Participants  Count of Participants         1.0  2019-10-28   \n",
       "\n",
       "                                         brief_title  \\\n",
       "0  A Study of LY3435151 in Participants With Soli...   \n",
       "1  A Study of LY3435151 in Participants With Soli...   \n",
       "2  A Study of LY3435151 in Participants With Soli...   \n",
       "3  A Study of LY3435151 in Participants With Soli...   \n",
       "4  A Study of LY3435151 in Participants With Soli...   \n",
       "\n",
       "                                      official_title overall_status    phase  \\\n",
       "0  A Phase 1a/1b Study of LY3435151 Administered ...     Terminated  Phase 1   \n",
       "1  A Phase 1a/1b Study of LY3435151 Administered ...     Terminated  Phase 1   \n",
       "2  A Phase 1a/1b Study of LY3435151 Administered ...     Terminated  Phase 1   \n",
       "3  A Phase 1a/1b Study of LY3435151 Administered ...     Terminated  Phase 1   \n",
       "4  A Phase 1a/1b Study of LY3435151 Administered ...     Terminated  Phase 1   \n",
       "\n",
       "   enrollment enrollment_type  number_of_arms  results        id  \\\n",
       "0         2.0          Actual             4.0        1  40828836   \n",
       "1         2.0          Actual             4.0        1  40828836   \n",
       "2         2.0          Actual             4.0        1  40828836   \n",
       "3         2.0          Actual             4.0        1  40828836   \n",
       "4         2.0          Actual             4.0        1  40828836   \n",
       "\n",
       "  intervention_type           name      description  race_dum  \n",
       "0              Drug  pembrolizumab  Administered IV         1  \n",
       "1              Drug  pembrolizumab  Administered IV         1  \n",
       "2              Drug  pembrolizumab  Administered IV         1  \n",
       "3              Drug  pembrolizumab  Administered IV         1  \n",
       "4              Drug  pembrolizumab  Administered IV         1  "
      ]
     },
     "execution_count": 197,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials_drugs_race.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 198,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "704"
      ]
     },
     "execution_count": 198,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials_drugs_race.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 199,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "Int64Index: 21812 entries, 0 to 21811\n",
      "Data columns (total 20 columns):\n",
      " #   Column             Non-Null Count  Dtype  \n",
      "---  ------             --------------  -----  \n",
      " 0   nct_id             21812 non-null  object \n",
      " 1   category           21812 non-null  object \n",
      " 2   title              21812 non-null  object \n",
      " 3   units              21812 non-null  object \n",
      " 4   param_type         21812 non-null  object \n",
      " 5   param_value        21762 non-null  object \n",
      " 6   start_date         21812 non-null  object \n",
      " 7   brief_title        21812 non-null  object \n",
      " 8   official_title     21812 non-null  object \n",
      " 9   overall_status     21812 non-null  object \n",
      " 10  phase              21812 non-null  object \n",
      " 11  enrollment         21812 non-null  float64\n",
      " 12  enrollment_type    21812 non-null  object \n",
      " 13  number_of_arms     21812 non-null  float64\n",
      " 14  results            21812 non-null  int64  \n",
      " 15  id                 21812 non-null  int64  \n",
      " 16  intervention_type  21812 non-null  object \n",
      " 17  name               21812 non-null  object \n",
      " 18  description        18676 non-null  object \n",
      " 19  race_dum           21812 non-null  int64  \n",
      "dtypes: float64(2), int64(3), object(15)\n",
      "memory usage: 3.5+ MB\n"
     ]
    }
   ],
   "source": [
    "trials_drugs_race.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 200,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Replace NaN values with 0 in 'param_value' column\n",
    "trials_drugs_race['param_value'] = trials_drugs_race['param_value'].fillna(0).astype(int)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 201,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_268/2677254127.py:1: FutureWarning: The default value of numeric_only in DataFrameGroupBy.sum is deprecated. In a future version, numeric_only will default to False. Either specify numeric_only or select only columns which should be valid for the function.\n",
      "  grouped_df = trials_drugs_race.groupby(['nct_id','category','title','units','param_type', 'start_date','brief_title','official_title','overall_status','phase','enrollment_type','id','intervention_type','name']).sum()\n"
     ]
    }
   ],
   "source": [
    "grouped_df = trials_drugs_race.groupby(['nct_id','category','title','units','param_type', 'start_date','brief_title','official_title','overall_status','phase','enrollment_type','id','intervention_type','name']).sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 202,
   "metadata": {},
   "outputs": [],
   "source": [
    "grouped_df.reset_index(inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 203,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>category</th>\n",
       "      <th>title</th>\n",
       "      <th>units</th>\n",
       "      <th>param_type</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>param_value</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>race_dum</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00946153</td>\n",
       "      <td>American Indian or Alaska Native</td>\n",
       "      <td>Race (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>2009-07-24</td>\n",
       "      <td>Study of Lenvatinib (E7080) in Participants Wi...</td>\n",
       "      <td>Phase I/II Study of E7080 in Patients With Adv...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>Actual</td>\n",
       "      <td>41355121</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>0</td>\n",
       "      <td>396.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>6</td>\n",
       "      <td>6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT00946153</td>\n",
       "      <td>Asian</td>\n",
       "      <td>Race (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>2009-07-24</td>\n",
       "      <td>Study of Lenvatinib (E7080) in Participants Wi...</td>\n",
       "      <td>Phase I/II Study of E7080 in Patients With Adv...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>Actual</td>\n",
       "      <td>41355121</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>132</td>\n",
       "      <td>396.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>6</td>\n",
       "      <td>6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT00946153</td>\n",
       "      <td>Black or African American</td>\n",
       "      <td>Race (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>2009-07-24</td>\n",
       "      <td>Study of Lenvatinib (E7080) in Participants Wi...</td>\n",
       "      <td>Phase I/II Study of E7080 in Patients With Adv...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>Actual</td>\n",
       "      <td>41355121</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>0</td>\n",
       "      <td>396.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>6</td>\n",
       "      <td>6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT00946153</td>\n",
       "      <td>More than one race</td>\n",
       "      <td>Race (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>2009-07-24</td>\n",
       "      <td>Study of Lenvatinib (E7080) in Participants Wi...</td>\n",
       "      <td>Phase I/II Study of E7080 in Patients With Adv...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>Actual</td>\n",
       "      <td>41355121</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>0</td>\n",
       "      <td>396.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>6</td>\n",
       "      <td>6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT00946153</td>\n",
       "      <td>Native Hawaiian or Other Pacific Islander</td>\n",
       "      <td>Race (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>2009-07-24</td>\n",
       "      <td>Study of Lenvatinib (E7080) in Participants Wi...</td>\n",
       "      <td>Phase I/II Study of E7080 in Patients With Adv...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>Actual</td>\n",
       "      <td>41355121</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>0</td>\n",
       "      <td>396.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>6</td>\n",
       "      <td>6</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id                                   category           title  \\\n",
       "0  NCT00946153           American Indian or Alaska Native  Race (NIH/OMB)   \n",
       "1  NCT00946153                                      Asian  Race (NIH/OMB)   \n",
       "2  NCT00946153                  Black or African American  Race (NIH/OMB)   \n",
       "3  NCT00946153                         More than one race  Race (NIH/OMB)   \n",
       "4  NCT00946153  Native Hawaiian or Other Pacific Islander  Race (NIH/OMB)   \n",
       "\n",
       "          units             param_type  start_date  \\\n",
       "0  Participants  Count of Participants  2009-07-24   \n",
       "1  Participants  Count of Participants  2009-07-24   \n",
       "2  Participants  Count of Participants  2009-07-24   \n",
       "3  Participants  Count of Participants  2009-07-24   \n",
       "4  Participants  Count of Participants  2009-07-24   \n",
       "\n",
       "                                         brief_title  \\\n",
       "0  Study of Lenvatinib (E7080) in Participants Wi...   \n",
       "1  Study of Lenvatinib (E7080) in Participants Wi...   \n",
       "2  Study of Lenvatinib (E7080) in Participants Wi...   \n",
       "3  Study of Lenvatinib (E7080) in Participants Wi...   \n",
       "4  Study of Lenvatinib (E7080) in Participants Wi...   \n",
       "\n",
       "                                      official_title overall_status  \\\n",
       "0  Phase I/II Study of E7080 in Patients With Adv...      Completed   \n",
       "1  Phase I/II Study of E7080 in Patients With Adv...      Completed   \n",
       "2  Phase I/II Study of E7080 in Patients With Adv...      Completed   \n",
       "3  Phase I/II Study of E7080 in Patients With Adv...      Completed   \n",
       "4  Phase I/II Study of E7080 in Patients With Adv...      Completed   \n",
       "\n",
       "             phase enrollment_type        id intervention_type        name  \\\n",
       "0  Phase 1/Phase 2          Actual  41355121              Drug  lenvatinib   \n",
       "1  Phase 1/Phase 2          Actual  41355121              Drug  lenvatinib   \n",
       "2  Phase 1/Phase 2          Actual  41355121              Drug  lenvatinib   \n",
       "3  Phase 1/Phase 2          Actual  41355121              Drug  lenvatinib   \n",
       "4  Phase 1/Phase 2          Actual  41355121              Drug  lenvatinib   \n",
       "\n",
       "   param_value  enrollment  number_of_arms  results  race_dum  \n",
       "0            0       396.0             6.0        6         6  \n",
       "1          132       396.0             6.0        6         6  \n",
       "2            0       396.0             6.0        6         6  \n",
       "3            0       396.0             6.0        6         6  \n",
       "4            0       396.0             6.0        6         6  "
      ]
     },
     "execution_count": 203,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grouped_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 204,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "704"
      ]
     },
     "execution_count": 204,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grouped_df.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 205,
   "metadata": {},
   "outputs": [],
   "source": [
    "grouped_df.to_csv('/project/approved_drugs_charts_data/grouped_race_drug.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Using OpenAI API, I used the Chat GPT Google Docs extension and classified the \"category\" column into 10 different Race/Erhnicity groups (White/ White Heritage, Black/ Black Heritage, Hispanic/ Latino, Asian/ Asian Heritage, American Indian/ Alaska Native, Middle Eastern, Hawaiian/ Other Pacific Islander, Other, Mixed, Unknown or Not Reported\") using the following prompt:\n",
    "\n",
    "=GPT_CLASSIFY(cell,\"White/ White Heritage, Black/ Black Heritage, Hispanic/ Latino, Asian/ Asian Heritage, American Indian/ Alaska Native, Middle Eastern, Hawaiian/ Other Pacific Islander, Other, Mixed, Unknown or Not Reported\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 206,
   "metadata": {},
   "outputs": [],
   "source": [
    "grouped_race = pd.read_csv('https://www.dropbox.com/scl/fi/aevsyt3n5reyu3n8xaism/trials_drugs_race_chat.csv?rlkey=s5ojzr12p9fv142k6aggasbn7&dl=1')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 207,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>category</th>\n",
       "      <th>race/ethnicity</th>\n",
       "      <th>title</th>\n",
       "      <th>units</th>\n",
       "      <th>param_type</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>param_value</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>race_dum</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00946153</td>\n",
       "      <td>American Indian or Alaska Native</td>\n",
       "      <td>American Indian/ Alaska Native</td>\n",
       "      <td>Race (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>24/07/2009</td>\n",
       "      <td>Study of Lenvatinib (E7080) in Participants Wi...</td>\n",
       "      <td>Phase I/II Study of E7080 in Patients With Adv...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>Actual</td>\n",
       "      <td>41355121</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>0</td>\n",
       "      <td>396</td>\n",
       "      <td>6</td>\n",
       "      <td>6</td>\n",
       "      <td>6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT00946153</td>\n",
       "      <td>Asian</td>\n",
       "      <td>Asian/ Asian Heritage</td>\n",
       "      <td>Race (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>24/07/2009</td>\n",
       "      <td>Study of Lenvatinib (E7080) in Participants Wi...</td>\n",
       "      <td>Phase I/II Study of E7080 in Patients With Adv...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>Actual</td>\n",
       "      <td>41355121</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>132</td>\n",
       "      <td>396</td>\n",
       "      <td>6</td>\n",
       "      <td>6</td>\n",
       "      <td>6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT00946153</td>\n",
       "      <td>Black or African American</td>\n",
       "      <td>Black/ Black Heritage</td>\n",
       "      <td>Race (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>24/07/2009</td>\n",
       "      <td>Study of Lenvatinib (E7080) in Participants Wi...</td>\n",
       "      <td>Phase I/II Study of E7080 in Patients With Adv...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>Actual</td>\n",
       "      <td>41355121</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>0</td>\n",
       "      <td>396</td>\n",
       "      <td>6</td>\n",
       "      <td>6</td>\n",
       "      <td>6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT00946153</td>\n",
       "      <td>More than one race</td>\n",
       "      <td>Mixed</td>\n",
       "      <td>Race (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>24/07/2009</td>\n",
       "      <td>Study of Lenvatinib (E7080) in Participants Wi...</td>\n",
       "      <td>Phase I/II Study of E7080 in Patients With Adv...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>Actual</td>\n",
       "      <td>41355121</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>0</td>\n",
       "      <td>396</td>\n",
       "      <td>6</td>\n",
       "      <td>6</td>\n",
       "      <td>6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT00946153</td>\n",
       "      <td>Native Hawaiian or Other Pacific Islander</td>\n",
       "      <td>Hawaiian/ Other Pacific Islander</td>\n",
       "      <td>Race (NIH/OMB)</td>\n",
       "      <td>Participants</td>\n",
       "      <td>Count of Participants</td>\n",
       "      <td>24/07/2009</td>\n",
       "      <td>Study of Lenvatinib (E7080) in Participants Wi...</td>\n",
       "      <td>Phase I/II Study of E7080 in Patients With Adv...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>Actual</td>\n",
       "      <td>41355121</td>\n",
       "      <td>Drug</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>0</td>\n",
       "      <td>396</td>\n",
       "      <td>6</td>\n",
       "      <td>6</td>\n",
       "      <td>6</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id                                   category  \\\n",
       "0  NCT00946153           American Indian or Alaska Native   \n",
       "1  NCT00946153                                      Asian   \n",
       "2  NCT00946153                  Black or African American   \n",
       "3  NCT00946153                         More than one race   \n",
       "4  NCT00946153  Native Hawaiian or Other Pacific Islander   \n",
       "\n",
       "                     race/ethnicity           title         units  \\\n",
       "0    American Indian/ Alaska Native  Race (NIH/OMB)  Participants   \n",
       "1             Asian/ Asian Heritage  Race (NIH/OMB)  Participants   \n",
       "2             Black/ Black Heritage  Race (NIH/OMB)  Participants   \n",
       "3                             Mixed  Race (NIH/OMB)  Participants   \n",
       "4  Hawaiian/ Other Pacific Islander  Race (NIH/OMB)  Participants   \n",
       "\n",
       "              param_type  start_date  \\\n",
       "0  Count of Participants  24/07/2009   \n",
       "1  Count of Participants  24/07/2009   \n",
       "2  Count of Participants  24/07/2009   \n",
       "3  Count of Participants  24/07/2009   \n",
       "4  Count of Participants  24/07/2009   \n",
       "\n",
       "                                         brief_title  \\\n",
       "0  Study of Lenvatinib (E7080) in Participants Wi...   \n",
       "1  Study of Lenvatinib (E7080) in Participants Wi...   \n",
       "2  Study of Lenvatinib (E7080) in Participants Wi...   \n",
       "3  Study of Lenvatinib (E7080) in Participants Wi...   \n",
       "4  Study of Lenvatinib (E7080) in Participants Wi...   \n",
       "\n",
       "                                      official_title overall_status  \\\n",
       "0  Phase I/II Study of E7080 in Patients With Adv...      Completed   \n",
       "1  Phase I/II Study of E7080 in Patients With Adv...      Completed   \n",
       "2  Phase I/II Study of E7080 in Patients With Adv...      Completed   \n",
       "3  Phase I/II Study of E7080 in Patients With Adv...      Completed   \n",
       "4  Phase I/II Study of E7080 in Patients With Adv...      Completed   \n",
       "\n",
       "             phase enrollment_type        id intervention_type        name  \\\n",
       "0  Phase 1/Phase 2          Actual  41355121              Drug  lenvatinib   \n",
       "1  Phase 1/Phase 2          Actual  41355121              Drug  lenvatinib   \n",
       "2  Phase 1/Phase 2          Actual  41355121              Drug  lenvatinib   \n",
       "3  Phase 1/Phase 2          Actual  41355121              Drug  lenvatinib   \n",
       "4  Phase 1/Phase 2          Actual  41355121              Drug  lenvatinib   \n",
       "\n",
       "   param_value  enrollment  number_of_arms  results  race_dum  \n",
       "0            0         396               6        6         6  \n",
       "1          132         396               6        6         6  \n",
       "2            0         396               6        6         6  \n",
       "3            0         396               6        6         6  \n",
       "4            0         396               6        6         6  "
      ]
     },
     "execution_count": 207,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grouped_race.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 208,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Unknown or Not Reported             1177\n",
       "White/ White Heritage                667\n",
       "Asian/ Asian Heritage                653\n",
       "Black/ Black Heritage                647\n",
       "American Indian/ Alaska Native       611\n",
       "Hawaiian/ Other Pacific Islander     604\n",
       "Other                                604\n",
       "Mixed                                579\n",
       "Hispanic/ Latino                     550\n",
       "Middle Eastern                         3\n",
       "Name: race/ethnicity, dtype: int64"
      ]
     },
     "execution_count": 208,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grouped_race['race/ethnicity'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 209,
   "metadata": {},
   "outputs": [],
   "source": [
    "grouped_race.drop(['category','title','units','param_type'], axis =1 , inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 210,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 6095 entries, 0 to 6094\n",
      "Data columns (total 16 columns):\n",
      " #   Column             Non-Null Count  Dtype \n",
      "---  ------             --------------  ----- \n",
      " 0   nct_id             6095 non-null   object\n",
      " 1   race/ethnicity     6095 non-null   object\n",
      " 2   start_date         6095 non-null   object\n",
      " 3   brief_title        6095 non-null   object\n",
      " 4   official_title     6095 non-null   object\n",
      " 5   overall_status     6095 non-null   object\n",
      " 6   phase              6095 non-null   object\n",
      " 7   enrollment_type    6095 non-null   object\n",
      " 8   id                 6095 non-null   int64 \n",
      " 9   intervention_type  6095 non-null   object\n",
      " 10  name               6095 non-null   object\n",
      " 11  param_value        6095 non-null   int64 \n",
      " 12  enrollment         6095 non-null   int64 \n",
      " 13  number_of_arms     6095 non-null   int64 \n",
      " 14  results            6095 non-null   int64 \n",
      " 15  race_dum           6095 non-null   int64 \n",
      "dtypes: int64(6), object(10)\n",
      "memory usage: 762.0+ KB\n"
     ]
    }
   ],
   "source": [
    "grouped_race.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 211,
   "metadata": {},
   "outputs": [],
   "source": [
    "# pivot the dataframe to create new columns for each category of the 'race' column\n",
    "pivoted_df = grouped_race.pivot_table(index=['nct_id', 'phase', 'start_date','enrollment_type','name','official_title','brief_title'], columns='race/ethnicity', values=['param_value'], aggfunc='sum').reset_index()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 212,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead tr th {\n",
       "        text-align: left;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>phase</th>\n",
       "      <th>start_date</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>name</th>\n",
       "      <th>official_title</th>\n",
       "      <th>brief_title</th>\n",
       "      <th colspan=\"10\" halign=\"left\">param_value</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>race/ethnicity</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00946153</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>24/07/2009</td>\n",
       "      <td>Actual</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>Phase I/II Study of E7080 in Patients With Adv...</td>\n",
       "      <td>Study of Lenvatinib (E7080) in Participants Wi...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>132.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01295827</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>04/03/2011</td>\n",
       "      <td>Actual</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Phase I Study of Single Agent Pembrolizumab (M...</td>\n",
       "      <td>Study of Pembrolizumab (MK-3475) in Participan...</td>\n",
       "      <td>4.0</td>\n",
       "      <td>162.0</td>\n",
       "      <td>52.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>126.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>8.0</td>\n",
       "      <td>2390.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>2288.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01298570</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>07/04/2011</td>\n",
       "      <td>Actual</td>\n",
       "      <td>regorafenib (bay 73-4506)</td>\n",
       "      <td>Multi-Center, Randomized, Placebo-Controlled P...</td>\n",
       "      <td>Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as ...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>62.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>294.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01354431</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>31/05/2011</td>\n",
       "      <td>Actual</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>A Randomized, Blinded, Phase 2 Dose-Ranging St...</td>\n",
       "      <td>BMS-936558 (MDX-1106) In Subjects With Advance...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>320.0</td>\n",
       "      <td>16.0</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01472081</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>09/02/2012</td>\n",
       "      <td>Actual</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>A Phase 1 Study of Nivolumab (BMS-936558) Plus...</td>\n",
       "      <td>Nivolumab (BMS-936558; MDX-1106) in Combinatio...</td>\n",
       "      <td>2.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>12.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>268.0</td>\n",
       "      <td>32.0</td>\n",
       "      <td>282.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                     nct_id            phase  start_date enrollment_type  \\\n",
       "race/ethnicity                                                             \n",
       "0               NCT00946153  Phase 1/Phase 2  24/07/2009          Actual   \n",
       "1               NCT01295827          Phase 1  04/03/2011          Actual   \n",
       "2               NCT01298570          Phase 2  07/04/2011          Actual   \n",
       "3               NCT01354431          Phase 2  31/05/2011          Actual   \n",
       "4               NCT01472081          Phase 1  09/02/2012          Actual   \n",
       "\n",
       "                                     name  \\\n",
       "race/ethnicity                              \n",
       "0                              lenvatinib   \n",
       "1                           pembrolizumab   \n",
       "2               regorafenib (bay 73-4506)   \n",
       "3                               nivolumab   \n",
       "4                               nivolumab   \n",
       "\n",
       "                                                   official_title  \\\n",
       "race/ethnicity                                                      \n",
       "0               Phase I/II Study of E7080 in Patients With Adv...   \n",
       "1               Phase I Study of Single Agent Pembrolizumab (M...   \n",
       "2               Multi-Center, Randomized, Placebo-Controlled P...   \n",
       "3               A Randomized, Blinded, Phase 2 Dose-Ranging St...   \n",
       "4               A Phase 1 Study of Nivolumab (BMS-936558) Plus...   \n",
       "\n",
       "                                                      brief_title  \\\n",
       "race/ethnicity                                                      \n",
       "0               Study of Lenvatinib (E7080) in Participants Wi...   \n",
       "1               Study of Pembrolizumab (MK-3475) in Participan...   \n",
       "2               Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as ...   \n",
       "3               BMS-936558 (MDX-1106) In Subjects With Advance...   \n",
       "4               Nivolumab (BMS-936558; MDX-1106) in Combinatio...   \n",
       "\n",
       "                                  param_value                        \\\n",
       "race/ethnicity American Indian/ Alaska Native Asian/ Asian Heritage   \n",
       "0                                         0.0                 132.0   \n",
       "1                                         4.0                 162.0   \n",
       "2                                         0.0                   0.0   \n",
       "3                                         NaN                   NaN   \n",
       "4                                         2.0                   6.0   \n",
       "\n",
       "                                                                       \\\n",
       "race/ethnicity Black/ Black Heritage Hawaiian/ Other Pacific Islander   \n",
       "0                                0.0                              0.0   \n",
       "1                               52.0                              4.0   \n",
       "2                               62.0                              0.0   \n",
       "3                                NaN                              NaN   \n",
       "4                               10.0                              0.0   \n",
       "\n",
       "                                                              \\\n",
       "race/ethnicity Hispanic/ Latino Middle Eastern Mixed   Other   \n",
       "0                           NaN            NaN   0.0     NaN   \n",
       "1                         126.0            NaN   8.0  2390.0   \n",
       "2                           NaN            NaN   0.0     NaN   \n",
       "3                           0.0            NaN   NaN   320.0   \n",
       "4                          12.0            NaN   0.0   268.0   \n",
       "\n",
       "                                                              \n",
       "race/ethnicity Unknown or Not Reported White/ White Heritage  \n",
       "0                                  0.0                   0.0  \n",
       "1                                  6.0                2288.0  \n",
       "2                                  6.0                 294.0  \n",
       "3                                 16.0                   NaN  \n",
       "4                                 32.0                 282.0  "
      ]
     },
     "execution_count": 212,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pivoted_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 213,
   "metadata": {},
   "outputs": [],
   "source": [
    "pivoted_df.to_csv('/project/approved_drugs_charts_data/pivoted_df.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 214,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_columns_drugs = pd.read_csv('https://raw.githubusercontent.com/AndreasPetrou/UCL_dissertation.github.io/main/Approved%20Drugs%20UK/trials_drugs_race_columns.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 215,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>phase</th>\n",
       "      <th>start_date</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>name</th>\n",
       "      <th>official_title</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00946153</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>24/07/2009</td>\n",
       "      <td>Actual</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>Phase I/II Study of E7080 in Patients With Adv...</td>\n",
       "      <td>Study of Lenvatinib (E7080) in Participants Wi...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>132.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01295827</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>04/03/2011</td>\n",
       "      <td>Actual</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Phase I Study of Single Agent Pembrolizumab (M...</td>\n",
       "      <td>Study of Pembrolizumab (MK-3475) in Participan...</td>\n",
       "      <td>4.0</td>\n",
       "      <td>162.0</td>\n",
       "      <td>52.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>126.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>8.0</td>\n",
       "      <td>2390.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>2288.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01298570</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>07/04/2011</td>\n",
       "      <td>Actual</td>\n",
       "      <td>regorafenib (bay 73-4506)</td>\n",
       "      <td>Multi-Center, Randomized, Placebo-Controlled P...</td>\n",
       "      <td>Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as ...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>62.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>294.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01354431</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>31/05/2011</td>\n",
       "      <td>Actual</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>A Randomized, Blinded, Phase 2 Dose-Ranging St...</td>\n",
       "      <td>BMS-936558 (MDX-1106) In Subjects With Advance...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>320.0</td>\n",
       "      <td>16.0</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01472081</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>09/02/2012</td>\n",
       "      <td>Actual</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>A Phase 1 Study of Nivolumab (BMS-936558) Plus...</td>\n",
       "      <td>Nivolumab (BMS-936558; MDX-1106) in Combinatio...</td>\n",
       "      <td>2.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>12.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>268.0</td>\n",
       "      <td>32.0</td>\n",
       "      <td>282.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id            phase  start_date enrollment_type  \\\n",
       "0  NCT00946153  Phase 1/Phase 2  24/07/2009          Actual   \n",
       "1  NCT01295827          Phase 1  04/03/2011          Actual   \n",
       "2  NCT01298570          Phase 2  07/04/2011          Actual   \n",
       "3  NCT01354431          Phase 2  31/05/2011          Actual   \n",
       "4  NCT01472081          Phase 1  09/02/2012          Actual   \n",
       "\n",
       "                        name  \\\n",
       "0                 lenvatinib   \n",
       "1              pembrolizumab   \n",
       "2  regorafenib (bay 73-4506)   \n",
       "3                  nivolumab   \n",
       "4                  nivolumab   \n",
       "\n",
       "                                      official_title  \\\n",
       "0  Phase I/II Study of E7080 in Patients With Adv...   \n",
       "1  Phase I Study of Single Agent Pembrolizumab (M...   \n",
       "2  Multi-Center, Randomized, Placebo-Controlled P...   \n",
       "3  A Randomized, Blinded, Phase 2 Dose-Ranging St...   \n",
       "4  A Phase 1 Study of Nivolumab (BMS-936558) Plus...   \n",
       "\n",
       "                                         brief_title  \\\n",
       "0  Study of Lenvatinib (E7080) in Participants Wi...   \n",
       "1  Study of Pembrolizumab (MK-3475) in Participan...   \n",
       "2  Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as ...   \n",
       "3  BMS-936558 (MDX-1106) In Subjects With Advance...   \n",
       "4  Nivolumab (BMS-936558; MDX-1106) in Combinatio...   \n",
       "\n",
       "   American Indian/ Alaska Native  Asian/ Asian Heritage  \\\n",
       "0                             0.0                  132.0   \n",
       "1                             4.0                  162.0   \n",
       "2                             0.0                    0.0   \n",
       "3                             NaN                    NaN   \n",
       "4                             2.0                    6.0   \n",
       "\n",
       "   Black/ Black Heritage  Hawaiian/ Other Pacific Islander  Hispanic/ Latino  \\\n",
       "0                    0.0                               0.0               NaN   \n",
       "1                   52.0                               4.0             126.0   \n",
       "2                   62.0                               0.0               NaN   \n",
       "3                    NaN                               NaN               0.0   \n",
       "4                   10.0                               0.0              12.0   \n",
       "\n",
       "   Middle Eastern  Mixed   Other  Unknown or Not Reported  \\\n",
       "0             NaN    0.0     NaN                      0.0   \n",
       "1             NaN    8.0  2390.0                      6.0   \n",
       "2             NaN    0.0     NaN                      6.0   \n",
       "3             NaN    NaN   320.0                     16.0   \n",
       "4             NaN    0.0   268.0                     32.0   \n",
       "\n",
       "   White/ White Heritage  \n",
       "0                    0.0  \n",
       "1                 2288.0  \n",
       "2                  294.0  \n",
       "3                    NaN  \n",
       "4                  282.0  "
      ]
     },
     "execution_count": 215,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_columns_drugs.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 216,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 704 entries, 0 to 703\n",
      "Data columns (total 17 columns):\n",
      " #   Column                            Non-Null Count  Dtype  \n",
      "---  ------                            --------------  -----  \n",
      " 0   nct_id                            704 non-null    object \n",
      " 1   phase                             704 non-null    object \n",
      " 2   start_date                        704 non-null    object \n",
      " 3   enrollment_type                   704 non-null    object \n",
      " 4   name                              704 non-null    object \n",
      " 5   official_title                    704 non-null    object \n",
      " 6   brief_title                       704 non-null    object \n",
      " 7   American Indian/ Alaska Native    611 non-null    float64\n",
      " 8   Asian/ Asian Heritage             649 non-null    float64\n",
      " 9   Black/ Black Heritage             647 non-null    float64\n",
      " 10  Hawaiian/ Other Pacific Islander  604 non-null    float64\n",
      " 11  Hispanic/ Latino                  550 non-null    float64\n",
      " 12  Middle Eastern                    3 non-null      float64\n",
      " 13  Mixed                             579 non-null    float64\n",
      " 14  Other                             554 non-null    float64\n",
      " 15  Unknown or Not Reported           688 non-null    float64\n",
      " 16  White/ White Heritage             664 non-null    float64\n",
      "dtypes: float64(10), object(7)\n",
      "memory usage: 93.6+ KB\n"
     ]
    }
   ],
   "source": [
    "race_columns_drugs.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 217,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Convert 'start_date' column to datetime format\n",
    "race_columns_drugs['start_date'] = pd.to_datetime(race_columns_drugs['start_date'], dayfirst=True)\n",
    "\n",
    "# Extract the year from 'start_date' column\n",
    "race_columns_drugs['year'] = race_columns_drugs['start_date'].dt.year"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 218,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_268/636946738.py:1: FutureWarning: The default value of numeric_only in DataFrameGroupBy.sum is deprecated. In a future version, numeric_only will default to False. Either specify numeric_only or select only columns which should be valid for the function.\n",
      "  race_drugs_groups = race_columns_drugs.groupby('name').sum()\n"
     ]
    }
   ],
   "source": [
    "race_drugs_groups = race_columns_drugs.groupby('name').sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 219,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_drugs_groups.reset_index(inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 220,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_drugs_groups.rename(columns={'name': 'drug'}, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 221,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_drugs_groups.drop(['year'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 222,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>drug</th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>abt199</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>30.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>atezolizumab</td>\n",
       "      <td>43.0</td>\n",
       "      <td>2648.0</td>\n",
       "      <td>277.0</td>\n",
       "      <td>18.0</td>\n",
       "      <td>910.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>16.0</td>\n",
       "      <td>14103.0</td>\n",
       "      <td>1440.0</td>\n",
       "      <td>8635.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>avelumab</td>\n",
       "      <td>25.0</td>\n",
       "      <td>2849.0</td>\n",
       "      <td>352.0</td>\n",
       "      <td>16.0</td>\n",
       "      <td>670.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>9226.0</td>\n",
       "      <td>1745.0</td>\n",
       "      <td>10506.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>axicabtagene ciloleucel</td>\n",
       "      <td>1.0</td>\n",
       "      <td>21.0</td>\n",
       "      <td>25.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>82.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>753.0</td>\n",
       "      <td>15.0</td>\n",
       "      <td>657.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>bms-936558</td>\n",
       "      <td>0.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>18.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>18.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>558.0</td>\n",
       "      <td>462.0</td>\n",
       "      <td>166.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                      drug  American Indian/ Alaska Native  \\\n",
       "0                   abt199                             0.0   \n",
       "1             atezolizumab                            43.0   \n",
       "2                 avelumab                            25.0   \n",
       "3  axicabtagene ciloleucel                             1.0   \n",
       "4               bms-936558                             0.0   \n",
       "\n",
       "   Asian/ Asian Heritage  Black/ Black Heritage  \\\n",
       "0                    0.0                    0.0   \n",
       "1                 2648.0                  277.0   \n",
       "2                 2849.0                  352.0   \n",
       "3                   21.0                   25.0   \n",
       "4                   10.0                   18.0   \n",
       "\n",
       "   Hawaiian/ Other Pacific Islander  Hispanic/ Latino  Middle Eastern  Mixed  \\\n",
       "0                               0.0               0.0             0.0    0.0   \n",
       "1                              18.0             910.0             0.0   16.0   \n",
       "2                              16.0             670.0             0.0    1.0   \n",
       "3                               2.0              82.0             0.0    0.0   \n",
       "4                               2.0              18.0             0.0    0.0   \n",
       "\n",
       "     Other  Unknown or Not Reported  White/ White Heritage  \n",
       "0      0.0                      3.0                   30.0  \n",
       "1  14103.0                   1440.0                 8635.0  \n",
       "2   9226.0                   1745.0                10506.0  \n",
       "3    753.0                     15.0                  657.0  \n",
       "4    558.0                    462.0                  166.0  "
      ]
     },
     "execution_count": 222,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_drugs_groups.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 223,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_drugs_groups.to_csv('/project/approved_drugs_charts_data/race_drugs_groups.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "create a graph in Tableau with the above dataset."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 224,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>id</th>\n",
       "      <th>nct_id</th>\n",
       "      <th>name</th>\n",
       "      <th>removed</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>33287963</td>\n",
       "      <td>NCT01538901</td>\n",
       "      <td>Austria</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>33034889</td>\n",
       "      <td>NCT03935568</td>\n",
       "      <td>United States</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>33541613</td>\n",
       "      <td>NCT01902173</td>\n",
       "      <td>United States</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>33287964</td>\n",
       "      <td>NCT01538914</td>\n",
       "      <td>Korea, Republic of</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>33287965</td>\n",
       "      <td>NCT01538927</td>\n",
       "      <td>India</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         id       nct_id                name  removed\n",
       "0  33287963  NCT01538901             Austria    False\n",
       "1  33034889  NCT03935568       United States    False\n",
       "2  33541613  NCT01902173       United States    False\n",
       "3  33287964  NCT01538914  Korea, Republic of    False\n",
       "4  33287965  NCT01538927               India    False"
      ]
     },
     "execution_count": 224,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "countries.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 225,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Rename the 'name' column to 'country'\n",
    "countries = countries.rename(columns={'name': 'country'})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 226,
   "metadata": {},
   "outputs": [],
   "source": [
    "countries.drop(['id','removed'],axis=1,inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 227,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_columns_drugs_countries = pd.merge(race_columns_drugs,countries,on='nct_id',how='left')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 228,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>phase</th>\n",
       "      <th>start_date</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>name</th>\n",
       "      <th>official_title</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "      <th>year</th>\n",
       "      <th>country</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00946153</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>2009-07-24</td>\n",
       "      <td>Actual</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>Phase I/II Study of E7080 in Patients With Adv...</td>\n",
       "      <td>Study of Lenvatinib (E7080) in Participants Wi...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>132.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2009</td>\n",
       "      <td>Japan</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT00946153</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>2009-07-24</td>\n",
       "      <td>Actual</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>Phase I/II Study of E7080 in Patients With Adv...</td>\n",
       "      <td>Study of Lenvatinib (E7080) in Participants Wi...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>132.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2009</td>\n",
       "      <td>Korea, Republic of</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01295827</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2011-03-04</td>\n",
       "      <td>Actual</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Phase I Study of Single Agent Pembrolizumab (M...</td>\n",
       "      <td>Study of Pembrolizumab (MK-3475) in Participan...</td>\n",
       "      <td>4.0</td>\n",
       "      <td>162.0</td>\n",
       "      <td>52.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>126.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>8.0</td>\n",
       "      <td>2390.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>2288.0</td>\n",
       "      <td>2011</td>\n",
       "      <td>Australia</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01295827</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2011-03-04</td>\n",
       "      <td>Actual</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Phase I Study of Single Agent Pembrolizumab (M...</td>\n",
       "      <td>Study of Pembrolizumab (MK-3475) in Participan...</td>\n",
       "      <td>4.0</td>\n",
       "      <td>162.0</td>\n",
       "      <td>52.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>126.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>8.0</td>\n",
       "      <td>2390.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>2288.0</td>\n",
       "      <td>2011</td>\n",
       "      <td>Canada</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01295827</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2011-03-04</td>\n",
       "      <td>Actual</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Phase I Study of Single Agent Pembrolizumab (M...</td>\n",
       "      <td>Study of Pembrolizumab (MK-3475) in Participan...</td>\n",
       "      <td>4.0</td>\n",
       "      <td>162.0</td>\n",
       "      <td>52.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>126.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>8.0</td>\n",
       "      <td>2390.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>2288.0</td>\n",
       "      <td>2011</td>\n",
       "      <td>France</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id            phase start_date enrollment_type           name  \\\n",
       "0  NCT00946153  Phase 1/Phase 2 2009-07-24          Actual     lenvatinib   \n",
       "1  NCT00946153  Phase 1/Phase 2 2009-07-24          Actual     lenvatinib   \n",
       "2  NCT01295827          Phase 1 2011-03-04          Actual  pembrolizumab   \n",
       "3  NCT01295827          Phase 1 2011-03-04          Actual  pembrolizumab   \n",
       "4  NCT01295827          Phase 1 2011-03-04          Actual  pembrolizumab   \n",
       "\n",
       "                                      official_title  \\\n",
       "0  Phase I/II Study of E7080 in Patients With Adv...   \n",
       "1  Phase I/II Study of E7080 in Patients With Adv...   \n",
       "2  Phase I Study of Single Agent Pembrolizumab (M...   \n",
       "3  Phase I Study of Single Agent Pembrolizumab (M...   \n",
       "4  Phase I Study of Single Agent Pembrolizumab (M...   \n",
       "\n",
       "                                         brief_title  \\\n",
       "0  Study of Lenvatinib (E7080) in Participants Wi...   \n",
       "1  Study of Lenvatinib (E7080) in Participants Wi...   \n",
       "2  Study of Pembrolizumab (MK-3475) in Participan...   \n",
       "3  Study of Pembrolizumab (MK-3475) in Participan...   \n",
       "4  Study of Pembrolizumab (MK-3475) in Participan...   \n",
       "\n",
       "   American Indian/ Alaska Native  Asian/ Asian Heritage  \\\n",
       "0                             0.0                  132.0   \n",
       "1                             0.0                  132.0   \n",
       "2                             4.0                  162.0   \n",
       "3                             4.0                  162.0   \n",
       "4                             4.0                  162.0   \n",
       "\n",
       "   Black/ Black Heritage  Hawaiian/ Other Pacific Islander  Hispanic/ Latino  \\\n",
       "0                    0.0                               0.0               NaN   \n",
       "1                    0.0                               0.0               NaN   \n",
       "2                   52.0                               4.0             126.0   \n",
       "3                   52.0                               4.0             126.0   \n",
       "4                   52.0                               4.0             126.0   \n",
       "\n",
       "   Middle Eastern  Mixed   Other  Unknown or Not Reported  \\\n",
       "0             NaN    0.0     NaN                      0.0   \n",
       "1             NaN    0.0     NaN                      0.0   \n",
       "2             NaN    8.0  2390.0                      6.0   \n",
       "3             NaN    8.0  2390.0                      6.0   \n",
       "4             NaN    8.0  2390.0                      6.0   \n",
       "\n",
       "   White/ White Heritage  year             country  \n",
       "0                    0.0  2009               Japan  \n",
       "1                    0.0  2009  Korea, Republic of  \n",
       "2                 2288.0  2011           Australia  \n",
       "3                 2288.0  2011              Canada  \n",
       "4                 2288.0  2011              France  "
      ]
     },
     "execution_count": 228,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_columns_drugs_countries.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 229,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_columns_drugs_countries.to_csv('/project/approved_drugs_charts_data/race_columns_drugs_countries.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 230,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "Int64Index: 644 entries, 0 to 703\n",
      "Data columns (total 18 columns):\n",
      " #   Column                            Non-Null Count  Dtype         \n",
      "---  ------                            --------------  -----         \n",
      " 0   nct_id                            644 non-null    object        \n",
      " 1   phase                             644 non-null    object        \n",
      " 2   start_date                        644 non-null    datetime64[ns]\n",
      " 3   enrollment_type                   644 non-null    object        \n",
      " 4   name                              644 non-null    object        \n",
      " 5   official_title                    644 non-null    object        \n",
      " 6   brief_title                       644 non-null    object        \n",
      " 7   American Indian/ Alaska Native    558 non-null    float64       \n",
      " 8   Asian/ Asian Heritage             594 non-null    float64       \n",
      " 9   Black/ Black Heritage             593 non-null    float64       \n",
      " 10  Hawaiian/ Other Pacific Islander  553 non-null    float64       \n",
      " 11  Hispanic/ Latino                  503 non-null    float64       \n",
      " 12  Middle Eastern                    3 non-null      float64       \n",
      " 13  Mixed                             529 non-null    float64       \n",
      " 14  Other                             507 non-null    float64       \n",
      " 15  Unknown or Not Reported           629 non-null    float64       \n",
      " 16  White/ White Heritage             609 non-null    float64       \n",
      " 17  year                              644 non-null    int64         \n",
      "dtypes: datetime64[ns](1), float64(10), int64(1), object(6)\n",
      "memory usage: 95.6+ KB\n"
     ]
    }
   ],
   "source": [
    "import re\n",
    "\n",
    "# Create a list of cancer-related terms\n",
    "cancer_terms = ['cancer', 'tumor', 'tumour', 'carcinoma', 'lymphoma', 'leukemia', 'sarcoma', 'glioblastoma',\n",
    "                'glioma', 'neuroblastoma', 'papilloma', 'melanoma', 'metastasis', 'malignant', 'benign',\n",
    "                'leukemia', 'histiocytoma', 'adenocarcinoma', 'aldosteronoma', 'adamantinoma', 'ameloblastoma',\n",
    "                'angiofibroma', 'angiosarcoma', 'astroblastoma', 'astrocytoma', 'liponeurocytoma', 'cholangiocarcinoma',\n",
    "                'chondroblastoma', 'chondrosarcoma', 'chordoma', 'nephroma', 'craniopharyngioma', 'cystadenoma',\n",
    "                'nephroblastoma', 'chondrosarcoma', 'trichoepithelioma', 'ependymoma', 'hemangioendothelioma',\n",
    "                'erythroleukemia', 'fibroadenoma', 'fibrosarcoma', 'germinoma', 'glioblastoma', 'osteosarcoma',\n",
    "                'rhabdomyosarcoma', 'leiomyosarcoma', 'myxosarcoma', 'mesenchymoma', 'astrocytoma', 'ependymoma',\n",
    "                'neuroblastoma', 'oligodendroglioma', 'pheochromocytoma', 'retinoblastoma', 'cholangiocarcinoma',\n",
    "                'myelodysplastic', 'liposarcoma', 'histiocytoma', 'macroglobulinaemia', 'polycythaemia vera',\n",
    "                'essential thrombocythaemia', 'myelofibrosis', 'gastrinoma', 'hemangioendothelioma', 'hepatoblastoma',\n",
    "                'insulinoma', 'keratoacanthoma', 'leiomyosarcoma', 'liposarcoma', 'mesenchymoma', 'medulloepithelioma',\n",
    "                'meningioma', 'nephroma', 'myxofibrosarcoma', 'nephroblastoma', 'esthesioneuroblastoma', 'pheochromocytoma',\n",
    "                'pineoblastoma', 'plasmacytoma', 'prolactinoma', 'fibrosarcoma', 'somatostatinoma', 'haemangioblastoma',\n",
    "                'thymoma', 'seminoma', 'dysgerminoma', 'oncocytic', 'paraganglioma', 'teratoma', 'mesothelioma',\n",
    "                'neoplasia', 'phaeochromocytoma', 'acoustic neuroma', 'neuroma', 'nephroblastoma', 'mycosis fungoides',\n",
    "                'vipoma', 'oncocytic', 'oncocytomas', 'teratoma', 'gestational trophoblastic disease', 'hodgkin',\n",
    "                'burkitt', 'wilms', 'kaposi', 'paget', 'edwig', 'schwannoma', 'verner-morrison', 'waldenström',\n",
    "                'von recklinghausen', 'von hippel-lindau', 'peutz-jeghers', 'neurofibromatosis type 2', 'carney', 'gorlin']\n",
    "\n",
    "# Create a regex pattern by joining the cancer terms and making them case-insensitive\n",
    "pattern = re.compile(r'|'.join(cancer_terms), re.IGNORECASE)\n",
    "\n",
    "# Filter for cancer-related trials\n",
    "cancer_df = race_columns_drugs[\n",
    "    (race_columns_drugs['official_title'].str.contains(pattern, na=False)) |\n",
    "    (race_columns_drugs['brief_title'].str.contains(pattern, na=False))\n",
    "]\n",
    "\n",
    "cancer_df.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 231,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>phase</th>\n",
       "      <th>start_date</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>name</th>\n",
       "      <th>official_title</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "      <th>year</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00946153</td>\n",
       "      <td>Phase 1/Phase 2</td>\n",
       "      <td>2009-07-24</td>\n",
       "      <td>Actual</td>\n",
       "      <td>lenvatinib</td>\n",
       "      <td>Phase I/II Study of E7080 in Patients With Adv...</td>\n",
       "      <td>Study of Lenvatinib (E7080) in Participants Wi...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>132.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2009</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT01295827</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2011-03-04</td>\n",
       "      <td>Actual</td>\n",
       "      <td>pembrolizumab</td>\n",
       "      <td>Phase I Study of Single Agent Pembrolizumab (M...</td>\n",
       "      <td>Study of Pembrolizumab (MK-3475) in Participan...</td>\n",
       "      <td>4.0</td>\n",
       "      <td>162.0</td>\n",
       "      <td>52.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>126.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>8.0</td>\n",
       "      <td>2390.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>2288.0</td>\n",
       "      <td>2011</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01298570</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2011-04-07</td>\n",
       "      <td>Actual</td>\n",
       "      <td>regorafenib (bay 73-4506)</td>\n",
       "      <td>Multi-Center, Randomized, Placebo-Controlled P...</td>\n",
       "      <td>Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as ...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>62.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>294.0</td>\n",
       "      <td>2011</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT01354431</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2011-05-31</td>\n",
       "      <td>Actual</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>A Randomized, Blinded, Phase 2 Dose-Ranging St...</td>\n",
       "      <td>BMS-936558 (MDX-1106) In Subjects With Advance...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>320.0</td>\n",
       "      <td>16.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2011</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT01472081</td>\n",
       "      <td>Phase 1</td>\n",
       "      <td>2012-02-09</td>\n",
       "      <td>Actual</td>\n",
       "      <td>nivolumab</td>\n",
       "      <td>A Phase 1 Study of Nivolumab (BMS-936558) Plus...</td>\n",
       "      <td>Nivolumab (BMS-936558; MDX-1106) in Combinatio...</td>\n",
       "      <td>2.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>12.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>268.0</td>\n",
       "      <td>32.0</td>\n",
       "      <td>282.0</td>\n",
       "      <td>2012</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id            phase start_date enrollment_type  \\\n",
       "0  NCT00946153  Phase 1/Phase 2 2009-07-24          Actual   \n",
       "1  NCT01295827          Phase 1 2011-03-04          Actual   \n",
       "2  NCT01298570          Phase 2 2011-04-07          Actual   \n",
       "3  NCT01354431          Phase 2 2011-05-31          Actual   \n",
       "4  NCT01472081          Phase 1 2012-02-09          Actual   \n",
       "\n",
       "                        name  \\\n",
       "0                 lenvatinib   \n",
       "1              pembrolizumab   \n",
       "2  regorafenib (bay 73-4506)   \n",
       "3                  nivolumab   \n",
       "4                  nivolumab   \n",
       "\n",
       "                                      official_title  \\\n",
       "0  Phase I/II Study of E7080 in Patients With Adv...   \n",
       "1  Phase I Study of Single Agent Pembrolizumab (M...   \n",
       "2  Multi-Center, Randomized, Placebo-Controlled P...   \n",
       "3  A Randomized, Blinded, Phase 2 Dose-Ranging St...   \n",
       "4  A Phase 1 Study of Nivolumab (BMS-936558) Plus...   \n",
       "\n",
       "                                         brief_title  \\\n",
       "0  Study of Lenvatinib (E7080) in Participants Wi...   \n",
       "1  Study of Pembrolizumab (MK-3475) in Participan...   \n",
       "2  Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as ...   \n",
       "3  BMS-936558 (MDX-1106) In Subjects With Advance...   \n",
       "4  Nivolumab (BMS-936558; MDX-1106) in Combinatio...   \n",
       "\n",
       "   American Indian/ Alaska Native  Asian/ Asian Heritage  \\\n",
       "0                             0.0                  132.0   \n",
       "1                             4.0                  162.0   \n",
       "2                             0.0                    0.0   \n",
       "3                             NaN                    NaN   \n",
       "4                             2.0                    6.0   \n",
       "\n",
       "   Black/ Black Heritage  Hawaiian/ Other Pacific Islander  Hispanic/ Latino  \\\n",
       "0                    0.0                               0.0               NaN   \n",
       "1                   52.0                               4.0             126.0   \n",
       "2                   62.0                               0.0               NaN   \n",
       "3                    NaN                               NaN               0.0   \n",
       "4                   10.0                               0.0              12.0   \n",
       "\n",
       "   Middle Eastern  Mixed   Other  Unknown or Not Reported  \\\n",
       "0             NaN    0.0     NaN                      0.0   \n",
       "1             NaN    8.0  2390.0                      6.0   \n",
       "2             NaN    0.0     NaN                      6.0   \n",
       "3             NaN    NaN   320.0                     16.0   \n",
       "4             NaN    0.0   268.0                     32.0   \n",
       "\n",
       "   White/ White Heritage  year  \n",
       "0                    0.0  2009  \n",
       "1                 2288.0  2011  \n",
       "2                  294.0  2011  \n",
       "3                    NaN  2011  \n",
       "4                  282.0  2012  "
      ]
     },
     "execution_count": 231,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cancer_df.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Cancers affecting black and asian ethnic groups more than white"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "From the British Journal of Cancer (Br J Cancer)  ISSN 1532-1827 (online)  ISSN 0007-0920 (print) https://www.nature.com/articles/s41416-022-01718-5/figures/1 we can see that from Figure 1 the cancers that affect more the Black and Asian ethnic groups than white are:\n",
    "- Gallbladder Cancer\n",
    "- Myeloma\n",
    "- Prostate Cancer\n",
    "\n",
    "I will filter these cancer names in the INDICATION column of the approved_drugs dataframe and then find the drugs used for these trials.\n",
    "\n",
    "Then i will find all the synonyms of these drugs and filter the world trials that used those drugs in their clinical study to explore the race distribution."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 232,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rec no.</th>\n",
       "      <th>TA ID</th>\n",
       "      <th>Year of Publication</th>\n",
       "      <th>Process</th>\n",
       "      <th>Technology</th>\n",
       "      <th>Technology type</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Categorisation (for specific recommendation)</th>\n",
       "      <th>Comment</th>\n",
       "      <th>year</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>3</td>\n",
       "      <td>TA003</td>\n",
       "      <td>2000-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Paclitaxel</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Ovarian cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Guidance has been replaced by TA55. Recommenda...</td>\n",
       "      <td>2000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>6</td>\n",
       "      <td>TA006</td>\n",
       "      <td>2000-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Docetaxel</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Advanced breast cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Guidance has been replaced by TA30. Recommenda...</td>\n",
       "      <td>2000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>7</td>\n",
       "      <td>TA006</td>\n",
       "      <td>2000-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Paclitaxel</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Advanced breast cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Guidance has been replaced by TA30. Recommenda...</td>\n",
       "      <td>2000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>35</td>\n",
       "      <td>TA023</td>\n",
       "      <td>2001-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Temozolomide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Brain cancer (recurrent)</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommendation in line with marketing authoris...</td>\n",
       "      <td>2001</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>42</td>\n",
       "      <td>TA025</td>\n",
       "      <td>2001-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Gemcitabine (1st line)</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>Pancreatic cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with clinical practice.</td>\n",
       "      <td>2001</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Rec no.  TA ID Year of Publication Process              Technology  \\\n",
       "0        3  TA003          2000-01-01     MTA              Paclitaxel   \n",
       "2        6  TA006          2000-01-01     MTA               Docetaxel   \n",
       "3        7  TA006          2000-01-01     MTA              Paclitaxel   \n",
       "5       35  TA023          2001-01-01     MTA            Temozolomide   \n",
       "6       42  TA025          2001-01-01     MTA  Gemcitabine (1st line)   \n",
       "\n",
       "  Technology type                Indication  \\\n",
       "0  Pharmaceutical            Ovarian cancer   \n",
       "2  Pharmaceutical    Advanced breast cancer   \n",
       "3  Pharmaceutical    Advanced breast cancer   \n",
       "5  Pharmaceutical  Brain cancer (recurrent)   \n",
       "6  Pharmaceutical        Pancreatic cancer    \n",
       "\n",
       "  Categorisation (for specific recommendation)  \\\n",
       "0                                  Recommended   \n",
       "2                                  Recommended   \n",
       "3                                  Recommended   \n",
       "5                                  Recommended   \n",
       "6                                  Recommended   \n",
       "\n",
       "                                             Comment  year  \n",
       "0  Guidance has been replaced by TA55. Recommenda...  2000  \n",
       "2  Guidance has been replaced by TA30. Recommenda...  2000  \n",
       "3  Guidance has been replaced by TA30. Recommenda...  2000  \n",
       "5  Recommendation in line with marketing authoris...  2001  \n",
       "6       Recommended in line with clinical practice.   2001  "
      ]
     },
     "execution_count": 232,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "approved_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 233,
   "metadata": {},
   "outputs": [],
   "source": [
    "search_terms = ['gallbladder', 'myeloma', 'prostate']\n",
    "\n",
    "# Convert the \"Indication\" column to lowercase for case-insensitive matching\n",
    "approved_df['Indication'] = approved_df['Indication'].str.lower()\n",
    "\n",
    "# Create a regular expression pattern to search for the terms\n",
    "pattern = '|'.join(re.escape(term.lower()) for term in search_terms)\n",
    "\n",
    "# Search for the pattern in the \"Indication\" column and create the new dataframe\n",
    "cancers_black_asian = approved_df[approved_df['Indication'].str.contains(pattern)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 234,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rec no.</th>\n",
       "      <th>TA ID</th>\n",
       "      <th>Year of Publication</th>\n",
       "      <th>Process</th>\n",
       "      <th>Technology</th>\n",
       "      <th>Technology type</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Categorisation (for specific recommendation)</th>\n",
       "      <th>Comment</th>\n",
       "      <th>year</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>239</td>\n",
       "      <td>TA101</td>\n",
       "      <td>2006-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Docetaxel</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>prostate cancer (hormone-refractory)</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommendation in line with marketing authoris...</td>\n",
       "      <td>2006</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>280</td>\n",
       "      <td>TA129</td>\n",
       "      <td>2007-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Bortezomib</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended after agreement of Patient Access ...</td>\n",
       "      <td>2007</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>351</td>\n",
       "      <td>TA171</td>\n",
       "      <td>2009-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Lenalidomide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple  myeloma</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended following agreement on Patient Acc...</td>\n",
       "      <td>2009</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>118</th>\n",
       "      <td>444</td>\n",
       "      <td>TA228</td>\n",
       "      <td>2011-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Thalidomide in combination with an alkylating ...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisation.</td>\n",
       "      <td>2011</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>119</th>\n",
       "      <td>445</td>\n",
       "      <td>TA228</td>\n",
       "      <td>2011-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Bortezomib in combination with an alkylating a...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for use in specific c...</td>\n",
       "      <td>2011</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>138</th>\n",
       "      <td>486</td>\n",
       "      <td>TA259</td>\n",
       "      <td>2012-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Abiraterone in combination with prednisolone o...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treatment of castration-resistant metastatic p...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2012</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>492</td>\n",
       "      <td>TA265</td>\n",
       "      <td>2012-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Denosumab</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>prevention of skeletal-related events in adult...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with clinical practice fol...</td>\n",
       "      <td>2012</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>156</th>\n",
       "      <td>545</td>\n",
       "      <td>TA311</td>\n",
       "      <td>2014-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Bortezomib in combination with dexamethasone, ...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>for induction therapy in multiple myeloma befo...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisation.</td>\n",
       "      <td>2014</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>157</th>\n",
       "      <td>553</td>\n",
       "      <td>TA316</td>\n",
       "      <td>2014-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Enzalutamide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>metastatic hormone-relapsed prostate cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2014</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>181</th>\n",
       "      <td>631</td>\n",
       "      <td>TA376</td>\n",
       "      <td>2015-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Radium-223 dichloride</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treating hormone-relapsed prostate cancer with...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for Radium‑223 dichlo...</td>\n",
       "      <td>2015</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>182</th>\n",
       "      <td>632</td>\n",
       "      <td>TA377</td>\n",
       "      <td>2015-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Enzalutamide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treating metastatic hormone-relapsed prostate ...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2015</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>184</th>\n",
       "      <td>635</td>\n",
       "      <td>TA380</td>\n",
       "      <td>2015-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Panobinostat in combination with bortezomib an...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treating multiple myeloma after at least 2 pre...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2015</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>188</th>\n",
       "      <td>647</td>\n",
       "      <td>TA387</td>\n",
       "      <td>2016-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Abiraterone in combination with prednisone or ...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treating metastatic hormone-relapsed prostate ...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with the marketing authori...</td>\n",
       "      <td>2016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195</th>\n",
       "      <td>658</td>\n",
       "      <td>TA391</td>\n",
       "      <td>2016-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Cabazitaxel in combination with prednisone or ...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treating hormone-relapsed metastatic prostate ...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with clinical practice and...</td>\n",
       "      <td>2016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>203</th>\n",
       "      <td>671</td>\n",
       "      <td>TA404</td>\n",
       "      <td>2016-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Degarelix</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>advanced hormone-dependent prostate cancer</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for degarelix as an o...</td>\n",
       "      <td>2016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>209</th>\n",
       "      <td>679</td>\n",
       "      <td>TA412</td>\n",
       "      <td>2016-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Radium‑223 dichloride</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treating hormone-relapsed prostate cancer with...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for radium‑223 dichlo...</td>\n",
       "      <td>2016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>223</th>\n",
       "      <td>699</td>\n",
       "      <td>TA427</td>\n",
       "      <td>2016-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Pomalidomide, in combination with low‑dose dex...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma previously treated with lenal...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with clinical practice and...</td>\n",
       "      <td>2016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>245</th>\n",
       "      <td>735</td>\n",
       "      <td>TA457</td>\n",
       "      <td>2017-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Carfilzomib in combination with dexamethasone</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>previously treated multiple myeloma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optmised recommendation for carfilzomib in com...</td>\n",
       "      <td>2017</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>272</th>\n",
       "      <td>809</td>\n",
       "      <td>TA505</td>\n",
       "      <td>2017-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Ixazomib with lenalidomide and dexamethasone</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>relapsed or refractory multiple myeloma</td>\n",
       "      <td>Optimised (CDF)</td>\n",
       "      <td>Optimised recommendation for ixazomib, with le...</td>\n",
       "      <td>2017</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>274</th>\n",
       "      <td>814</td>\n",
       "      <td>TA510</td>\n",
       "      <td>2017-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Daratumumab monotherapy</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>relapsed and refractory multiple myeloma</td>\n",
       "      <td>Optimised (CDF)</td>\n",
       "      <td>Optimised recommendation for  daratumumab mono...</td>\n",
       "      <td>2017</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>325</th>\n",
       "      <td>889</td>\n",
       "      <td>TA573</td>\n",
       "      <td>2019-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Daratumumab</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Recommended (CDF)</td>\n",
       "      <td>Recommended in the CDF</td>\n",
       "      <td>2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>334</th>\n",
       "      <td>902</td>\n",
       "      <td>TA586</td>\n",
       "      <td>2019-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Lenalidomide with dexamethasone</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma in adults who have hade at le...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for lenalidomide plus...</td>\n",
       "      <td>2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>335</th>\n",
       "      <td>903</td>\n",
       "      <td>TA587</td>\n",
       "      <td>2019-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Lenalidomide with dexamethasone</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>previously untreated multiple myeloma who are ...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for lenalidomide plus...</td>\n",
       "      <td>2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>376</th>\n",
       "      <td>974</td>\n",
       "      <td>TA657</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Carfilzomib for previously treated multiple my...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>previously treated multiple myeloma</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Reissue of TA457 to allow previous treatment w...</td>\n",
       "      <td>2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>377</th>\n",
       "      <td>975</td>\n",
       "      <td>TA658</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Isatuximab with pomalidomide and dexamethasone</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>relapsed and refractory multiple myeloma</td>\n",
       "      <td>Recommended (CDF)</td>\n",
       "      <td>Isatuximab, plus pomalidomide and dexamethason...</td>\n",
       "      <td>2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>378</th>\n",
       "      <td>977</td>\n",
       "      <td>TA660</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Darolutamide with androgen deprivation therapy</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>hormone-relapsed non-metastatic prostate cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with the marketing autoris...</td>\n",
       "      <td>2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>390</th>\n",
       "      <td>1004</td>\n",
       "      <td>TA680</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Lenalidomide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>maintenance treatment after an autologous stem...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for lenalidomide as m...</td>\n",
       "      <td>2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>403</th>\n",
       "      <td>1022</td>\n",
       "      <td>TA695</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Carfilzomib with dexamethasone and lenalidomide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>previously treated multiple myeloma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommenation for treating multiple ...</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>411</th>\n",
       "      <td>1040</td>\n",
       "      <td>TA712</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Enzalutamide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>hormone-sensitive metastatic prostate cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with the marketing authori...</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>427</th>\n",
       "      <td>1074</td>\n",
       "      <td>TA740</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Apalutamide with androgen deprivation therapy</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>high-risk hormone-relapsed non-metastatic pros...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with clinical practice and...</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>428</th>\n",
       "      <td>1075</td>\n",
       "      <td>TA741</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Apalutamide with androgen deprivation therapy</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>hormone-sensitive metastatic prostate cancer</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for treating hormone-...</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>439</th>\n",
       "      <td>1099</td>\n",
       "      <td>TA763</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Daratumumab in combination</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma when a stem cell transplant i...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>450</th>\n",
       "      <td>1119</td>\n",
       "      <td>TA783</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Daratumumab monotherapy for treating relapsed ...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>relapsed and refractory multiple myeloma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>CDF review of TA510 Optimised recommenation fo...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>491</th>\n",
       "      <td>1209</td>\n",
       "      <td>TA870</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Ixazomib with lenalidomide and dexamethasone</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>relapsed or refractory multiple myeloma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Review of TA505. Optimised recommenation for i...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     Rec no.  TA ID Year of Publication Process  \\\n",
       "51       239  TA101          2006-01-01     MTA   \n",
       "67       280  TA129          2007-01-01     STA   \n",
       "78       351  TA171          2009-01-01     STA   \n",
       "118      444  TA228          2011-01-01     MTA   \n",
       "119      445  TA228          2011-01-01     MTA   \n",
       "138      486  TA259          2012-01-01     STA   \n",
       "140      492  TA265          2012-01-01     MTA   \n",
       "156      545  TA311          2014-01-01     STA   \n",
       "157      553  TA316          2014-01-01     STA   \n",
       "181      631  TA376          2015-01-01     STA   \n",
       "182      632  TA377          2015-01-01     STA   \n",
       "184      635  TA380          2015-01-01     STA   \n",
       "188      647  TA387          2016-01-01     STA   \n",
       "195      658  TA391          2016-01-01     STA   \n",
       "203      671  TA404          2016-01-01     STA   \n",
       "209      679  TA412          2016-01-01     STA   \n",
       "223      699  TA427          2016-01-01     STA   \n",
       "245      735  TA457          2017-01-01     STA   \n",
       "272      809  TA505          2017-01-01     STA   \n",
       "274      814  TA510          2017-01-01     STA   \n",
       "325      889  TA573          2019-01-01     STA   \n",
       "334      902  TA586          2019-01-01     STA   \n",
       "335      903  TA587          2019-01-01     STA   \n",
       "376      974  TA657          2020-01-01     STA   \n",
       "377      975  TA658          2020-01-01     STA   \n",
       "378      977  TA660          2020-01-01     STA   \n",
       "390     1004  TA680          2020-01-01     STA   \n",
       "403     1022  TA695          2021-01-01     STA   \n",
       "411     1040  TA712          2021-01-01     STA   \n",
       "427     1074  TA740          2021-01-01     STA   \n",
       "428     1075  TA741          2021-01-01     STA   \n",
       "439     1099  TA763          2021-01-01     STA   \n",
       "450     1119  TA783          2022-01-01     STA   \n",
       "491     1209  TA870          2022-01-01     STA   \n",
       "\n",
       "                                            Technology Technology type  \\\n",
       "51                                           Docetaxel  Pharmaceutical   \n",
       "67                                          Bortezomib  Pharmaceutical   \n",
       "78                                        Lenalidomide  Pharmaceutical   \n",
       "118  Thalidomide in combination with an alkylating ...  Pharmaceutical   \n",
       "119  Bortezomib in combination with an alkylating a...  Pharmaceutical   \n",
       "138  Abiraterone in combination with prednisolone o...  Pharmaceutical   \n",
       "140                                          Denosumab  Pharmaceutical   \n",
       "156  Bortezomib in combination with dexamethasone, ...  Pharmaceutical   \n",
       "157                                       Enzalutamide  Pharmaceutical   \n",
       "181                              Radium-223 dichloride  Pharmaceutical   \n",
       "182                                       Enzalutamide  Pharmaceutical   \n",
       "184  Panobinostat in combination with bortezomib an...  Pharmaceutical   \n",
       "188  Abiraterone in combination with prednisone or ...  Pharmaceutical   \n",
       "195  Cabazitaxel in combination with prednisone or ...  Pharmaceutical   \n",
       "203                                          Degarelix  Pharmaceutical   \n",
       "209                              Radium‑223 dichloride  Pharmaceutical   \n",
       "223  Pomalidomide, in combination with low‑dose dex...  Pharmaceutical   \n",
       "245      Carfilzomib in combination with dexamethasone  Pharmaceutical   \n",
       "272       Ixazomib with lenalidomide and dexamethasone  Pharmaceutical   \n",
       "274                           Daratumumab monotherapy   Pharmaceutical   \n",
       "325                                        Daratumumab  Pharmaceutical   \n",
       "334                    Lenalidomide with dexamethasone  Pharmaceutical   \n",
       "335                    Lenalidomide with dexamethasone  Pharmaceutical   \n",
       "376  Carfilzomib for previously treated multiple my...  Pharmaceutical   \n",
       "377    Isatuximab with pomalidomide and dexamethasone   Pharmaceutical   \n",
       "378    Darolutamide with androgen deprivation therapy   Pharmaceutical   \n",
       "390                                      Lenalidomide   Pharmaceutical   \n",
       "403    Carfilzomib with dexamethasone and lenalidomide  Pharmaceutical   \n",
       "411                                       Enzalutamide  Pharmaceutical   \n",
       "427      Apalutamide with androgen deprivation therapy  Pharmaceutical   \n",
       "428     Apalutamide with androgen deprivation therapy   Pharmaceutical   \n",
       "439                        Daratumumab in combination   Pharmaceutical   \n",
       "450  Daratumumab monotherapy for treating relapsed ...  Pharmaceutical   \n",
       "491       Ixazomib with lenalidomide and dexamethasone  Pharmaceutical   \n",
       "\n",
       "                                            Indication  \\\n",
       "51                prostate cancer (hormone-refractory)   \n",
       "67                                    multiple myeloma   \n",
       "78                                  multiple  myeloma    \n",
       "118                                   multiple myeloma   \n",
       "119                                   multiple myeloma   \n",
       "138  treatment of castration-resistant metastatic p...   \n",
       "140  prevention of skeletal-related events in adult...   \n",
       "156  for induction therapy in multiple myeloma befo...   \n",
       "157        metastatic hormone-relapsed prostate cancer   \n",
       "181  treating hormone-relapsed prostate cancer with...   \n",
       "182  treating metastatic hormone-relapsed prostate ...   \n",
       "184  treating multiple myeloma after at least 2 pre...   \n",
       "188  treating metastatic hormone-relapsed prostate ...   \n",
       "195  treating hormone-relapsed metastatic prostate ...   \n",
       "203         advanced hormone-dependent prostate cancer   \n",
       "209  treating hormone-relapsed prostate cancer with...   \n",
       "223  multiple myeloma previously treated with lenal...   \n",
       "245                previously treated multiple myeloma   \n",
       "272            relapsed or refractory multiple myeloma   \n",
       "274           relapsed and refractory multiple myeloma   \n",
       "325                                   multiple myeloma   \n",
       "334  multiple myeloma in adults who have hade at le...   \n",
       "335  previously untreated multiple myeloma who are ...   \n",
       "376                previously treated multiple myeloma   \n",
       "377           relapsed and refractory multiple myeloma   \n",
       "378    hormone-relapsed non-metastatic prostate cancer   \n",
       "390  maintenance treatment after an autologous stem...   \n",
       "403                previously treated multiple myeloma   \n",
       "411       hormone-sensitive metastatic prostate cancer   \n",
       "427  high-risk hormone-relapsed non-metastatic pros...   \n",
       "428      hormone-sensitive metastatic prostate cancer    \n",
       "439  multiple myeloma when a stem cell transplant i...   \n",
       "450           relapsed and refractory multiple myeloma   \n",
       "491            relapsed or refractory multiple myeloma   \n",
       "\n",
       "    Categorisation (for specific recommendation)  \\\n",
       "51                                   Recommended   \n",
       "67                                   Recommended   \n",
       "78                                   Recommended   \n",
       "118                                  Recommended   \n",
       "119                                    Optimised   \n",
       "138                                  Recommended   \n",
       "140                                  Recommended   \n",
       "156                                  Recommended   \n",
       "157                                  Recommended   \n",
       "181                                    Optimised   \n",
       "182                                  Recommended   \n",
       "184                                  Recommended   \n",
       "188                                  Recommended   \n",
       "195                                  Recommended   \n",
       "203                                    Optimised   \n",
       "209                                    Optimised   \n",
       "223                                  Recommended   \n",
       "245                                    Optimised   \n",
       "272                              Optimised (CDF)   \n",
       "274                              Optimised (CDF)   \n",
       "325                            Recommended (CDF)   \n",
       "334                                    Optimised   \n",
       "335                                    Optimised   \n",
       "376                                  Recommended   \n",
       "377                            Recommended (CDF)   \n",
       "378                                  Recommended   \n",
       "390                                    Optimised   \n",
       "403                                    Optimised   \n",
       "411                                  Recommended   \n",
       "427                                  Recommended   \n",
       "428                                    Optimised   \n",
       "439                                  Recommended   \n",
       "450                                    Optimised   \n",
       "491                                    Optimised   \n",
       "\n",
       "                                               Comment  year  \n",
       "51   Recommendation in line with marketing authoris...  2006  \n",
       "67   Recommended after agreement of Patient Access ...  2007  \n",
       "78   Recommended following agreement on Patient Acc...  2009  \n",
       "118  Recommended in line with marketing authorisation.  2011  \n",
       "119  Optimised recommendation for use in specific c...  2011  \n",
       "138  Recommended in line with marketing authorisati...  2012  \n",
       "140  Recommended in line with clinical practice fol...  2012  \n",
       "156  Recommended in line with marketing authorisation.  2014  \n",
       "157  Recommended in line with marketing authorisati...  2014  \n",
       "181  Optimised recommendation for Radium‑223 dichlo...  2015  \n",
       "182  Recommended in line with marketing authorisati...  2015  \n",
       "184  Recommended in line with marketing authorisati...  2015  \n",
       "188  Recommended in line with the marketing authori...  2016  \n",
       "195  Recommended in line with clinical practice and...  2016  \n",
       "203  Optimised recommendation for degarelix as an o...  2016  \n",
       "209  Optimised recommendation for radium‑223 dichlo...  2016  \n",
       "223  Recommended in line with clinical practice and...  2016  \n",
       "245  Optmised recommendation for carfilzomib in com...  2017  \n",
       "272  Optimised recommendation for ixazomib, with le...  2017  \n",
       "274  Optimised recommendation for  daratumumab mono...  2017  \n",
       "325                             Recommended in the CDF  2019  \n",
       "334  Optimised recommendation for lenalidomide plus...  2019  \n",
       "335  Optimised recommendation for lenalidomide plus...  2019  \n",
       "376  Reissue of TA457 to allow previous treatment w...  2020  \n",
       "377  Isatuximab, plus pomalidomide and dexamethason...  2020  \n",
       "378  Recommended in line with the marketing autoris...  2020  \n",
       "390  Optimised recommendation for lenalidomide as m...  2020  \n",
       "403  Optimised recommenation for treating multiple ...  2021  \n",
       "411  Recommended in line with the marketing authori...  2021  \n",
       "427  Recommended in line with clinical practice and...  2021  \n",
       "428  Optimised recommendation for treating hormone-...  2021  \n",
       "439  Recommended in line with marketing authorisati...  2021  \n",
       "450  CDF review of TA510 Optimised recommenation fo...  2022  \n",
       "491  Review of TA505. Optimised recommenation for i...  2022  "
      ]
     },
     "execution_count": 234,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cancers_black_asian"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 235,
   "metadata": {},
   "outputs": [],
   "source": [
    "sorted_cancers_black_asian = cancers_black_asian.sort_values(by=['Technology', 'year'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 236,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rec no.</th>\n",
       "      <th>TA ID</th>\n",
       "      <th>Year of Publication</th>\n",
       "      <th>Process</th>\n",
       "      <th>Technology</th>\n",
       "      <th>Technology type</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Categorisation (for specific recommendation)</th>\n",
       "      <th>Comment</th>\n",
       "      <th>year</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>274</th>\n",
       "      <td>814</td>\n",
       "      <td>TA510</td>\n",
       "      <td>2017-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Daratumumab monotherapy</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>relapsed and refractory multiple myeloma</td>\n",
       "      <td>Optimised (CDF)</td>\n",
       "      <td>Optimised recommendation for  daratumumab mono...</td>\n",
       "      <td>2017</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>138</th>\n",
       "      <td>486</td>\n",
       "      <td>TA259</td>\n",
       "      <td>2012-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Abiraterone in combination with prednisolone o...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treatment of castration-resistant metastatic p...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2012</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>188</th>\n",
       "      <td>647</td>\n",
       "      <td>TA387</td>\n",
       "      <td>2016-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Abiraterone in combination with prednisone or ...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treating metastatic hormone-relapsed prostate ...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with the marketing authori...</td>\n",
       "      <td>2016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>427</th>\n",
       "      <td>1074</td>\n",
       "      <td>TA740</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Apalutamide with androgen deprivation therapy</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>high-risk hormone-relapsed non-metastatic pros...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with clinical practice and...</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>428</th>\n",
       "      <td>1075</td>\n",
       "      <td>TA741</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Apalutamide with androgen deprivation therapy</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>hormone-sensitive metastatic prostate cancer</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for treating hormone-...</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>280</td>\n",
       "      <td>TA129</td>\n",
       "      <td>2007-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Bortezomib</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended after agreement of Patient Access ...</td>\n",
       "      <td>2007</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>119</th>\n",
       "      <td>445</td>\n",
       "      <td>TA228</td>\n",
       "      <td>2011-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Bortezomib in combination with an alkylating a...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for use in specific c...</td>\n",
       "      <td>2011</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>156</th>\n",
       "      <td>545</td>\n",
       "      <td>TA311</td>\n",
       "      <td>2014-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Bortezomib in combination with dexamethasone, ...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>for induction therapy in multiple myeloma befo...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisation.</td>\n",
       "      <td>2014</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195</th>\n",
       "      <td>658</td>\n",
       "      <td>TA391</td>\n",
       "      <td>2016-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Cabazitaxel in combination with prednisone or ...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treating hormone-relapsed metastatic prostate ...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with clinical practice and...</td>\n",
       "      <td>2016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>376</th>\n",
       "      <td>974</td>\n",
       "      <td>TA657</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Carfilzomib for previously treated multiple my...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>previously treated multiple myeloma</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Reissue of TA457 to allow previous treatment w...</td>\n",
       "      <td>2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>245</th>\n",
       "      <td>735</td>\n",
       "      <td>TA457</td>\n",
       "      <td>2017-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Carfilzomib in combination with dexamethasone</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>previously treated multiple myeloma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optmised recommendation for carfilzomib in com...</td>\n",
       "      <td>2017</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>403</th>\n",
       "      <td>1022</td>\n",
       "      <td>TA695</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Carfilzomib with dexamethasone and lenalidomide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>previously treated multiple myeloma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommenation for treating multiple ...</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>325</th>\n",
       "      <td>889</td>\n",
       "      <td>TA573</td>\n",
       "      <td>2019-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Daratumumab</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Recommended (CDF)</td>\n",
       "      <td>Recommended in the CDF</td>\n",
       "      <td>2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>439</th>\n",
       "      <td>1099</td>\n",
       "      <td>TA763</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Daratumumab in combination</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma when a stem cell transplant i...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>450</th>\n",
       "      <td>1119</td>\n",
       "      <td>TA783</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Daratumumab monotherapy for treating relapsed ...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>relapsed and refractory multiple myeloma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>CDF review of TA510 Optimised recommenation fo...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>378</th>\n",
       "      <td>977</td>\n",
       "      <td>TA660</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Darolutamide with androgen deprivation therapy</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>hormone-relapsed non-metastatic prostate cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with the marketing autoris...</td>\n",
       "      <td>2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>203</th>\n",
       "      <td>671</td>\n",
       "      <td>TA404</td>\n",
       "      <td>2016-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Degarelix</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>advanced hormone-dependent prostate cancer</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for degarelix as an o...</td>\n",
       "      <td>2016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>492</td>\n",
       "      <td>TA265</td>\n",
       "      <td>2012-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Denosumab</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>prevention of skeletal-related events in adult...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with clinical practice fol...</td>\n",
       "      <td>2012</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>239</td>\n",
       "      <td>TA101</td>\n",
       "      <td>2006-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Docetaxel</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>prostate cancer (hormone-refractory)</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommendation in line with marketing authoris...</td>\n",
       "      <td>2006</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>157</th>\n",
       "      <td>553</td>\n",
       "      <td>TA316</td>\n",
       "      <td>2014-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Enzalutamide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>metastatic hormone-relapsed prostate cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2014</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>182</th>\n",
       "      <td>632</td>\n",
       "      <td>TA377</td>\n",
       "      <td>2015-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Enzalutamide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treating metastatic hormone-relapsed prostate ...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2015</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>411</th>\n",
       "      <td>1040</td>\n",
       "      <td>TA712</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Enzalutamide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>hormone-sensitive metastatic prostate cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with the marketing authori...</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>377</th>\n",
       "      <td>975</td>\n",
       "      <td>TA658</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Isatuximab with pomalidomide and dexamethasone</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>relapsed and refractory multiple myeloma</td>\n",
       "      <td>Recommended (CDF)</td>\n",
       "      <td>Isatuximab, plus pomalidomide and dexamethason...</td>\n",
       "      <td>2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>272</th>\n",
       "      <td>809</td>\n",
       "      <td>TA505</td>\n",
       "      <td>2017-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Ixazomib with lenalidomide and dexamethasone</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>relapsed or refractory multiple myeloma</td>\n",
       "      <td>Optimised (CDF)</td>\n",
       "      <td>Optimised recommendation for ixazomib, with le...</td>\n",
       "      <td>2017</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>491</th>\n",
       "      <td>1209</td>\n",
       "      <td>TA870</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Ixazomib with lenalidomide and dexamethasone</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>relapsed or refractory multiple myeloma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Review of TA505. Optimised recommenation for i...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>351</td>\n",
       "      <td>TA171</td>\n",
       "      <td>2009-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Lenalidomide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple  myeloma</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended following agreement on Patient Acc...</td>\n",
       "      <td>2009</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>390</th>\n",
       "      <td>1004</td>\n",
       "      <td>TA680</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Lenalidomide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>maintenance treatment after an autologous stem...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for lenalidomide as m...</td>\n",
       "      <td>2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>334</th>\n",
       "      <td>902</td>\n",
       "      <td>TA586</td>\n",
       "      <td>2019-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Lenalidomide with dexamethasone</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma in adults who have hade at le...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for lenalidomide plus...</td>\n",
       "      <td>2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>335</th>\n",
       "      <td>903</td>\n",
       "      <td>TA587</td>\n",
       "      <td>2019-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Lenalidomide with dexamethasone</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>previously untreated multiple myeloma who are ...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for lenalidomide plus...</td>\n",
       "      <td>2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>184</th>\n",
       "      <td>635</td>\n",
       "      <td>TA380</td>\n",
       "      <td>2015-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Panobinostat in combination with bortezomib an...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treating multiple myeloma after at least 2 pre...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2015</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>223</th>\n",
       "      <td>699</td>\n",
       "      <td>TA427</td>\n",
       "      <td>2016-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Pomalidomide, in combination with low‑dose dex...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma previously treated with lenal...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with clinical practice and...</td>\n",
       "      <td>2016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>181</th>\n",
       "      <td>631</td>\n",
       "      <td>TA376</td>\n",
       "      <td>2015-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Radium-223 dichloride</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treating hormone-relapsed prostate cancer with...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for Radium‑223 dichlo...</td>\n",
       "      <td>2015</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>209</th>\n",
       "      <td>679</td>\n",
       "      <td>TA412</td>\n",
       "      <td>2016-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Radium‑223 dichloride</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treating hormone-relapsed prostate cancer with...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for radium‑223 dichlo...</td>\n",
       "      <td>2016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>118</th>\n",
       "      <td>444</td>\n",
       "      <td>TA228</td>\n",
       "      <td>2011-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Thalidomide in combination with an alkylating ...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisation.</td>\n",
       "      <td>2011</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     Rec no.  TA ID Year of Publication Process  \\\n",
       "274      814  TA510          2017-01-01     STA   \n",
       "138      486  TA259          2012-01-01     STA   \n",
       "188      647  TA387          2016-01-01     STA   \n",
       "427     1074  TA740          2021-01-01     STA   \n",
       "428     1075  TA741          2021-01-01     STA   \n",
       "67       280  TA129          2007-01-01     STA   \n",
       "119      445  TA228          2011-01-01     MTA   \n",
       "156      545  TA311          2014-01-01     STA   \n",
       "195      658  TA391          2016-01-01     STA   \n",
       "376      974  TA657          2020-01-01     STA   \n",
       "245      735  TA457          2017-01-01     STA   \n",
       "403     1022  TA695          2021-01-01     STA   \n",
       "325      889  TA573          2019-01-01     STA   \n",
       "439     1099  TA763          2021-01-01     STA   \n",
       "450     1119  TA783          2022-01-01     STA   \n",
       "378      977  TA660          2020-01-01     STA   \n",
       "203      671  TA404          2016-01-01     STA   \n",
       "140      492  TA265          2012-01-01     MTA   \n",
       "51       239  TA101          2006-01-01     MTA   \n",
       "157      553  TA316          2014-01-01     STA   \n",
       "182      632  TA377          2015-01-01     STA   \n",
       "411     1040  TA712          2021-01-01     STA   \n",
       "377      975  TA658          2020-01-01     STA   \n",
       "272      809  TA505          2017-01-01     STA   \n",
       "491     1209  TA870          2022-01-01     STA   \n",
       "78       351  TA171          2009-01-01     STA   \n",
       "390     1004  TA680          2020-01-01     STA   \n",
       "334      902  TA586          2019-01-01     STA   \n",
       "335      903  TA587          2019-01-01     STA   \n",
       "184      635  TA380          2015-01-01     STA   \n",
       "223      699  TA427          2016-01-01     STA   \n",
       "181      631  TA376          2015-01-01     STA   \n",
       "209      679  TA412          2016-01-01     STA   \n",
       "118      444  TA228          2011-01-01     MTA   \n",
       "\n",
       "                                            Technology Technology type  \\\n",
       "274                           Daratumumab monotherapy   Pharmaceutical   \n",
       "138  Abiraterone in combination with prednisolone o...  Pharmaceutical   \n",
       "188  Abiraterone in combination with prednisone or ...  Pharmaceutical   \n",
       "427      Apalutamide with androgen deprivation therapy  Pharmaceutical   \n",
       "428     Apalutamide with androgen deprivation therapy   Pharmaceutical   \n",
       "67                                          Bortezomib  Pharmaceutical   \n",
       "119  Bortezomib in combination with an alkylating a...  Pharmaceutical   \n",
       "156  Bortezomib in combination with dexamethasone, ...  Pharmaceutical   \n",
       "195  Cabazitaxel in combination with prednisone or ...  Pharmaceutical   \n",
       "376  Carfilzomib for previously treated multiple my...  Pharmaceutical   \n",
       "245      Carfilzomib in combination with dexamethasone  Pharmaceutical   \n",
       "403    Carfilzomib with dexamethasone and lenalidomide  Pharmaceutical   \n",
       "325                                        Daratumumab  Pharmaceutical   \n",
       "439                        Daratumumab in combination   Pharmaceutical   \n",
       "450  Daratumumab monotherapy for treating relapsed ...  Pharmaceutical   \n",
       "378    Darolutamide with androgen deprivation therapy   Pharmaceutical   \n",
       "203                                          Degarelix  Pharmaceutical   \n",
       "140                                          Denosumab  Pharmaceutical   \n",
       "51                                           Docetaxel  Pharmaceutical   \n",
       "157                                       Enzalutamide  Pharmaceutical   \n",
       "182                                       Enzalutamide  Pharmaceutical   \n",
       "411                                       Enzalutamide  Pharmaceutical   \n",
       "377    Isatuximab with pomalidomide and dexamethasone   Pharmaceutical   \n",
       "272       Ixazomib with lenalidomide and dexamethasone  Pharmaceutical   \n",
       "491       Ixazomib with lenalidomide and dexamethasone  Pharmaceutical   \n",
       "78                                        Lenalidomide  Pharmaceutical   \n",
       "390                                      Lenalidomide   Pharmaceutical   \n",
       "334                    Lenalidomide with dexamethasone  Pharmaceutical   \n",
       "335                    Lenalidomide with dexamethasone  Pharmaceutical   \n",
       "184  Panobinostat in combination with bortezomib an...  Pharmaceutical   \n",
       "223  Pomalidomide, in combination with low‑dose dex...  Pharmaceutical   \n",
       "181                              Radium-223 dichloride  Pharmaceutical   \n",
       "209                              Radium‑223 dichloride  Pharmaceutical   \n",
       "118  Thalidomide in combination with an alkylating ...  Pharmaceutical   \n",
       "\n",
       "                                            Indication  \\\n",
       "274           relapsed and refractory multiple myeloma   \n",
       "138  treatment of castration-resistant metastatic p...   \n",
       "188  treating metastatic hormone-relapsed prostate ...   \n",
       "427  high-risk hormone-relapsed non-metastatic pros...   \n",
       "428      hormone-sensitive metastatic prostate cancer    \n",
       "67                                    multiple myeloma   \n",
       "119                                   multiple myeloma   \n",
       "156  for induction therapy in multiple myeloma befo...   \n",
       "195  treating hormone-relapsed metastatic prostate ...   \n",
       "376                previously treated multiple myeloma   \n",
       "245                previously treated multiple myeloma   \n",
       "403                previously treated multiple myeloma   \n",
       "325                                   multiple myeloma   \n",
       "439  multiple myeloma when a stem cell transplant i...   \n",
       "450           relapsed and refractory multiple myeloma   \n",
       "378    hormone-relapsed non-metastatic prostate cancer   \n",
       "203         advanced hormone-dependent prostate cancer   \n",
       "140  prevention of skeletal-related events in adult...   \n",
       "51                prostate cancer (hormone-refractory)   \n",
       "157        metastatic hormone-relapsed prostate cancer   \n",
       "182  treating metastatic hormone-relapsed prostate ...   \n",
       "411       hormone-sensitive metastatic prostate cancer   \n",
       "377           relapsed and refractory multiple myeloma   \n",
       "272            relapsed or refractory multiple myeloma   \n",
       "491            relapsed or refractory multiple myeloma   \n",
       "78                                  multiple  myeloma    \n",
       "390  maintenance treatment after an autologous stem...   \n",
       "334  multiple myeloma in adults who have hade at le...   \n",
       "335  previously untreated multiple myeloma who are ...   \n",
       "184  treating multiple myeloma after at least 2 pre...   \n",
       "223  multiple myeloma previously treated with lenal...   \n",
       "181  treating hormone-relapsed prostate cancer with...   \n",
       "209  treating hormone-relapsed prostate cancer with...   \n",
       "118                                   multiple myeloma   \n",
       "\n",
       "    Categorisation (for specific recommendation)  \\\n",
       "274                              Optimised (CDF)   \n",
       "138                                  Recommended   \n",
       "188                                  Recommended   \n",
       "427                                  Recommended   \n",
       "428                                    Optimised   \n",
       "67                                   Recommended   \n",
       "119                                    Optimised   \n",
       "156                                  Recommended   \n",
       "195                                  Recommended   \n",
       "376                                  Recommended   \n",
       "245                                    Optimised   \n",
       "403                                    Optimised   \n",
       "325                            Recommended (CDF)   \n",
       "439                                  Recommended   \n",
       "450                                    Optimised   \n",
       "378                                  Recommended   \n",
       "203                                    Optimised   \n",
       "140                                  Recommended   \n",
       "51                                   Recommended   \n",
       "157                                  Recommended   \n",
       "182                                  Recommended   \n",
       "411                                  Recommended   \n",
       "377                            Recommended (CDF)   \n",
       "272                              Optimised (CDF)   \n",
       "491                                    Optimised   \n",
       "78                                   Recommended   \n",
       "390                                    Optimised   \n",
       "334                                    Optimised   \n",
       "335                                    Optimised   \n",
       "184                                  Recommended   \n",
       "223                                  Recommended   \n",
       "181                                    Optimised   \n",
       "209                                    Optimised   \n",
       "118                                  Recommended   \n",
       "\n",
       "                                               Comment  year  \n",
       "274  Optimised recommendation for  daratumumab mono...  2017  \n",
       "138  Recommended in line with marketing authorisati...  2012  \n",
       "188  Recommended in line with the marketing authori...  2016  \n",
       "427  Recommended in line with clinical practice and...  2021  \n",
       "428  Optimised recommendation for treating hormone-...  2021  \n",
       "67   Recommended after agreement of Patient Access ...  2007  \n",
       "119  Optimised recommendation for use in specific c...  2011  \n",
       "156  Recommended in line with marketing authorisation.  2014  \n",
       "195  Recommended in line with clinical practice and...  2016  \n",
       "376  Reissue of TA457 to allow previous treatment w...  2020  \n",
       "245  Optmised recommendation for carfilzomib in com...  2017  \n",
       "403  Optimised recommenation for treating multiple ...  2021  \n",
       "325                             Recommended in the CDF  2019  \n",
       "439  Recommended in line with marketing authorisati...  2021  \n",
       "450  CDF review of TA510 Optimised recommenation fo...  2022  \n",
       "378  Recommended in line with the marketing autoris...  2020  \n",
       "203  Optimised recommendation for degarelix as an o...  2016  \n",
       "140  Recommended in line with clinical practice fol...  2012  \n",
       "51   Recommendation in line with marketing authoris...  2006  \n",
       "157  Recommended in line with marketing authorisati...  2014  \n",
       "182  Recommended in line with marketing authorisati...  2015  \n",
       "411  Recommended in line with the marketing authori...  2021  \n",
       "377  Isatuximab, plus pomalidomide and dexamethason...  2020  \n",
       "272  Optimised recommendation for ixazomib, with le...  2017  \n",
       "491  Review of TA505. Optimised recommenation for i...  2022  \n",
       "78   Recommended following agreement on Patient Acc...  2009  \n",
       "390  Optimised recommendation for lenalidomide as m...  2020  \n",
       "334  Optimised recommendation for lenalidomide plus...  2019  \n",
       "335  Optimised recommendation for lenalidomide plus...  2019  \n",
       "184  Recommended in line with marketing authorisati...  2015  \n",
       "223  Recommended in line with clinical practice and...  2016  \n",
       "181  Optimised recommendation for Radium‑223 dichlo...  2015  \n",
       "209  Optimised recommendation for radium‑223 dichlo...  2016  \n",
       "118  Recommended in line with marketing authorisation.  2011  "
      ]
     },
     "execution_count": 236,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sorted_cancers_black_asian"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 237,
   "metadata": {},
   "outputs": [],
   "source": [
    "sorted_cancers_black_asian.to_csv('/project/approved_drugs_charts_data/sorted_cancers_black_asian.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "By exploring the above dataframe, we can find the latest year which each drug was approved. This will allow us to search the trials from that year and before which focused on that drug.\n",
    "\n",
    "I will exclude the technologies which are a combination of two drugs."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 238,
   "metadata": {},
   "outputs": [],
   "source": [
    "filtered_cancers_black_asian = sorted_cancers_black_asian[~sorted_cancers_black_asian['Technology'].str.contains(r'\\bin|\\bwith', case=False)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 239,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rec no.</th>\n",
       "      <th>TA ID</th>\n",
       "      <th>Year of Publication</th>\n",
       "      <th>Process</th>\n",
       "      <th>Technology</th>\n",
       "      <th>Technology type</th>\n",
       "      <th>Indication</th>\n",
       "      <th>Categorisation (for specific recommendation)</th>\n",
       "      <th>Comment</th>\n",
       "      <th>year</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>274</th>\n",
       "      <td>814</td>\n",
       "      <td>TA510</td>\n",
       "      <td>2017-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Daratumumab monotherapy</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>relapsed and refractory multiple myeloma</td>\n",
       "      <td>Optimised (CDF)</td>\n",
       "      <td>Optimised recommendation for  daratumumab mono...</td>\n",
       "      <td>2017</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>280</td>\n",
       "      <td>TA129</td>\n",
       "      <td>2007-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Bortezomib</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended after agreement of Patient Access ...</td>\n",
       "      <td>2007</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>376</th>\n",
       "      <td>974</td>\n",
       "      <td>TA657</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Carfilzomib for previously treated multiple my...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>previously treated multiple myeloma</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Reissue of TA457 to allow previous treatment w...</td>\n",
       "      <td>2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>325</th>\n",
       "      <td>889</td>\n",
       "      <td>TA573</td>\n",
       "      <td>2019-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Daratumumab</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple myeloma</td>\n",
       "      <td>Recommended (CDF)</td>\n",
       "      <td>Recommended in the CDF</td>\n",
       "      <td>2019</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>450</th>\n",
       "      <td>1119</td>\n",
       "      <td>TA783</td>\n",
       "      <td>2022-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Daratumumab monotherapy for treating relapsed ...</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>relapsed and refractory multiple myeloma</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>CDF review of TA510 Optimised recommenation fo...</td>\n",
       "      <td>2022</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>203</th>\n",
       "      <td>671</td>\n",
       "      <td>TA404</td>\n",
       "      <td>2016-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Degarelix</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>advanced hormone-dependent prostate cancer</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for degarelix as an o...</td>\n",
       "      <td>2016</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>492</td>\n",
       "      <td>TA265</td>\n",
       "      <td>2012-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Denosumab</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>prevention of skeletal-related events in adult...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with clinical practice fol...</td>\n",
       "      <td>2012</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>239</td>\n",
       "      <td>TA101</td>\n",
       "      <td>2006-01-01</td>\n",
       "      <td>MTA</td>\n",
       "      <td>Docetaxel</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>prostate cancer (hormone-refractory)</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommendation in line with marketing authoris...</td>\n",
       "      <td>2006</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>157</th>\n",
       "      <td>553</td>\n",
       "      <td>TA316</td>\n",
       "      <td>2014-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Enzalutamide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>metastatic hormone-relapsed prostate cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2014</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>182</th>\n",
       "      <td>632</td>\n",
       "      <td>TA377</td>\n",
       "      <td>2015-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Enzalutamide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treating metastatic hormone-relapsed prostate ...</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with marketing authorisati...</td>\n",
       "      <td>2015</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>411</th>\n",
       "      <td>1040</td>\n",
       "      <td>TA712</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Enzalutamide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>hormone-sensitive metastatic prostate cancer</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended in line with the marketing authori...</td>\n",
       "      <td>2021</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>351</td>\n",
       "      <td>TA171</td>\n",
       "      <td>2009-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Lenalidomide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>multiple  myeloma</td>\n",
       "      <td>Recommended</td>\n",
       "      <td>Recommended following agreement on Patient Acc...</td>\n",
       "      <td>2009</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>390</th>\n",
       "      <td>1004</td>\n",
       "      <td>TA680</td>\n",
       "      <td>2020-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Lenalidomide</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>maintenance treatment after an autologous stem...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for lenalidomide as m...</td>\n",
       "      <td>2020</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>181</th>\n",
       "      <td>631</td>\n",
       "      <td>TA376</td>\n",
       "      <td>2015-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Radium-223 dichloride</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treating hormone-relapsed prostate cancer with...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for Radium‑223 dichlo...</td>\n",
       "      <td>2015</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>209</th>\n",
       "      <td>679</td>\n",
       "      <td>TA412</td>\n",
       "      <td>2016-01-01</td>\n",
       "      <td>STA</td>\n",
       "      <td>Radium‑223 dichloride</td>\n",
       "      <td>Pharmaceutical</td>\n",
       "      <td>treating hormone-relapsed prostate cancer with...</td>\n",
       "      <td>Optimised</td>\n",
       "      <td>Optimised recommendation for radium‑223 dichlo...</td>\n",
       "      <td>2016</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     Rec no.  TA ID Year of Publication Process  \\\n",
       "274      814  TA510          2017-01-01     STA   \n",
       "67       280  TA129          2007-01-01     STA   \n",
       "376      974  TA657          2020-01-01     STA   \n",
       "325      889  TA573          2019-01-01     STA   \n",
       "450     1119  TA783          2022-01-01     STA   \n",
       "203      671  TA404          2016-01-01     STA   \n",
       "140      492  TA265          2012-01-01     MTA   \n",
       "51       239  TA101          2006-01-01     MTA   \n",
       "157      553  TA316          2014-01-01     STA   \n",
       "182      632  TA377          2015-01-01     STA   \n",
       "411     1040  TA712          2021-01-01     STA   \n",
       "78       351  TA171          2009-01-01     STA   \n",
       "390     1004  TA680          2020-01-01     STA   \n",
       "181      631  TA376          2015-01-01     STA   \n",
       "209      679  TA412          2016-01-01     STA   \n",
       "\n",
       "                                            Technology Technology type  \\\n",
       "274                           Daratumumab monotherapy   Pharmaceutical   \n",
       "67                                          Bortezomib  Pharmaceutical   \n",
       "376  Carfilzomib for previously treated multiple my...  Pharmaceutical   \n",
       "325                                        Daratumumab  Pharmaceutical   \n",
       "450  Daratumumab monotherapy for treating relapsed ...  Pharmaceutical   \n",
       "203                                          Degarelix  Pharmaceutical   \n",
       "140                                          Denosumab  Pharmaceutical   \n",
       "51                                           Docetaxel  Pharmaceutical   \n",
       "157                                       Enzalutamide  Pharmaceutical   \n",
       "182                                       Enzalutamide  Pharmaceutical   \n",
       "411                                       Enzalutamide  Pharmaceutical   \n",
       "78                                        Lenalidomide  Pharmaceutical   \n",
       "390                                      Lenalidomide   Pharmaceutical   \n",
       "181                              Radium-223 dichloride  Pharmaceutical   \n",
       "209                              Radium‑223 dichloride  Pharmaceutical   \n",
       "\n",
       "                                            Indication  \\\n",
       "274           relapsed and refractory multiple myeloma   \n",
       "67                                    multiple myeloma   \n",
       "376                previously treated multiple myeloma   \n",
       "325                                   multiple myeloma   \n",
       "450           relapsed and refractory multiple myeloma   \n",
       "203         advanced hormone-dependent prostate cancer   \n",
       "140  prevention of skeletal-related events in adult...   \n",
       "51                prostate cancer (hormone-refractory)   \n",
       "157        metastatic hormone-relapsed prostate cancer   \n",
       "182  treating metastatic hormone-relapsed prostate ...   \n",
       "411       hormone-sensitive metastatic prostate cancer   \n",
       "78                                  multiple  myeloma    \n",
       "390  maintenance treatment after an autologous stem...   \n",
       "181  treating hormone-relapsed prostate cancer with...   \n",
       "209  treating hormone-relapsed prostate cancer with...   \n",
       "\n",
       "    Categorisation (for specific recommendation)  \\\n",
       "274                              Optimised (CDF)   \n",
       "67                                   Recommended   \n",
       "376                                  Recommended   \n",
       "325                            Recommended (CDF)   \n",
       "450                                    Optimised   \n",
       "203                                    Optimised   \n",
       "140                                  Recommended   \n",
       "51                                   Recommended   \n",
       "157                                  Recommended   \n",
       "182                                  Recommended   \n",
       "411                                  Recommended   \n",
       "78                                   Recommended   \n",
       "390                                    Optimised   \n",
       "181                                    Optimised   \n",
       "209                                    Optimised   \n",
       "\n",
       "                                               Comment  year  \n",
       "274  Optimised recommendation for  daratumumab mono...  2017  \n",
       "67   Recommended after agreement of Patient Access ...  2007  \n",
       "376  Reissue of TA457 to allow previous treatment w...  2020  \n",
       "325                             Recommended in the CDF  2019  \n",
       "450  CDF review of TA510 Optimised recommenation fo...  2022  \n",
       "203  Optimised recommendation for degarelix as an o...  2016  \n",
       "140  Recommended in line with clinical practice fol...  2012  \n",
       "51   Recommendation in line with marketing authoris...  2006  \n",
       "157  Recommended in line with marketing authorisati...  2014  \n",
       "182  Recommended in line with marketing authorisati...  2015  \n",
       "411  Recommended in line with the marketing authori...  2021  \n",
       "78   Recommended following agreement on Patient Acc...  2009  \n",
       "390  Optimised recommendation for lenalidomide as m...  2020  \n",
       "181  Optimised recommendation for Radium‑223 dichlo...  2015  \n",
       "209  Optimised recommendation for radium‑223 dichlo...  2016  "
      ]
     },
     "execution_count": 239,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "filtered_cancers_black_asian"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 240,
   "metadata": {},
   "outputs": [],
   "source": [
    "filtered_cancers_black_asian.to_csv('/project/approved_drugs_charts_data/filtered_cancers_black_asian.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Now, i will search the synonyms of these drugs from PubChem and later filter the world clinical studies that tested these drugs."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 241,
   "metadata": {},
   "outputs": [],
   "source": [
    "bortezomib = [\n",
    "    \"Bortezomib\",\n",
    "    \"179324-69-7\",\n",
    "    \"Velcade\",\n",
    "    \"PS-341\",\n",
    "    \"LDP-341\",\n",
    "    \"Bortezomib (PS-341)\",\n",
    "    \"Ps 341\",\n",
    "    \"radiciol\",\n",
    "    \"Bortezomib accord\",\n",
    "    \"((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronic acid\",\n",
    "    \"DPBA\",\n",
    "    \"NSC-681239\",\n",
    "    \"C19H25BN4O4\",\n",
    "    \"Peptide boronate\",\n",
    "    \"LDP 341\",\n",
    "    \"MLN-341\",\n",
    "    \"Pyz-Phe-boroLeu\",\n",
    "    \"[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid\",\n",
    "    \"PS 341 (pharmaceutical)\",\n",
    "    \"UNII-69G8BD63PP\",\n",
    "    \"MG 341\",\n",
    "    \"Velcade (TN)\",\n",
    "    \"NSC 681239\",\n",
    "    \"69G8BD63PP\",\n",
    "    \"Bortezomib (Velcade)\",\n",
    "    \"N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE\",\n",
    "    \"DTXSID3040980\",\n",
    "    \"CHEBI:52717\",\n",
    "    \"HSDB 7666\",\n",
    "    \"MG-341\",\n",
    "    \"Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-\",\n",
    "    \"PROSCRIPT BORONIC ACID\",\n",
    "    \"Bortezomib [USAN:INN:BAN]\",\n",
    "    \"CHEMBL325041\",\n",
    "    \"DTXCID1020980\",\n",
    "    \"LPD 341\",\n",
    "    \"LPD-341\",\n",
    "    \"NSC681239\",\n",
    "    \"NCGC00242506-02\",\n",
    "    \"S1013\",\n",
    "    \"BORTEZOMIB (MART.)\",\n",
    "    \"BORTEZOMIB [MART.]\",\n",
    "    \"N-((1S)-1-Benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)-2-oxoethyl)pyrazinecarboxamide\",\n",
    "    \"(R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid\",\n",
    "    \"N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide\",\n",
    "    \"[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid\",\n",
    "    \"Boronic acid, ((1R)-3-methyl-1-(((2S)-1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-\",\n",
    "    \"N-((1S)-1-benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)2-oxoethylpyrazinecarboxamide\",\n",
    "    \"Bortezomib [USAN:INN]\",\n",
    "    \"CAS-179324-69-7\",\n",
    "    \"[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid\",\n",
    "    \"bortezomibum\",\n",
    "    \"Brotezamide\",\n",
    "    \"Bortezomib hydrate\",\n",
    "    \"Bortezomib,Velcade\",\n",
    "    \"N-((1R)-1-(DIHYDROXYBORYL)-3-methylbutyl)-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide\",\n",
    "    \"NCGC00168751-01\",\n",
    "    \"NCGC00181022-01\",\n",
    "    \"N-((1R)-1-(dihydroxyboranyl)-3-methylbutyl)-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide\",\n",
    "    \"N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide\",\n",
    "    \"Bortezomib- Bio-X\",\n",
    "    \"Bortezomib [USAN]\",\n",
    "    \"MFCD09056737\",\n",
    "    \"Velcade (Millenium)\",\n",
    "    \"3mg0\",\n",
    "    \"BORTEZOMIB [MI]\",\n",
    "    \"BORTEZOMIB [INN]\",\n",
    "    \"BORTEZOMIB [JAN]\",\n",
    "    \"BORTEZOMIB [HSDB]\",\n",
    "    \"PS-341 [Bortezomib]\",\n",
    "    \"BORTEZOMIB [VANDF]\",\n",
    "    \"D0SH3I\",\n",
    "    \"BORTEZOMIB [WHO-DD]\",\n",
    "    \"Bortezomib(JAN/USAN/INN)\",\n",
    "    \"MLS004774142\",\n",
    "    \"Bortezomib (JAN/USAN/INN)\",\n",
    "    \"BORTEZOMIB [EMA EPAR]\",\n",
    "    \"SCHEMBL192129\",\n",
    "    \"GTPL6391\",\n",
    "    \"BORTEZOMIB [ORANGE BOOK]\",\n",
    "    \"BORTEZOMIB HYDRATE [JAN]\",\n",
    "    \"Bortezomib (Proteasome inhibitor)\",\n",
    "    \"L01XX32\",\n",
    "    \"((1R)-3-Methyl-1-(((2S)-3-phenyl-2-((pyrazinylcarbonyl)amino)propanoyl)amino)butyl)boronic acid\",\n",
    "    \"[(1R)-3-Methyl-1-[[(2S)-3-phenyl-2-[(pyrazinylcarbonyl)amino]propanoyl]amino]butyl]boronic acid\",\n",
    "    \"Boronic acid, (3-methyl-1-((1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-, (S-(R*,S*))-\",\n",
    "    \"Tox21_112630\",\n",
    "    \"Tox21_112672\",\n",
    "    \"BDBM50069989\",\n",
    "    \"C19-H25-B-N4-O4\",\n",
    "    \"HB4036\",\n",
    "    \"NSC756655\",\n",
    "    \"AKOS015909706\",\n",
    "    \"Tox21_112672_1\",\n",
    "    \"AM81235\",\n",
    "    \"CCG-268449\",\n",
    "    \"CS-1039\",\n",
    "    \"CS-O-00482\",\n",
    "    \"DB00188\",\n",
    "    \"NSC-756655\",\n",
    "    \"Bortezomib (Velcade,MG-341,PS-341)\",\n",
    "    \"NCGC00242506-01\",\n",
    "    \"NCGC00242506-06\",\n",
    "    \"NCGC00242506-07\",\n",
    "    \"AS-15721\",\n",
    "    \"BB164258\",\n",
    "    \"HY-10227\",\n",
    "    \"NCI60_029010\",\n",
    "    \"SMR003500787\",\n",
    "    \"Velcade, MG-341, PS-341, Bortezomib\",\n",
    "    \"B5741\",\n",
    "    \"SW208077-3\",\n",
    "    \"A18332\",\n",
    "    \"D03150\",\n",
    "    \"EN300-657180\",\n",
    "    \"AB01273951-01\",\n",
    "    \"AB01273951-02\",\n",
    "    \"AB01273951_03\",\n",
    "    \"Q419319\",\n",
    "    \"SR-01000939863\",\n",
    "    \"SR-01000939863-2\",\n",
    "    \"BRD-K88510285-001-02-0\",\n",
    "    \"Z2213886907\",\n",
    "    \"n-(2-pyrazine)carbonyl-l-phenylalanine-l-leucine boronic acid\",\n",
    "    \"((R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butyl)boronicacid\",\n",
    "    \"(R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-6-carboxamido)propanamido)butylboronic acid\",\n",
    "    \"[(1R)-3-methyl-1-[(2S)-3-phenyl-2-[(pyrazin-2-yl)formamido]propanamido]butyl]boronic acid\",\n",
    "    \"(1R)-3-Methyl-1-({(2S)-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propanoyl}amino)butylboronic acid, AldrichCPR\",\n",
    "    \"(R)-3-METHYL-1-((S)-3-PHENYL-2-(PYRAZINE-2-CARBOXAMIDO)PROPANAMIDO)BUTAN-2-YLBORONIC ACID\",\n",
    "    \"[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]-butyl]boronic acid\",\n",
    "    \"1610526-91-4\",\n",
    "    \"Boronic acid, [(1(R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-\"\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 242,
   "metadata": {},
   "outputs": [],
   "source": [
    "carfilzomib = [\n",
    "    'Carfilzomib',\n",
    "    '868540-17-4',\n",
    "    'Kyprolis',\n",
    "    'Carfilzomib (PR-171)',\n",
    "    'PR-171',\n",
    "    'Carfilzomib (PR171)',\n",
    "    'UNII-72X6E3J5AR',\n",
    "    'Carfilzomib [USAN]',\n",
    "    'Carfilzomib [USAN:INN]',\n",
    "    'NSC-758252',\n",
    "    '72X6E3J5AR',\n",
    "    'CHEMBL451887',\n",
    "    'DTXSID4048690',\n",
    "    'CHEBI:65347',\n",
    "    'NCGC00249613-01',\n",
    "    '(2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide',\n",
    "    '(alphaS)-alpha-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyl-2-oxiranyl]carbonyl]butyl]-L-phenylalaninamide',\n",
    "    '(S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide',\n",
    "    'N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide',\n",
    "    'DTXCID0028616',\n",
    "    'C40H57N5O7',\n",
    "    '(2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide',\n",
    "    '(S)-4-Methyl-N-((S)-1-((S)-4-Methyl-1-((R)-2- Methyloxiran-2-yl)-1 -oxopentan-2-ylaMino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-MorpholinoacetaMido)-4-phenylbutanaMido)pentanaMide',\n",
    "    '(S)-4-methyl-N-((S)-1-((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide',\n",
    "    'CAS-868540-17-4',\n",
    "    'MFCD11040997',\n",
    "    'PR 171',\n",
    "    'Kyprolis (TN)',\n",
    "    '(2S)-N-[(1S)-1-Benzyl-2-[[(1S)-3-methyl-1-[[(2R)-2-methyloxiran-2-yl]carbonyl]butyl]amino]-2-oxoethyl]-4-methyl-2-[[(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide',\n",
    "    'Carfilzomib; PR171',\n",
    "    'CARFILZOMIB [MI]',\n",
    "    'CARFILZOMIB [INN]',\n",
    "    'CARFILZOMIB [JAN]',\n",
    "    'D00UVA',\n",
    "    'CARFILZOMIB [VANDF]',\n",
    "    'SCHEMBL85165',\n",
    "    'CARFILZOMIB [WHO-DD]',\n",
    "    'MLS006011102',\n",
    "    'Carfilzomib (JAN/USAN/INN)',\n",
    "    'GTPL7420',\n",
    "    'AMY4357',\n",
    "    'CARFILZOMIB [ORANGE BOOK]',\n",
    "    'EX-A2037',\n",
    "    'ONO-7057',\n",
    "    'Tox21_113079',\n",
    "    'BDBM50277889',\n",
    "    'NSC756640',\n",
    "    'NSC758252',\n",
    "    's2853',\n",
    "    'AKOS025401910',\n",
    "    'Tox21_113079_1',\n",
    "    'CCG-270405',\n",
    "    'CS-0984',\n",
    "    'CS-W004540',\n",
    "    'DB08889',\n",
    "    'NSC 758252',\n",
    "    'NSC-756640',\n",
    "    'NCGC00249613-02',\n",
    "    'NCGC00249613-03',\n",
    "    'NCGC00249613-08',\n",
    "    'NCGC00249613-11',\n",
    "    'NCGC00249613-13',\n",
    "    'AC-27051',\n",
    "    'AS-17059',\n",
    "    'HY-10455',\n",
    "    'SMR004660024',\n",
    "    'SW218090-2',\n",
    "    'D08880',\n",
    "    'AB01565867_02',\n",
    "    'SR-01000941582',\n",
    "    'J-501773',\n",
    "    'SR-01000941582-1',\n",
    "    'Q15366934',\n",
    "    '(Alphas)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-l-leucyl-n-((1s)-3-methyl-1-(((2r)-2-methyloxiranyl)carbonyl)butyl)-l-phe nylalaninamide',\n",
    "    'L-PHENYLALANINAMIDE, (.ALPHA.S)-.ALPHA.-((4-MORPHOLINYLACETYL)AMINO)BENZENEBUTANOYL-L-LEUCYL-N-((1S)-3-METHYL-1-(((2R)-2-METHYLOXIRANYL)CARBONYL)BUTYL)-',\n",
    "    'L-Phenylalaninamide, (alphaS)-alpha-((4-morpholinylacetyl)amino)benzenebutanoyl-L-leucyl-N-((1S)-3-methyl-1-(((2R)-2-methyloxiranyl)carbonyl)butyl)-'\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 243,
   "metadata": {},
   "outputs": [],
   "source": [
    "daratumumab = [\n",
    "    \"DARATUMUMAB\",\n",
    "    \"945721-28-8\",\n",
    "    \"DARATUMUMAB COMPONENT OF DARZALEX FASPRO TM\",\n",
    "    \"DARATUMUMAB [JAN]\",\n",
    "    \"DARATUMUMAB [MI]\",\n",
    "    \"DARATUMUMAB [PURPLE BOOK CDER]\",\n",
    "    \"DARATUMUMAB [USAN]\",\n",
    "    \"DARZALEX\",\n",
    "    \"DARZALEX FASPRO TM COMPONENT DARATUMUMAB\",\n",
    "    \"Daratumumab [WHO-DD]\",\n",
    "    \"HUMAX-CD 38\",\n",
    "    \"HUMAX-CD38\",\n",
    "    \"IMMUNOGLOBULIN G1, ANTI-(HUMAN CD38 (ANTIGEN)) (HUMAN MONOCLONAL 3003-005 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL 3003-005 .KAPPA.-CHAIN, DIMER\",\n",
    "    \"daratumumab [INN]\",\n",
    "    \"4Z63YK6E0E\"\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 244,
   "metadata": {},
   "outputs": [],
   "source": [
    "degarelix = [\n",
    "    'Degarelix',\n",
    "    '214766-78-6',\n",
    "    'Degarelix acetate',\n",
    "    'Firmagon',\n",
    "    'SX0XJI3A11',\n",
    "    'CHEMBL415606',\n",
    "    'FE200486 (AS ACETATE SALT)',\n",
    "    'FE200486',\n",
    "    'DEGARELIX ACETATE [JAN]',\n",
    "    'FE-200486',\n",
    "    'Uglypeptide1',\n",
    "    'Degarelix [INN]',\n",
    "    'DEGARELIX [MI]',\n",
    "    'Degarelix (INN/USAN)',\n",
    "    'DEGARELIX [HSDB]',\n",
    "    'DEGARELIX [USAN]',\n",
    "    'DEGARELIX [VANDF]',\n",
    "    'D0Y7KH',\n",
    "    'DEGARELIX [MART.]',\n",
    "    'UNII-SX0XJI3A11',\n",
    "    'DEGARELIX [WHO-DD]',\n",
    "    'DEGARELIX [EMA EPAR]',\n",
    "    'Degarelix [USAN:INN:BAN]',\n",
    "    'FE-200486 (free base)',\n",
    "    'GTPL5585',\n",
    "    'SCHEMBL1397034',\n",
    "    'SCHEMBL21050504',\n",
    "    'HSDB 7817',\n",
    "    'CHEBI:135961',\n",
    "    'DTXSID801026401',\n",
    "    'GLXC-26186',\n",
    "    'BDBM50102450',\n",
    "    'HY-16168A',\n",
    "    'NSC771648',\n",
    "    'CS-5350',\n",
    "    'DB06699',\n",
    "    'NSC-771648',\n",
    "    'FE200486 ANHYDROUS FREE BASE',\n",
    "    'FE-200486 ANHYDROUS FREE BASE',\n",
    "    'AS-82636',\n",
    "    'D08901',\n",
    "    'F85338',\n",
    "    'EN300-20626108',\n",
    "    'Q1182795',\n",
    "    'Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2',\n",
    "    'Ac-D-2Nal-D-Phe(4-Cl)-D-3Pal-Ser-Phe(4-S-dihydroorotamido)-D-Phe(4-ureido)-Leu-Lys(iPr)-Pro-D-Ala-NH2',\n",
    "    'Acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide',\n",
    "    'D-Alaninamide, N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-',\n",
    "    'N-Acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N(sup 6)-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide'\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 245,
   "metadata": {},
   "outputs": [],
   "source": [
    "denosumab = [\n",
    "    'Denosumab',\n",
    "    'Prolia',\n",
    "    'Xgeva',\n",
    "    '615258-40-7',\n",
    "    'AMG 162',\n",
    "    '4EQZ6YO2HI',\n",
    "    'AMG-162',\n",
    "    'Immunoglobulin G2, anti-(human osteoclast differentiation factor) (human monoclonal AMG162 heavy chain), disulfide with human monoclonal AMG162 light chain, dimer',\n",
    "    'M05BX04',\n",
    "    'DENOSUMAB (MART.)',\n",
    "    'DENOSUMAB (PURPLE BOOK CDER)',\n",
    "    'Denosumab Biosimilar MW032',\n",
    "    'Denosumab Biosimilar QL1206',\n",
    "    'Denosumab Biosimilar TK-006',\n",
    "    'IMMUNOGLOBULIN G2, ANTI-(HUMAN OSTEOCLAST DIFFERENTIATION FACTOR) (HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER',\n",
    "    'IMMUNOGLOBULIN G2, ANTI-(HUMAN RANK LIGAND) (HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER',\n",
    "    'IMMUNOGLOBULIN G2, ANTI-(HUMAN RANK LIGAND) (HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER',\n",
    "    'Ranmark',\n",
    "    'TK-006',\n",
    "    'UNII-4EQZ6YO2HI',\n",
    "    'denosumabum'\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 246,
   "metadata": {},
   "outputs": [],
   "source": [
    "docetaxel = [\n",
    "    'docetaxel',\n",
    "    '114977-28-5',\n",
    "    'Taxotere',\n",
    "    'Docetaxel anhydrous',\n",
    "    'Docetaxol',\n",
    "    'Docetaxel Winthrop',\n",
    "    'EmDOC',\n",
    "    'RP-56976',\n",
    "    'Docetaxolum',\n",
    "    'Docefrez',\n",
    "    'Taxoel',\n",
    "    'Docetaxel Kabi',\n",
    "    'Docetaxel [INN]',\n",
    "    'NSC 628503',\n",
    "    'Docetaxel, Trihydrate',\n",
    "    'N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol',\n",
    "    'RP 56976',\n",
    "    'taxotel',\n",
    "    'Docecad',\n",
    "    'DTXSID0040464',\n",
    "    'Docetaxel Teva',\n",
    "    'Docetaxel Accord',\n",
    "    'Taxotere(R)',\n",
    "    'TXL',\n",
    "    'Taxotere (TN)',\n",
    "    'Docetaxel, anhydrous',\n",
    "    'NSC-628503',\n",
    "    'UNII-699121PHCA',\n",
    "    'CHEBI:4672',\n",
    "    'DOCETAXEL MYLAN',\n",
    "    'Docetaxel hydrate',\n",
    "    'HSDB 6965',\n",
    "    'N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol',\n",
    "    '699121PHCA',\n",
    "    'Docetaxolum [INN-Latin]',\n",
    "    'DOCETAXEL TEVA PHARMA',\n",
    "    'docetere',\n",
    "    'N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel',\n",
    "    'docetaxel 114977-28-5',\n",
    "    'DTXCID8020464',\n",
    "    'XRP-6976L',\n",
    "    'ANX-514',\n",
    "    'SDP-014',\n",
    "    'SID 530',\n",
    "    'Docetaxel (INN)',\n",
    "    'NSC628503',\n",
    "    'N-debenzoyl-N-Boc-10-deacetyl taxol',\n",
    "    'CABAZITAXEL METABOLITE (RP56976)',\n",
    "    '[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate',\n",
    "    'Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester',\n",
    "    'DOCETAXEL (USP-RS)',\n",
    "    'UNII-15H5577CQD',\n",
    "    'Docetaxel intermediate',\n",
    "    'BIND 014',\n",
    "    'DOCETAXEL (EP MONOGRAPH)',\n",
    "    'DOCETAXEL (USP IMPURITY)',\n",
    "    'CKD-810',\n",
    "    'DOCETAXEL (USP MONOGRAPH)',\n",
    "    '(1S,2S,3R,4S,5R,7S,8S,10R,13S)-4-Acetoxy-2-benzoyloxy-5,20-epoxy-1,7,10-trihydroxy-9-oxotax-11-en-13-yl (2R,3S)-3-(1,1-dimethylethyl)oxycarbonylamino-2-hydroxy-3-phenylpropanoate',\n",
    "    '(2aR-[2a?,4?,4a?,6?,9?(?R*,?S*),11?,12?,12a?,12b?]]-?-[[(1,1-Dimethylethoxy)carbonyl]amino]-?-hydroxy-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester benzenepropanoic acid',\n",
    "    '[acetoxy-[(2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenyl-propanoyl]oxy-trihydroxy-tetramethyl-oxo-[?]yl] benzoate',\n",
    "    '114915-20-7',\n",
    "    'Benzenepropanoic acid, beta-(((1,1-dimethylethoxy)carbonyl)amino)-alpha-hydroxy-, (2aR,4S,4aR,6R,9S,11S,12S,12aS,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,4a,6,11-tetrahydroxy-8,12a,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR)-'\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 247,
   "metadata": {},
   "outputs": [],
   "source": [
    "enzalutamide = [\n",
    "    'Enzalutamide',\n",
    "    '915087-33-1',\n",
    "    'MDV3100',\n",
    "    'MDV-3100',\n",
    "    '4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide',\n",
    "    'Enzalutamide (MDV3100)',\n",
    "    'MDV 3100',\n",
    "    'XTANDI',\n",
    "    'MDV3100 (Enzalutamide)',\n",
    "    'Enzalutamide [USAN]',\n",
    "    'Enzalutamide [USAN:INN]',\n",
    "    'UNII-93T0T9GKNU',\n",
    "    '93T0T9GKNU',\n",
    "    'CHEBI:68534',\n",
    "    '4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide',\n",
    "    '4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide',\n",
    "    '4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl}-2-fluoro-N-methylbenzamide',\n",
    "    'Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-',\n",
    "    'C21H16F4N4O2S',\n",
    "    'Xtandi (TN)',\n",
    "    'ENZALUTAMIDE [MI]',\n",
    "    'Enzalutamide; MDV3100',\n",
    "    'Enzalutamide (JAN/USAN)',\n",
    "    'ENZALUTAMIDE [INN]',\n",
    "    'ENZALUTAMIDE [JAN]',\n",
    "    'MDV3100, AldrichCPR',\n",
    "    'D0M1YR',\n",
    "    'D0QK5X',\n",
    "    'Enzalutamide (AR inhibitor)',\n",
    "    'ENZALUTAMIDE [VANDF]',\n",
    "    'MLS006010067',\n",
    "    'ENZALUTAMIDE [WHO-DD]',\n",
    "    'SCHEMBL189749',\n",
    "    'GTPL6812',\n",
    "    'CHEMBL1082407',\n",
    "    'DTXSID10912307',\n",
    "    'EX-A046',\n",
    "    'MDV3101',\n",
    "    'BCPP000169',\n",
    "    'ENZALUTAMIDE [ORANGE BOOK]',\n",
    "    'HMS3654L07',\n",
    "    'HMS3672M13',\n",
    "    'HMS3744C19',\n",
    "    'NC-54',\n",
    "    'AMY10296',\n",
    "    'ASP-9785',\n",
    "    'BCP02361',\n",
    "    'BBL102957',\n",
    "    'BDBM50425732',\n",
    "    'MFCD14155804',\n",
    "    'NSC755605',\n",
    "    'NSC766085',\n",
    "    's1250',\n",
    "    'STL556766',\n",
    "    'AKOS015851022',\n",
    "    'MDV-3100;Enzalutamide;MDV 3100',\n",
    "    'BCP9000901',\n",
    "    'CCG-264879',\n",
    "    'CS-0317',\n",
    "    'DB08899',\n",
    "    'NSC-755605',\n",
    "    'NSC-766085',\n",
    "    'SB20413',\n",
    "    'NCGC00263120-01',\n",
    "    '4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]-2-fluoro-N-methyl-benzamide',\n",
    "    'AC-26924',\n",
    "    'AS-17047',\n",
    "    'Benzamide,4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methyl-',\n",
    "    'HY-70002',\n",
    "    'MDV3100, 95%',\n",
    "    'SMR004701227',\n",
    "    'FT-0670957',\n",
    "    'SW219288-1',\n",
    "    'A25302',\n",
    "    'D10218',\n",
    "    'AB01565849_02',\n",
    "    'EN300-20605530',\n",
    "    'SR-01000941580',\n",
    "    'J-519668',\n",
    "    'Q1996756',\n",
    "    'SR-01000941580-1',\n",
    "    'BRD-K56851771-001-01-9'\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 248,
   "metadata": {},
   "outputs": [],
   "source": [
    "lenalidomide = [\n",
    "    'Lenalidomide',\n",
    "    '191732-72-6',\n",
    "    'Revlimid',\n",
    "    'Revimid',\n",
    "    '3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione',\n",
    "    'CC-5013',\n",
    "    'CDC 501',\n",
    "    'CDC-501',\n",
    "    'Lenalidomide (CC-5013)',\n",
    "    'IMiD3',\n",
    "    'Lenalidomide [USAN]',\n",
    "    'CC 5013',\n",
    "    '3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione',\n",
    "    '3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione',\n",
    "    '2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-',\n",
    "    'Lenadoamide',\n",
    "    'Revamid',\n",
    "    'Revlimid (TN)',\n",
    "    'NSC-747972',\n",
    "    'UNII-F0P408N6V4',\n",
    "    'DTXSID8046664',\n",
    "    'CHEBI:63791',\n",
    "    'ENMD 0997',\n",
    "    'HSDB 8220',\n",
    "    'F0P408N6V4',\n",
    "    'SYP-1512',\n",
    "    'Lenalidomide (USAN/INN)',\n",
    "    '(3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione',\n",
    "    '1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline',\n",
    "    'Lenalidomide [USAN:INN:BAN]',\n",
    "    'DTXCID6026664',\n",
    "    'ENMD-0997',\n",
    "    'IMID-5013',\n",
    "    'CDC-5013',\n",
    "    'MFCD07772307',\n",
    "    'NSC 747972',\n",
    "    'NCGC00167491-01',\n",
    "    '3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione',\n",
    "    'LENALIDOMIDE (MART.)',\n",
    "    'LENALIDOMIDE [MART.]',\n",
    "    '3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione',\n",
    "    'Revlimid (lenalidomide)',\n",
    "    '3-(4-Amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione',\n",
    "    'IMiD3 cpd',\n",
    "    'Revlimid (Celgene)',\n",
    "    'CAS-191732-72-6',\n",
    "    'lenalidomidum',\n",
    "    'Lenalidomida',\n",
    "    'IMiD3cpd',\n",
    "    'ALBB-015321',\n",
    "    'CC5013',\n",
    "    'LENALIDOMIDE [MI]',\n",
    "    'LENALIDOMIDE [INN]',\n",
    "    'LENALIDOMIDE [JAN]',\n",
    "    'CHEMBL848',\n",
    "    'D0Q5NX',\n",
    "    'Lenalidomide Celgene Europe',\n",
    "    'Revlimid (TN) (Celgene)',\n",
    "    'LENALIDOMIDE [VANDF]',\n",
    "    'SCHEMBL32978',\n",
    "    'Celgene brand of lenalidomide',\n",
    "    '443912-14-9',\n",
    "    'MLS003899194',\n",
    "    'Lenalidomide (Immunomodulator)',\n",
    "    'LENALIDOMIDE [WHO-DD]',\n",
    "    'GTPL7331',\n",
    "    'SCHEMBL1980410',\n",
    "    'LENALIDOMIDE [EMA EPAR]',\n",
    "    '3-(4-Amino-1-oxo-2-isoindolinyl)piperidine-2,6-dione',\n",
    "    'BDBM65454',\n",
    "    'L04AX04',\n",
    "    'BCPP000186',\n",
    "    'HMS3654G07',\n",
    "    'HMS3674C05',\n",
    "    'LENALIDOMIDE [ORANGE BOOK]',\n",
    "    'BCP01390',\n",
    "    'CC-5013, Revlimid, Lenalidomide',\n",
    "    'HY-A0003',\n",
    "    'Revlimid, Lenalidomide, CC-5013',\n",
    "    'Tox21_112492',\n",
    "    'AC-914',\n",
    "    'NSC703813',\n",
    "    'NSC747972',\n",
    "    's1029',\n",
    "    'STK639603',\n",
    "    '2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-',\n",
    "    'AKOS005146276',\n",
    "    'AKOS005174869',\n",
    "    'Tox21_112492_1',\n",
    "    'BCP9000847',\n",
    "    'CCG-264781',\n",
    "    'CS-0125',\n",
    "    'CS-O-30619',\n",
    "    'DB00480',\n",
    "    'KS-1207',\n",
    "    'SB66166',\n",
    "    'NCGC00167491-02',\n",
    "    'NCGC00167491-03',\n",
    "    'NCGC00167491-04',\n",
    "    'BL164614',\n",
    "    'BP-27972',\n",
    "    'SMR002529986',\n",
    "    'SY047646',\n",
    "    'LS-184040',\n",
    "    'AM20050439',\n",
    "    'FT-0659651',\n",
    "    'FT-0670758',\n",
    "    'FT-0670759',\n",
    "    'SW218084-2',\n",
    "    'EC-000.2340',\n",
    "    'D04687',\n",
    "    'EN300-118706',\n",
    "    'AB01273975-01',\n",
    "    'AB01273975-02',\n",
    "    'AB01273975_03',\n",
    "    'Q425681',\n",
    "    'SR-01000883999',\n",
    "    'Q-101410',\n",
    "    'SR-01000883999-1',\n",
    "    'Z1515385074',\n",
    "    '2, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-',\n",
    "    '3-(4-Amino-1,3-dihydro-1-oxo-2H-is-oindol-2-yl)-2,6-piperidinedione',\n",
    "    '3-(4-amino-1-oxo-1,3-dihydro-2h-isoindol-2-yl)-2,6-piperidinedione',\n",
    "    '3-(4-amino-1-oxo-2H-isoindol-2-yl)-2,6-dioxopiperidine',\n",
    "    '3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-piperidinedione',\n",
    "    '(3RS)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione',\n",
    "    '4-amino-2-(6-hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-2,3-dihydro-1H-isoindol-1-one'\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 249,
   "metadata": {},
   "outputs": [],
   "source": [
    "radium_223 = [\n",
    "    'RADIUM RA-223 DICHLORIDE',\n",
    "    '444811-40-9',\n",
    "    'ALPHARADIN',\n",
    "    'BAY 88-8223',\n",
    "    'BAY-88-8223',\n",
    "    'BAY88-8223',\n",
    "    'RADIUM CHLORIDE (223RACL2)',\n",
    "    'RADIUM CHLORIDE RA-223',\n",
    "    'RADIUM RA 223 DICHLORIDE',\n",
    "    'RADIUM RA 223 DICHLORIDE [USAN]',\n",
    "    'RADIUM RA-223 DICHLORIDE [ORANGE BOOK]',\n",
    "    'RADIUM RA223 DICHLORIDE',\n",
    "    'RADIUM RA223 DICHLORIDE [EMA EPAR]',\n",
    "    'RADIUM-223 CHLORIDE',\n",
    "    'RADIUM-223 CHLORIDE [MI]',\n",
    "    'RADIUM-223 DICHLORIDE',\n",
    "    'Radium Ra 223 dichloride [WHO-DD]',\n",
    "    'XOFIGO',\n",
    "    'RJ00KV3VTG'\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 250,
   "metadata": {},
   "outputs": [],
   "source": [
    "trials_drugs = pd.merge(world_trials_results_dummy, interventions, on='nct_id',how='left')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 251,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>start_date</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>official_title</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>phase</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>number_of_arms</th>\n",
       "      <th>results</th>\n",
       "      <th>id</th>\n",
       "      <th>intervention_type</th>\n",
       "      <th>name</th>\n",
       "      <th>description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT04311983</td>\n",
       "      <td>2020-03-31</td>\n",
       "      <td>Interventions to Help More Low-income Smokers ...</td>\n",
       "      <td>Expanding Population-level Interventions to He...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Not Applicable</td>\n",
       "      <td>1982.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41125793</td>\n",
       "      <td>Behavioral</td>\n",
       "      <td>Tobacco Quitline</td>\n",
       "      <td>Tobacco quitlines provide phone counseling fro...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04311983</td>\n",
       "      <td>2020-03-31</td>\n",
       "      <td>Interventions to Help More Low-income Smokers ...</td>\n",
       "      <td>Expanding Population-level Interventions to He...</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>Not Applicable</td>\n",
       "      <td>1982.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41125794</td>\n",
       "      <td>Behavioral</td>\n",
       "      <td>Smoke Free Home</td>\n",
       "      <td>The intervention guides participants though a ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT04841135</td>\n",
       "      <td>2021-06-03</td>\n",
       "      <td>Blood Microbiota Signature of Alzheimer's Disease</td>\n",
       "      <td>Analysis of the Blood Signature of the Microbi...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Not Applicable</td>\n",
       "      <td>120.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41125795</td>\n",
       "      <td>Other</td>\n",
       "      <td>Multiomics quantification</td>\n",
       "      <td>One time blood, stool and urine samples will b...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04841135</td>\n",
       "      <td>2021-06-03</td>\n",
       "      <td>Blood Microbiota Signature of Alzheimer's Disease</td>\n",
       "      <td>Analysis of the Blood Signature of the Microbi...</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Not Applicable</td>\n",
       "      <td>120.0</td>\n",
       "      <td>Anticipated</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0</td>\n",
       "      <td>41125796</td>\n",
       "      <td>Other</td>\n",
       "      <td>Polysomnography</td>\n",
       "      <td>Facultative polysomnography</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT03228355</td>\n",
       "      <td>2017-05-24</td>\n",
       "      <td>Headache Inducing Effect of Cromakalim in Migr...</td>\n",
       "      <td>The Effects of Levcromakalim on Cerebral Hemod...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Not Applicable</td>\n",
       "      <td>16.0</td>\n",
       "      <td>Actual</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0</td>\n",
       "      <td>40962173</td>\n",
       "      <td>Drug</td>\n",
       "      <td>Levcromakalim</td>\n",
       "      <td>To investigate the role of Levcromakalim on ce...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id  start_date                                        brief_title  \\\n",
       "0  NCT04311983  2020-03-31  Interventions to Help More Low-income Smokers ...   \n",
       "1  NCT04311983  2020-03-31  Interventions to Help More Low-income Smokers ...   \n",
       "2  NCT04841135  2021-06-03  Blood Microbiota Signature of Alzheimer's Disease   \n",
       "3  NCT04841135  2021-06-03  Blood Microbiota Signature of Alzheimer's Disease   \n",
       "4  NCT03228355  2017-05-24  Headache Inducing Effect of Cromakalim in Migr...   \n",
       "\n",
       "                                      official_title          overall_status  \\\n",
       "0  Expanding Population-level Interventions to He...  Active, not recruiting   \n",
       "1  Expanding Population-level Interventions to He...  Active, not recruiting   \n",
       "2  Analysis of the Blood Signature of the Microbi...              Recruiting   \n",
       "3  Analysis of the Blood Signature of the Microbi...              Recruiting   \n",
       "4  The Effects of Levcromakalim on Cerebral Hemod...               Completed   \n",
       "\n",
       "            phase  enrollment enrollment_type  number_of_arms  results  \\\n",
       "0  Not Applicable      1982.0          Actual             2.0        0   \n",
       "1  Not Applicable      1982.0          Actual             2.0        0   \n",
       "2  Not Applicable       120.0     Anticipated             3.0        0   \n",
       "3  Not Applicable       120.0     Anticipated             3.0        0   \n",
       "4  Not Applicable        16.0          Actual             2.0        0   \n",
       "\n",
       "         id intervention_type                       name  \\\n",
       "0  41125793        Behavioral           Tobacco Quitline   \n",
       "1  41125794        Behavioral            Smoke Free Home   \n",
       "2  41125795             Other  Multiomics quantification   \n",
       "3  41125796             Other            Polysomnography   \n",
       "4  40962173              Drug              Levcromakalim   \n",
       "\n",
       "                                         description  \n",
       "0  Tobacco quitlines provide phone counseling fro...  \n",
       "1  The intervention guides participants though a ...  \n",
       "2  One time blood, stool and urine samples will b...  \n",
       "3                        Facultative polysomnography  \n",
       "4  To investigate the role of Levcromakalim on ce...  "
      ]
     },
     "execution_count": 251,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials_drugs.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 252,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_268/1441781626.py:38: FutureWarning: The frame.append method is deprecated and will be removed from pandas in a future version. Use pandas.concat instead.\n",
      "  matching_drugs = matching_drugs.append(trials_drugs[mask])\n",
      "/tmp/ipykernel_268/1441781626.py:38: FutureWarning: The frame.append method is deprecated and will be removed from pandas in a future version. Use pandas.concat instead.\n",
      "  matching_drugs = matching_drugs.append(trials_drugs[mask])\n",
      "/tmp/ipykernel_268/1441781626.py:38: FutureWarning: The frame.append method is deprecated and will be removed from pandas in a future version. Use pandas.concat instead.\n",
      "  matching_drugs = matching_drugs.append(trials_drugs[mask])\n",
      "/tmp/ipykernel_268/1441781626.py:38: FutureWarning: The frame.append method is deprecated and will be removed from pandas in a future version. Use pandas.concat instead.\n",
      "  matching_drugs = matching_drugs.append(trials_drugs[mask])\n",
      "/tmp/ipykernel_268/1441781626.py:38: FutureWarning: The frame.append method is deprecated and will be removed from pandas in a future version. Use pandas.concat instead.\n",
      "  matching_drugs = matching_drugs.append(trials_drugs[mask])\n",
      "/tmp/ipykernel_268/1441781626.py:38: FutureWarning: The frame.append method is deprecated and will be removed from pandas in a future version. Use pandas.concat instead.\n",
      "  matching_drugs = matching_drugs.append(trials_drugs[mask])\n",
      "/tmp/ipykernel_268/1441781626.py:38: FutureWarning: The frame.append method is deprecated and will be removed from pandas in a future version. Use pandas.concat instead.\n",
      "  matching_drugs = matching_drugs.append(trials_drugs[mask])\n",
      "/tmp/ipykernel_268/1441781626.py:38: FutureWarning: The frame.append method is deprecated and will be removed from pandas in a future version. Use pandas.concat instead.\n",
      "  matching_drugs = matching_drugs.append(trials_drugs[mask])\n",
      "/tmp/ipykernel_268/1441781626.py:38: FutureWarning: The frame.append method is deprecated and will be removed from pandas in a future version. Use pandas.concat instead.\n",
      "  matching_drugs = matching_drugs.append(trials_drugs[mask])\n"
     ]
    }
   ],
   "source": [
    "# Convert the drug name lists to lowercase\n",
    "bortezomib = [name.lower() for name in bortezomib]\n",
    "carfilzomib = [name.lower() for name in carfilzomib]\n",
    "daratumumab = [name.lower() for name in daratumumab]\n",
    "degarelix = [name.lower() for name in degarelix]\n",
    "denosumab = [name.lower() for name in denosumab]\n",
    "docetaxel = [name.lower() for name in docetaxel]\n",
    "enzalutamide = [name.lower() for name in enzalutamide]\n",
    "lenalidomide = [name.lower() for name in lenalidomide]\n",
    "radium_223 = [name.lower() for name in radium_223]\n",
    "        \n",
    "# Create a dictionary of drug lists\n",
    "drug_lists = {\n",
    "    'bortezomib': bortezomib,\n",
    "    'carfilzomib': carfilzomib,\n",
    "    'daratumumab': daratumumab,\n",
    "    'degarelix': degarelix,\n",
    "    'denosumab': denosumab,\n",
    "    'docetaxel': docetaxel,\n",
    "    'enzalutamide': enzalutamide,\n",
    "    'lenalidomide': lenalidomide,\n",
    "    'radium_223': radium_223\n",
    "}\n",
    "\n",
    "# Convert the name column in the trials_drugs DataFrame to lowercase\n",
    "trials_drugs['name'] = trials_drugs['name'].str.lower()\n",
    "\n",
    "# Create a new DataFrame to store the matching rows\n",
    "matching_drugs = pd.DataFrame(columns=trials_drugs.columns)\n",
    "\n",
    "# Iterate over the drug name lists\n",
    "for drug_list_name, drug_list in drug_lists.items():\n",
    "    # Filter rows where the name column matches the drug list\n",
    "    mask = trials_drugs['name'].isin(drug_list)\n",
    "    # Create a new 'drug' column with the name of the drug list\n",
    "    trials_drugs.loc[mask, 'drug'] = drug_list_name\n",
    "    # Append the matching rows to the new DataFrame\n",
    "    matching_drugs = matching_drugs.append(trials_drugs[mask])\n",
    "\n",
    "# Reset the index of the new DataFrame\n",
    "matching_drugs.reset_index(drop=True, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 253,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Convert the 'start_date' column to datetime data type\n",
    "matching_drugs['start_date'] = pd.to_datetime(matching_drugs['start_date'])\n",
    "\n",
    "# Extract the year from the 'start_date' column\n",
    "matching_drugs['year'] = matching_drugs['start_date'].dt.year"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 254,
   "metadata": {},
   "outputs": [],
   "source": [
    "drop_criteria = {\n",
    "    'bortezomib': 2007,\n",
    "    'carfilzomib': 2020,\n",
    "    'daratumumab': 2022,\n",
    "    'degarelix': 2016,\n",
    "    'denosumab': 2012,\n",
    "    'docetaxel': 2006,\n",
    "    'enzalutamide': 2021,\n",
    "    'lenalidomide': 2020,\n",
    "    'radium_223': 2016\n",
    "}\n",
    "\n",
    "for drug, year in drop_criteria.items():\n",
    "    mask = (matching_drugs['drug'] == drug) & (matching_drugs['year'] >= year)\n",
    "    matching_drugs = matching_drugs.loc[~mask]\n",
    "\n",
    "# Reset the index of the updated DataFrame\n",
    "matching_drugs.reset_index(drop=True, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 255,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1628"
      ]
     },
     "execution_count": 255,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_drugs.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 256,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "lenalidomide    648\n",
       "docetaxel       345\n",
       "enzalutamide    188\n",
       "bortezomib      182\n",
       "daratumumab     149\n",
       "carfilzomib     146\n",
       "degarelix        85\n",
       "denosumab        42\n",
       "radium_223        6\n",
       "Name: drug, dtype: int64"
      ]
     },
     "execution_count": 256,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_drugs.drug.value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 257,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    0.615857\n",
       "1    0.384143\n",
       "Name: results, dtype: float64"
      ]
     },
     "execution_count": 257,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_drugs.results.value_counts(normalize=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 258,
   "metadata": {},
   "outputs": [],
   "source": [
    "matching_drugs_race = pd.merge(matching_drugs,race_df,on='nct_id')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 259,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "300"
      ]
     },
     "execution_count": 259,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "matching_drugs_race.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 260,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Replace NaN values with 0 in 'param_value' column\n",
    "matching_drugs_race['param_value'] = matching_drugs_race['param_value'].fillna(0).astype(int)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 261,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_268/2343220400.py:1: FutureWarning: The default value of numeric_only in DataFrameGroupBy.sum is deprecated. In a future version, numeric_only will default to False. Either specify numeric_only or select only columns which should be valid for the function.\n",
      "  grouped_df = matching_drugs_race.groupby(['nct_id','category','title','units','param_type', 'start_date','brief_title','official_title','overall_status','phase','enrollment_type','id','intervention_type','drug']).sum()\n"
     ]
    }
   ],
   "source": [
    "grouped_df = matching_drugs_race.groupby(['nct_id','category','title','units','param_type', 'start_date','brief_title','official_title','overall_status','phase','enrollment_type','id','intervention_type','drug']).sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 262,
   "metadata": {},
   "outputs": [],
   "source": [
    "grouped_df.reset_index(inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 263,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "300"
      ]
     },
     "execution_count": 263,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grouped_df.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 264,
   "metadata": {},
   "outputs": [],
   "source": [
    "grouped_df.to_csv('/project/approved_drugs_charts_data/matching_drugs_races.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Using OpenAI API, I used the Chat GPT Google Docs extension and classified the \"category\" column into 10 different Race/Erhnicity groups (White/ White Heritage, Black/ Black Heritage, Hispanic/ Latino, Asian/ Asian Heritage, American Indian/ Alaska Native, Middle Eastern, Hawaiian/ Other Pacific Islander, Other, Mixed, Unknown or Not Reported\") using the following prompt:\n",
    "\n",
    "=GPT_CLASSIFY(cell,\"White/ White Heritage, Black/ Black Heritage, Hispanic/ Latino, Asian/ Asian Heritage, American Indian/ Alaska Native, Middle Eastern, Hawaiian/ Other Pacific Islander, Other, Mixed, Unknown or Not Reported\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 266,
   "metadata": {},
   "outputs": [],
   "source": [
    "grouped_race = pd.read_csv('https://raw.githubusercontent.com/AndreasPetrou/UCL_dissertation.github.io/main/Approved%20Drugs%20UK/matched_drugs_race_chat.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 267,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "White/ White Heritage               501\n",
       "Unknown or Not Reported             477\n",
       "Black/ Black Heritage               294\n",
       "Asian/ Asian Heritage               292\n",
       "Hawaiian/ Other Pacific Islander    266\n",
       "American Indian/ Alaska Native      264\n",
       "Mixed                               254\n",
       "Hispanic/ Latino                    208\n",
       "Other                                32\n",
       "Middle Eastern                        1\n",
       "Name: race/ethnicity, dtype: int64"
      ]
     },
     "execution_count": 267,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grouped_race['race/ethnicity'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 268,
   "metadata": {},
   "outputs": [],
   "source": [
    "grouped_race.drop(['category','title','units','param_type'], axis =1 , inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 269,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 2589 entries, 0 to 2588\n",
      "Data columns (total 15 columns):\n",
      " #   Column             Non-Null Count  Dtype \n",
      "---  ------             --------------  ----- \n",
      " 0   nct_id             2589 non-null   object\n",
      " 1   race/ethnicity     2589 non-null   object\n",
      " 2   start_date         2589 non-null   object\n",
      " 3   brief_title        2589 non-null   object\n",
      " 4   official_title     2589 non-null   object\n",
      " 5   overall_status     2589 non-null   object\n",
      " 6   phase              2589 non-null   object\n",
      " 7   enrollment_type    2589 non-null   object\n",
      " 8   id                 2589 non-null   int64 \n",
      " 9   intervention_type  2589 non-null   object\n",
      " 10  drug               2589 non-null   object\n",
      " 11  enrollment         2589 non-null   int64 \n",
      " 12  number_of_arms     2589 non-null   int64 \n",
      " 13  year               2589 non-null   int64 \n",
      " 14  param_value        2589 non-null   int64 \n",
      "dtypes: int64(5), object(10)\n",
      "memory usage: 303.5+ KB\n"
     ]
    }
   ],
   "source": [
    "grouped_race.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 270,
   "metadata": {},
   "outputs": [],
   "source": [
    "# pivot the dataframe to create new columns for each category of the 'race' column\n",
    "pivoted_df = grouped_race.pivot_table(index=['nct_id', 'phase', 'start_date','enrollment_type','drug','official_title','brief_title'], columns='race/ethnicity', values=['param_value'], aggfunc='sum').reset_index()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 271,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead tr th {\n",
       "        text-align: left;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr>\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>phase</th>\n",
       "      <th>start_date</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>drug</th>\n",
       "      <th>official_title</th>\n",
       "      <th>brief_title</th>\n",
       "      <th colspan=\"10\" halign=\"left\">param_value</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>race/ethnicity</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00054665</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2003-02-28</td>\n",
       "      <td>Actual</td>\n",
       "      <td>bortezomib</td>\n",
       "      <td>PS-341 and PS-341 + Epoch Chemotherapy and Mol...</td>\n",
       "      <td>PS-341 Alone and PS-341 Plus EPOCH Chemotherap...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>93.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT00062439</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2003-07-31</td>\n",
       "      <td>Actual</td>\n",
       "      <td>docetaxel</td>\n",
       "      <td>A Phase II Trial of Induction Chemoradiotherap...</td>\n",
       "      <td>S0220: Chemoradiotherapy Followed By Surgery a...</td>\n",
       "      <td>1.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>40.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT00065182</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2003-08-14</td>\n",
       "      <td>Actual</td>\n",
       "      <td>docetaxel</td>\n",
       "      <td>WEEKLY IV TOPOTECAN/DOCETAXEL COMBINATION COMP...</td>\n",
       "      <td>Comparison of IV Topotecan/Docetaxel to Doceta...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>12.0</td>\n",
       "      <td>46.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>734.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT00089609</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2005-04-19</td>\n",
       "      <td>Actual</td>\n",
       "      <td>docetaxel</td>\n",
       "      <td>A Phase II Trial of Docetaxel, Thalidomide, Pr...</td>\n",
       "      <td>Docetaxel, Thalidomide, Prednisone, and Bevaci...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>22.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>8.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>260.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT00103376</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2004-10-31</td>\n",
       "      <td>Actual</td>\n",
       "      <td>bortezomib</td>\n",
       "      <td>VELCADE® (Bortezomib) for Injection Therapy fo...</td>\n",
       "      <td>Bortezomib With or Without Hormone Therapy in ...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>40.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                     nct_id    phase  start_date enrollment_type        drug  \\\n",
       "race/ethnicity                                                                 \n",
       "0               NCT00054665  Phase 2  2003-02-28          Actual  bortezomib   \n",
       "1               NCT00062439  Phase 2  2003-07-31          Actual   docetaxel   \n",
       "2               NCT00065182  Phase 2  2003-08-14          Actual   docetaxel   \n",
       "3               NCT00089609  Phase 2  2005-04-19          Actual   docetaxel   \n",
       "4               NCT00103376  Phase 2  2004-10-31          Actual  bortezomib   \n",
       "\n",
       "                                                   official_title  \\\n",
       "race/ethnicity                                                      \n",
       "0               PS-341 and PS-341 + Epoch Chemotherapy and Mol...   \n",
       "1               A Phase II Trial of Induction Chemoradiotherap...   \n",
       "2               WEEKLY IV TOPOTECAN/DOCETAXEL COMBINATION COMP...   \n",
       "3               A Phase II Trial of Docetaxel, Thalidomide, Pr...   \n",
       "4               VELCADE® (Bortezomib) for Injection Therapy fo...   \n",
       "\n",
       "                                                      brief_title  \\\n",
       "race/ethnicity                                                      \n",
       "0               PS-341 Alone and PS-341 Plus EPOCH Chemotherap...   \n",
       "1               S0220: Chemoradiotherapy Followed By Surgery a...   \n",
       "2               Comparison of IV Topotecan/Docetaxel to Doceta...   \n",
       "3               Docetaxel, Thalidomide, Prednisone, and Bevaci...   \n",
       "4               Bortezomib With or Without Hormone Therapy in ...   \n",
       "\n",
       "                                  param_value                        \\\n",
       "race/ethnicity American Indian/ Alaska Native Asian/ Asian Heritage   \n",
       "0                                         0.0                   0.0   \n",
       "1                                         1.0                   3.0   \n",
       "2                                         0.0                  12.0   \n",
       "3                                         0.0                   0.0   \n",
       "4                                         0.0                   0.0   \n",
       "\n",
       "                                                                       \\\n",
       "race/ethnicity Black/ Black Heritage Hawaiian/ Other Pacific Islander   \n",
       "0                                4.0                              0.0   \n",
       "1                                0.0                              0.0   \n",
       "2                               46.0                              0.0   \n",
       "3                               22.0                              0.0   \n",
       "4                                6.0                              0.0   \n",
       "\n",
       "                                                            \\\n",
       "race/ethnicity Hispanic/ Latino Middle Eastern Mixed Other   \n",
       "0                           1.0            NaN   0.0   NaN   \n",
       "1                           NaN            NaN   0.0   NaN   \n",
       "2                           NaN            NaN   0.0   NaN   \n",
       "3                           8.0            NaN   0.0   NaN   \n",
       "4                           NaN            NaN   0.0   NaN   \n",
       "\n",
       "                                                              \n",
       "race/ethnicity Unknown or Not Reported White/ White Heritage  \n",
       "0                                  2.0                  93.0  \n",
       "1                                  0.0                  40.0  \n",
       "2                                  6.0                 734.0  \n",
       "3                                  2.0                 260.0  \n",
       "4                                  0.0                  40.0  "
      ]
     },
     "execution_count": 271,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pivoted_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 272,
   "metadata": {},
   "outputs": [],
   "source": [
    "pivoted_df.to_csv('/project/approved_drugs_charts_data/pivoted_df_2.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 273,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_columns_drugs = pd.read_csv('https://raw.githubusercontent.com/AndreasPetrou/UCL_dissertation.github.io/main/Approved%20Drugs%20UK/trials_drugs_race_columns_2.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 274,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>phase</th>\n",
       "      <th>start_date</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>drug</th>\n",
       "      <th>official_title</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00054665</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>28/02/2003</td>\n",
       "      <td>Actual</td>\n",
       "      <td>bortezomib</td>\n",
       "      <td>PS-341 and PS-341 + Epoch Chemotherapy and Mol...</td>\n",
       "      <td>PS-341 Alone and PS-341 Plus EPOCH Chemotherap...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>93.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT00062439</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>31/07/2003</td>\n",
       "      <td>Actual</td>\n",
       "      <td>docetaxel</td>\n",
       "      <td>A Phase II Trial of Induction Chemoradiotherap...</td>\n",
       "      <td>S0220: Chemoradiotherapy Followed By Surgery a...</td>\n",
       "      <td>1.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>40.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT00065182</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>14/08/2003</td>\n",
       "      <td>Actual</td>\n",
       "      <td>docetaxel</td>\n",
       "      <td>WEEKLY IV TOPOTECAN/DOCETAXEL COMBINATION COMP...</td>\n",
       "      <td>Comparison of IV Topotecan/Docetaxel to Doceta...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>12.0</td>\n",
       "      <td>46.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>734.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT00089609</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>19/04/2005</td>\n",
       "      <td>Actual</td>\n",
       "      <td>docetaxel</td>\n",
       "      <td>A Phase II Trial of Docetaxel, Thalidomide, Pr...</td>\n",
       "      <td>Docetaxel, Thalidomide, Prednisone, and Bevaci...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>22.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>8.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>260.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT00103376</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>31/10/2004</td>\n",
       "      <td>Actual</td>\n",
       "      <td>bortezomib</td>\n",
       "      <td>VELCADE® (Bortezomib) for Injection Therapy fo...</td>\n",
       "      <td>Bortezomib With or Without Hormone Therapy in ...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>40.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id    phase  start_date enrollment_type        drug  \\\n",
       "0  NCT00054665  Phase 2  28/02/2003          Actual  bortezomib   \n",
       "1  NCT00062439  Phase 2  31/07/2003          Actual   docetaxel   \n",
       "2  NCT00065182  Phase 2  14/08/2003          Actual   docetaxel   \n",
       "3  NCT00089609  Phase 2  19/04/2005          Actual   docetaxel   \n",
       "4  NCT00103376  Phase 2  31/10/2004          Actual  bortezomib   \n",
       "\n",
       "                                      official_title  \\\n",
       "0  PS-341 and PS-341 + Epoch Chemotherapy and Mol...   \n",
       "1  A Phase II Trial of Induction Chemoradiotherap...   \n",
       "2  WEEKLY IV TOPOTECAN/DOCETAXEL COMBINATION COMP...   \n",
       "3  A Phase II Trial of Docetaxel, Thalidomide, Pr...   \n",
       "4  VELCADE® (Bortezomib) for Injection Therapy fo...   \n",
       "\n",
       "                                         brief_title  \\\n",
       "0  PS-341 Alone and PS-341 Plus EPOCH Chemotherap...   \n",
       "1  S0220: Chemoradiotherapy Followed By Surgery a...   \n",
       "2  Comparison of IV Topotecan/Docetaxel to Doceta...   \n",
       "3  Docetaxel, Thalidomide, Prednisone, and Bevaci...   \n",
       "4  Bortezomib With or Without Hormone Therapy in ...   \n",
       "\n",
       "   American Indian/ Alaska Native  Asian/ Asian Heritage  \\\n",
       "0                             0.0                    0.0   \n",
       "1                             1.0                    3.0   \n",
       "2                             0.0                   12.0   \n",
       "3                             0.0                    0.0   \n",
       "4                             0.0                    0.0   \n",
       "\n",
       "   Black/ Black Heritage  Hawaiian/ Other Pacific Islander  Hispanic/ Latino  \\\n",
       "0                    4.0                               0.0               1.0   \n",
       "1                    0.0                               0.0               NaN   \n",
       "2                   46.0                               0.0               NaN   \n",
       "3                   22.0                               0.0               8.0   \n",
       "4                    6.0                               0.0               NaN   \n",
       "\n",
       "   Middle Eastern  Mixed  Other  Unknown or Not Reported  \\\n",
       "0             NaN    0.0    NaN                      2.0   \n",
       "1             NaN    0.0    NaN                      0.0   \n",
       "2             NaN    0.0    NaN                      6.0   \n",
       "3             NaN    0.0    NaN                      2.0   \n",
       "4             NaN    0.0    NaN                      0.0   \n",
       "\n",
       "   White/ White Heritage  \n",
       "0                   93.0  \n",
       "1                   40.0  \n",
       "2                  734.0  \n",
       "3                  260.0  \n",
       "4                   40.0  "
      ]
     },
     "execution_count": 274,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_columns_drugs.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 275,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "300"
      ]
     },
     "execution_count": 275,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_columns_drugs.nct_id.nunique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 276,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Convert 'start_date' column to datetime format\n",
    "race_columns_drugs['start_date'] = pd.to_datetime(race_columns_drugs['start_date'], dayfirst=True)\n",
    "\n",
    "# Extract the year from 'start_date' column\n",
    "race_columns_drugs['year'] = race_columns_drugs['start_date'].dt.year"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 277,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Define the search terms\n",
    "search_terms = ['gallbladder', 'myeloma', 'prostate']\n",
    "\n",
    "# Create a function to check if any search term is present in the provided text\n",
    "def check_search_terms(text):\n",
    "    lowercase_text = text.lower()\n",
    "    for term in search_terms:\n",
    "        if term in lowercase_text:\n",
    "            return term\n",
    "    return 'Other'\n",
    "\n",
    "# Convert \"official_title\" and \"brief_title\" columns to lowercase\n",
    "race_columns_drugs['official_title'] = race_columns_drugs['official_title'].str.lower()\n",
    "race_columns_drugs['brief_title'] = race_columns_drugs['brief_title'].str.lower()\n",
    "\n",
    "# Apply the function to search for terms in the official_title and brief_title columns\n",
    "race_columns_drugs['cancer'] = race_columns_drugs['official_title'].fillna('') + race_columns_drugs['brief_title'].fillna('')\n",
    "race_columns_drugs['cancer'] = race_columns_drugs['cancer'].apply(check_search_terms)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 278,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Other       141\n",
       "myeloma      94\n",
       "prostate     77\n",
       "Name: cancer, dtype: int64"
      ]
     },
     "execution_count": 278,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_columns_drugs.cancer.value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 279,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>phase</th>\n",
       "      <th>start_date</th>\n",
       "      <th>enrollment_type</th>\n",
       "      <th>drug</th>\n",
       "      <th>official_title</th>\n",
       "      <th>brief_title</th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "      <th>year</th>\n",
       "      <th>cancer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT00054665</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2003-02-28</td>\n",
       "      <td>Actual</td>\n",
       "      <td>bortezomib</td>\n",
       "      <td>ps-341 and ps-341 + epoch chemotherapy and mol...</td>\n",
       "      <td>ps-341 alone and ps-341 plus epoch chemotherap...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>93.0</td>\n",
       "      <td>2003</td>\n",
       "      <td>Other</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT00062439</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2003-07-31</td>\n",
       "      <td>Actual</td>\n",
       "      <td>docetaxel</td>\n",
       "      <td>a phase ii trial of induction chemoradiotherap...</td>\n",
       "      <td>s0220: chemoradiotherapy followed by surgery a...</td>\n",
       "      <td>1.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>40.0</td>\n",
       "      <td>2003</td>\n",
       "      <td>Other</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT00065182</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2003-08-14</td>\n",
       "      <td>Actual</td>\n",
       "      <td>docetaxel</td>\n",
       "      <td>weekly iv topotecan/docetaxel combination comp...</td>\n",
       "      <td>comparison of iv topotecan/docetaxel to doceta...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>12.0</td>\n",
       "      <td>46.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>6.0</td>\n",
       "      <td>734.0</td>\n",
       "      <td>2003</td>\n",
       "      <td>Other</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT00089609</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2005-04-19</td>\n",
       "      <td>Actual</td>\n",
       "      <td>docetaxel</td>\n",
       "      <td>a phase ii trial of docetaxel, thalidomide, pr...</td>\n",
       "      <td>docetaxel, thalidomide, prednisone, and bevaci...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>22.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>8.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2.0</td>\n",
       "      <td>260.0</td>\n",
       "      <td>2005</td>\n",
       "      <td>prostate</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT00103376</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>2004-10-31</td>\n",
       "      <td>Actual</td>\n",
       "      <td>bortezomib</td>\n",
       "      <td>velcade® (bortezomib) for injection therapy fo...</td>\n",
       "      <td>bortezomib with or without hormone therapy in ...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>40.0</td>\n",
       "      <td>2004</td>\n",
       "      <td>prostate</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "        nct_id    phase start_date enrollment_type        drug  \\\n",
       "0  NCT00054665  Phase 2 2003-02-28          Actual  bortezomib   \n",
       "1  NCT00062439  Phase 2 2003-07-31          Actual   docetaxel   \n",
       "2  NCT00065182  Phase 2 2003-08-14          Actual   docetaxel   \n",
       "3  NCT00089609  Phase 2 2005-04-19          Actual   docetaxel   \n",
       "4  NCT00103376  Phase 2 2004-10-31          Actual  bortezomib   \n",
       "\n",
       "                                      official_title  \\\n",
       "0  ps-341 and ps-341 + epoch chemotherapy and mol...   \n",
       "1  a phase ii trial of induction chemoradiotherap...   \n",
       "2  weekly iv topotecan/docetaxel combination comp...   \n",
       "3  a phase ii trial of docetaxel, thalidomide, pr...   \n",
       "4  velcade® (bortezomib) for injection therapy fo...   \n",
       "\n",
       "                                         brief_title  \\\n",
       "0  ps-341 alone and ps-341 plus epoch chemotherap...   \n",
       "1  s0220: chemoradiotherapy followed by surgery a...   \n",
       "2  comparison of iv topotecan/docetaxel to doceta...   \n",
       "3  docetaxel, thalidomide, prednisone, and bevaci...   \n",
       "4  bortezomib with or without hormone therapy in ...   \n",
       "\n",
       "   American Indian/ Alaska Native  Asian/ Asian Heritage  \\\n",
       "0                             0.0                    0.0   \n",
       "1                             1.0                    3.0   \n",
       "2                             0.0                   12.0   \n",
       "3                             0.0                    0.0   \n",
       "4                             0.0                    0.0   \n",
       "\n",
       "   Black/ Black Heritage  Hawaiian/ Other Pacific Islander  Hispanic/ Latino  \\\n",
       "0                    4.0                               0.0               1.0   \n",
       "1                    0.0                               0.0               NaN   \n",
       "2                   46.0                               0.0               NaN   \n",
       "3                   22.0                               0.0               8.0   \n",
       "4                    6.0                               0.0               NaN   \n",
       "\n",
       "   Middle Eastern  Mixed  Other  Unknown or Not Reported  \\\n",
       "0             NaN    0.0    NaN                      2.0   \n",
       "1             NaN    0.0    NaN                      0.0   \n",
       "2             NaN    0.0    NaN                      6.0   \n",
       "3             NaN    0.0    NaN                      2.0   \n",
       "4             NaN    0.0    NaN                      0.0   \n",
       "\n",
       "   White/ White Heritage  year    cancer  \n",
       "0                   93.0  2003     Other  \n",
       "1                   40.0  2003     Other  \n",
       "2                  734.0  2003     Other  \n",
       "3                  260.0  2005  prostate  \n",
       "4                   40.0  2004  prostate  "
      ]
     },
     "execution_count": 279,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_columns_drugs.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 280,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_268/3766331017.py:1: FutureWarning: The default value of numeric_only in DataFrameGroupBy.sum is deprecated. In a future version, numeric_only will default to False. Either specify numeric_only or select only columns which should be valid for the function.\n",
      "  race_cancer_groups = race_columns_drugs.groupby(['cancer','drug']).sum()\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "      <th>year</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>cancer</th>\n",
       "      <th>drug</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th rowspan=\"8\" valign=\"top\">Other</th>\n",
       "      <th>bortezomib</th>\n",
       "      <td>2.0</td>\n",
       "      <td>23.0</td>\n",
       "      <td>40.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>39.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>74.0</td>\n",
       "      <td>1351.0</td>\n",
       "      <td>26070</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>carfilzomib</th>\n",
       "      <td>0.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>47.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>19.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>9.0</td>\n",
       "      <td>632.0</td>\n",
       "      <td>24168</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>daratumumab</th>\n",
       "      <td>18.0</td>\n",
       "      <td>285.0</td>\n",
       "      <td>64.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>64.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>304.0</td>\n",
       "      <td>2984.0</td>\n",
       "      <td>18148</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>denosumab</th>\n",
       "      <td>2.0</td>\n",
       "      <td>1553.0</td>\n",
       "      <td>312.0</td>\n",
       "      <td>16.0</td>\n",
       "      <td>652.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>80.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>14910.0</td>\n",
       "      <td>14058</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>docetaxel</th>\n",
       "      <td>1.0</td>\n",
       "      <td>58.0</td>\n",
       "      <td>115.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>37.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>38.0</td>\n",
       "      <td>1822.0</td>\n",
       "      <td>30058</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>enzalutamide</th>\n",
       "      <td>0.0</td>\n",
       "      <td>164.0</td>\n",
       "      <td>30.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>13.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>893.0</td>\n",
       "      <td>16123</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>lenalidomide</th>\n",
       "      <td>12.0</td>\n",
       "      <td>592.0</td>\n",
       "      <td>339.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>384.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>13.0</td>\n",
       "      <td>273.0</td>\n",
       "      <td>891.0</td>\n",
       "      <td>15671.0</td>\n",
       "      <td>152846</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>radium_223</th>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>2015</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"4\" valign=\"top\">myeloma</th>\n",
       "      <th>bortezomib</th>\n",
       "      <td>0.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>5.0</td>\n",
       "      <td>118.0</td>\n",
       "      <td>4011</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>carfilzomib</th>\n",
       "      <td>7.0</td>\n",
       "      <td>713.0</td>\n",
       "      <td>340.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>242.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>35.0</td>\n",
       "      <td>110.0</td>\n",
       "      <td>952.0</td>\n",
       "      <td>11431.0</td>\n",
       "      <td>56383</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>daratumumab</th>\n",
       "      <td>0.0</td>\n",
       "      <td>152.0</td>\n",
       "      <td>125.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>101.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>50.0</td>\n",
       "      <td>473.0</td>\n",
       "      <td>4191.0</td>\n",
       "      <td>20166</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>lenalidomide</th>\n",
       "      <td>18.0</td>\n",
       "      <td>743.0</td>\n",
       "      <td>1258.0</td>\n",
       "      <td>12.0</td>\n",
       "      <td>333.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>47.0</td>\n",
       "      <td>93.0</td>\n",
       "      <td>3451.0</td>\n",
       "      <td>19243.0</td>\n",
       "      <td>108686</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th rowspan=\"7\" valign=\"top\">prostate</th>\n",
       "      <th>bortezomib</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>40.0</td>\n",
       "      <td>2004</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>carfilzomib</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>22.0</td>\n",
       "      <td>2014</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>degarelix</th>\n",
       "      <td>526.0</td>\n",
       "      <td>80.0</td>\n",
       "      <td>1013.0</td>\n",
       "      <td>8.0</td>\n",
       "      <td>152.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>20.0</td>\n",
       "      <td>13787.0</td>\n",
       "      <td>38162</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>docetaxel</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>30.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>8.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>309.0</td>\n",
       "      <td>6013</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>enzalutamide</th>\n",
       "      <td>21.0</td>\n",
       "      <td>1867.0</td>\n",
       "      <td>822.0</td>\n",
       "      <td>16.0</td>\n",
       "      <td>706.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>8.0</td>\n",
       "      <td>7.0</td>\n",
       "      <td>760.0</td>\n",
       "      <td>22696.0</td>\n",
       "      <td>92663</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>lenalidomide</th>\n",
       "      <td>16.0</td>\n",
       "      <td>30.0</td>\n",
       "      <td>134.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>251.0</td>\n",
       "      <td>2067.0</td>\n",
       "      <td>8029</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>radium_223</th>\n",
       "      <td>0.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>9.0</td>\n",
       "      <td>248.0</td>\n",
       "      <td>6043</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                       American Indian/ Alaska Native  Asian/ Asian Heritage  \\\n",
       "cancer   drug                                                                  \n",
       "Other    bortezomib                               2.0                   23.0   \n",
       "         carfilzomib                              0.0                   10.0   \n",
       "         daratumumab                             18.0                  285.0   \n",
       "         denosumab                                2.0                 1553.0   \n",
       "         docetaxel                                1.0                   58.0   \n",
       "         enzalutamide                             0.0                  164.0   \n",
       "         lenalidomide                            12.0                  592.0   \n",
       "         radium_223                               0.0                    1.0   \n",
       "myeloma  bortezomib                               0.0                    3.0   \n",
       "         carfilzomib                              7.0                  713.0   \n",
       "         daratumumab                              0.0                  152.0   \n",
       "         lenalidomide                            18.0                  743.0   \n",
       "prostate bortezomib                               0.0                    0.0   \n",
       "         carfilzomib                              0.0                    0.0   \n",
       "         degarelix                              526.0                   80.0   \n",
       "         docetaxel                                0.0                    0.0   \n",
       "         enzalutamide                            21.0                 1867.0   \n",
       "         lenalidomide                            16.0                   30.0   \n",
       "         radium_223                               0.0                    4.0   \n",
       "\n",
       "                       Black/ Black Heritage  \\\n",
       "cancer   drug                                  \n",
       "Other    bortezomib                     40.0   \n",
       "         carfilzomib                    47.0   \n",
       "         daratumumab                    64.0   \n",
       "         denosumab                     312.0   \n",
       "         docetaxel                     115.0   \n",
       "         enzalutamide                   30.0   \n",
       "         lenalidomide                  339.0   \n",
       "         radium_223                      0.0   \n",
       "myeloma  bortezomib                      4.0   \n",
       "         carfilzomib                   340.0   \n",
       "         daratumumab                   125.0   \n",
       "         lenalidomide                 1258.0   \n",
       "prostate bortezomib                      6.0   \n",
       "         carfilzomib                     6.0   \n",
       "         degarelix                    1013.0   \n",
       "         docetaxel                      30.0   \n",
       "         enzalutamide                  822.0   \n",
       "         lenalidomide                  134.0   \n",
       "         radium_223                      3.0   \n",
       "\n",
       "                       Hawaiian/ Other Pacific Islander  Hispanic/ Latino  \\\n",
       "cancer   drug                                                               \n",
       "Other    bortezomib                                 2.0              39.0   \n",
       "         carfilzomib                                1.0              19.0   \n",
       "         daratumumab                                2.0              64.0   \n",
       "         denosumab                                 16.0             652.0   \n",
       "         docetaxel                                  0.0              37.0   \n",
       "         enzalutamide                               3.0              13.0   \n",
       "         lenalidomide                              10.0             384.0   \n",
       "         radium_223                                 0.0               0.0   \n",
       "myeloma  bortezomib                                 0.0               4.0   \n",
       "         carfilzomib                                6.0             242.0   \n",
       "         daratumumab                                2.0             101.0   \n",
       "         lenalidomide                              12.0             333.0   \n",
       "prostate bortezomib                                 0.0               0.0   \n",
       "         carfilzomib                                0.0               0.0   \n",
       "         degarelix                                  8.0             152.0   \n",
       "         docetaxel                                  0.0               8.0   \n",
       "         enzalutamide                              16.0             706.0   \n",
       "         lenalidomide                               2.0               2.0   \n",
       "         radium_223                                 0.0               3.0   \n",
       "\n",
       "                       Middle Eastern  Mixed  Other  Unknown or Not Reported  \\\n",
       "cancer   drug                                                                  \n",
       "Other    bortezomib               0.0    0.0    0.0                     74.0   \n",
       "         carfilzomib              0.0    0.0    2.0                      9.0   \n",
       "         daratumumab              0.0    2.0    4.0                    304.0   \n",
       "         denosumab                0.0    0.0   80.0                      3.0   \n",
       "         docetaxel                0.0    0.0    0.0                     38.0   \n",
       "         enzalutamide             0.0    0.0    3.0                     10.0   \n",
       "         lenalidomide             0.0   13.0  273.0                    891.0   \n",
       "         radium_223               0.0    0.0    0.0                      0.0   \n",
       "myeloma  bortezomib               0.0    0.0    0.0                      5.0   \n",
       "         carfilzomib              0.0   35.0  110.0                    952.0   \n",
       "         daratumumab              0.0    0.0   50.0                    473.0   \n",
       "         lenalidomide             0.0   47.0   93.0                   3451.0   \n",
       "prostate bortezomib               0.0    0.0    0.0                      0.0   \n",
       "         carfilzomib              0.0    0.0    0.0                      0.0   \n",
       "         degarelix                0.0    0.0    0.0                     20.0   \n",
       "         docetaxel                0.0    0.0    0.0                      2.0   \n",
       "         enzalutamide             2.0    8.0    7.0                    760.0   \n",
       "         lenalidomide             0.0    0.0    0.0                    251.0   \n",
       "         radium_223               0.0    1.0    0.0                      9.0   \n",
       "\n",
       "                       White/ White Heritage    year  \n",
       "cancer   drug                                         \n",
       "Other    bortezomib                   1351.0   26070  \n",
       "         carfilzomib                   632.0   24168  \n",
       "         daratumumab                  2984.0   18148  \n",
       "         denosumab                   14910.0   14058  \n",
       "         docetaxel                    1822.0   30058  \n",
       "         enzalutamide                  893.0   16123  \n",
       "         lenalidomide                15671.0  152846  \n",
       "         radium_223                      4.0    2015  \n",
       "myeloma  bortezomib                    118.0    4011  \n",
       "         carfilzomib                 11431.0   56383  \n",
       "         daratumumab                  4191.0   20166  \n",
       "         lenalidomide                19243.0  108686  \n",
       "prostate bortezomib                     40.0    2004  \n",
       "         carfilzomib                    22.0    2014  \n",
       "         degarelix                   13787.0   38162  \n",
       "         docetaxel                     309.0    6013  \n",
       "         enzalutamide                22696.0   92663  \n",
       "         lenalidomide                 2067.0    8029  \n",
       "         radium_223                    248.0    6043  "
      ]
     },
     "execution_count": 280,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_cancer_groups = race_columns_drugs.groupby(['cancer','drug']).sum()\n",
    "race_cancer_groups"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 281,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_cancer_groups.reset_index(inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 282,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>cancer</th>\n",
       "      <th>drug</th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "      <th>year</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Other</td>\n",
       "      <td>bortezomib</td>\n",
       "      <td>2.0</td>\n",
       "      <td>23.0</td>\n",
       "      <td>40.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>39.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>74.0</td>\n",
       "      <td>1351.0</td>\n",
       "      <td>26070</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Other</td>\n",
       "      <td>carfilzomib</td>\n",
       "      <td>0.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>47.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>19.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>9.0</td>\n",
       "      <td>632.0</td>\n",
       "      <td>24168</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Other</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>18.0</td>\n",
       "      <td>285.0</td>\n",
       "      <td>64.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>64.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>304.0</td>\n",
       "      <td>2984.0</td>\n",
       "      <td>18148</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Other</td>\n",
       "      <td>denosumab</td>\n",
       "      <td>2.0</td>\n",
       "      <td>1553.0</td>\n",
       "      <td>312.0</td>\n",
       "      <td>16.0</td>\n",
       "      <td>652.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>80.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>14910.0</td>\n",
       "      <td>14058</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Other</td>\n",
       "      <td>docetaxel</td>\n",
       "      <td>1.0</td>\n",
       "      <td>58.0</td>\n",
       "      <td>115.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>37.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>38.0</td>\n",
       "      <td>1822.0</td>\n",
       "      <td>30058</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Other</td>\n",
       "      <td>enzalutamide</td>\n",
       "      <td>0.0</td>\n",
       "      <td>164.0</td>\n",
       "      <td>30.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>13.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>893.0</td>\n",
       "      <td>16123</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Other</td>\n",
       "      <td>lenalidomide</td>\n",
       "      <td>12.0</td>\n",
       "      <td>592.0</td>\n",
       "      <td>339.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>384.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>13.0</td>\n",
       "      <td>273.0</td>\n",
       "      <td>891.0</td>\n",
       "      <td>15671.0</td>\n",
       "      <td>152846</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Other</td>\n",
       "      <td>radium_223</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>2015</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>myeloma</td>\n",
       "      <td>bortezomib</td>\n",
       "      <td>0.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>5.0</td>\n",
       "      <td>118.0</td>\n",
       "      <td>4011</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>myeloma</td>\n",
       "      <td>carfilzomib</td>\n",
       "      <td>7.0</td>\n",
       "      <td>713.0</td>\n",
       "      <td>340.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>242.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>35.0</td>\n",
       "      <td>110.0</td>\n",
       "      <td>952.0</td>\n",
       "      <td>11431.0</td>\n",
       "      <td>56383</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>myeloma</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>0.0</td>\n",
       "      <td>152.0</td>\n",
       "      <td>125.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>101.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>50.0</td>\n",
       "      <td>473.0</td>\n",
       "      <td>4191.0</td>\n",
       "      <td>20166</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>myeloma</td>\n",
       "      <td>lenalidomide</td>\n",
       "      <td>18.0</td>\n",
       "      <td>743.0</td>\n",
       "      <td>1258.0</td>\n",
       "      <td>12.0</td>\n",
       "      <td>333.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>47.0</td>\n",
       "      <td>93.0</td>\n",
       "      <td>3451.0</td>\n",
       "      <td>19243.0</td>\n",
       "      <td>108686</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>prostate</td>\n",
       "      <td>bortezomib</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>40.0</td>\n",
       "      <td>2004</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>prostate</td>\n",
       "      <td>carfilzomib</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>22.0</td>\n",
       "      <td>2014</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>prostate</td>\n",
       "      <td>degarelix</td>\n",
       "      <td>526.0</td>\n",
       "      <td>80.0</td>\n",
       "      <td>1013.0</td>\n",
       "      <td>8.0</td>\n",
       "      <td>152.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>20.0</td>\n",
       "      <td>13787.0</td>\n",
       "      <td>38162</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>prostate</td>\n",
       "      <td>docetaxel</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>30.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>8.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>309.0</td>\n",
       "      <td>6013</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>prostate</td>\n",
       "      <td>enzalutamide</td>\n",
       "      <td>21.0</td>\n",
       "      <td>1867.0</td>\n",
       "      <td>822.0</td>\n",
       "      <td>16.0</td>\n",
       "      <td>706.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>8.0</td>\n",
       "      <td>7.0</td>\n",
       "      <td>760.0</td>\n",
       "      <td>22696.0</td>\n",
       "      <td>92663</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>prostate</td>\n",
       "      <td>lenalidomide</td>\n",
       "      <td>16.0</td>\n",
       "      <td>30.0</td>\n",
       "      <td>134.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>251.0</td>\n",
       "      <td>2067.0</td>\n",
       "      <td>8029</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>prostate</td>\n",
       "      <td>radium_223</td>\n",
       "      <td>0.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>9.0</td>\n",
       "      <td>248.0</td>\n",
       "      <td>6043</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "      cancer          drug  American Indian/ Alaska Native  \\\n",
       "0      Other    bortezomib                             2.0   \n",
       "1      Other   carfilzomib                             0.0   \n",
       "2      Other   daratumumab                            18.0   \n",
       "3      Other     denosumab                             2.0   \n",
       "4      Other     docetaxel                             1.0   \n",
       "5      Other  enzalutamide                             0.0   \n",
       "6      Other  lenalidomide                            12.0   \n",
       "7      Other    radium_223                             0.0   \n",
       "8    myeloma    bortezomib                             0.0   \n",
       "9    myeloma   carfilzomib                             7.0   \n",
       "10   myeloma   daratumumab                             0.0   \n",
       "11   myeloma  lenalidomide                            18.0   \n",
       "12  prostate    bortezomib                             0.0   \n",
       "13  prostate   carfilzomib                             0.0   \n",
       "14  prostate     degarelix                           526.0   \n",
       "15  prostate     docetaxel                             0.0   \n",
       "16  prostate  enzalutamide                            21.0   \n",
       "17  prostate  lenalidomide                            16.0   \n",
       "18  prostate    radium_223                             0.0   \n",
       "\n",
       "    Asian/ Asian Heritage  Black/ Black Heritage  \\\n",
       "0                    23.0                   40.0   \n",
       "1                    10.0                   47.0   \n",
       "2                   285.0                   64.0   \n",
       "3                  1553.0                  312.0   \n",
       "4                    58.0                  115.0   \n",
       "5                   164.0                   30.0   \n",
       "6                   592.0                  339.0   \n",
       "7                     1.0                    0.0   \n",
       "8                     3.0                    4.0   \n",
       "9                   713.0                  340.0   \n",
       "10                  152.0                  125.0   \n",
       "11                  743.0                 1258.0   \n",
       "12                    0.0                    6.0   \n",
       "13                    0.0                    6.0   \n",
       "14                   80.0                 1013.0   \n",
       "15                    0.0                   30.0   \n",
       "16                 1867.0                  822.0   \n",
       "17                   30.0                  134.0   \n",
       "18                    4.0                    3.0   \n",
       "\n",
       "    Hawaiian/ Other Pacific Islander  Hispanic/ Latino  Middle Eastern  Mixed  \\\n",
       "0                                2.0              39.0             0.0    0.0   \n",
       "1                                1.0              19.0             0.0    0.0   \n",
       "2                                2.0              64.0             0.0    2.0   \n",
       "3                               16.0             652.0             0.0    0.0   \n",
       "4                                0.0              37.0             0.0    0.0   \n",
       "5                                3.0              13.0             0.0    0.0   \n",
       "6                               10.0             384.0             0.0   13.0   \n",
       "7                                0.0               0.0             0.0    0.0   \n",
       "8                                0.0               4.0             0.0    0.0   \n",
       "9                                6.0             242.0             0.0   35.0   \n",
       "10                               2.0             101.0             0.0    0.0   \n",
       "11                              12.0             333.0             0.0   47.0   \n",
       "12                               0.0               0.0             0.0    0.0   \n",
       "13                               0.0               0.0             0.0    0.0   \n",
       "14                               8.0             152.0             0.0    0.0   \n",
       "15                               0.0               8.0             0.0    0.0   \n",
       "16                              16.0             706.0             2.0    8.0   \n",
       "17                               2.0               2.0             0.0    0.0   \n",
       "18                               0.0               3.0             0.0    1.0   \n",
       "\n",
       "    Other  Unknown or Not Reported  White/ White Heritage    year  \n",
       "0     0.0                     74.0                 1351.0   26070  \n",
       "1     2.0                      9.0                  632.0   24168  \n",
       "2     4.0                    304.0                 2984.0   18148  \n",
       "3    80.0                      3.0                14910.0   14058  \n",
       "4     0.0                     38.0                 1822.0   30058  \n",
       "5     3.0                     10.0                  893.0   16123  \n",
       "6   273.0                    891.0                15671.0  152846  \n",
       "7     0.0                      0.0                    4.0    2015  \n",
       "8     0.0                      5.0                  118.0    4011  \n",
       "9   110.0                    952.0                11431.0   56383  \n",
       "10   50.0                    473.0                 4191.0   20166  \n",
       "11   93.0                   3451.0                19243.0  108686  \n",
       "12    0.0                      0.0                   40.0    2004  \n",
       "13    0.0                      0.0                   22.0    2014  \n",
       "14    0.0                     20.0                13787.0   38162  \n",
       "15    0.0                      2.0                  309.0    6013  \n",
       "16    7.0                    760.0                22696.0   92663  \n",
       "17    0.0                    251.0                 2067.0    8029  \n",
       "18    0.0                      9.0                  248.0    6043  "
      ]
     },
     "execution_count": 282,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_cancer_groups"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 283,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 0, 'Total Count of Participants')"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Drug')"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'Other Cancer: Race Distribution for Drugs')"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.axis.YTick at 0x7efe892e5250>,\n",
       " <matplotlib.axis.YTick at 0x7efe892d0a90>,\n",
       " <matplotlib.axis.YTick at 0x7efe8d594eb0>,\n",
       " <matplotlib.axis.YTick at 0x7efe891bf850>,\n",
       " <matplotlib.axis.YTick at 0x7efe891c7070>,\n",
       " <matplotlib.axis.YTick at 0x7efe891c7730>,\n",
       " <matplotlib.axis.YTick at 0x7efe891c7e80>,\n",
       " <matplotlib.axis.YTick at 0x7efe891c7ee0>]"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[Text(0, 0, 'bortezomib'),\n",
       " Text(0, 1, 'carfilzomib'),\n",
       " Text(0, 2, 'daratumumab'),\n",
       " Text(0, 3, 'denosumab'),\n",
       " Text(0, 4, 'docetaxel'),\n",
       " Text(0, 5, 'enzalutamide'),\n",
       " Text(0, 6, 'lenalidomide'),\n",
       " Text(0, 7, 'radium_223')]"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x7efe891bf4c0>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 0, 'Total Count of Participants')"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Drug')"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'myeloma Cancer: Race Distribution for Drugs')"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.axis.YTick at 0x7efe8e1b9310>,\n",
       " <matplotlib.axis.YTick at 0x7efe8914cca0>,\n",
       " <matplotlib.axis.YTick at 0x7efe8914c400>,\n",
       " <matplotlib.axis.YTick at 0x7efe878f9070>]"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[Text(0, 0, 'bortezomib'),\n",
       " Text(0, 1, 'carfilzomib'),\n",
       " Text(0, 2, 'daratumumab'),\n",
       " Text(0, 3, 'lenalidomide')]"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x7efe878f96a0>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 0, 'Total Count of Participants')"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Drug')"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'prostate Cancer: Race Distribution for Drugs')"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.axis.YTick at 0x7efe878d14f0>,\n",
       " <matplotlib.axis.YTick at 0x7efe878cae50>,\n",
       " <matplotlib.axis.YTick at 0x7efe8791fd30>,\n",
       " <matplotlib.axis.YTick at 0x7efe8780f220>,\n",
       " <matplotlib.axis.YTick at 0x7efe8780f970>,\n",
       " <matplotlib.axis.YTick at 0x7efe8780e100>,\n",
       " <matplotlib.axis.YTick at 0x7efe8780e850>]"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[Text(0, 0, 'bortezomib'),\n",
       " Text(0, 1, 'carfilzomib'),\n",
       " Text(0, 2, 'degarelix'),\n",
       " Text(0, 3, 'docetaxel'),\n",
       " Text(0, 4, 'enzalutamide'),\n",
       " Text(0, 5, 'lenalidomide'),\n",
       " Text(0, 6, 'radium_223')]"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x7efe8780ef70>"
      ]
     },
     "execution_count": 283,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Define the race group colors and order\n",
    "race_colors = ['#fde624', '#3b518b', '#21908c', '#5cc862', '#EE6A50', 'orange', '#430154', 'black', 'skyblue', 'green']\n",
    "race_order = ['White/ White Heritage', 'Black/ Black Heritage', 'Hispanic/ Latino', 'Asian/ Asian Heritage',\n",
    "              'Unknown or Not Reported', 'American Indian/ Alaska Native', 'Middle Eastern',\n",
    "              'Hawaiian/ Other Pacific Islander', 'Other', 'Mixed']\n",
    "\n",
    "# Plot side-by-side horizontal bar charts for each cancer type\n",
    "cancer_types = race_cancer_groups['cancer'].unique()\n",
    "num_race_groups = len(race_order)\n",
    "bar_width = 0.08\n",
    "spacing = 0.02\n",
    "\n",
    "for cancer_type in cancer_types:\n",
    "    fig, ax = plt.subplots(figsize=(10, 6))\n",
    "    cancer_df = race_cancer_groups[race_cancer_groups['cancer'] == cancer_type]\n",
    "    drugs = cancer_df['drug']\n",
    "    \n",
    "    # Calculate the center position for each group of bars\n",
    "    center_positions = np.arange(len(drugs))\n",
    "    bar_positions = [\n",
    "        center_positions - ((num_race_groups - 1) / 2) * (bar_width + spacing) + i * (bar_width + spacing)\n",
    "        for i in range(num_race_groups)\n",
    "    ]\n",
    "    \n",
    "    # Plot the bars for each race group\n",
    "    for i, race_group in enumerate(race_order):\n",
    "        values = cancer_df[race_group]\n",
    "        ax.barh(bar_positions[i], values, height=bar_width, color=race_colors[i], label=race_group)\n",
    "    \n",
    "    ax.set_xlabel('Total Count of Participants')\n",
    "    ax.set_ylabel('Drug')\n",
    "    ax.set_title(f'{cancer_type} Cancer: Race Distribution for Drugs')\n",
    "    ax.set_yticks(center_positions)\n",
    "    ax.set_yticklabels(drugs)\n",
    "    \n",
    "    # Place the legend below the chart with 2 columns and 5 rows\n",
    "    ax.legend(loc='upper center', bbox_to_anchor=(0.5, -0.15), ncol=2, mode='expand', frameon=False)\n",
    "    \n",
    "    plt.tight_layout()\n",
    "    \n",
    "    # Save the figure\n",
    "    plt.savefig(r'/project/approved_drugs_charts_data/'f'{cancer_type}_race_distribution.png')\n",
    "    \n",
    "    plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 284,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 8 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 0, 'Total Count of Participants')"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Drug')"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'Other Cancer: Race Distribution for Drugs')"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.axis.YTick at 0x7efe891ab7c0>,\n",
       " <matplotlib.axis.YTick at 0x7efe892bc190>,\n",
       " <matplotlib.axis.YTick at 0x7efe892c5ee0>,\n",
       " <matplotlib.axis.YTick at 0x7efe87721040>,\n",
       " <matplotlib.axis.YTick at 0x7efe87721730>,\n",
       " <matplotlib.axis.YTick at 0x7efe87721e80>,\n",
       " <matplotlib.axis.YTick at 0x7efe8771d610>,\n",
       " <matplotlib.axis.YTick at 0x7efe8771dd60>]"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[Text(0, 0, 'bortezomib'),\n",
       " Text(0, 1, 'carfilzomib'),\n",
       " Text(0, 2, 'daratumumab'),\n",
       " Text(0, 3, 'denosumab'),\n",
       " Text(0, 4, 'docetaxel'),\n",
       " Text(0, 5, 'enzalutamide'),\n",
       " Text(0, 6, 'lenalidomide'),\n",
       " Text(0, 7, 'radium_223')]"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x7efe8771dd90>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAA9wAAAI/CAYAAACF99GFAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjUuMywgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/NK7nSAAAACXBIWXMAAA9hAAAPYQGoP6dpAAC6rklEQVR4nOzdd3yN5//H8ffJTmSIIAlCSIyYsWq2qKo9qsMmpVqtvaqqZtXearSKqKrRFlVaW+xN0EpRFVGNTWIVSe7fH345X0eGBEeM1/PxOI+H+7qv+74+930lRz7nuu7rmAzDMAQAAAAAAB4rm4wOAAAAAACA5xEJNwAAAAAAVkDCDQAAAACAFZBwAwAAAABgBSTcAAAAAABYAQk3AAAAAABWQMINAAAAAIAVkHADAAAAAGAFJNwAAAAAAFgBCTcAvOB27Niht99+W76+vnJwcJCPj4/eeustbd++PUndbdu2adCgQbpy5UqSff7+/qpXr94TiDh1t27d0pdffqnKlSvL09NTDg4Oypkzp9555x1t3Lgxo8N74gYNGiSTyWR+2dvbK3fu3Grfvr3OnDmT0eGlKDQ01CJuJycn+fj4qFq1aho+fLjOnTuX5JjEa02PGzduaNCgQQoLC0vXccm1ZY3fge+//14TJkxIdp/JZNKgQYMea3tptXDhQhUpUkTOzs4ymUwKDw+3WlthYWEWPwsODg7Kli2bKlWqpH79+unkyZNWaxsAHhUJNwC8wCZPnqxKlSrpn3/+0ahRo7R27VqNGTNGp0+fVuXKlfXll19a1N+2bZsGDx6cbML9NLhw4YIqVaqkHj16qGjRogoNDdW6des0duxY2draqnr16jpw4EBGh5khVq5cqe3bt+u3335T06ZNNWvWLFWvXl137tzJ6NBSNXv2bG3fvl1r1qzRlClTFBwcrJEjRyooKEhr1661qPvee+8l+0FRam7cuKHBgwenO+F+mLYeRmoJ9/bt2/Xee+9ZPYb7nT9/Xq1atVJAQID556pAgQJWb3fYsGHavn27NmzYoJkzZ6pq1aqaNWuWgoKCNG/ePKu3DwAPwy6jAwAAZIytW7eqW7duqlOnjpYsWSI7u//9l9C0aVO98cYb6tq1q0qWLKlKlSplYKT/Ex8fr7i4ODk6Oia7v3Xr1jpw4IBWrVqlV1991WJf06ZN1aNHD3l6ej6JUK3izp07MplMFn2VVqVLl1bWrFklSa+99pouXLig2bNna8uWLapWrdrjDvWxKVq0qMqUKWPefvPNN9W9e3dVrlxZjRs31rFjx+Tt7S1JypUrl3LlymXVeG7cuCEXF5cn0taDlC9fPkPaPXr0qO7cuaOWLVuqSpUqj+Wcifc1Nfnz57e45gYNGqhnz5567bXXFBISouLFi6tYsWKP1AYAPG6McAPAC2r48OEymUyaNm1akgTOzs5OU6dOlclk0ogRIyTdnULbu3dvSVLevHnN0zvvHxlcuXKlSpUqJWdnZxUqVEizZs1K0vaZM2f0wQcfKFeuXHJwcFDevHk1ePBgxcXFmetERkbKZDJp1KhRGjp0qPLmzStHR0dt2LAh2evZu3evfvvtN7Vr1y5Jsp2obNmyyp07t6S7o3QfffSRChcuLFdXV2XPnl2vvvqqNm/ebHFMYhxjxozRuHHjlDdvXrm6uqpChQrasWNHkjZ27typ+vXry8vLS05OTgoICFC3bt0s6hw7dkzNmzdX9uzZ5ejoqKCgIE2ZMsWiTuI02rlz56pnz57KmTOnHB0d9ddffyV7bemVmMSePXvWXJbWeyLdnbo/ZMgQBQUFycnJSV5eXqpWrZq2bdtmrmMYhqZOnarg4GA5OzvL09NTb731lv7+++9Hij137twaO3asrl69qq+++spcntw07/Xr16tq1ary8vKSs7OzcufOrTfffFM3btxQZGSksmXLJkkaPHiw+Wc6JCTE4nz79u3TW2+9JU9PTwUEBKTYVqIlS5aoePHicnJyUr58+TRp0iSL/YnT5SMjIy3KE/s88XeqatWqWrFihU6ePGkxpTpRclPKf//9dzVs2FCenp5ycnJScHCw5syZk2w78+fPV79+/ZQjRw65u7vrtdde05EjR1K+8ZJCQkJUuXJlSVKTJk1kMplUtWpV8/5ly5apQoUKcnFxkZubm2rUqJFkJkBq9zW9smTJoq+++kpxcXEaP358mtqoWrWqRcz3Xpu/v79F2T///KO33npLbm5uypw5s1q0aKHdu3fLZDIpNDTUXO/vv/9W06ZNlSNHDjk6Osrb21vVq1e36lR7AM8GRrgB4AUUHx+vDRs2qEyZMimO0vn5+al06dJav3694uPj9d577+nSpUuaPHmyFi9eLF9fX0lS4cKFzcccOHBAPXv21CeffCJvb2998803ateunQIDA/XKK69Iuptsv/TSS7KxsdGAAQMUEBCg7du3a+jQoYqMjNTs2bMt4pg0aZIKFCigMWPGyN3dXfnz50823tWrV0uSGjVqlKZ7cOnSJUnSwIED5ePjo2vXrmnJkiWqWrWq1q1bl+QP8ilTpqhQoULm6b39+/dXnTp1dOLECXl4eEiSVq1apfr16ysoKEjjxo1T7ty5FRkZaY5Nkg4fPqyKFSuak0YfHx+tWrVKXbp00YULFzRw4ECLdvv27asKFSpo+vTpsrGxUfbs2RUZGam8efOqTZs2Fn/0p8eJEyckyWIqcFrvSVxcnGrXrq3NmzerW7duevXVVxUXF6cdO3YoKipKFStWlCR98MEHCg0NVZcuXTRy5EhdunRJQ4YMUcWKFXXgwAHzyPTDqFOnjmxtbbVp06YU60RGRqpu3bp6+eWXNWvWLGXOnFmnT5/WypUrdfv2bfn6+mrlypWqVauW2rVrZ56enZiEJ2rcuLGaNm2qDh066Pr166nGFR4erm7dumnQoEHy8fHRvHnz1LVrV92+fVu9evVK1zVOnTpV77//vo4fP64lS5Y8sP6RI0dUsWJFZc+eXZMmTZKXl5e+++47hYSE6OzZs/r4448t6n/66aeqVKmSvvnmG8XGxqpPnz6qX7++IiIiZGtrm2wb/fv310svvaSOHTtq2LBhqlatmtzd3SXdnf7eokULvf7665o/f75u3bqlUaNGmX9+EhP1ROm5r6kpW7asfH19k/1ZeJQ2rl+/rmrVqunSpUsaOXKkAgMDtXLlSjVp0iRJ3Tp16ig+Pl6jRo1S7ty5deHCBW3btu2pffwGwBNkAABeOGfOnDEkGU2bNk21XpMmTQxJxtmzZw3DMIzRo0cbkowTJ04kqZsnTx7DycnJOHnypLns5s2bRpYsWYwPPvjAXPbBBx8Yrq6uFvUMwzDGjBljSDL++OMPwzAM48SJE4YkIyAgwLh9+/YDr6lDhw6GJOPPP/98YN3kxMXFGXfu3DGqV69uvPHGG+byxDiKFStmxMXFmct37dplSDLmz59vLgsICDACAgKMmzdvpthOzZo1jVy5chkxMTEW5Z06dTKcnJyMS5cuGYZhGBs2bDAkGa+88kqSc0RGRhq2trZG27ZtH3hdAwcONCQZZ86cMe7cuWNcvnzZWLRokZEpUyajWbNmqR6b0j359ttvDUnGjBkzUjx2+/bthiRj7NixFuWnTp0ynJ2djY8//jjVtmfPnm1IMnbv3p1iHW9vbyMoKCjJtSb68ccfDUlGeHh4iuc4f/68IckYOHBgkn2J5xswYECK++6VJ08ew2QyJWmvRo0ahru7u3H9+nWLa7v/9yixzzds2GAuq1u3rpEnT55kY78/7qZNmxqOjo5GVFSURb3atWsbLi4uxpUrVyzaqVOnjkW9RYsWGZKM7du3J9ve/XH+8MMP5rL4+HgjR44cRrFixYz4+Hhz+dWrV43s2bMbFStWNJeldl/T2t79ypUrZzg7O6epjSpVqhhVqlRJUt6mTRuLez1lyhRDkvHbb79Z1Pvggw8MScbs2bMNwzCMCxcuGJKMCRMmpOl6ALxYmFIOAEiRYRiSlOaVn4ODg81TtiXJyclJBQoUsFhFePny5apWrZpy5MihuLg486t27dqSlGQl8QYNGsje3v5RLyVZ06dPV6lSpeTk5CQ7OzvZ29tr3bp1ioiISFK3bt26FqN+xYsXlyTztR09elTHjx9Xu3bt5OTklGx7//33n9atW6c33nhDLi4uFtdfp04d/ffff0mmqb/55ptJzpMnTx7FxcVp5syZab5WHx8f2dvby9PTU++8845Kly6dZKpxWu/Jb7/9JicnJ7Vt2zbF9pYvXy6TyaSWLVtaXKePj49KlCiR7kXKkpP485mS4OBgOTg46P3339ecOXMeeip7cn2QkiJFiqhEiRIWZc2bN1dsbKz27dv3UO2n1fr161W9enX5+flZlIeEhOjGjRtJpnY3aNDAYvv+n+n0OHLkiP7991+1atVKNjb/+/PS1dVVb775pnbs2KEbN25YHJOe+/ogKf0sPEobGzdulJubm2rVqmVR3qxZM4vtLFmyKCAgQKNHj9a4ceO0f/9+JSQkPHS7AJ4vJNwA8ALKmjWrXFxczNOKUxIZGSkXFxdlyZIlTef18vJKUubo6KibN2+at8+ePatffvlF9vb2Fq8iRYpIurvS+L0Sp64/SGKi/6BrSjRu3Dh9+OGHKleunH766Sft2LFDu3fvVq1atSziTenaEhduS6x7/vx5SUp1Ia2LFy8qLi5OkydPTnL9derUkfTw1/8ga9eu1e7du7Vq1Sq9+eab2rRpkzp37mxRJ6335Pz588qRI4dFYnW/s2fPyjAMeXt7J7nWHTt2JLnO9Lp+/bouXryoHDlypFgnICBAa9euVfbs2dWxY0cFBAQoICBAEydOTFdb6ekDHx+fFMsuXryYrnbT6+LFi8nGmniP7m//QT/T6W1bSv5e5ciRQwkJCbp8+bJF+eP62ZakqKioZH8WHqWNixcvJvvYw/1lJpNJ69atU82aNTVq1CiVKlVK2bJlU5cuXXT16tWHbh/A84FnuAHgBWRra6tq1app5cqV+ueff5JNEv/55x/t3btXtWvXTvF5zoeRNWtWFS9eXF988UWy++//ozmto+s1a9bUp59+qqVLlyYZkUrOd999p6pVq2ratGkW5Q/7B3Lic7///PNPinU8PT1la2urVq1aqWPHjsnWyZs3r8V2er9XOiUlSpQwr1Jeo0YN1axZU19//bXatWunsmXLSkr7PcmWLZu2bNmihISEFJPurFmzymQyafPmzcmuKp/SSvNptWLFCsXHxye7+NW9Xn75Zb388suKj4/Xnj17NHnyZHXr1k3e3t5q2rRpmtpKTx8k993miWWJCW7iDIhbt25Z1HvUDyG8vLwUHR2dpPzff/+VJHP/W0PitaXUvo2NTZJvCHhcP9u7du3SmTNn1K5duyT7kmvDyclJMTExScrvv/9eXl7atWtXknrJ9XGePHnMM06OHj2qRYsWadCgQbp9+7amT5+e5msB8PxhhBsAXlB9+/aVYRj66KOPFB8fb7EvPj5eH374oQzDUN++fc3ljzIClqhevXr6/fffFRAQoDJlyiR5pTZimZpSpUqpdu3amjlzptavX59snT179igqKkrS3T/E70/6Dh48+NDfrVygQAEFBARo1qxZSRKpRC4uLqpWrZr279+v4sWLJ3v9yc0SeNxMJpOmTJkiW1tbffbZZxblabkntWvX1n///Zfqgm316tWTYRg6ffp0steZ2tc3PUhUVJR69eolDw8PffDBB2k6xtbWVuXKlTOvBp84vftx/Ezf648//kjyXe/ff/+93NzcVKpUKUkyr4R98OBBi3rLli1Lcr77Z4ikpnr16lq/fr05wU707bffysXFxapfI1awYEHlzJlT33//vcX07uvXr+unn34yr1z+uF26dEkdOnSQvb29unfvnqZj/P39dfToUYvf04sXL1qssC9JVapU0dWrV/Xbb79ZlC9YsCDV8xcoUECfffaZihUrZvXHCAA8/RjhBoAXVKVKlTRhwgR169ZNlStXVqdOnZQ7d25FRUVpypQp2rlzpyZMmGBecVqSOUmaOHGi2rRpI3t7exUsWFBubm5pbnfIkCFas2aNKlasqC5duqhgwYL677//FBkZqV9//VXTp09/6O83/vbbb1WrVi3Vrl1bbdu2Ve3ateXp6ano6Gj98ssvmj9/vvbu3avcuXOrXr16+vzzzzVw4EBVqVJFR44c0ZAhQ5Q3b16LrydLjylTpqh+/foqX768unfvbr6fq1at0rx58yTdvXeVK1fWyy+/rA8//FD+/v66evWq/vrrL/3yyy8pflhwr5MnTyogIEBt2rRJ13Pc98qfP7/ef/99TZ06VVu2bFHlypXTfE+aNWum2bNnq0OHDjpy5IiqVaumhIQE7dy5U0FBQWratKkqVaqk999/X++++6727NmjV155RZkyZVJ0dLS2bNmiYsWK6cMPP3xgnL///rv5+e9z585p8+bNmj17tmxtbbVkyZIkK4rfa/r06Vq/fr3q1q2r3Llz67///jN/Td1rr70mSXJzc1OePHn0888/q3r16sqSJYuyZs2a5Ouh0ipHjhxq0KCBBg0aJF9fX3333Xdas2aNRo4caU44y5Ytq4IFC6pXr16Ki4uTp6enlixZoi1btiQ5X7FixbR48WJNmzZNpUuXlo2NjcX3kt9r4MCB5jUSBgwYoCxZsmjevHlasWKFRo0aZV5N3xpsbGw0atQotWjRQvXq1dMHH3ygW7duafTo0bpy5Yr56wUfxbFjx7Rjxw4lJCTo4sWL2rlzp2bOnKnY2Fh9++235sdSHqRVq1b66quv1LJlS7Vv314XL17UqFGjzKutJ2rTpo3Gjx+vli1baujQoQoMDNRvv/2mVatWma9ZuvvBSadOnfT2228rf/78cnBw0Pr163Xw4EF98sknj3zdAJ5xGbdeGwDgabB9+3bjrbfeMry9vQ07Ozsje/bsRuPGjY1t27YlW79v375Gjhw5DBsbG4sVlfPkyWPUrVs3Sf3kVgQ+f/680aVLFyNv3ryGvb29kSVLFqN06dJGv379jGvXrhmG8b/VwUePHp2u67l586YxadIko0KFCoa7u7thZ2dn5MiRw2jcuLGxYsUKc71bt24ZvXr1MnLmzGk4OTkZpUqVMpYuXZpkpeLU4lAyq1tv377dqF27tuHh4WE4OjoaAQEBRvfu3S3qnDhxwmjbtq2RM2dOw97e3siWLZtRsWJFY+jQoeY6qa3MnBhTmzZtHng/EldrPn/+fJJ9Z8+eNVxdXY1q1aql654Yxt37PGDAACN//vyGg4OD4eXlZbz66qtJfm5mzZpllCtXzsiUKZPh7OxsBAQEGK1btzb27NmTatyJK3knvhwcHIzs2bMbVapUMYYNG2acO3cuxWtNtH37duONN94w8uTJYzg6OhpeXl5GlSpVjGXLllkct3btWqNkyZKGo6OjxX1N7d6ltEp53bp1jR9//NEoUqSI4eDgYPj7+xvjxo1LcvzRo0eN119/3XB3dzeyZctmdO7c2VixYkWSVcovXbpkvPXWW0bmzJkNk8lk0WZyP3+HDh0y6tevb3h4eBgODg5GiRIlzKtpJ0rpZyvx5+r++vdL7Wdz6dKlRrly5QwnJycjU6ZMRvXq1Y2tW7da1EntvqbWXuLLzs7O8PLyMipUqGB8+umnRmRkZJJjHtTGnDlzjKCgIMPJyckoXLiwsXDhwmR/zqOioozGjRsbrq6uhpubm/Hmm28av/76qyHJ+Pnnnw3DuPt7FBISYhQqVMjIlCmT4erqahQvXtwYP368xTcbAHgxmQzjAUt8AgAAAJAkDRs2TJ999pmioqIeejYOgBcHU8oBAACAZHz55ZeSpEKFCunOnTtav369Jk2apJYtW5JsA0gTEm4AAAAgGS4uLho/frwiIyN169Yt5c6dW3369LFYbBAAUsOUcgAAAAAArICvBQMAAAAAwApIuAEAAAAAsAISbgAAAAAArIBF05AmCQkJ+vfff+Xm5iaTyZTR4QAAAADAE2cYhq5evaocOXLIxubB49ck3EiTf//9V35+fhkdBgAAAABkuFOnTqXp6wFJuJEmbm5uku7+YLm7u2dwNAAAAADw5MXGxsrPz8+cHz0ICTfSJHEaubu7Owk3AAAAgBdaWh+zZdE0AAAAAACsgIQbAAAAAAArIOEGAAAAAMAKSLgBAAAAALACEm4AAAAAAKyAhBsAAAAAACsg4QYAAAAAwApIuAEAAAAAsAISbgAAAAAArICEGwAAAAAAKyDhBgAAAADACki4AQAAAACwAhJuAAAAAACsgIQbAAAAAAArIOEGAAAAAMAKSLgBAAAAALACEm4AAAAAAKyAhBsAAAAAACsg4QYAAAAAwApIuAEAAAAAsAISbgAAAAAArICEGwAAAAAAKyDhBgAAAADACki4AQAAAACwAhJuAAAAAACsgIQbAAAAAAArIOEGAAAAAMAKSLglhYaGKnPmzObtQYMGKTg4OMPiAQAAAAA8+0i4k9GrVy+tW7cuQ2MICwtTw4YN5evrq0yZMik4OFjz5s2zqLN48WLVqFFD2bJlk7u7uypUqKBVq1YlqVOmTBllzpzZfJ65c+c+yUsBAAAAgBfSc5Vw3759+7Gcx9XVVV5eXo/lXA9r27ZtKl68uH766ScdPHhQbdu2VevWrfXLL7+Y62zatEk1atTQr7/+qr1796patWqqX7++9u/fb66TJUsW9evXT9u3b9fBgwf17rvv6t13302SmAMAAAAAHi+TYRhGRgfxsKpWraqiRYvKwcFB3377rYoUKaKGDRtq9uzZ+vvvv5UlSxbVr19fo0aNkqurq/m40NBQDRgwQBcuXFDNmjVVuXJlff7557py5Yqku1PKly5dqvDwcHM7wcHBmjBhgvkcjRo1UubMmRUaGipJ8vf313vvvaejR49q8eLF8vLy0qRJk1SxYkW99957WrdunfLmzavZs2erTJkyD3W9devWlbe3t2bNmpVinSJFiqhJkyYaMGBAinVKlSqlunXr6vPPP09z27GxsfLw8FBMTIzc3d3TFTcAAAAAPA/Smxc98yPcc+bMkZ2dnbZu3aqvvvpKNjY2mjRpkn7//XfNmTNH69ev18cff2yuv3PnTrVt21YfffSRwsPDVa1aNQ0dOvSxxDJ+/HhVqlRJ+/fvV926ddWqVSu1bt1aLVu21L59+xQYGKjWrVvrYT/jiImJUZYsWVLcn5CQoKtXr6ZYxzAMrVu3TkeOHNErr7ySalu3bt1SbGysxQsAAAAAkHZ2GR3AowoMDNSoUaPM24UKFTL/O2/evPr888/14YcfaurUqZKkiRMnqmbNmvrkk08kSQUKFNC2bdu0cuXKR46lTp06+uCDDyRJAwYM0LRp01S2bFm9/fbbkqQ+ffqoQoUKOnv2rHx8fNJ17h9//FG7d+/WV199lWKdsWPH6vr163rnnXcsymNiYpQzZ07dunVLtra2mjp1qmrUqJFqe8OHD9fgwYPTFSMAAAAA4H+e+RHu+6dnb9iwQTVq1FDOnDnl5uam1q1b6+LFi7p+/bokKSIiQhUqVLA45v7th1W8eHHzv729vSVJxYoVS1J27ty5dJ03LCxMISEhmjFjhooUKZJsnfnz52vQoEFauHChsmfPbrHPzc1N4eHh2r17t7744gv16NFDYWFhqbbZt29fxcTEmF+nTp1KV8wAAAAA8KJ75ke4M2XKZP73yZMnVadOHXXo0EGff/65smTJoi1btqhdu3a6c+eOJD3UdG4bG5skxyWe71729vbmf5tMphTLEhIS0tz2xo0bVb9+fY0bN06tW7dOts7ChQvVrl07/fDDD3rttdeSjT8wMFCSFBwcrIiICA0fPlxVq1ZNsV1HR0c5OjqmOU4AAAAAgKVnfoT7Xnv27FFcXJzGjh2r8uXLq0CBAvr3338t6hQuXFg7duywKLt/+37ZsmVTdHS0eTs+Pl6///774ws8BWFhYapbt65GjBih999/P9k68+fPV0hIiL7//nvVrVs3Tec1DEO3bt16nKECAAAAAO7zzI9w3ysgIEBxcXGaPHmy6tevr61bt2r69OkWdbp06aKKFStq1KhRatSokVavXv3A57dfffVV9ejRQytWrFBAQIDGjx9vXtHcWhKT7a5du+rNN9/UmTNnJEkODg7mRdHmz5+v1q1ba+LEiSpfvry5jrOzszw8PCTdfRa7TJkyCggI0O3bt/Xrr7/q22+/1bRp06waPwAAAAC86J6rEe7g4GCNGzdOI0eOVNGiRTVv3jwNHz7cok758uX1zTffaPLkyQoODtbq1av12WefpXretm3bqk2bNmrdurWqVKmivHnzqlq1ata8FIWGhurGjRsaPny4fH19za/GjRub63z11VeKi4tTx44dLep07drVXOf69ev66KOPVKRIEVWsWFE//vijvvvuO7333ntWjR8AAAAAXnTP9Pdw48nhe7gBAAAAvOheuO/hBgAAAADgaUTCnUFq164tV1fXZF/Dhg3L6PAAAAAAAI/ouVo07VnyzTff6ObNm8nuS1wUDQAAAADw7CLhziA5c+bM6BAAAAAAAFbElHIAAAAAAKyAhBsAAAAAACsg4QYAAAAAwApIuAEAAAAAsAISbgAAAAAArICEGwAAAAAAKyDhBgAAAADACki4AQAAAACwAhJuAAAAAACsgIQbAAAAAAArIOEGAAAAAMAKSLgBAAAAALACEm4AAAAAAKzALqMDwLPFY7iH5GRZZgw0MiYYAAAAAHiKMcINAAAAAIAVkHADAAAAAGAFTClHusT0jZG7u3tGhwEAAAAATz0SbqTLuAMX5eR6O6PDwDPgk5JZMzoEAAAAIEMxpRwAAAAAACsg4QYAAAAAwAqYUo506VHCi2e4AQAAACANSLiRLh4eHhbbhsF3cAMAAABAcphSDgAAAACAFZBwAwAAAABgBSTcSJeYmBgZhmF+AQAAAACSR8INAAAAAIAVPBMJd9WqVdWtW7cn2qbJZNLSpUslSZGRkTKZTAoPD0+xflhYmEwmk65cuWLVuEJDQ5U5c+ZU6wwaNEjBwcFWjQMAAAAAkLpnIuHOaH5+foqOjlbRokUzOhQ1adJER48ezegwAAAAAAAPwNeCpYGtra18fHwyOgxJkrOzs5ydnTM6DAAAAADAAzxzI9y3b9/Wxx9/rJw5cypTpkwqV66cwsLCzPsTp1yvWrVKQUFBcnV1Va1atRQdHW2us3v3btWoUUNZs2aVh4eHqlSpon379qXYZnJTyn/99VcVKFBAzs7OqlatmiIjI5Mc99NPP6lIkSJydHSUv7+/xo4da7Hf399fQ4cOVevWreXq6qo8efLo559/1vnz59WwYUO5urqqWLFi2rNnT5Lru9eIESPk7e0tNzc3tWvXTv/991+SWGbPnq2goCA5OTmpUKFCmjp1aorXm6pFHtL3JssXAAAAACCJZy7hfvfdd7V161YtWLBABw8e1Ntvv61atWrp2LFj5jo3btzQmDFjNHfuXG3atElRUVHq1auXef/Vq1fVpk0bbd68WTt27FD+/PlVp04dXb16NU0xnDp1So0bN1adOnUUHh6u9957T5988olFnb179+qdd95R06ZNdejQIQ0aNEj9+/dXaGioRb3x48erUqVK2r9/v+rWratWrVqpdevWatmypfbt26fAwEC1bt06xRXBFy1apIEDB+qLL77Qnj175OvrmySZnjFjhvr166cvvvhCERERGjZsmPr37685c+akeI23bt1SbGysxQsAAAAAkA7GM6BKlSpG165djb/++sswmUzG6dOnLfZXr17d6Nu3r2EYhjF79mxDkvHXX3+Z90+ZMsXw9vZO8fxxcXGGm5ub8csvv5jLJBlLliwxDMMwTpw4YUgy9u/fbxiGYfTt29cICgoyEhISzPX79OljSDIuX75sGIZhNG/e3KhRo4ZFO7179zYKFy5s3s6TJ4/RsmVL83Z0dLQhyejfv7+5bPv27YYkIzo62nx9Hh4e5v0VKlQwOnToYNFOuXLljBIlSpi3/fz8jO+//96izueff25UqFAhxXsycOBAQ1KSV8wMGca8+14AAAAA8AKIiYm5mxfFxKSp/jM1wr1v3z4ZhqECBQrI1dXV/Nq4caOOHz9urufi4qKAgADztq+vr86dO2fePnfunDp06KACBQrIw8NDHh4eunbtmqKiotIUR0REhMqXLy+T6X/TqStUqJCkTqVKlSzKKlWqpGPHjik+Pt5cVrx4cfO/vb29JUnFihVLUnZv/Pe3c3/b926fP39ep06dUrt27Szu2dChQy3u2f369u2rmJgY8+vUqVMp1gUAAAAAJPVMLZqWkJAgW1tb7d27V7a2thb7XF1dzf+2t7e32GcymSymZIeEhOj8+fOaMGGC8uTJI0dHR1WoUEG3b99OUxxGCtO7769zb0Ke0nH3xppYP7myhISENMV2v8TjZsyYoXLlylnsu/8e3svR0VGOjo5Jd7wTI7m7P1QsAAAAAPAieaYS7pIlSyo+Pl7nzp3Tyy+//NDn2bx5s6ZOnao6depIuvtM9oULF9J8fOHChc3f0Z1ox44dSeps2bLFomzbtm0qUKBAqoluegUFBWnHjh1q3bp1srF4e3srZ86c+vvvv9WiRYtHbu9yz+aKd7B/cEUAAF4wnlOWZHQIAICnzDOVcBcoUEAtWrRQ69atNXbsWJUsWVIXLlzQ+vXrVaxYMXMC/SCBgYGaO3euypQpo9jYWPXu3TtdX7XVoUMHjR07Vj169NAHH3ygvXv3JlkMrWfPnipbtqw+//xzNWnSRNu3b9eXX3758KuDp6Br165q06aNypQpo8qVK2vevHn6448/lC9fPnOdQYMGqUuXLnJ3d1ft2rV169Yt7dmzR5cvX1aPHj0eazwAAAAAgLueqWe4pbtfb9W6dWv17NlTBQsWVIMGDbRz5075+fml+RyzZs3S5cuXVbJkSbVq1UpdunRR9uzZ03x87ty59dNPP+mXX35RiRIlNH36dA0bNsyiTqlSpbRo0SItWLBARYsW1YABAzRkyBCFhISkuZ20aNKkiQYMGKA+ffqodOnSOnnypD788EOLOu+9956++eYbhYaGqlixYqpSpYpCQ0OVN2/exxoLAAAAAOB/TEZaHkjGCy82NlYeHh6KiYmRO89wAwAAAHgBpTcveqamlCPjtd/TUQ6ZHDI6DABIl7nlZmZ0CAAA4AX0zE0pBwAAAADgWUDCDQAAAACAFTClHOkyo8wUnuEGAAAAgDQg4Ua6FJ82WTZOThkdBvBU+Ltrz4wOAQAAAE8xppQDAAAAAGAFJNwAAAAAAFgBU8qRLgc/7Mwz3AAAAACQBiTcSJfXW0ySnT3PcOPZsWVxr4wOAQAAAC8oppQDAAAAAGAFJNwAAAAAAFgBCTcAAAAAAFbAM9xIl9XzurBoGgAAAACkASPcAAAAAABYAQk3AAAAAABWQMINAAAAAIAVkHADAAAAAGAFJNwAAAAAAFgBCTcAAAAAAFZAwg0AAAAAgBWQcAMAAAAAYAUk3AAAAAAAWAEJNwAAAAAAVkDCDQAAAACAFZBwAwAAAABgBSTcAAAAAABYAQk3AAAAAABWQMINAAAAAIAVkHADAAAAAGAFJNwAAAAAAFgBCfd9Bg0apODg4IwOI0VhYWEymUy6cuVKinVCQ0OVOXPmJxYTAAAAACApEu7HwN/fXxMmTHgibVWsWFHR0dHy8PB4Iu0BAAAAAB6OXUYHgPRxcHCQj49PRocBAAAAAHiAp26E2zAMjRo1Svny5ZOzs7NKlCihH3/8UdL/plOvW7dOZcqUkYuLiypWrKgjR46Yj/f395fJZEryStSnTx8VKFBALi4uypcvn/r37687d+6kGE/VqlXVrVs3i7JGjRopJCTEvP/kyZPq3r27RVsXL15Us2bNlCtXLrm4uKhYsWKaP39+knN37txZ3bp1k6enp7y9vfX111/r+vXrevfdd+Xm5qaAgAD99ttv5mOSm1IeGhqq3Llzy8XFRW+88YYuXryY5Dp++eUXlS5dWk5OTsqXL58GDx6suLi41DsDAAAAAPDQnrqE+7PPPtPs2bM1bdo0/fHHH+revbtatmypjRs3muv069dPY8eO1Z49e2RnZ6e2bdua9+3evVvR0dGKjo7WP//8o/Lly+vll18273dzc1NoaKgOHz6siRMnasaMGRo/fvxDx7t48WLlypVLQ4YMMbcrSf/9959Kly6t5cuX6/fff9f777+vVq1aaefOnRbHz5kzR1mzZtWuXbvUuXNnffjhh3r77bdVsWJF7du3TzVr1lSrVq1048aNZNvfuXOn2rZtq48++kjh4eGqVq2ahg4dalFn1apVatmypbp06aLDhw/rq6++UmhoqL744osUr+vWrVuKjY21eAEAAAAA0sF4ily7ds1wcnIytm3bZlHerl07o1mzZsaGDRsMScbatWvN+1asWGFIMm7evJnkfF26dDHy5MljnDt3LsU2R40aZZQuXdq8PXDgQKNEiRLm7SpVqhhdu3a1OKZhw4ZGmzZtzNt58uQxxo8f/8Drq1OnjtGzZ0+Lc1euXNm8HRcXZ2TKlMlo1aqVuSw6OtqQZGzfvt0wDMN8Dy5fvmwYhmE0a9bMqFWrlkU7TZo0MTw8PMzbL7/8sjFs2DCLOnPnzjV8fX1TjHXgwIGGpCSvmJiYB14nAAAAADyPYmJi0pUXPVXPcB8+fFj//fefatSoYVF++/ZtlSxZ0rxdvHhx8799fX0lSefOnVPu3LnN5V9//bVmzpyprVu3Klu2bObyH3/8URMmTNBff/2la9euKS4uTu7u7o/9WuLj4zVixAgtXLhQp0+f1q1bt3Tr1i1lypTJot6912JraysvLy8VK1bMXObt7W2+vuRERETojTfesCirUKGCVq5cad7eu3evdu/ebTGiHR8fr//++083btyQi4tLkvP27dtXPXr0MG/HxsbKz88vLZcOAAAAANBTtmhaQkKCJGnFihXKmTOnxT5HR0cdP35ckmRvb28uT3xmOvFY6e5zzp07d9b8+fNVokQJc/mOHTvUtGlTDR48WDVr1pSHh4cWLFigsWPHphiTjY2NDMOwKEvtme9EY8eO1fjx4zVhwgQVK1ZMmTJlUrdu3XT79m2LevdeS+L1POj67nV/bMlJSEjQ4MGD1bhx4yT7nJyckj3G0dFRjo6ODzw3AAAAACB5T1XCXbhwYTk6OioqKkpVqlRJsj8x4U7NX3/9pTfffFOffvppkgRz69atypMnj/r162cuO3nyZKrny5Ytm/m5bOnuyPDvv/+uatWqmcscHBwUHx9vcdzmzZvVsGFDtWzZUtLdpPfYsWMKCgp64DWkR+HChbVjxw6Lsvu3S5UqpSNHjigwMPCR27vcs7niHf73gYDnlCWPfE4AAAAAeB49VQm3m5ubevXqpe7duyshIUGVK1dWbGystm3bJldXV+XJkyfV42/evKn69esrODhY77//vs6cOWPe5+Pjo8DAQEVFRWnBggUqW7asVqxYoSVLUk8YX331VfXo0UMrVqxQQECAxo8fb7FCuHR3ZfRNmzapadOmcnR0VNasWRUYGKiffvpJ27Ztk6enp8aNG6czZ8489oS7S5cuqlixokaNGqVGjRpp9erVFtPJJWnAgAGqV6+e/Pz89Pbbb8vGxkYHDx7UoUOHkiywBgAAAAB4PJ66Vco///xzDRgwQMOHD1dQUJBq1qypX375RXnz5n3gsWfPntWff/6p9evXK0eOHPL19TW/JKlhw4bq3r27OnXqpODgYG3btk39+/dP9Zxt27ZVmzZt1Lp1a1WpUkV58+a1GN2WpCFDhigyMlIBAQHm58X79++vUqVKqWbNmqpatap8fHzUqFGjh7spqShfvry++eYbTZ48WcHBwVq9erU+++wzizo1a9bU8uXLtWbNGpUtW1bly5fXuHHjHvgBBgAAAADg4ZmMtDwEjBdebGysPDw8FBMTY5VF5gAAAADgaZfevOipmlKOp1/7PR3lkMkho8N4LswtNzOjQwAAAABgRU/dlHIAAAAAAJ4HJNwAAAAAAFgBU8qRLjPKTOEZbgAAAABIAxJupEvxaZNl4+RkUfZ3154ZFA0AAAAAPL2YUg4AAAAAgBWQcAMAAAAAYAVMKUe6HPywM89wAwAAAEAakHAjXV5vMUl29k4PrnifLYt7WSEaAAAAAHh6MaUcAAAAAAArIOEGAAAAAMAKSLgBAAAAALACnuFGuqye14VF0wAAAAAgDRjhBgAAAADACki4AQAAAACwAhJuAAAAAACsgIQbAAAAAAArIOEGAAAAAMAKSLgBAAAAALACEm4AAAAAAKyAhBsAAAAAACsg4QYAAAAAwApIuAEAAAAAsAISbgAAAAAArICEGwAAAAAAKyDhBgAAAADACki4AQAAAACwAhJuAAAAAACsgIQbAAAAAAArIOEGAAAAAMAKSLjvU7VqVXXr1i2jw7C6F+U6AQAAACCjkHBnoLCwMJlMJl25ciWjQwEAAAAAPGYk3AAAAAAAWMELnXBfv35drVu3lqurq3x9fTV27FiL/ZcvX1br1q3l6ekpFxcX1a5dW8eOHbOos3XrVlWpUkUuLi7y9PRUzZo1dfnyZUmSYRgaNWqU8uXLJ2dnZ5UoUUI//vijJCkyMlLVqlWTJHl6espkMikkJESStHLlSlWuXFmZM2eWl5eX6tWrp+PHj5vb/Pbbb+Xq6moRS+fOnVWgQAFdv35dknT48GHVqVNHrq6u8vb2VqtWrXThwoXHewMBAAAAACl6oRPu3r17a8OGDVqyZIlWr16tsLAw7d2717w/JCREe/bs0bJly7R9+3YZhqE6derozp07kqTw8HBVr15dRYoU0fbt27VlyxbVr19f8fHxkqTPPvtMs2fP1rRp0/THH3+oe/fuatmypTZu3Cg/Pz/99NNPkqQjR44oOjpaEydOlHT3g4AePXpo9+7dWrdunWxsbPTGG28oISFBktS6dWvVqVNHLVq0UFxcnFauXKmvvvpK8+bNU6ZMmRQdHa0qVaooODhYe/bs0cqVK3X27Fm98847ab43t27dUmxsrMULAAAAAJB2JsMwjIwOIiNcu3ZNXl5e+vbbb9WkSRNJ0qVLl5QrVy69//776tixowoUKKCtW7eqYsWKkqSLFy/Kz89Pc+bM0dtvv63mzZsrKipKW7ZsSXL+69evK2vWrFq/fr0qVKhgLn/vvfd048YNff/99woLC1O1atV0+fJlZc6cOcVYz58/r+zZs+vQoUMqWrSopLuj78WLF1f9+vW1ePFide7cWf369ZMkDRgwQDt37tSqVavM5/jnn3/k5+enI0eOqECBAqpataqCg4M1YcKEZNscNGiQBg8enKQ8JiZG7u7uqd9cAAAAAHgOxcbGysPDI8150Qs7wn38+HHdvn3bIhnOkiWLChYsKEmKiIiQnZ2dypUrZ97v5eWlggULKiIiQtL/RriTc/jwYf3333+qUaOGXF1dza9vv/3WYnp4SrE1b95c+fLlk7u7u/LmzStJioqKMtfx9PTUzJkzNW3aNAUEBOiTTz4x79u7d682bNhg0W6hQoXM506Lvn37KiYmxvw6depUmo4DAAAAANxll9EBZJQHDeyntN8wDJlMJkmSs7NziscnTv9esWKFcubMabHP0dEx1bbr168vPz8/zZgxQzly5FBCQoKKFi2q27dvW9TbtGmTbG1t9e+//+r69evmT1gSEhJUv359jRw5Msm5fX19U2373hgfFCcAAAAAIGUvbMIdGBgoe3t77dixQ7lz55Z0d5r20aNHVaVKFRUuXFhxcXHauXOnxZTyo0ePKigoSJJUvHhxrVu3Ltmp14ULF5ajo6OioqJUpUqVZGNwcHCQJPMz34ltRERE6KuvvtLLL78sSclOWd+2bZtGjRqlX375RZ988ok6d+6sOXPmSJJKlSqln376Sf7+/rKze7xdfLlnc8U72D/yeTynLHkM0QAAAADA0+uFnVLu6uqqdu3aqXfv3lq3bp1+//13hYSEyMbm7i3Jnz+/GjZsqPbt22vLli06cOCAWrZsqZw5c6phw4aS7k673r17tz766CMdPHhQf/75p6ZNm6YLFy7Izc1NvXr1Uvfu3TVnzhwdP35c+/fv15QpU8yJcZ48eWQymbR8+XKdP39e165dk6enp7y8vPT111/rr7/+0vr169WjRw+L2K9evapWrVqpc+fOql27tr7//nstWrRIP/zwgySpY8eOunTpkpo1a6Zdu3bp77//1urVq9W2bVuL5B4AAAAAYD0vbMItSaNHj9Yrr7yiBg0a6LXXXlPlypVVunRp8/7Zs2erdOnSqlevnipUqCDDMPTrr7/K3v7uCG+BAgW0evVqHThwQC+99JIqVKign3/+2Tyq/Pnnn2vAgAEaPny4goKCVLNmTf3yyy/mZ7Jz5sypwYMH65NPPpG3t7c6deokGxsbLViwQHv37lXRokXVvXt3jR492iLurl27KlOmTBo2bJgkqUiRIho5cqQ6dOig06dPK0eOHNq6davi4+NVs2ZNFS1aVF27dpWHh4f5AwUAAAAAgHW9sKuUI33SuxofAAAAADxv0psXvbDPcOPhtN/TUQ6ZHJ5Ye3PLzXxibQEAAADA48T8YgAAAAAArOChRrhLlixp/mqse5lMJjk5OSkwMFAhISGqVq3aIwcIAAAAAMCz6KES7lq1amnatGkqVqyYXnrpJRmGoT179ujgwYMKCQnR4cOH9dprr2nx4sXmFb3xfJhRZgrPcAMAAABAGjxUwn3hwgX17NlT/fv3tygfOnSoTp48qdWrV2vgwIH6/PPPSbifM8WnTZaNk9Mjn+fvrj0fQzQAAAAA8PR6qGe4Fy1apGbNmiUpb9q0qRYtWiRJatasmY4cOfJo0QEAAAAA8Ix6qITbyclJ27ZtS1K+bds2Of3/6GdCQoIcHR0fLToAAAAAAJ5RDzWlvHPnzurQoYP27t2rsmXLymQyadeuXfrmm2/06aefSpJWrVqlkiVLPtZgkfEOftiZZ7gBAAAAIA1MhmEYD3PgvHnz9OWXX5qnjRcsWFCdO3dW8+bNJUk3b940r1qOZ1/iF7yXq/e57Oyf/z7dsrhXRocAAAAA4CmTmBfFxMSkaSDyoUa4JalFixZq0aJFivudnZ0f9tQAAAAAADzzHuoZbgAAAAAAkLqHGuG2sbGRyWRKcX98fPxDBwQAAAAAwPPgoRLuJUuWWGzfuXNH+/fv15w5czR48ODHEhieTqvndWHRNAAAAABIg4deNC0533//vRYuXKiff/75cZ0ST4n0Lg4AAAAAAM+b9OZFj/UZ7nLlymnt2rWP85QAAAAAADyTHlvCffPmTU2ePFm5cuV6XKcEAAAAAOCZ9VDPcHt6elosmmYYhq5evSoXFxd99913jy04AAAAAACeVQ+VcE+YMMFi28bGRtmyZVO5cuXk6en5OOICAAAAAOCZlu6EOy4uTpGRkWrbtq38/PysERMAAAAAAM+8dD/DbWdnpzFjxvBd2wAAAAAApOKhFk2rXr26wsLCHnMoAAAAAAA8Px7qGe7atWurb9+++v3331W6dGllypTJYn+DBg0eS3B4+ow7cFFOrrczOowUfVIya0aHAAAAAACSHjLh/vDDDyVJ48aNS7LPZDIx3RwAAAAA8MJ7qIQ7ISHhcccBAAAAAMBzJd0Jd0JCgkJDQ7V48WJFRkbKZDIpX758evPNN9WqVSuL7+fG86dHCS+5u7tndBgAAAAA8NRL16JphmGoQYMGeu+993T69GkVK1ZMRYoUUWRkpEJCQvTGG29YK048JTw8PGQymZJ9AQAAAAD+J10j3KGhodq0aZPWrVunatWqWexbv369GjVqpG+//VatW7d+rEECAAAAAPCsSdcI9/z58/Xpp58mSbYl6dVXX9Unn3yiefPmPbbgAAAAAAB4VqUr4T548KBq1aqV4v7atWvrwIEDjxwUAAAAAADPunQl3JcuXZK3t3eK+729vXX58uVHDgpPr5iYGBmGkewLAAAAAPA/6Uq44+PjZWeX8mPftra2iouLe+SgHoeqVauqW7duGR1GhktcST48PDyjQwEAAACAF0q6Fk0zDEMhISFydHRMdv+tW7ceS1AAAAAAADzr0pVwt2nT5oF1WKEcAAAAAIB0TimfPXt2ml5P2vXr19W6dWu5urrK19dXY8eOtdh/+/Ztffzxx8qZM6cyZcqkcuXKKSwszLw/NDRUmTNn1qpVqxQUFCRXV1fVqlVL0dHR5joJCQkaMmSIcuXKJUdHRwUHB2vlypUWbXTq1Em+vr5ycnKSv7+/hg8fLin5ad1XrlyRyWQyxxEWFiaTyaRVq1apZMmScnZ21quvvqpz587pt99+U1BQkNzd3dWsWTPduHHDfJ6VK1eqcuXKypw5s7y8vFSvXj0dP348yT36888/VbFiRTk5OalIkSIW1w8AAAAAePzSlXA/rXr37q0NGzZoyZIlWr16tcLCwrR3717z/nfffVdbt27VggULdPDgQb399tuqVauWjh07Zq5z48YNjRkzRnPnztWmTZsUFRWlXr16mfdPnDhRY8eO1ZgxY3Tw4EHVrFlTDRo0MJ9j0qRJWrZsmRYtWqQjR47ou+++k7+/f7qvZdCgQfryyy+1bds2nTp1Su+8844mTJig77//XitWrNCaNWs0efJkc/3r16+rR48e2r17t9atWycbGxu98cYbSkhISHKPevbsqf3796tixYpq0KCBLl68mGIct27dUmxsrMULAAAAAJAOxjPu6tWrhoODg7FgwQJz2cWLFw1nZ2eja9euxl9//WWYTCbj9OnTFsdVr17d6Nu3r2EYhjF79mxDkvHXX3+Z90+ZMsXw9vY2b+fIkcP44osvLM5RtmxZ46OPPjIMwzA6d+5svPrqq0ZCQkKSGE+cOGFIMvbv328uu3z5siHJ2LBhg2EYhrFhwwZDkrF27VpzneHDhxuSjOPHj5vLPvjgA6NmzZop3o9z584ZkoxDhw5ZtD1ixAhznTt37hi5cuUyRo4cmeJ5Bg4caEhK8oqJiUnxGAAAAAB4nsXExKQrL3rmR7iPHz+u27dvq0KFCuayLFmyqGDBgpKkffv2yTAMFShQQK6urubXxo0bLaZeu7i4KCAgwLzt6+urc+fOSZJiY2P177//qlKlShZtV6pUSREREZKkkJAQhYeHq2DBgurSpYtWr179UNdTvHhx87+9vb3l4uKifPnyWZQlxpV4/c2bN1e+fPnk7u6uvHnzSpKioqIsznvv/bGzs1OZMmXMsSenb9++iomJMb9OnTr1UNcDAAAAAC+qdC2a9jQyHvD9zwkJCbK1tdXevXtla2trsc/V1dX8b3t7e4t9JpMpyblNJlOSthPLSpUqpRMnTui3337T2rVr9c477+i1117Tjz/+KBsbmySx3rlzJ9l4743DZDIlG9e908Xr168vPz8/zZgxQzly5FBCQoKKFi2q27dvJ39DUrmeezk6Oqa4Gj0AAAAA4MGe+RHuwMBA2dvba8eOHeayy5cv6+jRo5KkkiVLKj4+XufOnVNgYKDFy8fHJ01tuLu7K0eOHNqyZYtF+bZt2xQUFGRRr0mTJpoxY4YWLlyon376SZcuXVK2bNkkyWIRtsfxvdgXL15URESEPvvsM1WvXl1BQUG6fPlysnXvvT9xcXHau3evChUq9MgxAAAAAACS98yPcLu6uqpdu3bq3bu3vLy85O3trX79+plHlQsUKKAWLVqodevWGjt2rEqWLKkLFy5o/fr1KlasmOrUqZOmdnr37q2BAwcqICBAwcHBmj17tsLDwzVv3jxJ0vjx4+Xr66vg4GDZ2Njohx9+kI+PjzJnziwbGxuVL19eI0aMkL+/vy5cuKDPPvvska/d09NTXl5e+vrrr+Xr66uoqCh98sknydadMmWK8ufPr6CgII0fP16XL19W27ZtHzkGAAAAAEDynvmEW5JGjx6ta9euqUGDBnJzc1PPnj0VExNj3j979mwNHTpUPXv21OnTp+Xl5aUKFSqkOdmWpC5duig2NlY9e/bUuXPnVLhwYS1btkz58+eXdDfxHzlypI4dOyZbW1uVLVtWv/76qznxnzVrltq2basyZcqoYMGCGjVqlF5//fVHum4bGxstWLBAXbp0UdGiRVWwYEFNmjRJVatWTVJ3xIgRGjlypPbv36+AgAD9/PPPypo16yO1DwAAAABImcl40EPQgO4uHOfh4aGYmBi5u7tndDgAAAAA8MSlNy96Lka48eS039NRDpkcMjoMAAAAAM+pueVmZnQIj80zv2gaAAAAAABPIxJuAAAAAACsgCnlSJcZZabwDDcAAAAApAEJN9Kl+LTJsnFyyugwAOCZ8XfXnhkdAgAAyCBMKQcAAAAAwApIuAEAAAAAsAISbgAAAAAArIBnuJEuPlsM2dkbGR0GXkBbFvfK6BAAAACAdGGEGwAAAAAAKyDhBgAAAADACki4AQAAAACwAp7hRrqsntdF7u7uGR0GAAAAADz1GOEGAAAAAMAKSLgBAAAAALACEm4AAAAAAKyAhBsAAAAAACsg4QYAAAAAwApIuAEAAAAAsAISbgAAAAAArICEGwAAAAAAKyDhRrqMO3Axo0MAAAAAgGcCCTcAAAAAAFZAwg0AAAAAgBWQcCNdepTwyugQAAAAAOCZQMINAAAAAIAVkHADAAAAAGAFJNwAAAAAAFgBCTcAAAAAAFZAwg0AAAAAgBU8dQl31apV1a1bt4wO47kRFhYmk8mkK1euZHQoAAAAAPBCeeoS7ifF399fEyZMyOgwAAAAAADPqecq4TYMQ3FxcRkdBgAAAAAAGZtwX79+Xa1bt5arq6t8fX01duxYi/3fffedypQpIzc3N/n4+Kh58+Y6d+6ceX/idOlVq1apTJkycnR01ObNm3X8+HE1bNhQ3t7ecnV1VdmyZbV27VrzcVWrVtXJkyfVvXt3mUwmmUwmSdKgQYMUHBxsEcOECRPk7+9v3g4JCVGjRo00bNgweXt7K3PmzBo8eLDi4uLUu3dvZcmSRbly5dKsWbOSxHnvtO7w8HCZTCZFRkZKkkJDQ5U5c2YtX75cBQsWlIuLi9566y1dv35dc+bMkb+/vzw9PdW5c2fFx8en+R4l2rp1q0qUKCEnJyeVK1dOhw4dSnM/AQAAAADSL0MT7t69e2vDhg1asmSJVq9erbCwMO3du9e8//bt2/r888914MABLV26VCdOnFBISEiS83z88ccaPny4IiIiVLx4cV27dk116tTR2rVrtX//ftWsWVP169dXVFSUJGnx4sXKlSuXhgwZoujoaEVHR6cr7vXr1+vff//Vpk2bNG7cOA0aNEj16tWTp6endu7cqQ4dOqhDhw46depUus5748YNTZo0SQsWLNDKlSsVFhamxo0b69dff9Wvv/6quXPn6uuvv9aPP/6Y7nvUu3dvjRkzRrt371b27NnVoEED3blzJ8VYbt26pdjYWIuXJGmRh/S9KeUXAAAAAECSZJdRDV+7dk0zZ87Ut99+qxo1akiS5syZo1y5cpnrtG3b1vzvfPnyadKkSXrppZd07do1ubq6mvcNGTLEfA5J8vLyUokSJczbQ4cO1ZIlS7Rs2TJ16tRJWbJkka2trXlUOL2yZMmiSZMmycbGRgULFtSoUaN048YNffrpp5Kkvn37asSIEdq6dauaNm2a5vPeuXNH06ZNU0BAgCTprbfe0ty5c3X27Fm5urqqcOHCqlatmjZs2KAmTZqk6x4NHDgwyX1esmSJ3nnnnWRjGT58uAYPHpy+GwMAAAAAMMuwEe7jx4/r9u3bqlChgrksS5YsKliwoHl7//79atiwofLkySM3NzdVrVpVkswj1YnKlCljsX39+nV9/PHHKly4sDJnzixXV1f9+eefSY57WEWKFJGNzf9unbe3t4oVK2betrW1lZeXV7JTu1Pj4uJiTrYTz+vv72+ROHt7e1ucN633KLn7HBERkWIsffv2VUxMjPmV3tF6AAAAAHjRZdgIt2EYqe6/fv26Xn/9db3++uv67rvvlC1bNkVFRalmzZq6ffu2Rd1MmTJZbPfu3VurVq3SmDFjFBgYKGdnZ7311ltJjrufjY1NkriSm3Ztb29vsW0ymZItS0hIMJ9Xsrzmx3He9Nyj5CQ+u54cR0dHOTo6Jt3xTozk7v7AcwMAAADAiy7DEu7AwEDZ29trx44dyp07tyTp8uXLOnr0qKpUqaI///xTFy5c0IgRI+Tn5ydJ2rNnT5rOvXnzZoWEhOiNN96QdHf6euLiZIkcHBwsFh+TpGzZsunMmTMyDMOcjIaHhz/CVf7vvJIUHR0tT0/Px3be9Nyj5O5zoUKF0t3m5Z7NFe9g/+CKwCPynLIko0MAAAAAHkmGTSl3dXVVu3bt1Lt3b61bt06///67QkJCzKPBuXPnloODgyZPnqy///5by5Yt0+eff56mcwcGBmrx4sUKDw/XgQMH1Lx5c/OocCJ/f39t2rRJp0+f1oULFyTdXb38/PnzGjVqlI4fP64pU6bot99+e+RrDQwMlJ+fnwYNGqSjR49qxYoVSVZkfxjpuUdDhgyxuM9Zs2ZVo0aNHjkGAAAAAEDyMnSV8tGjR+uVV15RgwYN9Nprr6ly5coqXbq0pLujwqGhofrhhx9UuHBhjRgxQmPGjEnTecePHy9PT09VrFhR9evXV82aNVWqVCmLOkOGDFFkZKQCAgLMI9BBQUGaOnWqpkyZohIlSmjXrl3q1avXI1+nvb295s+frz///FMlSpTQyJEjNXTo0Ec+b3ru0YgRI9S1a1eVLl1a0dHRWrZsmRwcHB45BgAAAABA8kzGgx6mBiTFxsbKw8NDMTExcucZbgAAAAAvoPTmRRn2DDeeTe33dJRDJkbG8fDmlpuZ0SEAAAAAT0SGTikHAAAAAOB5RcINAAAAAIAVMKUc6TKjzBSe4QYAAACANCDhRroUnzZZNk5OGdb+3117ZljbAAAAAJAeTCkHAAAAAMAKSLgBAAAAALACEm4AAAAAAKyAZ7iRLj5bDNnZGxkXQNeMaxoAAAAA0oMRbgAAAAAArICEGwAAAAAAKyDhBgAAAADACniGG+myel4Xubu7Z3QYAAAAAPDUY4QbAAAAAAArIOEGAAAAAMAKSLgBAAAAALACEm4AAAAAAKyAhBsAAAAAACsg4QYAAAAAwApIuAEAAAAAsAISbgAAAAAArICEGwAAAAAAKyDhBgAAAADACki4AQAAAACwAhJuAAAAAACsgIQbAAAAAAArIOEGAAAAAMAKSLgBAAAAALACEm4AAAAAAKyAhBsAAAAAACsg4U4HwzD0/vvvK0uWLDKZTAoPD1fVqlXVrVs3cx1/f39NmDAhw2KUpJCQEDVq1Mi8fX+MAAAAAADrs8voAJ4lK1euVGhoqMLCwpQvXz5lzZpVixcvlr29fUaHZmHixIkyDCOjwwAAAACAFxoJdxrcuXNH9vb2On78uHx9fVWxYkXzvixZsmRgZMnz8PDI6BAAAAAA4IX33E4pT0hI0MiRIxUYGChHR0flzp1bX3zxhSSpT58+KlCggFxcXJQvXz71799fd+7cMR87aNAgBQcHa9asWcqXL58cHR3Vpk0bde7cWVFRUTKZTPL395eU+nTt0NBQmUymJK9BgwaZYxwyZIhy5colR0dHBQcHa+XKlebjIyMjZTKZtGjRIr388stydnZW2bJldfToUe3evVtlypSRq6uratWqpfPnz5uPu39KuSTFxcWpU6dOypw5s7y8vPTZZ58xCg4AAAAAVvTcjnD37dtXM2bM0Pjx41W5cmVFR0frzz//lCS5ubkpNDRUOXLk0KFDh9S+fXu5ubnp448/Nh//119/adGiRfrpp59ka2urPHnyKDAwUF9//bV2794tW1vbB8bQpEkT1apVy7wdFhamVq1aqVKlSpLuTv0eO3asvvrqK5UsWVKzZs1SgwYN9Mcffyh//vzm4wYOHKgJEyYod+7catu2rZo1ayZ3d3dNnDhRLi4ueueddzRgwABNmzYtxVjmzJmjdu3aaefOndqzZ4/ef/995cmTR+3bt0+2/q1bt3Tr1i3zdmxs7AOvFwAAAADwP89lwn316lVNnDhRX375pdq0aSNJCggIUOXKlSVJn332mbmuv7+/evbsqYULF1ok3Ldv39bcuXOVLVs2c5mbm5tsbW3l4+OTpjicnZ3l7OwsSTp+/Lg6deqkYcOGqUaNGpKkMWPGqE+fPmratKkkaeTIkdqwYYMmTJigKVOmmM/Tq1cv1axZU5LUtWtXNWvWTOvWrTMn7u3atVNoaGiqsfj5+Wn8+PEymUwqWLCgDh06pPHjx6eYcA8fPlyDBw9O03UCAAAAAJJ6LqeUR0RE6NatW6pevXqy+3/88UdVrlxZPj4+cnV1Vf/+/RUVFWVRJ0+ePBbJ9qOIiYlRvXr1VLt2bfXu3VvS3RHjf//915w0J6pUqZIiIiIsyooXL27+t7e3tySpWLFiFmXnzp1LNYby5cvLZDKZtytUqKBjx44pPj4+2fp9+/ZVTEyM+XXq1Kk0XCkAAAAAINFzmXAnjionZ8eOHWratKlq166t5cuXa//+/erXr59u375tUS9TpkyPJZb4+Hg1adJE7u7umjFjRpL99ybB0t2vHru/7N5V0BP33V+WkJDwWOJN5OjoKHd3d4sXAAAAACDtnssp5fnz55ezs7PWrVun9957z2Lf1q1blSdPHvXr189cdvLkSavF0r17dx06dEi7d++Wk5OTudzd3V05cuTQli1b9Morr5jLt23bppdeeumxx7Fjx44k2/nz50/Ts+j3utyzueId7ib7nlOWPLb4AAAAAOB581wm3E5OTurTp48+/vhjOTg4qFKlSjp//rz++OMPBQYGKioqSgsWLFDZsmW1YsUKLVlincRx9uzZmjp1qpYsWSIbGxudOXNGkuTq6ipXV1f17t1bAwcOVEBAgIKDgzV79myFh4dr3rx5jz2WU6dOqUePHvrggw+0b98+TZ48WWPHjn3s7QAAAAAA7nouE25J6t+/v+zs7DRgwAD9+++/8vX1VYcOHdSuXTt1795dnTp10q1bt1S3bl3179/f/FVdj9PGjRsVHx+vBg0aWJQPHDhQgwYNUpcuXRQbG6uePXvq3LlzKly4sJYtW2axQvnj0rp1a928eVMvvfSSbG1t1blzZ73//vuPvR0AAAAAwF0mgy9jRhrExsbKw8NDMTExPM8NAAAA4IWU3rzouR3hhnW039NRDpkczNtzy83MwGgAAAAA4On1XK5SDgAAAABARiPhBgAAAADACphSjnSZUWYKz3ADAAAAQBqQcCNdik+bLJt7vk/8fn937fkEowEAAACApxdTygEAAAAAsAISbgAAAAAArICEGwAAAAAAK+AZbqSLzxZDdvZGivsrbxzz0OfesrjXQx8LAAAAAE8bRrgBAAAAALACEm4AAAAAAKyAhBsAAAAAACvgGW6ky+p5XeTu7p7RYQAAAADAU48RbgAAAAAArICEGwAAAAAAKyDhBgAAAADACki4AQAAAACwAhJuAAAAAACsgIQbAAAAAAArIOEGAAAAAMAKSLgBAAAAALACEm4AAAAAAKyAhBsAAAAAACsg4QYAAAAAwApIuAEAAAAAsAISbgAAAAAArICEGwAAAAAAKyDhBgAAAADACki4AQAAAACwAhJuAAAAAACs4LlKuKtWrapu3bpldBgZKiwsTCaTSVeuXJEkhYaGKnPmzBkaEwAAAAC8iJ6rhNtaQkJC1KhRo4wOI00qVqyo6OhoeXh4ZHQoAAAAAPBCs8voAJ5m8fHxMplMGR1Gujg4OMjHxyejwwAAAACAF95zN8IdFxenTp06KXPmzPLy8tJnn30mwzAkSZcvX1br1q3l6ekpFxcX1a5dW8eOHTMfmzj9evny5SpcuLAcHR317rvvas6cOfr5559lMplkMpkUFhYmSTp9+rSaNGkiT09PeXl5qWHDhoqMjDSfL7H+vS9/f3/z/o0bN+qll16So6OjfH199cknnyguLs68v2rVqurcubO6desmT09PeXt76+uvv9b169f17rvvys3NTQEBAfrtt9/Mx9w/pTzR0qVLVaBAATk5OalGjRo6derU47vpAAAAAIAknruEe86cObKzs9POnTs1adIkjR8/Xt98842ku1PD9+zZo2XLlmn79u0yDEN16tTRnTt3zMffuHFDw4cP1zfffKM//vhDkyZN0jvvvKNatWopOjpa0dHRqlixom7cuKFq1arJ1dVVmzZt0pYtW+Tq6qpatWrp9u3bkmSuHx0drb/++kuBgYF65ZVXJN1N1uvUqaOyZcvqwIEDmjZtmmbOnKmhQ4cmuZ6sWbNq165d6ty5sz788EO9/fbbqlixovbt26eaNWuqVatWunHjRor35MaNG/riiy80Z84cbd26VbGxsWratGmq9/HWrVuKjY21eAEAAAAA0sF4jlSpUsUICgoyEhISzGV9+vQxgoKCjKNHjxqSjK1bt5r3XbhwwXB2djYWLVpkGIZhzJ4925BkhIeHW5y3TZs2RsOGDS3KZs6caRQsWNCirVu3bhnOzs7GqlWrLOomJCQYb7zxhlG6dGnjxo0bhmEYxqeffprk+ClTphiurq5GfHy8+XoqV65s3h8XF2dkypTJaNWqlbksOjrakGRs377dMAzD2LBhgyHJuHz5ssU17dixw3xMRESEIcnYuXNnivdy4MCBhqQkr5iYmBSPAQAAAIDnWUxMTLryouduhLt8+fIWz11XqFBBx44d0+HDh2VnZ6dy5cqZ93l5ealgwYKKiIgwlzk4OKh48eIPbGfv3r3666+/5ObmJldXV7m6uipLliz677//dPz4cYu6n376qbZv366lS5fK2dlZkhQREaEKFSpYxFqpUiVdu3ZN//zzj7ns3lhsbW3l5eWlYsWKmcu8vb0lSefOnUsxVjs7O5UpU8a8XahQIWXOnNniuu/Xt29fxcTEmF9MQQcAAACA9HnhF00zDMMi6XV2dk7TQmkJCQkqXbq05s2bl2RftmzZzP/+7rvvNH78eIWFhSlXrlwptptYJsmi3N7e3qKOyWSyKEusm5CQkGq8yV1Tatfp6OgoR0fHVM8JAAAAAEjZc5dw79ixI8l2/vz5VbhwYcXFxWnnzp2qWLGiJOnixYs6evSogoKCUj2ng4OD4uPjLcpKlSqlhQsXKnv27HJ3d0/2uO3bt+u9997TV199pfLly1vsK1y4sH766SeLxHvbtm1yc3NTzpw503XNDxIXF6c9e/bopZdekiQdOXJEV65cUaFChdJ9rss9myvewf7BFZ8gzylLMjoEAAAAAEjiuZtSfurUKfXo0UNHjhzR/PnzNXnyZHXt2lX58+dXw4YN1b59e23ZskUHDhxQy5YtlTNnTjVs2DDVc/r7++vgwYM6cuSILly4oDt37qhFixbKmjWrGjZsqM2bN+vEiRPauHGjunbtqn/++UdnzpzRG2+8oaZNm6pmzZo6c+aMzpw5o/Pnz0uSPvroI506dUqdO3fWn3/+qZ9//lkDBw5Ujx49ZGPzeLvF3t5enTt31s6dO7Vv3z69++67Kl++vDkBBwAAAAA8fs9dwt26dWvdvHlTL730kjp27KjOnTvr/ffflyTNnj1bpUuXVr169VShQgUZhqFff/01ybTt+7Vv314FCxZUmTJllC1bNm3dulUuLi7atGmTcufOrcaNGysoKEht27bVzZs35e7urj///FNnz57VnDlz5Ovra36VLVtWkpQzZ079+uuv2rVrl0qUKKEOHTqoXbt2+uyzzx77PXFxcVGfPn3UvHlzVahQQc7OzlqwYMFjbwcAAAAA8D8mI/HBYSAVsbGx8vDwUExMTIpT6AEAAADgeZbevOi5e4Yb1tV+T0c5ZHJ4YL255WY+gWgAAAAA4On13E0pBwAAAADgaUDCDQAAAACAFZBwAwAAAABgBTzDjXTZubuQbJycHlgv346xD6zzd9eejyMkAAAAAHgqMcINAAAAAIAVkHADAAAAAGAFJNwAAAAAAFgBz3AjXQ5+2DlNX/AOAAAAAC86Em6ky+stJsnO/sGLpqXFlsW9Hst5AAAAAOBpxJRyAAAAAACsgIQbAAAAAAArYEo50mX1vC48ww0AAAAAacAINwAAAAAAVkDCDQAAAACAFZBwAwAAAABgBSTcAAAAAABYAQk3AAAAAABWQMINAAAAAIAVkHADAAAAAGAFJNwAAAAAAFgBCTcAAAAAAFZAwg0AAAAAgBWQcAMAAAAAYAUk3AAAAAAAWAEJNwAAAAAAVkDCDQAAAACAFdhldAB4NhiGIUmKjY3N4EgAAAAAIGMk5kOJ+dGDkHAjTS5evChJ8vPzy+BIAAAAACBjXb16VR4eHg+sR8KNNMmSJYskKSoqKk0/WHgyYmNj5efnp1OnTsnd3T2jw8E96JunF33z9KJvnl70zdOJfnl60TdPr0ftG8MwdPXqVeXIkSNN9Um4kSY2Nncf9/fw8OBN4ynk7u5Ovzyl6JunF33z9KJvnl70zdOJfnl60TdPr0fpm/QMQLJoGgAAAAAAVkDCDQAAAACAFZBwI00cHR01cOBAOTo6ZnQouAf98vSib55e9M3Ti755etE3Tyf65elF3zy9nnTfmIy0rmcOAAAAAADSjBFuAAAAAACsgIQbAAAAAAArIOEGAAAAAMAKSLgBAAAAALACEm4AAAAAAKyAhBsPNHXqVOXNm1dOTk4qXbq0Nm/enNEhPdeGDx+usmXLys3NTdmzZ1ejRo105MgRizqGYWjQoEHKkSOHnJ2dVbVqVf3xxx8WdW7duqXOnTsra9asypQpkxo0aKB//vnnSV7Kc2/48OEymUzq1q2buYy+yTinT59Wy5Yt5eXlJRcXFwUHB2vv3r3m/fRNxoiLi9Nnn32mvHnzytnZWfny5dOQIUOUkJBgrkPfWN+mTZtUv3595ciRQyaTSUuXLrXY/7j64PLly2rVqpU8PDzk4eGhVq1a6cqVK1a+umdban1z584d9enTR8WKFVOmTJmUI0cOtW7dWv/++6/FOegb63jQ7829PvjgA5lMJk2YMMGinL6xjrT0TUREhBo0aCAPDw+5ubmpfPnyioqKMu9/Un1Dwo1ULVy4UN26dVO/fv20f/9+vfzyy6pdu7bFDyser40bN6pjx47asWOH1qxZo7i4OL3++uu6fv26uc6oUaM0btw4ffnll9q9e7d8fHxUo0YNXb161VynW7duWrJkiRYsWKAtW7bo2rVrqlevnuLj4zPisp47u3fv1tdff63ixYtblNM3GePy5cuqVKmS7O3t9dtvv+nw4cMaO3asMmfObK5D32SMkSNHavr06fryyy8VERGhUaNGafTo0Zo8ebK5Dn1jfdevX1eJEiX05ZdfJrv/cfVB8+bNFR4erpUrV2rlypUKDw9Xq1atrH59z7LU+ubGjRvat2+f+vfvr3379mnx4sU6evSoGjRoYFGPvrGOB/3eJFq6dKl27typHDlyJNlH31jHg/rm+PHjqly5sgoVKqSwsDAdOHBA/fv3l5OTk7nOE+sbA0jFSy+9ZHTo0MGirFChQsYnn3ySQRG9eM6dO2dIMjZu3GgYhmEkJCQYPj4+xogRI8x1/vvvP8PDw8OYPn26YRiGceXKFcPe3t5YsGCBuc7p06cNGxsbY+XKlU/2Ap5DV69eNfLnz2+sWbPGqFKlitG1a1fDMOibjNSnTx+jcuXKKe6nbzJO3bp1jbZt21qUNW7c2GjZsqVhGPRNRpBkLFmyxLz9uPrg8OHDhiRjx44d5jrbt283JBl//vmnla/q+XB/3yRn165dhiTj5MmThmHQN09KSn3zzz//GDlz5jR+//13I0+ePMb48ePN++ibJyO5vmnSpIn5/5nkPMm+YYQbKbp9+7b27t2r119/3aL89ddf17Zt2zIoqhdPTEyMJClLliySpBMnTujMmTMW/eLo6KgqVaqY+2Xv3r26c+eORZ0cOXKoaNGi9N1j0LFjR9WtW1evvfaaRTl9k3GWLVumMmXK6O2331b27NlVsmRJzZgxw7yfvsk4lStX1rp163T06FFJ0oEDB7RlyxbVqVNHEn3zNHhcfbB9+3Z5eHioXLly5jrly5eXh4cH/fQYxcTEyGQymWfw0DcZJyEhQa1atVLv3r1VpEiRJPvpm4yRkJCgFStWqECBAqpZs6ayZ8+ucuXKWUw7f5J9Q8KNFF24cEHx8fHy9va2KPf29taZM2cyKKoXi2EY6tGjhypXrqyiRYtKkvnep9YvZ86ckYODgzw9PVOsg4ezYMEC7du3T8OHD0+yj77JOH///bemTZum/Pnza9WqVerQoYO6dOmib7/9VhJ9k5H69OmjZs2aqVChQrK3t1fJkiXVrVs3NWvWTBJ98zR4XH1w5swZZc+ePcn5s2fPTj89Jv/9958++eQTNW/eXO7u7pLom4w0cuRI2dnZqUuXLsnup28yxrlz53Tt2jWNGDFCtWrV0urVq/XGG2+ocePG2rhxo6Qn2zd2j3AteEGYTCaLbcMwkpTBOjp16qSDBw9qy5YtSfY9TL/Qd4/m1KlT6tq1q1avXm3xDND96JsnLyEhQWXKlNGwYcMkSSVLltQff/yhadOmqXXr1uZ69M2Tt3DhQn333Xf6/vvvVaRIEYWHh6tbt27KkSOH2rRpY65H32S8x9EHydWnnx6PO3fuqGnTpkpISNDUqVMfWJ++sa69e/dq4sSJ2rdvX7rvIX1jXYmLcjZs2FDdu3eXJAUHB2vbtm2aPn26qlSpkuKx1ugbRriRoqxZs8rW1jbJJzjnzp1L8ik4Hr/OnTtr2bJl2rBhg3LlymUu9/HxkaRU+8XHx0e3b9/W5cuXU6yD9Nu7d6/OnTun0qVLy87OTnZ2dtq4caMmTZokOzs7872lb548X19fFS5c2KIsKCjIvMAjvzcZp3fv3vrkk0/UtGlTFStWTK1atVL37t3Ns0Tom4z3uPrAx8dHZ8+eTXL+8+fP00+P6M6dO3rnnXd04sQJrVmzxjy6LdE3GWXz5s06d+6ccufObf6b4OTJk+rZs6f8/f0l0TcZJWvWrLKzs3vg3wVPqm9IuJEiBwcHlS5dWmvWrLEoX7NmjSpWrJhBUT3/DMNQp06dtHjxYq1fv1558+a12J83b175+PhY9Mvt27e1ceNGc7+ULl1a9vb2FnWio6P1+++/03ePoHr16jp06JDCw8PNrzJlyqhFixYKDw9Xvnz56JsMUqlSpSRfn3f06FHlyZNHEr83GenGjRuysbH8c8PW1tY8AkHfZLzH1QcVKlRQTEyMdu3aZa6zc+dOxcTE0E+PIDHZPnbsmNauXSsvLy+L/fRNxmjVqpUOHjxo8TdBjhw51Lt3b61atUoSfZNRHBwcVLZs2VT/LniifZPm5dXwQlqwYIFhb29vzJw50zh8+LDRrVs3I1OmTEZkZGRGh/bc+vDDDw0PDw8jLCzMiI6ONr9u3LhhrjNixAjDw8PDWLx4sXHo0CGjWbNmhq+vrxEbG2uu06FDByNXrlzG2rVrjX379hmvvvqqUaJECSMuLi4jLuu5de8q5YZB32SUXbt2GXZ2dsYXX3xhHDt2zJg3b57h4uJifPfdd+Y69E3GaNOmjZEzZ05j+fLlxokTJ4zFixcbWbNmNT7++GNzHfrG+q5evWrs37/f2L9/vyHJGDdunLF//37zStePqw9q1aplFC9e3Ni+fbuxfft2o1ixYka9evWe+PU+S1Lrmzt37hgNGjQwcuXKZYSHh1v8XXDr1i3zOegb63jQ78397l+l3DDoG2t5UN8sXrzYsLe3N77++mvj2LFjxuTJkw1bW1tj8+bN5nM8qb4h4cYDTZkyxciTJ4/h4OBglCpVyvz1VLAOScm+Zs+eba6TkJBgDBw40PDx8TEcHR2NV155xTh06JDFeW7evGl06tTJyJIli+Hs7GzUq1fPiIqKesJX8/y7P+GmbzLOL7/8YhQtWtRwdHQ0ChUqZHz99dcW++mbjBEbG2t07drVyJ07t+Hk5GTky5fP6Nevn0WyQN9Y34YNG5L9v6VNmzaGYTy+Prh48aLRokULw83NzXBzczNatGhhXL58+Qld5bMptb45ceJEin8XbNiwwXwO+sY6HvR7c7/kEm76xjrS0jczZ840AgMDDScnJ6NEiRLG0qVLLc7xpPrGZBiGkfbxcAAAAAAAkBY8ww0AAAAAgBWQcAMAAAAAYAUk3AAAAAAAWAEJNwAAAAAAVkDCDQAAAACAFZBwAwAAAABgBSTcAAAAAABYAQk3AADPIH9/f02YMCGjw8gQX3/9tfz8/GRjY/NU3IPQ0FBlzpw5zfVf5L4DgBcNCTcAAI/AZDKl+goJCXng8UuXLrVKbLGxserXr58KFSokJycn+fj46LXXXtPixYtlGIZV2kzJ40oyY2Nj1alTJ/Xp00enT5/W+++/n2y9e/vAzc1NZcqU0eLFix+5/eSuo0mTJjp69Giaz7F79+4U47amqlWrqlu3bk+8XQB4kdlldAAAADzLoqOjzf9euHChBgwYoCNHjpjLnJ2dMyIsXblyRZUrV1ZMTIyGDh2qsmXLys7OThs3btTHH3+sV199NV2jsk+LqKgo3blzR3Xr1pWvr2+qdWfPnq1atWrpypUrGj16tN5++21t2bJFFSpUSHe7t2/floODQ7L7nJ2d09XP2bJlS3f7AIBnEyPcAAA8Ah8fH/PLw8NDJpPJouz7779XQECAHBwcVLBgQc2dO9d8rL+/vyTpjTfekMlkMm8fP35cDRs2lLe3t1xdXVW2bFmtXbs2XXF9+umnioyM1M6dO9WmTRsVLlxYBQoUUPv27RUeHi5XV1dJ0uXLl9W6dWt5enrKxcVFtWvX1rFjx8znGTRokIKDgy3OPWHCBHOskhQSEqJGjRppzJgx8vX1lZeXlzp27Kg7d+5IujuyevLkSXXv3t086pySqKgoNWzYUK6urnJ3d9c777yjs2fPSro7dbtYsWKSpHz58slkMikyMjLFc2XOnFk+Pj4qVKiQpk+fLicnJy1btkzx8fFq166d8ubNK2dnZxUsWFATJ060ODbxmoYPH64cOXKoQIECKV5HclPKly1bpjJlysjJyUlZs2ZV48aNzfvuHyU3mUyaNm2aateuLWdnZ+XNm1c//PCDxfn69OmjAgUKyMXFRfny5VP//v3N91f6Xz/NnTtX/v7+8vDwUNOmTXX16lXz9WzcuFETJ040xx4ZGanLly+rRYsWypYtm5ydnZU/f37Nnj07xXsKAEgfEm4AAKxkyZIl6tq1q3r27Knff/9dH3zwgd59911t2LBB0t2pxdLdkdjo6Gjz9rVr11SnTh2tXbtW+/fvV82aNVW/fn1FRUWlqd2EhAQtWLBALVq0UI4cOZLsd3V1lZ3d3UluISEh2rNnj5YtW6bt27fLMAzVqVPHIplLiw0bNuj48ePasGGD5syZo9DQUIWGhkqSFi9erFy5cmnIkCGKjo62mBVwL8Mw1KhRI126dEkbN27UmjVrdPz4cTVp0kTS3anbiR887Nq1S9HR0fLz80tTfPb29rKzs9OdO3eUkJCgXLlyadGiRTp8+LAGDBigTz/9VIsWLbI4Zt26dYqIiNCaNWu0fPnyNF/HihUr1LhxY9WtW1f79+/XunXrVKZMmVTj69+/v958800dOHBALVu2VLNmzRQREWHe7+bmptDQUB0+fFgTJ07UjBkzNH78eItzHD9+XEuXLtXy5cu1fPlybdy4USNGjJAkTZw4URUqVFD79u3Nsfv5+al///46fPiwfvvtN0VERGjatGnKmjVrmu4pAODBmFIOAICVjBkzRiEhIfroo48kST169NCOHTs0ZswYVatWzTy1OHEkNlGJEiVUokQJ8/bQoUO1ZMkSLVu2TJ06dXpguxcuXNDly5dVqFChVOsdO3ZMy5Yt09atW1WxYkVJ0rx58+Tn56elS5fq7bffTvO1enp66ssvv5Stra0KFSqkunXrat26dWrfvr2yZMkiW1tbubm5WVzn/dauXauDBw/qxIkT5kR67ty5KlKkiHbv3q2yZcvKy8tL0t1p2amd6163bt3S6NGjFRsbq+rVq8ve3l6DBw8278+bN6+2bdumRYsW6Z133jGXZ8qUSd98843FVPK0XMcXX3yhpk2bWrRxb38m5+2339Z7770nSfr888+1Zs0aTZ48WVOnTpUkffbZZ+a6/v7+6tmzpxYuXKiPP/7YXJ6QkKDQ0FC5ublJklq1aqV169bpiy++kIeHhxwcHOTi4mIRe1RUlEqWLGn+QODemQsAgEfHCDcAAFYSERGhSpUqWZRVqlTJYuQyOdevX9fHH3+swoULK3PmzHJ1ddWff/6Z5hHuxAXRUpu6nRifnZ2dypUrZy7z8vJSwYIFHxjj/YoUKSJbW1vztq+vr86dO5euc0RERMjPz89i1DrxHqQ3Hklq1qyZXF1d5eLionHjxmnMmDGqXbu2JGn69OkqU6aMsmXLJldXV82YMSPJ/S1WrFiKz22nJjw8XNWrV0/XMfc/V16hQgWLa/7xxx9VuXJl+fj4yNXVVf37908Sr7+/vznZltLWBx9++KEWLFig4OBgffzxx9q2bVu64gYApI6EGwAAK7o/6TUM44GJcO/evfXTTz/piy++0ObNmxUeHq5ixYrp9u3baWozW7Zs8vT0fGCSmtJK5ffGaGNjk6RectPN7e3tLbZNJpMSEhLSFG9y7aal/EHGjx+v8PBwRUdH69KlS+rZs6ckadGiRerevbvatm2r1atXKzw8XO+++26S+5spU6Z0tyk9voXyEq95x44datq0qWrXrq3ly5dr//796tevX5J4H6YPateurZMnT6pbt276999/Vb16dfXq1euxxA8AIOEGAMBqgoKCtGXLFouybdu2KSgoyLxtb2+v+Ph4izqbN29WSEiI3njjDRUrVkw+Pj6pLg52PxsbGzVp0kTz5s3Tv//+m2T/9evXFRcXp8KFCysuLk47d+4077t48aKOHj1qjjFbtmw6c+aMRdIdHh6e5lgSOTg4JLnO+xUuXFhRUVE6deqUuezw4cOKiYmxuGdp5ePjo8DAQGXPnt2ifPPmzapYsaI++ugjlSxZUoGBgTp+/Phju47ixYtr3bp16Yp1x44dSbYTHwnYunWr8uTJo379+qlMmTLKnz+/Tp48ma7zSynHni1bNoWEhOi7777ThAkT9PXXX6f73ACA5JFwAwBgJb1791ZoaKimT5+uY8eOady4cVq8eLHFCKK/v7/WrVunM2fO6PLly5KkwMBALV68WOHh4Tpw4ICaN2+e7tHiYcOGyc/PT+XKldO3336rw4cP69ixY5o1a5aCg4N17do15c+fXw0bNlT79u21ZcsW84JdOXPmVMOGDSXdXWH8/PnzGjVqlI4fP64pU6bot99+S/e98Pf316ZNm3T69GlduHAh2TqvvfaaihcvrhYtWmjfvn3atWuXWrdurSpVqjxw0bH0CAwM1J49e7Rq1SodPXpU/fv3Ny9Y9ziuY+DAgZo/f74GDhyoiIgIHTp0SKNGjUr1vD/88INmzZqlo0ePauDAgdq1a5f5ef3AwEBFRUVpwYIFOn78uCZNmqQlS5ak76L/P/adO3cqMjJSFy5cUEJCggYMGKCff/5Zf/31l/744w8tX778oT7cAAAkj4QbAAAradSokSZOnKjRo0erSJEi+uqrrzR79mxVrVrVXGfs2LFas2aN/Pz8VLJkSUl3p0J7enqqYsWKql+/vmrWrKlSpUqlq21PT0/t2LFDLVu21NChQ1WyZEm9/PLLmj9/vkaPHi0PDw9Jd1dIL126tOrVq6cKFSrIMAz9+uuv5unJQUFBmjp1qqZMmaISJUpo165dDzXleMiQIYqMjFRAQECK30NtMpm0dOlSeXp66pVXXtFrr72mfPnyaeHCheluLzUdOnRQ48aN1aRJE5UrV04XL140L2z3IGm5jqpVq+qHH37QsmXLFBwcrFdffdViFkFyBg8erAULFqh48eKaM2eO5s2bp8KFC0uSGjZsqO7du6tTp04KDg7Wtm3b1L9///RdtKRevXrJ1tZWhQsXVrZs2RQVFSUHBwf17dtXxYsX1yuvvCJbW1stWLAg3ecGACTPZKT0ABcAAACszmQyacmSJWrUqFFGhwIAeMwY4QYAAAAAwApIuAEAAAAAsAK7jA4AAADgRcbTfQDw/GKEGwAAAAAAKyDhBgAAAADACki4AQAAAACwAhJuAAAAAACsgIQbAAAAAAArIOEGAAAAAMAKSLgBAAAAALACEm4AAAAAAKyAhBsAAAAAACsg4QYAAAAAwApIuAEAAAAAsAISbgAAAAAArICEGwAAAAAAKyDhBgAAAADACki4AQAAAACwAhJuAAAAAACsgIQbAAAAAAArIOEGAAAAAMAKSLgBAAAAALACEm4AAAAAAKyAhBsAAAAAACsg4QYAAAAAwApIuAEAAAAAsAISbgB4BFWrVlW3bt1SrePv768JEyakWsdkMmnp0qWSpMjISJlMJoWHhz+WGAE826zxnnDve441hYWFyWQy6cqVK4/lfE/r++OTup8Anj12GR0AgBfLazZvP9H21ib8kK76ISEhmjNnjj744ANNnz7dYt9HH32kadOmqU2bNgoNDZUkLV68WPb29o8r3McmLCxM1apVS3ZfdHS0fHx8HrkNf39/devW7YEfOAAZqXLjMU+0vS2Le6WrfuJ7TqIsWbKobNmyGjVqlIoXL/64w0u3qlWrqmnTpurQoUOy+zZu3CjpbsKZLVs2vfLKKxozZozy5MnzpENN0aBBg7R06dIkSXpkZKTy5s2r/fv3Kzg4+JHaiI6Olqen52M/L4BnHyPcAHAfPz8/LViwQDdv3jSX/ffff5o/f75y585tUTdLlixyc3N70iGm2ZEjRxQdHW3xyp49e0aHZeH27dsZHQKQoWrVqmX+/Vy3bp3s7OxUr169jA5Lly5d0rZt21S/fv0U67Rv317R0dE6ffq0fv75Z506dUotW7Z8glFmrMT3Lx8fHzk6OmZwNACeRiTcAHCfUqVKKXfu3Fq8eLG5bPHixfLz81PJkiUt6t4/pfzcuXOqX7++nJ2dlTdvXs2bNy/J+Y8dO6ZXXnlFTk5OKly4sNasWfPAmA4fPqw6derI1dVV3t7eatWqlS5cuPDA47Jnzy4fHx+Ll43N3bf+3bt3q0aNGsqaNas8PDxUpUoV7du3z+L4QYMGKXfu3HJ0dFSOHDnUpUsX83WfPHlS3bt3l8lkkslkMh+zbds2vfLKK3J2dpafn5+6dOmi69evm/f7+/tr6NChCgkJkYeHh9q3b6/Q0FBlzpxZq1atUlBQkFxdXc1JCPC8c3R0NP9+BgcHq0+fPjp16pTOnz+fbP34+Hi1a9dOefPmlbOzswoWLKiJEycmqTdr1iwVKVJEjo6O8vX1VadOnVKMYciQIfL29rYYBV6xYoVKlCihnDlzpnici4uLfHx85Ovrq/Lly6tjx45J3kfudfHiRTVr1ky5cuWSi4uLihUrpvnz51vUSUhI0MiRIxUYGChHR0flzp1bX3zxRbLnS0hIUPv27VWgQAGdPHkyxXbT6kHvtVWrVlWnTp3Uo0cPZc2aVTVq1JBkOaU8b968kqSSJUvKZDKpatWqktL2nvvnn3+qcuXK5v8f1q5dm2S6+unTp9WkSRN5enrKy8tLDRs2VGRk5CNfOwDrIOEGgGS8++67mj17tnl71qxZatu27QOPCwkJUWRkpNavX68ff/xRU6dO1blz58z7ExIS1LhxY9na2mrHjh2aPn26+vTpk+o5o6OjVaVKFQUHB2vPnj1auXKlzp49q3feeefhL1DS1atX1aZNG23evFk7duxQ/vz5VadOHV29elWS9OOPP2r8+PH66quvdOzYMS1dulTFihWTdPcDiFy5cmnIkCHmkTlJOnTokGrWrKnGjRvr4MGDWrhwobZs2ZLkD/3Ro0eraNGi2rt3r/r37y9JunHjhsaMGaO5c+dq06ZNioqKUq9e6ZueCzzrrl27pnnz5ikwMFBeXl7J1klISFCuXLm0aNEiHT58WAMGDNCnn36qRYsWmetMmzZNHTt21Pvvv69Dhw5p2bJlCgwMTHIuwzDUtWtXzZw5U1u2bLGYAr1s2TI1bNgwzbFfunRJP/zwg8qVK5dinf/++0+lS5fW8uXL9fvvv+v9999Xq1attHPnTnOdvn37auTIkerfv78OHz6s77//Xt7e3knOdfv2bb3zzjvas2ePtmzZ8sjT2NP6XjtnzhzZ2dlp69at+uqrr5KcZ9euXZKktWvXKjo62vzh7YPecxMSEtSoUSO5uLho586d+vrrr9WvXz+Lc9+4cUPVqlWTq6urNm3apC1btpg/oGS2EPB04hluAEhGq1at1LdvX/MCPVu3btWCBQsUFhaW4jFHjx7Vb7/9ph07dpj/4Jw5c6aCgoLMddauXauIiAhFRkYqV65ckqRhw4apdu3aKZ532rRpKlWqlIYNG2YumzVrlvz8/HT06FEVKFAgxWMT20iUM2dOHTlyRJL06quvWuz76quv5OnpqY0bN6pevXqKioqSj4+PXnvtNdnb2yt37tx66aWXJN2dSm9rays3NzeL58FHjx6t5s2bm0f98+fPr0mTJqlKlSqaNm2anJyczG3fm0xv2bJFd+7c0fTp0xUQECBJ6tSpk4YMGZLitQHPi+XLl8vV1VWSdP36dfn6+mr58uXm2Sj3s7e31+DBg83befPm1bZt27Ro0SJzcjh06FD17NlTXbt2NdcrW7asxXni4uLUunVr7dmzR1u3brV4v7h165ZWrVqlAQMGpBr71KlT9c0338gwDN24cUMFChTQqlWrUqyfM2dOi9/9zp07a+XKleZE/erVq5o4caK+/PJLtWnTRpIUEBCgypUrW5zn2rVrqlu3rm7evKmwsDB5eHikGuehQ4fM9ziRYRgW22l9rw0MDNSoUaNSbCtbtmySJC8vL4v3xwe9565evVrHjx9XWFiY+bgvvvjCPIouSQsWLJCNjY2++eYb88yi2bNnK3PmzAoLC9Prr7+e6n0A8OSRcANAMrJmzaq6detqzpw5MgxDdevWVdasWVM9JiIiQnZ2dipTpoy5rFChQsqcObNFndy5c1v8YVuhQoVUz7t3715t2LAhyR+LknT8+PFUE+7NmzdbPGNuZ/e/t/1z585pwIABWr9+vc6ePav4+HjduHFDUVFRkqS3335bEyZMUL58+VSrVi3VqVNH9evXtzhHcrH+9ddfFlPpDcNQQkKCTpw4Yf7w4d57lMjFxcWcbEuSr6+vxewA4HlVrVo1TZs2TdLdUeKpU6eqdu3a2rVrV4qjttOnT9c333yjkydP6ubNm7p9+7Z5dPrcuXP6999/Vb169VTb7d69uxwdHbVjx44k72/r16+Xl5eXeVZLSlq0aGEehT179qyGDRum119/XXv37k12fYv4+HiNGDFCCxcu1OnTp3Xr1i3dunVLmTJlknT3PfLWrVsPjD1xWvq6devk4uKSal1JKliwoJYtW2ZRdvr0afN0bynt77XJvX+lxYPec48cOSI/Pz+LJD3xQ857Y/zrr7+S3Nv//vtPx48ff6i4AFgXCTcApKBt27bmqdBTpkx5YP3E0ZJ7n2dOqc69Uqsv3Z1mWL9+fY0cOTLJPl9f31SPzZs3r0XCf6+QkBCdP39eEyZMUJ48eeTo6KgKFSqYpyX6+fnpyJEjWrNmjdauXauPPvpIo0eP1saNG1NcmT0hIUEffPCB+Vnve9274FziH9f3uv+cJpMp2fsFPG8yZcpkMd27dOnS8vDw0IwZMzR06NAk9RctWqTu3btr7NixqlChgtzc3DR69GjztGxnZ+c0tVujRg3Nnz9fq1atUosWLSz2pXU6uYeHhzn2wMBAzZw5U76+vlq4cKHee++9JPXHjh2r8ePHa8KECSpWrJgyZcqkbt26md930hp7nTp19N1332nHjh1JRo6T4+DgkGRK/f0fHqb1vTa596+0eNB7rmEYafr/oHTp0smuD5I4sg7g6ULCDQApuPeZuJo1az6wflBQkOLi4rRnzx7zqMSRI0csvn+2cOHCioqK0r///qscOXJIkrZv357qeUuVKqWffvpJ/v7+qY4up9fmzZs1depU1alTR5J06tSpJAuxOTs7q0GDBmrQoIE6duyoQoUK6dChQypVqpQcHBwUHx+fJNY//vgj2WdFAaSNyWSSjY2NxTcl3Gvz5s2qWLGiPvroI3PZvaObbm5u8vf317p161L8ekBJatCggerXr6/mzZvL1tZWTZs2lXQ38fvll1/07bffpjt2W1tbSUo19oYNG5pXMk9ISNCxY8fMs1/y588vZ2dnrVu3LtmEPdGHH36ookWLqkGDBlqxYoWqVKmS7ljv97jeax0cHCQpyfvjg95zCxUqpKioKJ09e9b8zPru3buTxLhw4UJlz55d7u7uDx0jgCeHRdMAIAW2traKiIhQRESE+Y/I1BQsWFC1atVS+/bttXPnTu3du1fvvfeexYjNa6+9poIFC6p169Y6cOCANm/enGRRnPt17NhRly5dUrNmzbRr1y79/fffWr16tdq2bZvkD7r7nTt3TmfOnLF43blzR9Ld0ai5c+cqIiJCO3fuVIsWLSxiDQ0N1cyZM/X777/r77//1ty5c+Xs7Gye4urv/3/t3Xlcjen/+PHXUVI5bQqFSLIUspvJUpnRZJ0sgyHR2MmSGcP42MI0lpFtrEOLjBnLII0tREkZS2QrWySfkTHWD1mr8/vDr/vraG/EZz7ez8ejB+e+rvu63vd9Tnfnfa7rvo4NBw8e5I8//lDeNE6YMIHDhw/j4+NDQkICly5dIjw8nFGjRhV4/oR4Xz179kz5/UxKSmLUqFE8evQoz6/jsrOz4/jx40RERHDx4kWmTJmSIzHz8/MjICCAxYsXc+nSJU6cOMEPP/yQo62uXbuydu1avvjiC3799Vfg5bTl9PR0nJ2dC4z98ePHSuynTp1ixIgR6Ovr53kvsZ2dHXv37iUuLo6kpCSGDh3KzZs3lXJ9fX0mTJjA+PHjCQ0NJTk5md9//53AwMAcbY0aNYpvv/2WTp06cejQoQJjLcjfuda+qkKFChgYGCiLrj148EA59vyuuW5ubtSoUYP+/ftz+vRpYmNjlb8P2SPfnp6eWFhY4OHhQUxMDFevXiU6OpoxY8bw73//+2+fAyHEmycJtxBC5MPY2LhIowjBwcFYW1vj4uJCt27dGDJkiNb3XpcqVYqtW7fy7NkzmjdvzqBBg/L8uptslSpVIjY2lszMTNzd3alXrx5jxozBxMQkz0WVstWuXRsrKyutn/j4eODlYkD37t2jUaNGeHl5MXr0aK1YTU1NWbVqFS1btsTR0ZHIyEh+++03ZeXkGTNmkJKSQo0aNZSpjI6OjkRHR3Pp0iVat25No0aNmDJlSoFT34V4n+3evVv5/fzggw84duwYmzZt0rq/+FXDhg2jW7du9OrViw8++IA7d+5ojXYD9O/fn4ULF7Js2TLq1q1Lp06duHTpUq7tffbZZ6xZswYvLy+2bNnCtm3b6NixY6FGeVetWqXE3qZNG/766y927txJ7dq1c60/ZcoUGjdujLu7O66urlhaWtKlS5ccdb766iumTp2Kvb09vXr1ynM9B19fX6ZPn06HDh2Ii4srMN78/J1r7at0dXVZvHgxK1eupFKlSsrU/IKuuTo6OoSFhfHo0SOaNWvGoEGDmDx5MoCy4KShoSEHDx6katWqdOvWDXt7ewYMGMCTJ09kxFuI/1IqjdwgJ4QQQggh/j9HR0cmT578t796UPx9sbGxtGrVisuXL2stKimE+OeQe7iFEEIIIQTw8rutu3fvnu9XFYqSs3XrVtRqNTVr1uTy5cuMGTOGli1bSrItxD+YjHALIYQQQgjxXyA0NJSZM2dy/fp1LCwsaNu2LQEBAcqtPEKIfx5JuIUQQgghhBBCiBIgi6YJIYQQQgghhBAlQBJuIYQQQgghhBCiBEjCLYQQQgghhBBClABJuIUQQgghhBBCiBIgCbcQQgghhBBCCFECJOEWQgghhBBCCCFKgCTcQgjxD+Hq6oqvr6/y2MbGhoULF76zeIorKioKlUrF/fv333Uob8Trz8vjx4/p3r07xsbGynG+zefqbfXl7e1Nly5dSrwf8VJISAimpqbvOgwtKSkpqFQqEhIS3nUoBXr991QIId4W3XcdgBDi/aJSqd5qfxqNpkj1vb29uX//PmFhYVrbo6KiaNOmDffu3Xtnb3q3bNlC6dKllcfHjh2jbNmyJdKXn58f58+fZ/369bmW3717lxkzZhAWFsaNGzcwNzenXbt2TJ8+napVqyr1XF1dadiw4Tv9YMDV1ZXo6GgA9PT0qFatGt7e3kyYMAEdHZ2/3f7rz8uaNWuIiYkhLi4OCwsLTExM/vZzZWNjg6+vryQMxWC7KOCt9ndlzFdFql/Ya06vXr3o0KHDG4z077O2tiYtLQ0LC4si7Zff9cXPz4+wsLBiJ/F5Xatf/z0VQoi3RUa4hRDiH6JcuXIYGRkpj8uXL4+hoWGJ9BUeHo6Hh0euZXfv3uXDDz9k3759LFu2jMuXL7NhwwaSk5Np1qwZV65cKZGYCvLixYs8ywYPHkxaWhoXLlxg9OjRTJ48mXnz5r2Rfl9/XpKTk7G3t6devXpYWlqiUqlK9Ln6p9JoNGRkZLzrMP4xDAwMqFChwrsOQ4uOjg6Wlpbo6hZt/Ca/60tJef33VAgh3hZJuIUQohju3LlD7969qVKlCoaGhtSvX59ffvlFKf/tt98wNTUlKysLgISEBFQqFV9//bVSZ+jQofTu3btQ7UHBU8rnz59P/fr1KVu2LNbW1owYMYJHjx4p5dlTUiMiIrC3t0etVtOuXTvS0tK0+rl+/Tpnz56lffv2uR77pEmTuHHjBvv27aNDhw5UrVoVZ2dnIiIiKF26ND4+PsDLkbvo6GgWLVqESqVCpVKRkpKitBMfH0/Tpk0xNDSkRYsWXLhwQauf3377jSZNmqCvr4+trS3Tp0/XStBUKhUrVqzAw8ODsmXL8u233+YaL4ChoSGWlpbY2NgwcuRIPv74Y2VEsaDzBhAbG4uLiwuGhoaYmZnh7u7OvXv3cjwvrq6uBAQEcPDgQVQqFa6urrk+V/fv32fIkCFUrFgRfX196tWrx/bt2/OM/3V+fn5UrVqVMmXKUKlSJUaPHp1n3TfxusjMzOTLL7/E1NQUc3Nzxo8fn2P2iEajYe7cudja2mJgYECDBg349ddflfLsWwkiIiJo2rQpZcqUISYmptDH/L57fUr5qVOnaNOmDUZGRhgbG9OkSROOHz+uVTcsLIxatWqhr6+Pm5sb169fV/ZPTk7Gw8ODihUrolaradasGfv27dPq08bGhu+++44BAwZgZGRE1apV+fHHH5Xy3KaUnzt3jo4dO2JsbIyRkRGtW7cmOTlZKS/o+lKQn376iaZNm2JkZISlpSV9+vTh1q1bSjxt2rQBwMzMDJVKhbe3N5D79TO/YwM4c+YMH330EQYGBpibmzNkyJAc1wYhhCiIJNxCCFEMT58+pUmTJmzfvp2zZ88yZMgQvLy8OHLkCADOzs48fPiQkydPAhAdHY2FhYUytRleJiAuLi6Faq8wSpUqxeLFizl79ixr1qxh//79jB8/XqvO48ePmTdvHmvXruXgwYOkpqYybtw4rTrh4eE4OzvnOnU+KyuL9evX4+npiaWlpVaZgYEBI0aMICIigrt377Jo0SKcnJyU0eW0tDSsra2V+pMmTSIgIIDjx4+jq6vLgAEDlLKIiAj69u3L6NGjSUxMZOXKlYSEhODv76/V57Rp0/Dw8ODMmTNa+xfEwMBAGREv6LwlJCTw8ccfU7duXQ4fPsyhQ4fo3LkzmZmZOdrdsmULgwcPxsnJibS0NLZs2ZLrOWzfvj1xcXH89NNPJCYmMnv27EJPb//1119ZsGABK1eu5NKlS4SFhVG/fv0867+J10VAQABBQUEEBgZy6NAh7t69y9atW7XamDx5MsHBwSxfvpxz584xduxY+vbtq/WaBxg/fjyzZs0iKSkJR0fHQh2zyMnT05MqVapw7Ngx4uPj+eabb7SmTD9+/Bh/f3/WrFlDbGws//nPf/j888+V8kePHtGhQwf27dvHyZMncXd3p3PnzqSmpmr1ExAQQNOmTTl58iQjRoxg+PDhnD9/PteY/vjjD5ydndHX12f//v3Ex8czYMAArQ/K8ru+FMbz58+ZOXMmp06dIiwsjKtXrypJtbW1NZs3bwbgwoULpKWlsWjRojzbyu/YHj9+TLt27TAzM+PYsWNs2rSJffv2MXLkyGLFLYR4f8k93EII8Zrt27ejVqu1tr2eXFWuXFkrIRk1ahS7d+9m06ZNfPDBB5iYmNCwYUOioqJo0qQJUVFRjB07lunTp/Pw4UPS09O5ePGiMgJaUHuF8eroTfXq1Zk5cybDhw9n2bJlyvYXL16wYsUKatSoAcDIkSOZMWOGVjvbtm3Lc7rnX3/9xf3797G3t8+13N7eHo1Gw+XLl2nevDl6enrK6PLr/P39lQ8cvvnmGzp27MjTp0/R19fH39+fb775hv79+wNga2vLzJkzGT9+PNOmTVPa6NOnT5ES7aysLPbs2UNERIRyvgo6b3PnzqVp06Za57Fu3bq5tl+uXDkMDQ3R09PL9ZgB9u3bx9GjR0lKSqJWrVrK8RVWamoqlpaWtG3bltKlS1O1alWaN2+eZ/038bpYuHAhEydOpHv37gCsWLGCiIgIpTw9PZ358+ezf/9+nJyclGM6dOgQK1euVJ5ngBkzZuDm5lbo430fFOaa87rU1FS+/vpr6tSpA0DNmjW1yl+8eMGSJUuU68eaNWuwt7fn6NGjNG/enAYNGtCgQQOl/rfffsvWrVsJDw/XSio7dOjAiBEjAJgwYQILFiwgKipK6fdVS5cuxcTEhPXr1yvJf/ZrPFt+15fCePX33dbWlsWLF9O8eXMePXqEWq2mXLlyAFSoUKHApD6/Y1u3bh1PnjwhNDRUWX9hyZIldO7cmTlz5lCxYsViH4MQ4v0iI9xCCPGaNm3akJCQoPWzevVqrTqZmZn4+/vj6OiIubk5arWaPXv2aI0Oubq6EhUVhUajISYmBg8PD+rVq8ehQ4c4cOAAFStWVN60Fqa9ghw4cAA3NzcqV66MkZER/fr1486dO6Snpyt1DA0NlaQKwMrKSpmOCfCf//yH6OhoPv300yKfN/i/ReoKszjeq6ObVlZWAEos8fHxzJgxA7Varfxkj5Q/fvxY2a9p06aFimvZsmWo1Wr09fX59NNP6du3r5K4F3Teske435SEhASqVKmSIxEprB49evDkyRNsbW0ZPHgwW7duzfde6L/7unjw4AFpaWlKIg2gq6urde4TExN5+vQpbm5uWs9ZaGio1nRiKPxz9j4pzDXndV9++SWDBg2ibdu2zJ49O8d5fv05qlOnDqampiQlJQEvPyQZP348Dg4OmJqaolarOX/+fI5rzqu/pyqVCktLS61rxqsSEhJo3bp1nouT/d3rC8DJkyfx8PCgWrVqGBkZKR9aFuVamS2/Y0tKSqJBgwZaix22bNmSrKysHLe/CCFEfiThFkKI15QtWxY7Ozutn8qVK2vVCQgIYMGCBYwfP579+/eTkJCAu7s7z58/V+q4uroSExPDqVOnKFWqFA4ODri4uBAdHa01nbyw7eXn2rVrdOjQgXr16rF582bi4+NZunQpoL2Y2OtvhFUqlda9uLt27cLe3p5q1arl2k/58uUxNTUlMTEx1/Lz58+jUqm0kre8vBpLdoKefc97VlYW06dP10pAzpw5w6VLl9DX11f2K+zK356eniQkJJCcnMyTJ08IDAzE0NCwUOfNwMCgUH0U1t9tz9ramgsXLrB06VJlGr+zs3Oui8a9qddFQbKftx07dmg9Z4mJiVr3cUPhn7P3SWGuOa/z8/NT7pfev38/Dg4OOab55/bBV/a2r7/+ms2bN+Pv709MTAwJCQnUr18/xzUnt9dG9vP9uoJe2wVdXwqSnp7OJ598glqt5qeffuLYsWPKMRf2Wvmq/I5No9Hk+cHh2/62DSHEP5sk3EIIUQzZI9Z9+/alQYMG2NracunSJa062fdxL1y4EBcXF1QqFS4uLkRFReVIuAvTXn6OHz9ORkYGAQEBfPjhh9SqVYsbN24U+bi2bduW7+hTqVKl6NmzJz///DM3b97UKnvy5AnLli3D3d1dmdapp6dX4NTY3DRu3JgLFy7kSELs7OwoVarof7pMTEyws7PD2tpa617pwpw3R0dHIiMji9xnXhwdHfn3v//NxYsXi92GgYEBn376KYsXLyYqKorDhw9z5syZHPXexOvCxMQEKysrfv/9d2VbRkYG8fHxymMHBwfKlClDampqjufr1fv2xZtVq1Ytxo4dy549e+jWrRvBwcFKWUZGhrKIGry8p/n+/fvKrJqYmBi8vb3p2rUr9evXx9LSUmtRw+JwdHQkJiYmz28MKOj6UpDz589z+/ZtZs+eTevWralTp06O0XY9PT2g4Cn5BXFwcCAhIUFrJkhsbCylSpUq9uwUIcT7SRJuIYQoBjs7O/bu3UtcXBxJSUkMHTo0RwKafR/3Tz/9pEx7dHZ25sSJE1r3bxe2vfzUqFGDjIwMfvjhB65cucLatWtZsWJFkY4pIyODXbt2FXh/pb+/P5aWlri5ubFr1y6uX7/OwYMHcXd358WLF8oIKrxcCfjIkSOkpKRw+/btPEfGXjd16lRCQ0OVUbykpCQ2bNjA5MmTi3RMBSnMeZs4cSLHjh1jxIgRnD59mvPnz7N8+XJu375drD5dXFxwdname/fu7N27l6tXr7Jr1y52795dqP1DQkIIDAzk7NmzSswGBga5jhq+idcFwJgxY5g9ezZbt27l/PnzjBgxgvv37yvlRkZGjBs3jrFjx7JmzRqSk5M5efIkS5cuZc2aNUXuT+TvyZMnjBw5kqioKK5du0ZsbCzHjh3TWluhdOnSjBo1iiNHjnDixAm++OILPvzwQ+V+fzs7O7Zs2UJCQgKnTp2iT58+hf79zMvIkSOVxdmOHz/OpUuXWLt2LRcuXCj09SX7+F6fYn/58mWqVq2Knp6e8noODw9n5syZWvtWq1YNlUrF9u3b+euvv4q9qrinpyf6+vr079+fs2fPcuDAAUaNGoWXl5fcvy2EKBJJuIUQohimTJlC48aNcXd3x9XVFUtLS7p06ZKjXps2bcjMzFSSazMzMxwcHChfvrzWm+PCtpeXhg0bMn/+fObMmUO9evVYt24ds2bNKtIxRUdHo1aradKkSb71LCws+P3332nTpg1Dhw7F1taWnj17Ymtry7Fjx7QWABs3bhw6OjrKMRf2Pkt3d3e2b9/O3r17adasGR9++CHz588v9lTUvBTmvNWqVYs9e/Zw6tQpmjdvjpOTE9u2bSvydw+/avPmzTRr1ozevXvj4ODA+PHjCz0iZ2pqyqpVq2jZsqUy+v7bb79hbm5erOMrjK+++op+/frh7e2Nk5MTRkZGdO3aVavOzJkzmTp1KrNmzcLe3h53d3d+++03qlevXuT+RP50dHS4c+cO/fr1o1atWvTs2ZP27dszffp0pY6hoSETJkygT58+ODk5YWBgwPr165XyBQsWYGZmRosWLejcuTPu7u40btz4b8Vlbm7O/v37efToES4uLjRp0oRVq1ZRunTpQl9fAC5evEijRo20fgYNGkT58uUJCQlh06ZNODg4MHv2bObNm6e1b+XKlZk+fTrffPMNFStWLPaq4oaGhso3LjRr1ozPPvuMjz/+mCVLlhSrPSHE+0ulKcpNWkIIIf5njR49moyMDK3Vq4UQ/zwhISH4+vpqzUJ41+T6IoR4X8nXggkhhACgXr16WitRCyHEmyLXFyHE+0oSbiGEEAAMGTLkXYcghPgfJdcXIcT7SqaUCyGEEEIIIYQQJUAWTRNCCCGEEEIIIUqAJNxCCCGEEEIIIUQJkIRbCCGEEEIIIYQoAZJwCyGEEEIIIYQQJUASbiGEEEIIIYQQogRIwi2EEEIIIYQQQpQASbiFEOINCgkJwdTU9F2HIYR4T6SkpKBSqUhISHjXoRRZVFQUKpWK+/fvv+tQ/jaVSkVYWNi7DkMI8V9I910HIIR4v8w+efut9vdNI4ti7Xf9+nX8/PzYtWsXt2/fxsrKii5dujB16lTMzc0BsLGxwdfXF19f3zcYsRDiTfI6MvCt9rf2g8Bi7RcXF0fr1q1xc3Nj9+7dhd7P2tqatLQ0LCyKd60riKurK59//jnDhg3Ls87PP/+Ml5cXgwcPZsWKFYVuu0WLFqSlpWFiYvImQs2Tn58fYWFhOT6USElJoXr16pw8eZKGDRv+rT7S0tIwMzN74+0KIf75ZIRbCCFec+XKFZo2bcrFixf55ZdfuHz5MitWrCAyMhInJyfu3r371mN68eLFW+9TCPH2BAUFMWrUKA4dOkRqamqh99PR0cHS0hJd3Tc/hnL37l3i4uLo3LlzvvWCgoIYP34869ev5/Hjx4VuX09PD0tLS1Qq1d8N9Z15/vw5AJaWlpQpU+YdRyOE+G8kCbcQQrzGx8cHPT099uzZg4uLC1WrVqV9+/bs27ePP/74g0mTJuHq6sq1a9cYO3YsKpUqxxvGiIgI7O3tUavVtGvXjrS0NK3y4OBg7O3t0dfXp06dOixbtkwpy54iunHjRlxdXdHX1+enn356K8cuhHj70tPT2bhxI8OHD6dTp06EhIRold+7dw9PT0/Kly+PgYEBNWvWJDg4GMg5pTwzM5OBAwdSvXp1DAwMqF27NosWLdJqz9vbmy5dujBv3jysrKwwNzfHx8cnxwd7O3bsoEGDBlSuXDnP2FNSUoiLi+Obb76hTp06/Prrr1rl165do3PnzpiZmVG2bFnq1q3Lzp07gZxTyu/cuUPv3r2pUqUKhoaG1K9fn19++UWrPVdXV0aPHs348eMpV64clpaW+Pn5FeY0F0piYiIdOnRArVZTsWJFvLy8uH37/2Zmubq6MnLkSL788kssLCxwc3MDtKeUV69eHYBGjRqhUqlwdXUF4NixY7i5uWFhYYGJiQkuLi6cOHFCq//z58/TqlUr9PX1cXBwYN++fTmmq//xxx/06tULMzMzzM3N8fDwICUl5Y2dAyHEmyUJtxBCvOLu3btEREQwYsQIDAwMtMosLS3x9PRkw4YNbN68mSpVqjBjxgzS0tK0EurHjx8zb9481q5dy8GDB0lNTWXcuHFK+apVq5g0aRL+/v4kJSXx3XffMWXKFNasWaPV34QJExg9ejRJSUm4u7uX7IELId6ZDRs2ULt2bWrXrk3fvn0JDg5Go9Eo5VOmTCExMZFdu3aRlJTE8uXL85xCnpWVRZUqVdi4cSOJiYlMnTqVf/3rX2zcuFGr3oEDB0hOTubAgQOsWbOGkJCQHIl+eHg4Hh4e+cYeFBREx44dMTExoW/fvgQGak+p9/Hx4dmzZxw8eJAzZ84wZ84c1Gp1rm09ffqUJk2asH37ds6ePcuQIUPw8vLiyJEjWvXWrFlD2bJlOXLkCHPnzmXGjBns3bs33zgLIy0tDRcXFxo2bMjx48fZvXs3f/75Jz179szRv66uLrGxsaxcuTJHO0ePHgVg3759pKWlsWXLFgAePnxI//79iYmJ4ffff6dmzZp06NCBhw8fAi+fuy5dumBoaMiRI0f48ccfmTRpklbbjx8/pk2bNqjVag4ePMihQ4eUD3azR9uFEP9d5B5uIYR4xaVLl9BoNNjb2+dabm9vz71798jMzERHRwcjIyMsLS216rx48YIVK1ZQo0YNAEaOHMmMGTOU8pkzZxIQEEC3bt2Al6MhiYmJrFy5kv79+yv1fH19lTpCiP9dgYGB9O3bF4B27drx6NEjIiMjadu2LQCpqak0atSIpk2bAi/Xj8hL6dKlmT59uvK4evXqxMXFsXHjRq3E0czMjCVLlqCjo0OdOnXo2LEjkZGRDB48GIBnz54RERHB1KlT8+wrKyuLkJAQfvjhBwA+//xzvvzySy5fvoydnZ0Se/fu3alfvz4Atra2ebZXuXJlrQ8nR40axe7du9m0aRMffPCBst3R0ZFp06YBULNmTZYsWUJkZKQy2pybM2fO5Ej0X/1QA2D58uU0btyY7777TtkWFBSEtbU1Fy9epFatWgDY2dkxd+7cPPsqX748AObm5lp/Hz766COteitXrsTMzIzo6Gg6derEnj17SE5OJioqStnP399f67jWr19PqVKlWL16tTKzKjg4GFNTU6Kiovjkk0/yjEsI8W5Iwi2EEEWQ/QYtv3sODQ0NlWQbwMrKilu3bgHw119/cf36dQYOHKi8sQXIyMjIsXBQ9ptrIcT/rgsXLnD06FFlFFRXV5devXoRFBSkJNzDhw+ne/funDhxgk8++YQuXbrQokWLPNtcsWIFq1ev5tq1azx58oTnz5/nWLyrbt266OjoKI+trKw4c+aM8nj//v2Ym5sriXJu9uzZQ3p6Ou3btwfAwsKCTz75hKCgICVpHT16NMOHD2fPnj20bduW7t274+jomGt7mZmZzJ49mw0bNvDHH3/w7Nkznj17RtmyZbXqvb7/q9fYvNSuXZvw8HCtbX/88Ycy3RsgPj6eAwcO5DoCn5ycrCTcxb0237p1i6lTp7J//37+/PNPMjMzefz4sXLP/oULF7C2ttZK0ps3b67VRnx8PJcvX8bIyEhr+9OnT0lOTi5WXEKIkiUJtxBCvMLOzg6VSkViYiJdunTJUX7+/HnMzMzyXRG4dOnSWo9VKpWSqGdlZQEvp5W/OmIDaL35BXK8yRRC/O8JDAwkIyND6z5pjUZD6dKluXfvHmZmZrRv355r166xY8cO9u3bx8cff4yPjw/z5s3L0d7GjRsZO3YsAQEBODk5YWRkxPfff59jWnZu16ns6xMUfjr53bt3MTQ0VLZlZWVx8uRJZs6ciY6ODoMGDcLd3Z0dO3awZ88eZs2aRUBAAKNGjcrRXkBAAAsWLGDhwoXUr1+fsmXL4uvrm2OqdEGx50ZPT08Zdc/2+kJzWVlZdO7cmTlz5uTY38rKSvl/ca/N3t7e/PXXXyxcuJBq1apRpkwZnJyclOPTaDQFLiCXlZVFkyZNWLduXY6y7JF1IcR/F0m4hRDiFebm5ri5ubFs2TLGjh2rdR/3zZs3WbduHf369UOlUqGnp0dmZmaR2q9YsSKVK1fmypUreHp6vunwhRD/IBkZGYSGhhIQEJBjKnD37t1Zt24dI0eOBF4mU97e3nh7e9O6dWu+/vrrXBPumJgYWrRowYgRI5RtRR351Gg0/Pbbb4SGhuZZ586dO2zbto3169dTt25dZXtWVhatW7dm165ddOrUCXj51WXDhg1j2LBhTJw4kVWrVuWacMfExODh4aFMr8/KyuLSpUt53uLzpjVu3JjNmzdjY2Pzt1Z919PTA8jx9yEmJoZly5bRoUMH4OXXT766IFudOnVITU3lzz//pGLFisDLhdZej3HDhg1UqFABY2PjYscohHh7ZNE0IYR4zZIlS3j27Bnu7u4cPHiQ69evs3v3btzc3KhcuTL+/v7Ay/soDx48yB9//KH1pqkgfn5+zJo1i0WLFnHx4kXOnDlDcHAw8+fPL6lDEkL8F9q+fTv37t1j4MCB1KtXT+vns88+UxYgmzp1Ktu2bePy5cucO3eO7du355mE2tnZcfz4cSIiIrh48SJTpkzJkbQVJD4+nvT0dJydnfOss3btWszNzenRo4dW3I6OjnTq1EmJ3dfXl4iICK5evcqJEyfYv39/vrHv3buXuLg4kpKSGDp0KDdv3ixS7H+Hj48Pd+/epXfv3hw9epQrV66wZ88eBgwYUKQPVytUqICBgYGy6NqDBw+Al8e3du1akpKSOHLkCJ6enlof6rq5uVGjRg369+/P6dOniY2NVRZNyx759vT0xMLCAg8PD2JiYrh69SrR0dGMGTOGf//732/wbAgh3hRJuIUQ4jU1a9bk+PHj1KhRg169elGjRg2GDBlCmzZtOHz4MOXKlQNgxowZpKSkUKNGjSJN5Rs0aBCrV68mJCSE+vXr4+LiQkhIiPJVMkKI90NgYCBt27bNsX4DvBzhTkhI4MSJE+jp6TFx4kQcHR1xdnZGR0eH9evX59rmsGHD6NatG7169eKDDz7gzp07WqPdhbFt2zY6duyY7yhvUFAQXbt2pVSpnG8lu3fvzvbt25X7lH18fLC3t6ddu3bUrl1b62sQXzVlyhQaN26Mu7s7rq6uWFpa5nprT0mpVKkSsbGxZGZm4u7uTr169RgzZgwmJia5HmdedHV1Wbx4MStXrqRSpUrK1PygoCDu3btHo0aN8PLyYvTo0VSoUEHZT0dHh7CwMB49ekSzZs0YNGgQkydPBkBfXx94uUbIwYMHqVq1Kt26dcPe3p4BAwbw5MkTGfEW4r+USvP6Eo1CCCGEEOK95ejoyOTJk3N8HZZ4+2JjY2nVqhWXL1/WWoxTCPHPIfdwCyGEEEIIAJ4/f0737t2VlcfF27V161bUajU1a9bk8uXLjBkzhpYtW0qyLcQ/mIxwCyGEEEII8V8gNDSUmTNncv36dSwsLGjbti0BAQGYm5u/69CEEMUkCbcQQgghhBBCCFECZNE0IYQQQgghhBCiBEjCLYQQQgghhBBClABJuIUQQgghhBBCiBIgCbcQQgghhBBCCFECJOEWQgghhBBCCCFKgCTcQgghhBBCCCFECZCEWwghisnV1RVfX98S7cPPz4+GDRuWaB9CiP8Nb+OaJMSr5DUnRMF033UAQoj3i2q66q32p5mmKVJ9b29v1qxZw9ChQ1mxYoVW2YgRI1i+fDn9+/cnJCSELVu2ULp06TcZrhDiDbvn0/Wt9me2dGuR6ru6utKwYUMWLlyotT0sLIyuXbui0RTtGib+T0pKCtWrV6d8+fIkJydjZGSklDVs2JAuXbrg5+dXqLZCQkLw9fXl/v37Bdb74osvlMcVKlSgefPmzJ49m7p16xbnMN64vF5zQoiSISPcQgjxGmtra9avX8+TJ0+UbU+fPuWXX36hatWqyrZy5cppvYETQgjx9mVmZpKVlZVn+cOHD5k3b95bi8fY2Ji0tDRu3LjBjh07SE9Pp2PHjjx//vytxZCbFy9evNP+hXhfScIthBCvady4MVWrVmXLli3Kti1btmBtbU2jRo2Uba9OpTt//jyGhob8/PPPWvvo6+tz5swZAB48eMCQIUOoUKECxsbGfPTRR5w6dUqr79mzZ1OxYkWMjIwYOHAgT58+LcEjFUL8U2TfXrJ27VpsbGwwMTHh888/5+HDh3nus3v3bkxMTAgNDQVezuDp0qUL8+bNw8rKCnNzc3x8fLQSsXv37tGvXz/MzMwwNDSkffv2XLp0CQCNRkP58uXZvHmzUr9hw4ZUqFBBeXz48GFKly7No0ePAFCpVKxevZquXbtiaGhIzZo1CQ8Pz/dY84sBXo4im5qasn37dhwcHChTpgzXrl3Ls71Ro0Yxf/58bt26Vaw+o6Ki+OKLL3jw4AEqlQqVSpXvyLhKpcLS0hIrKyuaNm3K2LFjuXbtGhcuXFDqxMXF4ezsjIGBAdbW1owePZr09HSl3MbGhpkzZ9KnTx/UajWVKlXihx9+0OonNTUVDw8P1Go1xsbG9OzZkz///FMpz37NBAUFYWtrS5kyZejfvz/R0dEsWrRIOZaUlBQAEhMT6dChA2q1mooVK+Ll5cXt27eV9tLT0+nXrx9qtRorKysCAgLyPAdCiP8jCbcQQuTiiy++IDg4WHkcFBTEgAED8qxfp04d5s2bx4gRI7h27Ro3btxg8ODBzJ49m/r166PRaOjYsSM3b95k586dxMfH07hxYz7++GPu3r0LwMaNG5k2bRr+/v4cP34cKysrli1bVuLHKoT4Z0hOTiYsLIzt27ezfft2oqOjmT17dq51169fT8+ePQkNDaVfv37K9gMHDpCcnMyBAwdYs2YNISEhhISEKOXe3t4cP36c8PBwDh8+jEajoUOHDrx48QKVSoWzszNRUVHAyyQ1MTGRFy9ekJiYCLxMTps0aYJarVbanD59Oj179uT06dN06NABT09P5bqXm/xiyPb48WNmzZrF6tWrOXfunFbS/7revXtjZ2fHjBkzitVnixYtWLhwoTJynZaWxrhx4/Js61X3799XPojNvgXpzJkzuLu7061bN06fPs2GDRs4dOgQI0eO1Nr3+++/x9HRkRMnTjBx4kTGjh3L3r17gZcffnTp0oW7d+8SHR3N3r17SU5OplevXlptXL58mY0bN7J582YSEhJYvHgxTk5ODB48WDkWa2tr0tLScHFxoWHDhhw/fpzdu3fz559/0rNnT6Wtr7/+mgMHDrB161b27NlDVFQU8fHxhToPQrzP5B5uIYTIhZeXFxMnTiQlJQWVSkVsbCzr169X3mjmZsSIEezcuRMvLy/09PRo0qQJY8aMAV6+yT1z5gy3bt2iTJkyAMybN4+wsDB+/fVXhgwZwsKFCxkwYACDBg0C4Ntvv2Xfvn0yyi2EACArK4uQkBDlVhYvLy8iIyPx9/fXqrds2TL+9a9/sW3bNtq0aaNVZmZmxpIlS9DR0aFOnTp07NiRyMhIBg8ezKVLlwgPDyc2NpYWLVoAsG7dOqytrQkLC6NHjx64urry448/AnDw4EEaNGhA1apViYqKwsHBgaioKFxdXbX69Pb2pnfv3gB89913/PDDDxw9epR27drlOMbCxAAvp0cvW7aMBg0aFHjeVCoVs2fPpnPnzowdO5YaNWoUuU8TExNl5LogDx48QK1Wo9FoePz4MQCffvopderUAV4m0n369FFmSNWsWZPFixfj4uLC8uXL0dfXB6Bly5Z88803ANSqVYvY2FgWLFiAm5sb+/bt4/Tp01y9ehVra2sA1q5dS926dTl27BjNmjUD4Pnz56xdu5by5csr8enp6WFoaKh1LMuXL6dx48Z89913yragoCCsra25ePEilSpVIjAwkNDQUNzc3ABYs2YNVapUKfB8CPG+kxFuIYTIhYWFBR07dmTNmjUEBwfTsWNHLCwsCtwvKCiI06dPc+LECUJCQlCpXi4SFx8fz6NHjzA3N0etVis/V69eJTk5GYCkpCScnJy02nv9sRDi/WVjY6O1boSVlVWOadKbN2/G19eXPXv25Ei2AerWrYuOjk6ubSQlJaGrq8sHH3yglJubm1O7dm2SkpKAl7fSnDt3jtu3bxMdHY2rqyuurq5ER0eTkZFBXFwcLi4uWn06Ojoq/y9btixGRkZ5Tu8uTAzwMml8td2CuLu706pVK6ZMmVLsPgvLyMiIhIQE4uPjWbFiBTVq1NBahDM+Pp6QkBCtvwXu7u5kZWVx9epVpV5ufw+y40lKSsLa2lpJtgEcHBwwNTXVirlatWpayXZe4uPjOXDggFZM2R8QJCcnk5yczPPnz7ViKleuHLVr1y7i2RHi/SMj3EIIkYcBAwYoU/yWLl1aqH1OnTpFeno6pUqV4ubNm1SqVAl4OTJlZWWV6wi5qanpmwpZCPEPY2xszIMHD3Jsv3//PsbGxlrbXv9WBJVKlWOxsIYNG3LixAmCg4Np1qyZ8qFfYdrIa0V0jUajtFOvXj3Mzc2Jjo4mOjqaGTNmYG1tjb+/P8eOHePJkye0atWqyHG/2ldBMQAYGBjkOLaCzJ49GycnJ77++uti9VlYpUqVws7ODnh5u9HNmzfp1asXBw8eBF7+PRg6dCijR4/Ose+rC3PmJjuevGJ7fXvZsmULFXNWVhadO3dmzpw5OcqsrKy07qEXQhSNjHALIUQe2rVrx/Pnz3n+/Dnu7u4F1r979y7e3t5MmjSJL774Ak9PT2Wl88aNG3Pz5k10dXWxs7PT+skeObe3t+f333/XavP1x0KI/y116tTh+PHjObYfO3asWKOHNWrU4MCBA2zbto1Ro0YVaV8HBwcyMjI4cuSIsu3OnTtcvHgRe3t7AOU+7m3btnH27Flat25N/fr1efHiBStWrKBx48Z/69sbChNDcTVv3pxu3bop07SL0qeenh6ZmZnF6nfs2LGcOnWKrVtffmVc48aNOXfuXI6/BXZ2dujp6Sn75fb3IHvU2cHBgdTUVK5fv66UJyYm8uDBgwLPU27Hkh2TjY1NjpjKli2LnZ0dpUuX1orp3r17XLx4sVjnRIj3iSTcQgiRBx0dHZKSkkhKStKagpmXYcOGYW1tzeTJk5k/fz4ajUZZWKdt27Y4OTnRpUsXIiIiSElJIS4ujsmTJytvtseMGUNQUBBBQUFcvHiRadOmce7cuRI9RiHEuzVixAiSk5Px8fHh1KlTXLx4kaVLlxIYGJhjJLawatWqxYEDB5Tp5YVVs2ZNPDw8GDx4MIcOHeLUqVP07duXypUr4+HhodRzdXXl559/xtHREWNjYyUJX7duXY77t4uqsDEUl7+/P/v379daMbwwfdrY2PDo0SMiIyO5ffu2cm92YRgbGzNo0CCmTZuGRqNhwoQJHD58GB8fHxISEpR7yF//gCQ2Npa5c+cqr4lNmzYp64K0bdsWR0dHPD09OXHiBEePHqVfv364uLjQtGnTfOOxsbHhyJEjpKSkcPv2bbKysvDx8eHu3bv07t2bo0ePcuXKFfbs2cOAAQPIzMxErVYzcOBAvv76ayIjIzl79ize3t6UKiWphBAFkd8SIYTIh7GxcY5pnbkJDQ1l586drF27Fl1dXQwNDVm3bh2rV69m586dqFQqdu7cibOzMwMGDKBWrVp8/vnnpKSkULFiRQB69erF1KlTmTBhAk2aNOHatWsMHz68pA9RCPEO2djYEBMTQ3JyMp988gnNmjVTVg7PXiCsOGrXrs3+/fv55Zdf+Oqrrwq9X3BwME2aNKFTp044OTmh0WjYuXOn1rTwNm3akJmZqZVcu7i4kJmZmeP+7eIoTAzFVatWLQYMGJBjMcqC+mzRogXDhg2jV69elC9fnrlz5xap3zFjxpCUlMSmTZtwdHQkOjqaS5cu0bp1axo1asSUKVOwsrLS2uerr74iPj6eRo0aMXPmTAICApTZViqVirCwMMzMzHB2dqZt27bY2tqyYcOGAmMZN24cOjo6ODg4UL58eVJTU6lUqRKxsbFkZmbi7u5OvXr1GDNmDCYmJkpS/f333+Ps7Mynn35K27ZtadWqFU2aNCnSeRDifaTS5HXjihBCCCGEEOKts7GxwdfXt0gzFIQQ/51khFsIIYQQQgghhCgBknALIYQQQgghhBAlQKaUCyGEEEIIIYQQJUBGuIUQQgghhBBCiBIgCbcQQgghhBBCCFECJOEWQgghhBBCCCFKgCTcQgghhBBCCCFECZCEWwghhBBCCCGEKAGScAshhBBCCCGEECVAEm4hhBBCCKHw8/OjYcOG7zqMN+L1Y/H29qZLly7vLJ6C2NjYsHDhwjfSVlRUFCqVivv377+R9t6WN3kOhPhvoPuuAxBCCCGEKDE/q95uf300xdotLi6O1q1b4+bmxu7du99wUEUzbtw4Ro0a9U5jSElJoXr16pw8efKNJv+LFi1Coynec1SQqKgoevfuzY0bN1Cp8n7d1a5dm6tXr3L16lUqV65cIrGUlKioKNq0aUPdunU5deoUOjo6SpmpqSkLFy7E29u7UG2FhITg6+ub4wOBY8eOUbZs2TcYtRDvloxwCyGEEEK8Y0FBQYwaNYpDhw6Rmpr6TmLQaDRkZGSgVqsxNzd/JzGUNBMTE0xNTUuk7fDwcD799NN8k+1Dhw7x9OlTevToQUhISInE8TYkJycTGhpaIm2XL18eQ0PDEmlbiHdBEm4hhBBCiHcoPT2djRs3Mnz4cDp16pQjEcueGhwREUGjRo0wMDDgo48+4tatW+zatQt7e3uMjY3p3bs3jx8/VvbTaDTMnTsXW1tbDAwMaNCgAb/++muu7TZt2pQyZcoQExOT65TyoKAg6tatS5kyZbCysmLkyJFK2fz586lfvz5ly5bF2tqaESNG8OjRI6U8JCQEU1NTIiIisLe3R61W065dO9LS0gp9jrJjjYyMpGnTphgaGtKiRQsuXLigVW/27NlUrFgRIyMjBg4cyNOnT7XKX59Svnv3blq1aoWpqSnm5uZ06tSJ5ORkpTwlJQWVSsWWLVto06YNhoaGNGjQgMOHD+eIMTvhzk9gYCB9+vTBy8uLoKCgAkfbCzq3165do3PnzpiZmVG2bFnq1q3Lzp07c23ryZMndOzYkQ8//JC7d+9y584devfuTZUqVTA0NKR+/fr88ssv+caTbdSoUUybNi3H+S1s7FFRUXzxxRc8ePAAlUqFSqXCz88P0J5S3rt3bz7//HOtdl+8eIGFhQXBwcFAwa9zId41SbiFEEIIId6hDRs2ULt2bWrXrk3fvn0JDg7ONRHz8/NjyZIlxMXFcf36dXr27MnChQv5+eef2bFjB3v37uWHH35Q6k+ePJng4GCWL1/OuXPnGDt2LH379iU6Olqr3fHjxzNr1iySkpJwdHTM0e/y5cvx8fFhyJAhnDlzhvDwcOzs7JTyUqVKsXjxYs6ePcuaNWvYv38/48eP12rj8ePHzJs3j7Vr13Lw4EFSU1MZN25ckc/VpEmTCAgI4Pjx4+jq6jJgwAClbOPGjUybNg1/f3+OHz+OlZUVy5Yty7e99PR0vvzyS44dO0ZkZCSlSpWia9euZGVl5eh33LhxJCQkUKtWLXr37k1GRoZSfu7cOW7evMnHH3+cZ18PHz5k06ZN9O3bFzc3N9LT04mKiso3voLOrY+PD8+ePePgwYOcOXOGOXPmoFarc7Tz4MEDPvnkE54/f05kZCTlypXj6dOnNGnShO3bt3P27FmGDBmCl5cXR44cyTcmAF9fXzIyMliyZEmxYm/RogULFy7E2NiYtLQ00tLScn09eHp6Eh4ervUhQ0REBOnp6XTv3h0o/OtciHdGI4QQQgjxv2odb/enGFq0aKFZuHChRqPRaF68eKGxsLDQ7N27Vyk/cOCABtDs27dP2TZr1iwNoElOTla2DR06VOPu7q7RaDSaR48eafT19TVxcXFafQ0cOFDTu3dvrXbDwsK06kybNk3ToEED5XGlSpU0kyZNKvTxbNy4UWNubq48Dg4O1gCay5cvK9uWLl2qqVixYp5tXL16VQNoTp48qRXrq+dgx44dGkDz5MkTjUaj0Tg5OWmGDRum1c4HH3ygdSz9+/fXeHh45NnvrVu3NIDmzJkzWnGsXr1aqXPu3DkNoElKSlK2+fv7a7p165ZnuxqNRvPjjz9qGjZsqDweM2aMxtPTU6tOtWrVNAsWLMizjdfPbf369TV+fn651s0+Z+fPn9c0aNBA061bN82zZ8/yjbFDhw6ar776Ks/y7Dbv3bunWbFihaZcuXKa+/fvazQajcbExEQTHBxc6NiDg4M1JiYmOeq9eg6eP3+usbCw0ISGhirlvXv31vTo0UOj0RTudS7EuyYj3EIIIYQQ78iFCxc4evSoMm1WV1eXXr16ERQUlKPuq6PPFStWxNDQEFtbW61tt27dAiAxMZGnT5/i5uaGWq1WfkJDQ7WmTAM0bdo0z/hu3brFjRs38h25PXDgAG5ublSuXBkjIyP69evHnTt3SE9PV+oYGhpSo0YN5bGVlZUSa1G8eg6srKyUGAGSkpJwcnLSqv/649clJyfTp08fbG1tMTY2pnr16gA57qPPr1+Abdu2FWo6ed++fZXHffv2ZcuWLfmuIl7QuR09ejTffvstLVu2ZNq0aZw+fTpHG23btsXW1paNGzeip6enbM/MzMTf3x9HR0fMzc1Rq9Xs2bOn0GsIDBw4EAsLC+bMmVOs2AujdOnS9OjRg3Xr1gEvZyRs27YNT09PoGivcyHeFUm4hRBCCCHekcDAQDIyMqhcuTK6urro6uqyfPlytmzZwr1797Tqli5dWvm/SqXSepy9LXsqdPa/O3bsICEhQflJTEzMcX9rfitCGxgY5Bv/tWvX6NChA/Xq1WPz5s3Ex8ezdOlS4OW9trnFnh2rphirhb9+DoAc07+LonPnzty5c4dVq1Zx5MgRZTr18+fPC93vzZs3OXHiBB07dsyzn8TERI4cOcL48eOV5/nDDz/kyZMned43XZhzO2jQIK5cuYKXlxdnzpyhadOmWrcVAHTs2JGYmBgSExO1tgcEBLBgwQLGjx/P/v37SUhIwN3dPcex50VXV5dvv/2WRYsWcePGjSLHXlienp7s27ePW7duERYWhr6+Pu3btweK9joX4l2RrwUTQgghhHgHMjIyCA0NJSAggE8++USrrHv37qxbt05rcbKicHBwoEyZMqSmpuLi4lLsGI2MjLCxsSEyMpI2bdrkKD9+/DgZGRkEBARQqtTLcZyNGzcWu7+/w97ent9//51+/fop237//fc869+5c4ekpCRWrlxJ69atgZeriBdVeHg4Tk5OWFhY5FknMDAQZ2dnJenMtnbtWgIDAxk+fHiOfQp7bq2trRk2bBjDhg1j4sSJrFq1Sutr3WbPno1arebjjz8mKioKBwcHAGJiYvDw8FBG3bOysrh06RL29vaFPvYePXrw/fffM3369CLHrqenR2ZmZoF9tGjRAmtrazZs2MCuXbvo0aOHMlL/pl7nQpQkSbiFEEIIId6B7du3c+/ePQYOHIiJiYlW2WeffUZgYGCxE24jIyPGjRvH2LFjycrKolWrVvznP/8hLi4OtVpN//79C92Wn58fw4YNo0KFCrRv356HDx8SGxvLqFGjqFGjBhkZGfzwww907tyZ2NhYVqxYUayY/64xY8bQv39/mjZtSqtWrVi3bh3nzp3Tmnb/KjMzM8zNzfnxxx+xsrIiNTWVb775psj9hoeH4+HhkWf5ixcvWLt2LTNmzKBevXpaZYMGDWLu3LmcOnWKBg0aaJUV5tz6+vrSvn17atWqxb1799i/f3+uCfO8efPIzMzko48+Iioqijp16mBnZ8fmzZuJi4vDzMyM+fPnc/PmzSIl3PAyoXd3dy9y7DY2Njx69IjIyEgaNGiAoaFhrl8HplKp6NOnDytWrODixYscOHBAKXuTr3MhSook3EIIIYT439Wn6NOW35bAwEDatm2bI9mGlyPc3333HSdOnCh2+zNnzqRChQrMmjWLK1euYGpqSuPGjfnXv/5VpHb69+/P06dPWbBgAePGjcPCwoLPPvsMgIYNGzJ//nzmzJnDxIkTcXZ2ZtasWVqjzG9Lr169SE5OZsKECTx9+pTu3bszfPhwIiIicq1fqlQp1q9fz+jRo6lXrx61a9dm8eLFuLq6FrrP9PR0IiMjWbBgQZ51wsPDuXPnDl27ds1RVrNmTerXr09gYCCLFy/WKivMuc3MzMTHx4d///vfGBsb065duzxjWbBggVbSPWXKFK5evYq7uzuGhoYMGTKELl268ODBg0IfP8BHH33ERx99xJ49e4oUe4sWLRg2bBi9evXizp07TJs2TflqsNd5enry3XffUa1aNVq2bKlV9qZe50KUFJWmODfQCCGEEEII8Z7bsmULkydPznF/tBBCZJNF04QQQgghhCgGtVqd5yrdQggBMsIthBBCCCGEEEKUCBnhFkIIIYQQQgghSoAk3EIIIYQQQgghRAmQhFsIIYQQQgghhCgBknALIYQQQgghhBAlQBJuIYQQQgghhBCiBEjCLYQQQgghhBBClABJuIUQQgghhBBCiBIgCbcQQgghhBBCCFECJOEWQgghhBBCCCFKgCTcQgghhBBCCCFECZCEWwghhBBCCCGEKAGScAshhBBCCCGEECVAEm4hhBBCCCGEEKIESMIthBBCCCGEEEKUAEm4hRBCCCGEEEKIEvD/AN8UTyUhl66NAAAAAElFTkSuQmCC\n",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 4 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 0, 'Total Count of Participants')"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Drug')"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'myeloma Cancer: Race Distribution for Drugs')"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.axis.YTick at 0x7efe8767e7c0>,\n",
       " <matplotlib.axis.YTick at 0x7efe8767e160>,\n",
       " <matplotlib.axis.YTick at 0x7efe876776d0>,\n",
       " <matplotlib.axis.YTick at 0x7efe87663e50>]"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[Text(0, 0, 'bortezomib'),\n",
       " Text(0, 1, 'carfilzomib'),\n",
       " Text(0, 2, 'daratumumab'),\n",
       " Text(0, 3, 'lenalidomide')]"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x7efe875f45e0>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 7 artists>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 0, 'Total Count of Participants')"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Drug')"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'prostate Cancer: Race Distribution for Drugs')"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.axis.YTick at 0x7efe875c0820>,\n",
       " <matplotlib.axis.YTick at 0x7efe875c01c0>,\n",
       " <matplotlib.axis.YTick at 0x7efe875ba820>,\n",
       " <matplotlib.axis.YTick at 0x7efe857c5760>,\n",
       " <matplotlib.axis.YTick at 0x7efe857cb040>,\n",
       " <matplotlib.axis.YTick at 0x7efe857cb640>,\n",
       " <matplotlib.axis.YTick at 0x7efe857cbd90>]"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[Text(0, 0, 'bortezomib'),\n",
       " Text(0, 1, 'carfilzomib'),\n",
       " Text(0, 2, 'degarelix'),\n",
       " Text(0, 3, 'docetaxel'),\n",
       " Text(0, 4, 'enzalutamide'),\n",
       " Text(0, 5, 'lenalidomide'),\n",
       " Text(0, 6, 'radium_223')]"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x7efe857cbd60>"
      ]
     },
     "execution_count": 284,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Define the race group colors and order (excluding \"White/ White Heritage\")\n",
    "race_colors = ['#3b518b', '#21908c', '#5cc862', '#EE6A50', 'orange', '#430154', 'black', 'skyblue', 'green']\n",
    "race_order = ['Black/ Black Heritage', 'Hispanic/ Latino', 'Asian/ Asian Heritage',\n",
    "              'Unknown or Not Reported', 'American Indian/ Alaska Native', 'Middle Eastern',\n",
    "              'Hawaiian/ Other Pacific Islander', 'Other', 'Mixed']\n",
    "\n",
    "# Plot side-by-side horizontal bar charts for each cancer type\n",
    "cancer_types = race_cancer_groups['cancer'].unique()\n",
    "num_race_groups = len(race_order)\n",
    "bar_width = 0.08\n",
    "spacing = 0.02\n",
    "\n",
    "for cancer_type in cancer_types:\n",
    "    fig, ax = plt.subplots(figsize=(10, 6))\n",
    "    cancer_df = race_cancer_groups[race_cancer_groups['cancer'] == cancer_type]\n",
    "    drugs = cancer_df['drug']\n",
    "    \n",
    "    # Calculate the center position for each group of bars\n",
    "    center_positions = np.arange(len(drugs))\n",
    "    bar_positions = [\n",
    "        center_positions - ((num_race_groups - 1) / 2) * (bar_width + spacing) + i * (bar_width + spacing)\n",
    "        for i in range(num_race_groups)\n",
    "    ]\n",
    "    \n",
    "    # Plot the bars for each race group (excluding \"White/ White Heritage\")\n",
    "    for i, race_group in enumerate(race_order):\n",
    "        values = cancer_df[race_group]\n",
    "        ax.barh(bar_positions[i], values, height=bar_width, color=race_colors[i], label=race_group)\n",
    "    \n",
    "    ax.set_xlabel('Total Count of Participants')\n",
    "    ax.set_ylabel('Drug')\n",
    "    ax.set_title(f'{cancer_type} Cancer: Race Distribution for Drugs')\n",
    "    ax.set_yticks(center_positions)\n",
    "    ax.set_yticklabels(drugs)\n",
    "    \n",
    "    # Place the legend below the chart with 2 columns and 5 rows\n",
    "    ax.legend(loc='upper center', bbox_to_anchor=(0.5, -0.15), ncol=2, mode='expand', frameon=False)\n",
    "    \n",
    "    plt.tight_layout()\n",
    "    plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 285,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_268/3418553897.py:1: FutureWarning: The default value of numeric_only in DataFrameGroupBy.sum is deprecated. In a future version, numeric_only will default to False. Either specify numeric_only or select only columns which should be valid for the function.\n",
      "  black_year_cancer = race_columns_drugs.groupby(['cancer','year']).sum()\n"
     ]
    }
   ],
   "source": [
    "black_year_cancer = race_columns_drugs.groupby(['cancer','year']).sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 286,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>cancer</th>\n",
       "      <th>year</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th rowspan=\"5\" valign=\"top\">Other</th>\n",
       "      <th>2002</th>\n",
       "      <td>0.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>182.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2003</th>\n",
       "      <td>1.0</td>\n",
       "      <td>105.0</td>\n",
       "      <td>50.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>8.0</td>\n",
       "      <td>930.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2004</th>\n",
       "      <td>0.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>17.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>13.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>6.0</td>\n",
       "      <td>230.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2005</th>\n",
       "      <td>0.0</td>\n",
       "      <td>46.0</td>\n",
       "      <td>63.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>31.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>40.0</td>\n",
       "      <td>1088.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2006</th>\n",
       "      <td>2.0</td>\n",
       "      <td>38.0</td>\n",
       "      <td>36.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>42.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>75.0</td>\n",
       "      <td>7983.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "             American Indian/ Alaska Native  Asian/ Asian Heritage  \\\n",
       "cancer year                                                          \n",
       "Other  2002                             0.0                   10.0   \n",
       "       2003                             1.0                  105.0   \n",
       "       2004                             0.0                    3.0   \n",
       "       2005                             0.0                   46.0   \n",
       "       2006                             2.0                   38.0   \n",
       "\n",
       "             Black/ Black Heritage  Hawaiian/ Other Pacific Islander  \\\n",
       "cancer year                                                            \n",
       "Other  2002                    6.0                               0.0   \n",
       "       2003                   50.0                               0.0   \n",
       "       2004                   17.0                               0.0   \n",
       "       2005                   63.0                               0.0   \n",
       "       2006                   36.0                               4.0   \n",
       "\n",
       "             Hispanic/ Latino  Middle Eastern  Mixed  Other  \\\n",
       "cancer year                                                   \n",
       "Other  2002               0.0             0.0    0.0    0.0   \n",
       "       2003               1.0             0.0    0.0    0.0   \n",
       "       2004              13.0             0.0    0.0    0.0   \n",
       "       2005              31.0             0.0    0.0    0.0   \n",
       "       2006              42.0             0.0    0.0    0.0   \n",
       "\n",
       "             Unknown or Not Reported  White/ White Heritage  \n",
       "cancer year                                                  \n",
       "Other  2002                      2.0                  182.0  \n",
       "       2003                      8.0                  930.0  \n",
       "       2004                      6.0                  230.0  \n",
       "       2005                     40.0                 1088.0  \n",
       "       2006                     75.0                 7983.0  "
      ]
     },
     "execution_count": 286,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "black_year_cancer.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 287,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Calculate the total for each row\n",
    "black_year_cancer['total participants'] = black_year_cancer.sum(axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 288,
   "metadata": {},
   "outputs": [],
   "source": [
    "black_year_cancer.to_csv('/project/approved_drugs_charts_data/black_prostate_myeloma_count.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 289,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>cancer</th>\n",
       "      <th>year</th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Other</td>\n",
       "      <td>2002</td>\n",
       "      <td>0.00</td>\n",
       "      <td>5.00</td>\n",
       "      <td>3.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.00</td>\n",
       "      <td>91.00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Other</td>\n",
       "      <td>2003</td>\n",
       "      <td>0.09</td>\n",
       "      <td>9.59</td>\n",
       "      <td>4.57</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.09</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.73</td>\n",
       "      <td>84.93</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Other</td>\n",
       "      <td>2004</td>\n",
       "      <td>0.00</td>\n",
       "      <td>1.12</td>\n",
       "      <td>6.32</td>\n",
       "      <td>0.00</td>\n",
       "      <td>4.83</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.23</td>\n",
       "      <td>85.50</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Other</td>\n",
       "      <td>2005</td>\n",
       "      <td>0.00</td>\n",
       "      <td>3.63</td>\n",
       "      <td>4.97</td>\n",
       "      <td>0.00</td>\n",
       "      <td>2.44</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>3.15</td>\n",
       "      <td>85.80</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Other</td>\n",
       "      <td>2006</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.46</td>\n",
       "      <td>0.44</td>\n",
       "      <td>0.05</td>\n",
       "      <td>0.51</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.92</td>\n",
       "      <td>97.59</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  cancer  year  American Indian/ Alaska Native  Asian/ Asian Heritage  \\\n",
       "0  Other  2002                            0.00                   5.00   \n",
       "1  Other  2003                            0.09                   9.59   \n",
       "2  Other  2004                            0.00                   1.12   \n",
       "3  Other  2005                            0.00                   3.63   \n",
       "4  Other  2006                            0.02                   0.46   \n",
       "\n",
       "   Black/ Black Heritage  Hawaiian/ Other Pacific Islander  Hispanic/ Latino  \\\n",
       "0                   3.00                              0.00              0.00   \n",
       "1                   4.57                              0.00              0.09   \n",
       "2                   6.32                              0.00              4.83   \n",
       "3                   4.97                              0.00              2.44   \n",
       "4                   0.44                              0.05              0.51   \n",
       "\n",
       "   Middle Eastern  Mixed  Other  Unknown or Not Reported  \\\n",
       "0             0.0    0.0    0.0                     1.00   \n",
       "1             0.0    0.0    0.0                     0.73   \n",
       "2             0.0    0.0    0.0                     2.23   \n",
       "3             0.0    0.0    0.0                     3.15   \n",
       "4             0.0    0.0    0.0                     0.92   \n",
       "\n",
       "   White/ White Heritage  \n",
       "0                  91.00  \n",
       "1                  84.93  \n",
       "2                  85.50  \n",
       "3                  85.80  \n",
       "4                  97.59  "
      ]
     },
     "execution_count": 289,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Calculate the ratio for each race/ethnic group\n",
    "black_year_cancer_ratio = black_year_cancer.div(black_year_cancer['total participants'], axis=0)\n",
    "\n",
    "# Drop the 'total participants' column\n",
    "black_year_cancer_ratio.drop('total participants', axis=1, inplace=True)\n",
    "\n",
    "# Multiply each value by 100\n",
    "black_year_cancer_ratio = black_year_cancer_ratio.multiply(100)\n",
    "\n",
    "# Round the values to 2 decimal places\n",
    "black_year_cancer_ratio = black_year_cancer_ratio.round(2)\n",
    "\n",
    "black_year_cancer_ratio.reset_index(inplace=True)\n",
    "black_year_cancer_ratio.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 290,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.collections.PolyCollection at 0x7efe8574b850>"
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'Other: Black/ Black Heritage Ratio Over the Years')"
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Black/ Black Heritage Ratio')"
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "(2002.0, 2019.0)"
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.axis.XTick at 0x7efe85721340>,\n",
       " <matplotlib.axis.XTick at 0x7efe85721310>,\n",
       " <matplotlib.axis.XTick at 0x7efe85769130>,\n",
       " <matplotlib.axis.XTick at 0x7efe856e3190>,\n",
       " <matplotlib.axis.XTick at 0x7efe856e37f0>,\n",
       " <matplotlib.axis.XTick at 0x7efe856e40a0>,\n",
       " <matplotlib.axis.XTick at 0x7efe856e46d0>,\n",
       " <matplotlib.axis.XTick at 0x7efe856e4e20>,\n",
       " <matplotlib.axis.XTick at 0x7efe856e49a0>,\n",
       " <matplotlib.axis.XTick at 0x7efe856e38b0>,\n",
       " <matplotlib.axis.XTick at 0x7efe856ec640>,\n",
       " <matplotlib.axis.XTick at 0x7efe856ecd90>,\n",
       " <matplotlib.axis.XTick at 0x7efe856f2520>,\n",
       " <matplotlib.axis.XTick at 0x7efe856f2c70>,\n",
       " <matplotlib.axis.XTick at 0x7efe856f8400>,\n",
       " <matplotlib.axis.XTick at 0x7efe856f28e0>,\n",
       " <matplotlib.axis.XTick at 0x7efe856e31f0>,\n",
       " <matplotlib.axis.XTick at 0x7efe856f8160>,\n",
       " <matplotlib.axis.XTick at 0x7efe856ff0a0>]"
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAA1IAAAIOCAYAAACyHTw/AAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjUuMywgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy/NK7nSAAAACXBIWXMAAA9hAAAPYQGoP6dpAACBR0lEQVR4nO3dd3RU1frG8Se00CO9g6hYEUGxgBW8KiD23gt6xV4vV7z+xI4dO4oFVBQsgKIiXJAuHUInoaUR0nudZGb27w9uIiEhmUlm5pzJfD9rZS0yOZnzzDDJyTt773eHGWOMAAAAAAAea2B1AAAAAAAINhRSAAAAAOAlCikAAAAA8BKFFAAAAAB4iUIKAAAAALxEIQUAAAAAXqKQAgAAAAAvUUgBAAAAgJcopAAAAADASxRSgM2tWrVK1113nbp06aImTZqoc+fOuvbaa7Vy5cpKx65YsULPP/+8srOzK33tyCOP1MiRIwOQ2DtTpkxRWFhYhY8OHTroggsu0G+//Vbp+LCwMD3//PN+yxMWFqaHHnrI4+OvvvpqXXHFFYf9+uLFiys9vjZt2ujMM8/UV199Ven4I488UnfeeWdtonukLq+DCy64QH379q3ya+np6X75v4mNjVVYWJimTJlSflt1r3O7ef755yv83zdu3Fg9e/bUvffeq+Tk5FrdZ2FhoZ5//nktXry40tfKfp5iY2PrFvwQO3bs0J133qmePXuqSZMmat++vUaMGKE//vjDp+fxheqen7L/j/T0dL+df+TIkTriiCOUkJBQ6WuZmZnq0qWLzj77bLndbr9lABAYFFKAjX3wwQc6++yztW/fPr3xxhtasGCB3nrrLSUmJuqcc87Rhx9+WOH4FStW6IUXXgiKPzAPNXnyZK1cuVIrVqzQpEmT1LBhQ1122WX69ddfrY52WAUFBZo7d66uueaaGo999dVXtXLlSq1cuVLffPONevXqpTvvvFMffPBBAJIGry5dumjlypW69NJLy28Lxtf53LlztXLlSv3xxx+68cYb9eWXX+rCCy9UaWmp1/dVWFioF154ocpC4dJLL9XKlSvVpUsXH6Q+YObMmRowYIDWrFmj//u//9OCBQs0ceJESdKIESM0ZswYn53LF6p7fgLh888/V6NGjXTPPfdU+tpDDz2kvLw8ffXVV2rQgD/BgGDXyOoAAKr2119/6bHHHtOIESM0a9YsNWr094/rjTfeqKuuukqPPvqoBgwYoLPPPtvCpH9zuVxyOp0KDw/3+nv79u2rgQMHln8+bNgwtWnTRtOmTdNll13my5g+M2fOHDmdTo/y9enTR2eddVb55yNGjNDatWs1bdo0Pfzww/6MGZQOfi0d/LwFq9NOO03t27eXJP3jH/9Qenq6Jk+erOXLl2vIkCE+O0+HDh3UoUMHn93fnj17dNttt+nkk0/W4sWL1aJFi/KvXXfddbr//vv15ptv6tRTT9WNN97os/PWpLS0VGFhYRV+L9pF586d9fHHH+uGG27Qp59+qvvuu0+SNGvWLE2bNk0ff/yxjjnmGL/nqMvvYwCe4e0QwKbGjx+vsLAwTZw4sdIfC40aNdLHH3+ssLAwvfbaa5IOTFn517/+JUnq3bt3+VSiQ9+VnTt3rk499VQ1a9ZMxx9/vL788stK505OTtZ9992n7t27q0mTJurdu7deeOEFOZ3O8mPKply98cYbevnll9W7d2+Fh4dr0aJFPnn8TZs2VZMmTdS4ceNqj0tLS9MDDzygE088US1btlTHjh01dOhQLVu2rNKxDodDL774ok444QQ1bdpU7dq105AhQ7RixYrD3r8xRs8884waN26szz77rMLXZsyYoaFDh6pNmzZeP74GDRqoZcuWNT6+4uJiPfnkk+rfv78iIiLUtm1bDRo0SL/88kulY91utz744AP1799fzZo10xFHHKGzzjpLs2fPrvYcH3/8sRo1aqRx48Z5/ThqUtfX0qFT+2p6nX///fe6+OKL1aVLFzVr1kwnnHCCnn76aRUUFFTK9tlnn+nYY49VeHi4TjzxRH333Xe68847deSRR1Y4rqSkRC+//LKOP/54hYeHq0OHDrrrrruUlpZW6+el7E2DlJSU8ts8eS3HxsaWF0ovvPBC+eMvmw56uKl9X375pU455RQ1bdpUbdu21VVXXaUdO3bUmHPChAkqLCzUBx98UKGIKvP222/riCOO0CuvvCJJ2rRpk8LCwvTFF19UOvaPP/5QWFhYhdfjrl27dPPNN6tjx44KDw/XCSecoI8++qjC95VNj/3mm2/05JNPqlu3bgoPD9fu3bsrnaOm56dMSkqKbrrpJkVERKhTp066++67lZOTU+EYY4w+/vjj8p+nNm3a6Nprr9XevXtrfN6uv/563XjjjXrqqacUGxurjIwMjR49WhdddJHuv/9+SdK6det0+eWXq23btmratKkGDBigH374ocL9ePr7rbqfIbfbrZdfflnHHXdc+e+Ffv366b333qvxcQConv3eygEgl8ulRYsWaeDAgerevXuVx/To0UOnnXaaFi5cKJfLpXvuuUeZmZn64IMPNHPmzPKpPSeeeGL592zatElPPvmknn76aXXq1Emff/65Ro0apWOOOUbnnXeepAN/+J5xxhlq0KCBnnvuOR199NFauXKlXn75ZcXGxmry5MkVcrz//vs69thj9dZbb6l169bq06ePpANrjc4//3yPp9eUvXtqjFFKSorefPNNFRQU6Oabb672+zIzMyVJ48aNU+fOnZWfn69Zs2bpggsu0J9//qkLLrhAkuR0OjV8+HAtW7ZMjz32mIYOHSqn06lVq1YpPj5egwcPrnTfDodDd955p37//Xf9+uuvGjZsWPnXiouL9fvvv+udd97x6PG53e7y4iEjI0OTJ0/W1q1bNWnSpGq/z+FwKDMzU0899ZS6deumkpISLViwQFdffbUmT56s22+/vfzYO++8U1OnTtWoUaP04osvqkmTJtqwYcNh18sYY/Svf/1L77//vj7//HOP12YdXASVcblclW7z1WvpYDW9znft2qURI0boscceU4sWLRQVFaXXX39da9as0cKFC8vvZ9KkSbrvvvt0zTXXaMKECcrJydELL7wgh8NR4Xxut1tXXHGFli1bpjFjxmjw4MGKi4vTuHHjdMEFF2jdunVq1qyZR8/bwWJiYiRJxx57bPltnryWu3Tporlz52rYsGEaNWpU+fSx6kahxo8fr2eeeUY33XSTxo8fr4yMDD3//PMaNGiQ1q5dW+XzXGb+/Pnq1KnTYUcFmzdvrosvvlg//PCDkpOTdcopp2jAgAGaPHmyRo0aVeHYKVOmqGPHjhoxYoQkafv27Ro8eLB69uypt99+W507d9a8efP0yCOPKD09vVJhP3bsWA0aNEiffPKJGjRooI4dO1bK4+nzc8011+iGG27QqFGjtGXLFo0dO1aSKryxdN9992nKlCl65JFH9PrrryszM1MvvviiBg8erE2bNqlTp06Hfd4k6aOPPtKSJUt09913q0OHDiopKSm//0WLFmnYsGE688wz9cknnygiIkLTp0/XDTfcoMLCwvKfRU9/v5Wp6mfojTfe0PPPP69nn31W5513nkpLSxUVFRVUU2MB2zIAbCc5OdlIMjfeeGO1x91www1GkklJSTHGGPPmm28aSSYmJqbSsb169TJNmzY1cXFx5bcVFRWZtm3bmvvuu6/8tvvuu8+0bNmywnHGGPPWW28ZSWbbtm3GGGNiYmKMJHP00UebkpKSSudr2LChGTp0aI2PdfLkyUZSpY/w8HDz8ccfVzpekhk3btxh78/pdJrS0lJz4YUXmquuuqr89q+//tpIMp999lm1eSSZBx980GRkZJhzzjnHdOvWzWzcuLHScT///LNp2LChSU1Nrfb+Fi1aVOXja9CggfnPf/5T6fhevXqZO+64o8bHN2rUKDNgwIDy25cuXWokVXmfh97/pZdeagoLC80111xjIiIizIIFC6r9njLnn39+lY/l4I+D/2988Voq+9rkyZPLb6vudX4wt9ttSktLzZIlS4wks2nTJmOMMS6Xy3Tu3NmceeaZFY6Pi4szjRs3Nr169Sq/bdq0aUaSmTFjRoVj165dayRV+Ro92Lhx44wkk5ycbEpLS01WVpb54YcfTIsWLcxNN91U7fce7rWclpZ22J+Dsp+nsucmKyvLNGvWzIwYMaLCcfHx8SY8PNzcfPPN1WZo2rSpOeuss6o95t///reRZFavXm2MMeb99983kkx0dHT5MZmZmSY8PNw8+eST5bddcsklpnv37iYnJ6fC/T300EOmadOmJjMz0xjz98/QeeedV22OMtU9P2X/H2+88UaF2x944AHTtGlT43a7jTHGrFy50kgyb7/9doXjEhISTLNmzcyYMWM8yjJnzpzyn41vvvmm/Pbjjz/eDBgwwJSWllY4fuTIkaZLly7G5XJVeX+He01U9zM0cuRI079/f4/yAvAOU/uAIGaMkXRg9McT/fv3V8+ePcs/b9q0qY499ljFxcWV3/bbb79pyJAh6tq1q5xOZ/nH8OHDJUlLliypcJ+XX355ldPTnE6n/vzzT48fy9dff621a9dq7dq1+uOPP3THHXfowQcfrNRQoyqffPKJTj31VDVt2lSNGjVS48aN9eeff1aYuvTHH3+oadOmuvvuu2u8v5iYGA0aNEi5ublatWqVTjnllErHzJgxQ+eee67H61Fef/318sc3f/58jRkzRq+99lr5NLXq/Pjjjzr77LPVsmXL8sf3xRdfVHp8kvTggw/WeH8ZGRkaOnSo1qxZo+XLl+vCCy/06DFI0tFHH13+OA7+WLBgQaVjffVa8sbevXt18803q3PnzmrYsKEaN26s888/X5LKn6/o6GglJyfr+uuvr/C9PXv2rLTe8LffftMRRxyhyy67rMJj6N+/vzp37uzxiGvnzp3VuHFjtWnTRtdff71OO+20Krs2evJa9sbKlStVVFRUabSxR48eGjp0qFc/o4dz6O+hW265ReHh4RU6LU6bNk0Oh0N33XWXpAMjun/++aeuuuoqNW/evMJzO2LECBUXF2vVqlUVzuNJUxdPXX755RU+79evn4qLi5WamirpwP97WFiYbr311grZOnfurFNOOcXj//fhw4frrLPOUp8+fXTrrbdKknbv3q2oqCjdcsstklTpsSclJSk6Orr8Prx5TVT1M3TGGWdo06ZNeuCBBzRv3jzl5uZ6/DwBqB5T+wAbat++vZo3b14+/edwYmNj1bx5c7Vt29aj+23Xrl2l28LDw1VUVFT+eUpKin799dfD/kF7aNtgX3UHO+GEEyo1m4iLi9OYMWN066236ogjjqjy+9555x09+eSTGj16tF566SW1b99eDRs21P/93/9V+EMjLS1NXbt29ahT1po1a5Senq5XXnmlyqmVpaWl+vXXX/XSSy95/PiOOuqoCo/vH//4h7KysvT2229r1KhROv7446v8vpkzZ+r666/Xddddp3/961/q3LmzGjVqpIkTJ1aYhpSWlqaGDRuqc+fONWbZuXOnsrKydO+99x62nfnhNG3atMLjKFNVO+lAv5by8/N17rnnqmnTpnr55Zd17LHHqnnz5kpISNDVV19d/jrPyMiQpCqnZnXq1KnCz11KSoqys7PVpEkTjx7D4SxYsEARERHKzMzUpEmTNGPGDD388MP65JNPyo/x9LXsjbLHWtVz27VrV82fP7/a7+/Zs6dHv4ekA8WZJLVt21aXX365vv76a7300ktq2LChpkyZojPOOEMnnXRSeS6n06kPPvjgsJ0r/fW7Rqr8u7CsIUPZayQlJUXGmMNO3zvqqKM8Pld4eHiF10/ZurinnnpKTz31VJXfU/bYvX1NVPUcjR07Vi1atNDUqVP1ySefqGHDhjrvvPP0+uuvV/mzDMBzFFKADTVs2FBDhgzR3LlztW/fvir/mN+3b5/Wr1+v4cOHq2HDhj47d/v27dWvX7/yxeOH6tq1a4XPPR0Nq41+/fpp3rx52rlzp84444wqj5k6daouuOCC8nbMZfLy8ip83qFDBy1fvlxut7vGYuqGG25Q586d9Z///Edut1vPPvtsha8vWLBAOTk5uuqqq2rxqP7Wr18/GWO0efPmwxZSU6dOVe/evfX9999XeK4PXcvToUMHuVwuJScn1/gH56BBg3TdddeVr2GZOHGiX1oxB/q1tHDhQu3fv1+LFy8uH4WSVGktSNkf0Qc3eihz6N5O7du3V7t27TR37twqz9mqVSuPsp1yyinlXfsuuugiXXLJJZo0aZJGjRql008/XZLnr2VvlD3WpKSkSl/bv39/eabDueiii/TRRx9p1apVVa6TKiws1Pz589W3b98KRfxdd92lH3/8UfPnz1fPnj21du3aCo+rTZs2atiwoW677bbDjqL27t27wuf+/F1zqPbt2yssLEzLli2rsutdXTrhlT3nY8eO1dVXX13lMccdd5wk718TVT1HjRo10hNPPKEnnnhC2dnZWrBggZ555hldcsklSkhIUPPmzWv9WIBQRyEF2NTYsWP1xx9/6IEHHtCsWbMqFEsul0v333+/jDHli6Slyu+q1sbIkSM1Z84cHX300bXqRudLGzdulFT9QvqwsLBKf9Rs3rxZK1euLH+HXDowxWbatGmaMmWKR9P7nn32WbVq1UqPP/64CgoKNH78+PKvzZgxQ2eddZa6devm5SOqqOzxVbVovkxYWJiaNGlS4Q+k5OTkSl37hg8frvHjx2vixIl68cUXazz3HXfcoRYtWujmm29WQUGBvvrqK58W5JL/XkuHe52XPUeHvh4+/fTTCp8fd9xx6ty5s3744Qc98cQT5bfHx8drxYoVFQq8kSNHavr06XK5XDrzzDN9kj8sLEwfffSRTjzxRD377LOaN29e+e2evJa9+TkfNGiQmjVrpqlTp+q6664rv33fvn1auHChrr322mq///HHH9eXX36phx9+uFL7c+nAqEpWVlalP/QvvvhidevWTZMnT1bPnj3VtGlT3XTTTeVfb968uYYMGaLIyEj169fvsCN+teGr34OvvfaaEhMTK00BravjjjtOffr00aZNm/Tqq69We6ynrwlPHXHEEbr22muVmJioxx57TLGxsRUaEgHwDoUUYFNnn3223n33XT322GM655xz9NBDD6lnz56Kj4/XRx99pNWrV+vdd9+t0G3u5JNPliS99957uuOOO9S4cWMdd9xxHr9rLkkvvvii5s+fr8GDB+uRRx7Rcccdp+LiYsXGxmrOnDn65JNPDttJ8GCNGjXS+eef7/EajK1bt1boajdz5kzNnz9fV111VaV3pg82cuRIvfTSSxo3bpzOP/98RUdH68UXX1Tv3r0rdJe76aabNHnyZI0ePVrR0dEaMmSI3G63Vq9erRNOOKHKPXAeffRRtWzZUv/85z+Vn5+v999/X263W7/88ouefvppjx5XmV27dpWv+cjJydGCBQv0xRdfaODAgTr33HOrfXwzZ87UAw88oGuvvVYJCQl66aWX1KVLF+3atav8uHPPPVe33XabXn75ZaWkpGjkyJEKDw9XZGSkmjdvXuVeVddee62aN2+ua6+9VkVFRZo2bZpP/6D11WvpUId7nQ8ePFht2rTR6NGjNW7cODVu3FjffvutNm3aVOH7GzRooBdeeEH33Xefrr32Wt19993Kzs7WCy+8oC5dulQYnbvxxhv17bffasSIEXr00Ud1xhlnqHHjxtq3b58WLVqkK664olYjk3369NE///lPffzxx1q+fLnOOeccj1/LrVq1Uq9evfTLL7/owgsvVNu2bdW+fftKbdulA384/9///Z+eeeYZ3X777brpppuUkZGhF154QU2bNq2x5f3RRx+tb775RrfccotOP/10PfHEEzruuOOUkpKiL7/8Un/88Yeeeuop3XDDDRW+r2HDhrr99tv1zjvvqHXr1rr66qsVERFR4Zj33ntP55xzjs4991zdf//9OvLII5WXl6fdu3fr119/rdBl0RvePD+Hc/bZZ+uf//yn7rrrLq1bt07nnXeeWrRooaSkJC1fvlwnn3xyeRvz2vj00081fPhwXXLJJbrzzjvVrVs3ZWZmaseOHdqwYYN+/PFHSZ7/fqvOZZddVr5PX4cOHRQXF6d3331XvXr1qrZjIwAPWNrqAkCNVq5caa699lrTqVMn06hRI9OxY0dz9dVXmxUrVlR5/NixY03Xrl1NgwYNjCSzaNEiY8zf3doOdf7555vzzz+/wm1paWnmkUceMb179zaNGzc2bdu2Naeddpr5z3/+Y/Lz840xf3eJevPNN6vMIanS/Valqq59ERERpn///uadd94xxcXFle734G5cDofDPPXUU6Zbt26madOm5tRTTzU///yzueOOOyp0XzPmQJfC5557zvTp08c0adLEtGvXzgwdOrTCc6n/de072LRp00yjRo3MXXfdZRYsWGAkmb1799b42IypumtfixYtzIknnmjGjRtXqWNZVV37XnvtNXPkkUea8PBwc8IJJ5jPPvusvPvYwVwul5kwYYLp27evadKkiYmIiDCDBg0yv/76a4X7P/R1sGjRItOyZUszbNgwU1hYeNjHcv7555uTTjqpyq8drlNaXV9LVXXtM+bwr/MVK1aYQYMGmebNm5sOHTqYe+65x2zYsKHK+5g0aZI55phjTJMmTcyxxx5rvvzyS3PFFVdU6IZojDGlpaXmrbfeMqeccopp2rSpadmypTn++OPNfffdZ3bt2nXY58uYv7vEpaWlVfpaSkqKadmypRkyZIgxxrvX8oIFC8yAAQNMeHi4kVT+mjm0a1+Zzz//3PTr16/8dXHFFVeUd030xLZt28wdd9xhunfvXv7/OGzYMPP7778f9nt27txZ/pqfP39+lcfExMSYu+++23Tr1s00btzYdOjQwQwePNi8/PLL5ceU/Qz9+OOPHuc93PNzuP+Pwz1vX375pTnzzDNNixYtTLNmzczRRx9tbr/9drNu3TqPsxzu52bTpk3m+uuvNx07djSNGzc2nTt3NkOHDjWffPJJ+TGeviaq+xl6++23zeDBg0379u1NkyZNTM+ePc2oUaNMbGysx48BQNXCjPlfux0AQI0eeOABrV69WuvXr7c6CnwsOztbxx57rK688soa9/cCAIBCCgAQcpKTk/XKK69oyJAhateuneLi4jRhwgRFRUVp3bp15d3lAAA4HNZIAQBCTnh4uGJjY/XAAw8oMzNTzZs311lnnaVPPvmEIgoA4BFGpAAAAADAS77fOAQAAAAA6jkKKQAAAADwEoUUAAAAAHgpqJtNuN1u7d+/X61atSrf0R4AAABA6DHGKC8vT127dq2wubq/BHUhtX//fvXo0cPqGAAAAABsIiEhQd27d/f7eYK6kGrVqpWkA09W69atLU4DAAAAwCq5ubnq0aNHeY3gb0FdSJVN52vdujWFFAAAAICALfmh2QQAAAAAeIlCCgAAAAC8RCEFAAAAAF6ikAIAAAAAL1FIAQAAAICXKKQAAAAAwEsUUgAAAADgJQopAAAAAPAShRQAAAAAeIlCCgAAAAC8RCEFAAAAAF6ikAIAAAAAL1FIAQAAAICXKKQAAAAAwEsUUgAAAADgJQopAAAAAPAShRQAAAAAeIlCCgAAAAC8RCGFoLc+LsvqCAAAAAgxFFIIarHpBXr4uw0qcbqtjgIAAIAQQiGFoDZzwz7tzynWrMh9VkcBAABACKGQQtByu41mRiZKkiYu3iOni1EpAAAABAaFFILWmthM7csqkiTFZhTq9y1JFicCAABAqKCQQtCasb7idL6PF+2R220sSgMAAIBQQiGFoFRY4tScQ0agolPy9GdUqkWJAAAAEEoopBCU/rstRQUlrkq3f7hot4xhVAoAAAD+RSGFoDRjQ9Vd+jYlZOuv3RkBTgMAAIBQQyGFoJOUU6Tlu9MP+/UPF+0KYBoAAACEIgopBJ1ZkYmqbvbeqr2ZWh+XGbhAAAAACDkUUggqxphK3fqq8uHC3QFIAwAAgFBFIYWgsnlfjvakFdR43KLoNG1NzAlAIgAAAIQiCikElcM1majKxMV7/JgEAAAAoYxCCkHD4XRp9qb9Hh8/Z2uSdqfm+zERAAAAQhWFFILGoqhUZReWeny8MYxKAQAAwD8opBA0ZmxI9Pp7ft6YqITMQj+kAQAAQCizvJBKTEzUrbfeqnbt2ql58+bq37+/1q9fb3Us2ExGvkOLolK9/j6X2+jTpYxKAQAAwLcsLaSysrJ09tlnq3Hjxvrjjz+0fft2vf322zriiCOsjAUbmr1pv5zuajaPqsYP6/YpNbfYx4kAAAAQyhpZefLXX39dPXr00OTJk8tvO/LII60LBNvyplvfoUqcbn22bK/+c+mJPkwEAACAUGbpiNTs2bM1cOBAXXfdderYsaMGDBigzz77zMpIsKHo5DxtTcyt0318uzpeWQUlPkoEAACAUGdpIbV3715NnDhRffr00bx58zR69Gg98sgj+vrrr6s83uFwKDc3t8IH6r+ZdRiNKlNY4tLkFbF1DwMAAADI4kLK7Xbr1FNP1auvvqoBAwbovvvu07333quJEydWefz48eMVERFR/tGjR48AJ0agOV1uzYr0vltfVab8FaO8Ys/bpwMAAACHY2kh1aVLF514YsV1KyeccILi4+OrPH7s2LHKyckp/0hISAhETFho+e50peY5fHJfucVOTV1V9WsLAAAA8IalhdTZZ5+t6OjoCrft3LlTvXr1qvL48PBwtW7dusIH6rfa7B1VnS+W71Vxqcun9wkAAIDQY2kh9fjjj2vVqlV69dVXtXv3bn333XeaNGmSHnzwQStjwSZyi0v1323JPr3P9PwSTV/DqBQAAADqxtJC6vTTT9esWbM0bdo09e3bVy+99JLeffdd3XLLLVbGgk3M2Zwkh9Pt8/v9dOlelfjhfgEAABA6LN1HSpJGjhypkSNHWh0DNlSXvaOqk5RTrJ8jE3X96TQrAQAAQO1YOiIFHE5cRoHWxmb57f4nLtkjl9v47f4BAABQv1FIwZZm+rjJxKFi0gv0+5Ykv54DAAAA9ReFFGzH7TaaGemfaX0H+3jRbrkZlQIAAEAtUEjBdtbGZiohs8jv54lKztOfUal+Pw8AAADqHwop2I6/mkxU5cNFu2UMo1IAAADwDoUUbKWoxKU5W3y7d1R1NiVk66/dGQE7HwAAAOoHCinYyn+3Jyvf4QzoOT9atDug5wMAAEDwo5CCrfy0PnDT+sqs3Juh9XH+a7UOAACA+odCCraRnFOsv3anW3JuRqUAAADgDQop2MasyERZ1Y18YVSqtu3PsebkAAAACDoUUrAFY4xmBrBbX1U+XrTH0vMDAAAgeFBIwRa2JOZoV2q+pRnmbE3SboszAAAAIDhQSMEWZljQZOJQxkgTFzMqBQAAgJpRSMFyJU63Zm/ab3UMSdLPGxOVkFlodQwAAADYHIUULLcwKlVZhaVWx5AkudxGk5butToGAAAAbI5CCpazusnEob5fl6DU3GKrYwAAAMDGKKRgqcyCEi2KTrU6RgUlTrc+Xx5jdQwAAADYGIUULDV7Y6JKXRZtHlWNqavilFVQYnUMAAAA2BSFFCw1Y0Oi1RGqVFji0uQVsVbHAAAAgE1RSMEyO1PytCUxx+oYhzXlrxjlFdujCQYAAADshUIKlplhsyYTh8otdurb1fFWxwAAAIANUUjBEi630c+R9pzWd7DPl8WouNRldQwAAADYDIUULLF8d7pSch1Wx6hRer5D369NsDoGAAAAbIZCCpaw295R1fl0yR6VON1WxwAAAICNUEgh4PKKSzVvW7LVMTy2P6c4KKYhAgAAIHAopBBwc7Ykqbg0uEZ4Ji7ZI5fbfvtdAQAAwBoUUgi4GeuDb3QnJr1Av29JsjoGAAAAbIJCCgEVn1GoNbGZVseolY8X7ZYxjEoBAACAQgoBNjMyeJpMHCoqOU9/7ki1OgYAAABsgEIKAWOM0cwNwTet72AfMioFAAAAUUghgNbGZik+s9DqGHWyMSFbK/ZkWB0DAAAAFqOQQsDMWB+80/oO9uHC3VZHAAAAgMUopBAQxaWuetP1buXeDK2Py7I6BgAAACxEIYWAmLctWfkOp9UxfObjRYxKAQAAhDIKKQTEjCBvMnGoP6NStX1/rtUxAAAAYBEKKfhdSm6xlu9KszqGz320mFEpAACAUEUhBb+bFZkodz3sGD5nS5L2pOVbHQMAAAAWoJCCXxlj6k23vkMZI01cvMfqGAAAALAAhRT8amtirnal1t9Rm58jE7UvK7j3xgIAAID3KKTgVzM21M/RqDJOt9GnS/ZaHQMAAAABRiEFvylxuvXLxvrVra8q369LUGpesdUxAAAAEEAUUvCbxdGpyiostTqG35U43fpiWYzVMQAAABBAFFLwm/o+re9gU1fFKbuwxOoYIcvpclsdAQAAhBgKKfhFVkGJFkalWh0jYApKXJr8V6zVMULW+rgsqyMAAIAQQyEFv5i9ab9KXfVw86hqTFkRq3yH0+oYIWnethSrIwAAgBBDIQW/CKVpfWVyiko1dVWc1TFC0p9RKUzvAwAAAUUhBZ/blZKnzftyrI5hic+Xxai41GV1jJBSXOpSXEahYtILrI4CAABCCIUUfG7Ghvrf8vxw0vMd+mFdgtUxQkrZhsg7kvMsTgIAAEIJhRR8yuU2mhUZetP6Dvbpkr0qZZpZwMRlHCikopJyLU4CAABCCYUUfOqv3elKyXVYHcNSidlFmhUZuqNygRaf+b9CihEpAAAQQBRS8KmZIdhkoioTF++Ryx1aXQutUl5IMSIFAAACiEIKPpNXXKq525KtjmELMekFmrMlyeoYISH+f1P79ucUK6ew1OI0AAAgVFBIwWf+2JKs4lLWBpX5aNFuGcOolL+VjUhJUlQyo1IAACAwKKTgMz8xra+CqOQ8/bkj1eoY9ZrbbQ4ppFgnBQAAAoNCCj6RkFmoNTGZVsewnQ8ZlfKrtHyHHM6/R0EZkQIAAIFCIQWfmBnCe0dVZ2NCtlbuybA6Rr118GiUJO1IYkQKAAAEhqWF1PPPP6+wsLAKH507d7YyEmrBGKOZIb53VHU+XLTb6gj1VtkeUmWik/PkplsiAAAIAMtHpE466SQlJSWVf2zZssXqSPDSurisSn/Q4m8r9mRoQ3yW1THqpUNHpIpKXZVuAwAA8AfLC6lGjRqpc+fO5R8dOnSwOhK8NGM9o1E1+Wgho1L+EJ9RUOk21kkBAIBAsLyQ2rVrl7p27arevXvrxhtv1N69ew97rMPhUG5uboUPWKu41KXfN7NfUk3+jErV9v28Xn2tqtGn7ayTAgAAAWBpIXXmmWfq66+/1rx58/TZZ58pOTlZgwcPVkZG1Yvzx48fr4iIiPKPHj16BDgxDvXf7SnKczitjhEUPlrMqJSvxWcWVbotKomCFQAA+J+lhdTw4cN1zTXX6OSTT9Y//vEP/f7775Kkr776qsrjx44dq5ycnPKPhISEQMZFFZjW57k5W5K0Jy3f6hj1RoHDqfR8R6Xb2UsKAAAEQiOrAxysRYsWOvnkk7Vr164qvx4eHq7w8PAAp8LhpOQWa9muNKtjBA1jpEVRqTq6Q0uro9QLCVlVN5WIzyxUvsOpluG2+vUGAADqGcvXSB3M4XBox44d6tKli9VR4IFfNiaKTtPeiUmv3BwBtVNdp8hoRqUAAICfWVpIPfXUU1qyZIliYmK0evVqXXvttcrNzdUdd9xhZSx4wBijGevZhNdbsVV0mUPtJFTT5pzOfQAAwN8snfuyb98+3XTTTUpPT1eHDh101llnadWqVerVq5eVseCBbftzFZ3Cu/7eik1njyNfqW6/qCg69wEAAD+ztJCaPn26ladHHfxEk4la2Z9TpOJSl5o2bmh1lKBX3dQ+RqQAAIC/2WqNFIJDidOt2Zv2Wx0jKBkj7TtMkwR4p9qpfUl5MoYFfAAAwH8opOC1JTvTlFlQYnWMoBXD9L46c7nNYbv2SVKew6nE7Mp7TAEAAPgKhRS8xt5RdRNL5746S84tVqmr+hEn1kkBAAB/opCCV7IKSvRnVIrVMYIanfvqLs6D55B1UgAAwJ8opOCVXzfvr3EkANWjkKq76tZHldnBXlIAAMCPKKTglRkb2DuqrmiBXnfVtT4vsyOJESkAAOA/FFLw2O7UfG1KyLY6RtAra4GO2quu9XmZ2PQCFZXwPAMAAP+gkILHZmygyYQvGOPZ1DQcnifPn9tIu1KZ3gcAAPyDQgoecbmNZjGtz2diPRhRweHFeViI0rkPAAD4C4UUPLJiT7qSc4utjlFv0AK99nKKSpVdWOrRsTvo3AcAAPyEQgoemclolE/F0Lmv1ryZFsmIFAAA8BcKKdQo3+HU3K3JVseoVzzZBwlV86RjX5mo5FwZQ7t+AADgexRSqNGcLUkqosucT9ECvfa8KaSyCkuVmufwYxoAABCqKKRQoxnr6dbna7RArz1PWp8fjP2kAACAP1BIoVoJmYVaHZNpdYx6hxboteft8xaVzDopAADgexRSqNasSJpM+EsMnftqxZupfZIUxYgUAADwAwopHJYxRjPZhNdvvJ2iBqnU5VZidpFX38OIFAAA8AcKKRzW+rgsNo71I1qgey8pu1gut3dd+Han5qvE6fZTIgAAEKoopHBYMxiN8itaoHsvLtP758zpNtqdmu+HNAAAIJRRSKFKxaUu/bY5yeoY9Rot0L3n7fqoMlHJrJMCAAC+RSGFKs3fnqK8YqfVMeo1WqB7r/aFFOukAACAb1FIoUo/sXeU39EC3XvxtVyzx15SAADA1xrV5puys7P1xRdfaMeOHQoLC9MJJ5ygUaNGKSIiwtf5YIGEzEIt3ZVmdYyQEJNeoD6dWlkdI2gwIgUAAOzC6xGpdevW6eijj9aECROUmZmp9PR0TZgwQUcffbQ2bNjgj4wIsG9Xx8t41xgNtRRLwwmPGWNqPSKVludQer7Dx4kAAEAo83pE6vHHH9fll1+uzz77TI0aHfh2p9Ope+65R4899piWLl3q85AIHIfTpR/WJVgdI2TQXt5z2YWlynPUft1edHKe2h8T7sNEAAAglNVqROrf//53eRElSY0aNdKYMWO0bt06n4ZD4P2xJVmZBSVWxwgZsemMSHkqro7ryVgnBQAAfMnrQqp169aKj4+vdHtCQoJatWKtR7D7ZlWc1RFCShwjUh6r7fqoMqyTAgAAvuR1IXXDDTdo1KhR+v7775WQkKB9+/Zp+vTpuueee3TTTTf5IyMCZPv+XK2Py7I6RkihBbrn6trhkL2kAACAL3m9Ruqtt95SWFiYbr/9djmdB9YrNG7cWPfff79ee+01nwdE4ExdzWhUoBlzYKTlWDr31Siujo05dqbky+lyq1FDdn0AAAB153Uh1aRJE7333nsaP3689uzZI2OMjjnmGDVv3twf+RAgucWl+jky0eoYISk2vYBCygN1ndpX4nQrNqNAx3TkuQYAAHVXq32kJKl58+Y6+eSTfZkFFpq1IVGFJUwxswIt0D1T29bnB9uRlEchBQAAfMKjQurqq6/WlClT1Lp1a1199dXVHjtz5kyfBEPgGGM0lSYTlqEFes0cTpeScovrfD87knJ12SldfZAIAACEOo8KqYiICIWFhUk60LWv7N+oH1bHZGpXar7VMUIWLdBrlphV5JNNouncBwAAfMWjQmry5Mnl/54yZYq/ssAitDy3FoVUzeq6h1SZKPaSAgAAPuJ1+6qhQ4cqOzu70u25ubkaOnSoLzIhgFLzijVva7LVMULa/pxiWqDXoK6tz8vszylWTmGpT+4LAACENq8LqcWLF6ukpKTS7cXFxVq2bJlPQiFwvl+TIKfbB3OmUCd17UhX3/ly42L2kwIAAL7gcde+zZs3l/97+/btSk7+exTD5XJp7ty56tatm2/Twa+cLre+WxNvdQxIiqEFerV8WWhGJefpzKPa+ez+AABAaPK4kOrfv7/CwsIUFhZW5RS+Zs2a6YMPPvBpOPjXwqhUJeXUvRMa6q6um83Wd76a2icxIgUAAHzD40IqJiZGxhgdddRRWrNmjTp06FD+tSZNmqhjx45q2LChX0LCP2gyYR8x6UztOxxjjE9HpHYk0bkPAADUnceFVK9evSRJbrfbb2EQODHpBVq2K93qGPgfRqQOLz2/xKebRUcn58ntNmrQgG0cAABA7XlcSB1q+/btio+Pr9R44vLLL69zKPjfd6sZjbITWqAfXnymb5+bolKX4jMLdWT7Fj69XwAAEFq8LqT27t2rq666Slu2bFFYWJjM/3bJLNuk1+WijbPdFZe69MO6fVbHwEHKWqA3bcz02EP5o6NhVHIuhRQAAKgTr9ufP/roo+rdu7dSUlLUvHlzbdu2TUuXLtXAgQO1ePFiP0SEr/22OUk5ReylYze0QK9afEaRz++TdVIAAKCuvC6kVq5cqRdffFEdOnRQgwYN1KBBA51zzjkaP368HnnkEX9khI/RZMKeYpjeV6U4H0/tk+jcBwAA6s7rQsrlcqlly5aSpPbt22v//v2SDjSjiI6O9m06+NyWfTnalJBtdQxUgYYTVfNl6/MyUcmMSAEAgLrxeo1U3759tXnzZh111FE688wz9cYbb6hJkyaaNGmSjjrqKH9khA9NZTTKtmiBXrW4DN8/L3EZhcp3ONUyvNb9dgAAQIjzekTq2WefLW+B/vLLLysuLk7nnnuu5syZo/fee8/nAeE7OYWl+mVTotUxcBh07qusqMSl1DyHX+47mlEpAABQB16/HXvJJZeU//uoo47S9u3blZmZqTZt2pR37oM9/bRhn4pL2QfMrpjaV1lClv9G6aKSc3VarzZ+u38AAFC/eT0iVZW2bdsqOTlZDz30kC/uDn5gjNG3TOuztbIW6PhbvB+m9ZWJonMfAACoA68Kqe3bt+ujjz7SpEmTlJ2dLUlKT0/X448/rqOOOkoLFy70R0b4wIo9GdrL1DHbowV6Rf58PujcBwAA6sLjQuq3337TgAED9PDDD2v06NEaOHCgFi1apBNOOEEbN27Ujz/+qO3bt/szK+rgm5WMRgUDWqBX5NdCKimvfENxAAAAb3lcSL3yyisaPXq0cnNz9dZbb2nv3r0aPXq0ZsyYoUWLFmnkyJH+zIk6SM4p1vwdKVbHgAdoOFGRPwupPIdTidm+3+wXAACEBo8LqR07dujBBx9Uy5Yt9cgjj6hBgwZ69913dd555/kzH3xg2pp4udy88x4MYv24JigY+bsBB+ukAABAbXlcSOXm5uqII46QJDVq1EjNmjXTscce669c8JFSl1vT1sRbHQMeYkTqb263UUKWf0eMWCcFAABqy6v259u3b1dycrKkA13goqOjVVBQ8Q+/fv36+S4d6mzB9hS/7cMD34ulBXq51DyHSpz+bde/g72kAABALXlVSF144YUVFmeXrYsKCwuTMUZhYWFyuWrXvnn8+PF65pln9Oijj+rdd9+t1X2gsm9oeR5Ukv7XAr1p44ZWR7FcIPbVikpiRAoAANSOx4VUTEyM30KsXbtWkyZNYjTLx3an5mvFngyrY8BLcRmFOq5zK6tjWC4QreBj0gsoXAEAQK14XEj16tXLLwHy8/N1yy236LPPPtPLL7/sl3OEqm9XMxoVjGIzCiikFJhCym2kXSn5Orl7hN/PBQAA6hevNuT1hwcffFCXXnqp/vGPf9R4rMPhUG5uboUPVK2wxKmf1u+zOgZqgYYTBwRqc+IdTO8DAAC14NUaKV+bPn26NmzYoLVr13p0/Pjx4/XCCy/4OVX9MHvjfuUVO62OgVqg4cQBASuk6NwHAABqwbIRqYSEBD366KOaOnWqmjZt6tH3jB07Vjk5OeUfCQkJfk4ZnIwxNJkIYrHp7CUlSfEB2lOLvaQAAEBtWDYitX79eqWmpuq0004rv83lcmnp0qX68MMP5XA41LBhxQXg4eHhCg8PD3TUoLMxIVvb9vMue7BiRErKdziVUVASkHNFJeeWdx0FAADwVK0KKafTqcWLF2vPnj26+eab1apVK+3fv1+tW7dWy5YtPbqPCy+8UFu2bKlw21133aXjjz9e//73vysVUfDc1FVswBvMaIEeuNEoScoqLFVqnkOdWns2Mg4AACDVopCKi4vTsGHDFB8fL4fDoYsuukitWrXSG2+8oeLiYn3yySce3U+rVq3Ut2/fCre1aNFC7dq1q3Q7PJdVUKJfN++3OgbqKNRboAdqfVSZHUm5FFIAAMArXq+RevTRRzVw4EBlZWWpWbNm5bdfddVV+vPPP30aDt77cX2CSpxuq2OgjmJCvHNffGZgH39UMuukAACAd7wekVq+fLn++usvNWnSpMLtvXr1UmJiYp3CLF68uE7fH+rcbqNvVzOtrz6IC/F1UoEekYqiBToAAPCS1yNSbrdbLper0u379u1Tq1ahOxXJDpbtTldcANeWwH9CveFEfGZRQM/HiBQAAPCW14XURRddpHfffbf887CwMOXn52vcuHEaMWKEL7PBS9+spOV5fRHqLdDjA1xI7k7NZ0osAADwitdT+yZMmKAhQ4boxBNPVHFxsW6++Wbt2rVL7du317Rp0/yRER5IzC7SwqgUq2PAR0J5RMrlNtqXFdgRKafbaE9avk7o0jqg5wUAAMHL60Kqa9eu2rhxo6ZNm6YNGzbI7XZr1KhRuuWWWyo0n0BgTVsdL7exOgV8JSmnWEUlLjVrEnot0PdnF8lpwYs5KjmXQgoAAHisVvtINWvWTHfffbfuvvtuX+dBLZQ43Zq+liYT9U18Zmi2QE8IcKOJMlFJedIAS04NAACCkNeF1OzZs6u8PSwsTE2bNtUxxxyj3r171zkYPDdvW7LS80usjgEfi0kvCMlCKtAd+8psp3MfAADwgteF1JVXXqmwsDAZU3HqTdltYWFhOuecc/Tzzz+rTZs2PguKw/tmFU0m6qNQXScVZ9WIFJ37AACAF7zu2jd//nydfvrpmj9/vnJycpSTk6P58+frjDPO0G+//aalS5cqIyNDTz31lD/y4hDRyXlaE5NpdQz4QajuJWXViFRankPp+Q5Lzg0AAIKP1yNSjz76qCZNmqTBgweX33bhhReqadOm+uc//6lt27bp3XffZf1UgHy7mtGo+iomPUQLKQv3QotOzlP7Y8ItOz8AAAgeXo9I7dmzR61bV+5s1bp1a+3du1eS1KdPH6Wnp9c9HaqV73Bq5oZEq2PAT0J1c2WrRqQkaQfrpAAAgIe8LqROO+00/etf/1JaWlr5bWlpaRozZoxOP/10SdKuXbvUvXt336VElX6OTFS+w2l1DPhJWQv0UJJTWKqcolLLzs86KQAA4CmvC6kvvvhCMTEx6t69u4455hj16dNH3bt3V2xsrD7//HNJUn5+vv7v//7P52HxN2OMptJkot6Lywyt6X1WjkZJB/aSAgAA8ITXa6SOO+447dixQ/PmzdPOnTtljNHxxx+viy66SA0aHKjLrrzySl/nxCHWx2Xx7nkIiE0v1PGdQ2eTWKsLqZ0p+XK63GrU0Ov3mAAAQIip1Ya8YWFhGjZsmIYNG+brPPAQo1GhIdRaoFs9AlfidCs2o0DHdAy9/bsAAIB3alVIFRQUaMmSJYqPj1dJScWNYB955BGfBMPhpec7NGdLstUxEACh1gI9weIRKUnakZRHIQUAAGrkdSEVGRmpESNGqLCwUAUFBWrbtq3S09PVvHlzdezYkUIqAH5Yl6ASl9vqGAiAUGuBbvXUPunAOqnLTulqdQwAAGBzXi8EePzxx3XZZZcpMzNTzZo106pVqxQXF6fTTjtNb731lj8y4iAut9F3q+OtjoEAiU23vrAIJDu0fI9KYu0hAAComdeF1MaNG/Xkk0+qYcOGatiwoRwOh3r06KE33nhDzzzzjD8y4iBLdqZqX1aR1TEQIMm5odMCvdTl1v5s61/bNHEBAACe8LqQaty4scLCwiRJnTp1Unz8gdGRiIiI8n/Df75ZSZOJUGN1A4ZAScwqkttYnUJKzC6ydC8rAAAQHLwupAYMGKB169ZJkoYMGaLnnntO3377rR577DGdfPLJPg+IvyVkFmrxzrSaD0S9EirT++ywPqpMVBL7SQEAgOp5XUi9+uqr6tKliyTppZdeUrt27XT//fcrNTVVn376qc8D4m/fro6XscE79gisUGmBHmenQorpfQAAoAZed+0bOHBg+b87dOigOXPm+DQQquZwuvTDugSrY8ACsSHSuc8Orc/LRCUzIgUAAKrn9YjU0KFDlZ2dXen23NxcDR061BeZUIU/tiQrs6Ck5gNR74TKiFS8DTr2ldlB5z4AAFADrwupxYsXV9qEV5KKi4u1bNkyn4RCZd+soslEqAqVNVJ2mtoXnZwntx06XwAAANvyeGrf5s2by/+9fft2JScnl3/ucrk0d+5cdevWzbfpIEnavj9X6+OyrI4Bi5S1QG/WpKHVUfzGGGOrqX1FpS7FZxbqyPYtrI4CAABsyuNCqn///goLC1NYWFiVU/iaNWumDz74wKfhcMDU1YxGhbq4zAId37m11TH8JrOgRPkOp9UxKohKzqWQAgAAh+VxIRUTEyNjjI466iitWbNGHTp0KP9akyZN1LFjRzVsWH/fMbdKbnGpfo5MtDoGLBabXr8LKTu1Pi+zIylPw/p2sToGAACwKY8LqV69ekmS3G6338KgslkbElVY4rI6BiwWa6NGDP5gx0KKzn0AAKA6HhVSs2fP1vDhw9W4cWPNnj272mMvv/xynwTDgXUjU2kyAdX/Fuh26thXhr2kAABAdTwqpK688kolJyerY8eOuvLKKw97XFhYmFwuRk98ZXVMpnal5lsdAzYQU98LKRuOSMVlFKrA4VSLcK+32wMAACHAo78QDp7Ox9S+wKHlOcrE2XDExpfs1Pr8YNEpeTq1ZxurYwAAABvyah+p0tJSDRkyRDt37vRXHvxPal6x5m1NrvlAhISyFuj1lZ1anx8sio15AQDAYXhVSDVu3Fhbt25VWFiYv/Lgf75fkyAnG4LiIHGZ9XN6X3GpS8m5xVbHqNKOJBpOAACAqnlVSEnS7bffri+++MIfWfA/Tpdb09bEWx0DNlNfG07syyqSsel7BnTuAwAAh+P1KuqSkhJ9/vnnmj9/vgYOHKgWLSpuWPnOO+/4LFyoWhiVqv059nyHHtaJSbfn9Le6suu0PunA1D5jDKPwAACgEq8Lqa1bt+rUU0+VpEprpfhjwzdoMoGqxGXUzxEpOz+uPIdTidlF6t6mudVRAACAzXhdSC1atMgfOfA/sekFWrYr3eoYsKH62gI9PrPI6gjVikrKo5ACAACVeL1Gqszu3bs1b948FRUd+CPI2HWRQ5D5djWjUaharI1HburCjntIHYx1UgAAoCpeF1IZGRm68MILdeyxx2rEiBFKSkqSJN1zzz168sknfR4wlBSXuvTDun1Wx4BNpeQ6VFjitDqGz8XbvBvhjmRaoAMAgMq8LqQef/xxNW7cWPHx8Wre/O/pLjfccIPmzp3r03Ch5rfNScopKrU6Bmysvm3Ma4yx/4gULdABAEAVvF4j9d///lfz5s1T9+7dK9zep08fxcUxLa0uaDKBmsRlFOiELq2tjuEzaXkOFZe6rY5RrZj0AhWXutS0cUOrowAAABvxekSqoKCgwkhUmfT0dIWHh/skVCjasi9HmxKyrY4Bm6tvLdDtPholSW4j7UrJtzoGAACwGa8LqfPOO09ff/11+edhYWFyu9168803NWTIEJ+GCyVTGY2CB+rbprzBMlVxBw0nAADAIbye2vfmm2/qggsu0Lp161RSUqIxY8Zo27ZtyszM1F9//eWPjPVeTmGpftmUaHUMBIH61rkvGEakpAMt0AEAAA7m9YjUiSeeqM2bN+uMM87QRRddpIKCAl199dWKjIzU0Ucf7Y+M9d5PG/bZfp0I7KG+FVIJwVJIMSIFAAAO4fWIlCR17txZL7zwgq+zhCRjjL5lWh88VNYCvXmTWv3o2k5ckBRSO5JyZYxRWFiY1VEAAIBNePzX2ObNmz06rl+/frUOE4pW7MnQ3nq27gX+FZdRWG869wXL1L6swlKl5jnUqXVTq6MAAACb8LiQ6t+/v8LCwmSMkaTyd2bLPi+7zeVy+Thi/fbNSkaj4J3Y9PrRAr2wxKm0PIfVMTy2IymXQsrGfo5MlNsYjTi5C63qAQAB4XEhFRMTU/5vY4z69u2rOXPmqFevXn4JFgqSc4o1f0eK1TEQZGKDpNNdTRIyi6yO4JWo5DxdcFxHq2OgCvkOp174dZuyCkv18u87dP3AHrrlzJ7q0bbyVh0AAPiKx4XUoQVTWFiYunfvTiFVB9PWxMvlNjUfCBykvrRAD5ZpfWWikmg4YVdT/opRVmGpJCmzoESfLNmjT5fu0YXHd9StZ/XSeX06qEED1rcBAHyrfqxYD0KlLremrYm3OgaCUH3p3BcXZI8jKpkW6HaUU1SqSUv3VrrdGGnBjlQt2JGqI9s1161n9dK1p3XXEc2bWJASAFAfed3+HL6xYHuKUoNofQjso74UUsHS+rzM7tR8lTjZpsBuvlweo9xiZ7XHxGYU6uXfd+jMV//UmJ82aWtiToDSAQDqszoVUrQCrr1vaHmOWiprgR7sgqX1eRmn22hPWr7VMXCQ7MISfbk8puYD/8fhdOuHdfs08oPluvKjvzRzwz4Vl9IgCQBQOx5P7RswYECFwqmoqEiXXXaZmjSpOE1iw4YNvktXT+1OzdeKPRlWx0AQqw8t0INtjZR0YGPeYH/e65PPlu1VnqN2bypsTMjWxoRsmlMAAGrN40LqyiuvrPD5FVdc4essIePb1YxGoW6CvQW62220L8i69klSVFKeNMDqFJCkjHyHJv8VW+f7oTkFAKC2PC6kxo0b5/OTT5w4URMnTlRsbKwk6aSTTtJzzz2n4cOH+/xcdlFY4tRP6/dZHQNBLibI10kl5xarxBV864120HDCNj5duleFJb6blkdzCgCAtyxtNtG9e3e99tprWrdundatW6ehQ4fqiiuu0LZt26yM5Ve/btqvvBoWRgM1iUsPvmlxBwvGaX0SLdDtIjWvWF+vjPXb/Zc1pzhrPM0pAACHZ2n788suu6zC56+88oomTpyoVatW6aSTTrIolf8YY/T1Sqb1oe6CfUQqPkg3FU7Ncygj36F2LcOtjhLSJi7eo+JS/49oFpceaE7xw7p96t/jCN0+qJdGnNxFTRs39Pu5AQD2Z5v25y6XS9OnT1dBQYEGDRpkdRy/2JiQrW37eUcbdRdsezAdKlhHpCT2k7Jack6xvl0d+D34NiZk64kfNmnwawv12h9RQde+HwDge5ZvyLtlyxYNGjRIxcXFatmypWbNmqUTTzyxymMdDoccjr/3XsrNDa6iZOoqNuCFb5S1QG/exPIf4VoJttbnB9uRlKuzj2lvdYyQ9dGi3Zbu50VzCgBAGa9HpBISEg77tVWrVnkd4LjjjtPGjRu1atUq3X///brjjju0ffv2Ko8dP368IiIiyj969Ojh9fmstCuVd7LhO7FBvE6KESnUxr6sQk1fa483pMqaU9w5ea2Gvr1Yny/bq+zCEqtjAQACyOtC6qKLLlJGRuU9kP766y8NGzbM6wBNmjTRMccco4EDB2r8+PE65ZRT9N5771V57NixY5WTk1P+UV1RB9R3wTy9L5inRUUlB9dIeH3y0aLdKnUZq2NUQnMKAAhNXhdS5557ri6++GLl5f39ruzSpUs1YsQIn7RIN8ZUmL53sPDwcLVu3brCBxCqgrXhRF5xqTILgved+50p+XIGYev2YBefUagf19l764iy5hQjP1iuqz7+SzM37FNxqe9atAMA7MXrQmrSpEnq3bu3Lr30UhUXF2vRokW69NJL9eKLL+rxxx/36r6eeeYZLVu2TLGxsdqyZYv+85//aPHixbrlllu8jQWEnGBtgR7M0/okqcTpVmyQFrHB7P2Fu+R022806nAi42lOAQD1ndcr1cPCwjRt2jRdeumluvDCC7V582aNHz9eDz30kNcnT0lJ0W233aakpCRFRESoX79+mjt3ri666CKv7wsINcE6IhWsrc8PtiMpT8d0bGV1jJCxNy1fMzfYezTqcA5tTnHboCN17jHtaU4BAPWAR4XU5s2bK902btw43XTTTbr11lt13nnnlR/Tr18/j0/+xRdfeHwsgIpi04O0kKoH78xHJefqslO6Wh0jZLz35y4F0WBUlcqaUyzYkaqj2rfQi1f01Tl96P4IAMHMo0Kqf//+CgsLkzF/X8nKPv/00081adIkGWMUFhYml4v54EAgpOYFZwv0elFIJdG5L1B2peRp9qb9Vsfwqb3pBbr1i9W6fmB3/WfEiYpo3tjqSACAWvDoL7CYmBh/5wBQC7HphTqxa3A1XakXhRQt0APm3QW7ZIJ8NOpwfli3T4ui0/TSFX01rG9nq+MAALzkUSHVq1cvf+cAUAtxGQUUUhZIzC5STlGpIpoxkuBPO5Jy9fuWJKtj+FVankOjp67XiJM76/nLT1LHVk2tjgQA8JDXXfvGjx+vL7/8stLtX375pV5//XWfhALgmWBrOOF0uZWYVWR1DJ+IZlTK7ybM32l1hICZsyVZF72zVD+t31dhGj0AwL68LqQ+/fRTHX/88ZVuP+mkk/TJJ5/4JBQAzwRbw4mknOKgamFdHTbm9a8t+3L03+0pVscIqJyiUj314ybd/uUa2qUDQBDwupBKTk5Wly5dKt3eoUMHJSXV7ykYgN3EBlkr8fowra/MDhpO+NWEBaEzGnWoZbvSdcm7SzXlrxi56skbDwBQH3ldSPXo0UN//fVXpdv/+usvde1KO2AgkIJtRCouyAq/6uxIYkTKXzbEZ2lhVKrVMSxVWOLS879u13WfrNDuVIp2ALAjr/sm33PPPXrsscdUWlqqoUOHSpL+/PNPjRkzRk8++aTPAwI4vNQ8hwocTrUID44W6PVpRCo6OU9ut2FjVT8IpbVRNdkQn60R7y3Xw0OP0egLjlbjhl6//wkA8BOv//oaM2aMMjMz9cADD6ikpESS1LRpU/373//W2LFjfR4QQPXiMoKnBXp8ZnCNoFWnqNSl+MxCHdm+hdVR6pW1sZlativd6hi2UuJy6+35O/X7liS9ee0pOrl7hNWRAACqxdS+sLAwvf7660pLS9OqVau0adMmZWZm6rnnnvNHPgA1iA2izn31aURKouGEP7z932irI9hWVHKervhoucb/sUPFpS6r4wBAyKv1HIGWLVvq9NNPV9++fRUeHu7LTAC8EFSFVD1aIyXRcMLXVuxJ16q9mVbHsDW3kT5dslfD3l2qVXszrI4DACGtVgsr1q5dqx9//FHx8fHl0/vKzJw50yfBAHgmWBpOZBeWKLfYaXUMn2JEyneMMXrnv6yN8lRsRqFunLRKN5/ZU08PP16tm7I5NAAEmtcjUtOnT9fZZ5+t7du3a9asWSotLdX27du1cOFCRUQwbxsItNj04BjlqW/T+qQDU63gG8t2pWtdXJbVMYLOd6vjdfE7S/XnjtDacwsA7MDrQurVV1/VhAkT9Ntvv6lJkyZ67733tGPHDl1//fXq2bOnPzICqEawTO2rT63Py8RlFKrAUb9G2axgjNHbdOqrteTcYo36ap0emRapjHyH1XEAIGR4XUjt2bNHl156qSQpPDxcBQUFCgsL0+OPP65Jkyb5PCCA6pW1QLe7+jgiJUnRKYxK1dWi6FRtSsi2OkbQm71pv/7xzhL9sjFRxrCRLwD4m9eFVNu2bZWXd+APh27dumnr1q2SpOzsbBUW1s8/lAC7C4bRnvrWaKJMFA0n6sQYo3cYjfKZrMJSPTp9o0Z9tU77s4usjgMA9ZrXhdS5556r+fPnS5Kuv/56Pfroo7r33nt100036cILL/R5QAA1C4bpffV1RIqGE3Uzb1uKtibyHPrawqhUXTxhqaauipPbzegUAPiD1137PvzwQxUXF0uSxo4dq8aNG2v58uW6+uqr9X//938+DwigZjFB0Lmv3hZSjEjVmttt9O4CRqP8Jd/h1LM/b9XsTfv12tUn66gOLa2OBAD1iteFVNu2bcv/3aBBA40ZM0ZjxozxaSgA3omz+YhUidOtpJz6Oc1oR3KujDEKCwuzOkrQmbM1ic6HAbAmJlPD31umxy86Vvec01uNGtZ6C0kAwEE8KqRycz2fdtG6detahwFQO3ZvgZ6YXaT6Orsor9ipxOwidW/T3OooQcXlNnp3wS6rY4QMh9Ot1/6I0m+b9+v1a/rppK5sVwIAdeVRIXXEEUfU+G5r2TuyLpfLJ8EAeC7G5iNSdh8xq6uopDwKKS/9umm/dqfmWx0j5GxNzNXlH/6l0ecfpYeH9lHTxg2tjgQAQcujQmrRokX+zgGgDtL+1wK9RbjXs3UDIqGero8qE5Wcq3+c2MnqGEHD6XLrvT8ZjbKKy2300aI9+mNrst64pp8GHtm25m8CAFTi0V9d559/vr9zAKij2IwC207Xqa+NJsrsYJ2PV2ZFJgZFg5T6bm9aga77dKVuP6uX/jXseLW06RsxAGBXdVpxWlBQoC+//FIfffSRdu3i3UXASnbeS8rO2XwhKon23Z4qdbn1/kKuF3ZhjPTVyjhdMmGpFkenWh0HAIKKx4VUfHy8zj//fLVq1UoXXXSR4uPjdeqpp+qee+7Rww8/rP79+2vp0qX+zAqgGnZ+h7++j0jFpBeouJT1oZ74af0+JWTWzw6OwSwxu0h3Tl6rJ37YqKyCEqvjAEBQ8LiQeuqpp1RSUqKJEyeqefPmuuSSS9SnTx8lJSUpJSVFI0aM0PPPP+/HqACqE2vTQsoYU+8LKbeRdqXQOKEmDqdLH7A2ytZmbkjURROW6PfNSTKmnrbaBAAf8XhC9NKlSzV79mydccYZGjFihNq3b68vv/xSnTodWGD97LPP6sILL/RbUADVs+v0uYyCEhWW1P/Rmh3JuTq5uz3XqNnF92sTtD+n2OoYqEF6foke/G6DLjqxk16+sq86tW5qdSQAsCWPR6TS0tLUq1cvSQc25W3evHl5ESVJnTt3VlZWlu8TAvCIXVug1/fRqDJRSTScqE5xqUsfLdptdQx4Yf72FI14b5kymeoHAFXyuJAq2yeqTE37SgEIrLIW6HYTb9ORMl+LSqbhRHW+XR2vlFyH1THgpYyCEr38+3arYwCALXnV6/S5555T8+YHNp0sKSnRK6+8ooiIA1NZCgtD448lwM7s2AI9VEakdiTlVnrDCQcUljg1cTGjUcFq5oZEXTWgm87t08HqKABgKx4XUuedd56io6PLPx88eLD27t1b6RgA1olNL7RdIWXXtVu+llVYqrQ8hzqynqSSb1bGKT2f6WHB7D+ztmreY+epWZOGVkcBANvwuJBavHixH2MA8IVYG66TSgiRESnpwMa8FFIV5Tuc+mTJHqtjoI7iMwv17p87NXb4CVZHAQDbqNOGvADsxY4t0ENlap90YHofKvpqRayyCkutjgEf+HxZjLYm5lgdAwBsg0IKqEfsNo2uuNSl5NzQaXcdRSFVQW5xqSYt3VvzgQgKLrfR2Jlb5HKzvxQASBRSQL1itxbo+7LsVdj5W1QyLdAP9uXyGOUUMRpVn2xJzNHkv2KsjgEAtkAhBdQjaXkO5duoBbrdRsj8bXdqvkqcbqtj2EJ2YYm+WMYf3PXR2//dGVJrHwHgcDwupCZNmqTk5GR/ZgHgA3E2GpUKpfVRkuR0G+1Jy7c6hi18tmyv8mxU1MN3ikpdevbnrTKGKX4AQpvHhdS0adN05JFH6swzz9Srr76qbdu2+TMXgFqKTbdP8RJqI1ISG/NKUmZBiSb/FWt1DPjRkp1pmr1pv9UxAMBSHhdSixYtUlJSkh5++GFt3LhRgwcP1tFHH60nnnhCixcvltvNdBbADuzUAj0Up/9EJbFO6tMle1RY4rI6BvzsxV+3K7uQ/cEAhC6v1ki1adNGt956q3744QelpaXpo48+UnFxsW677TZ16NBBt99+u3766ScVFNjnDzkg1NipBXqoTe2TDuwlFcrS8hz6amWs1TEQABkFJXrl9x1WxwAAy9S62USTJk00bNgwffzxx0pISNC8efN05JFH6qWXXtI777zjy4wAvGCXESm324RkIRXqLdAnLt6j4lJmKISKH9fv04rd6VbHAABLeF1Ibd68ucrbBw4cqFNPPVWbNm3S008/XedgAGon1ibrktLyHXKEYAe71DyHMvIdVsewRHJOsaaujrM6BgLsmVlbVFzKVE4AocfrQuqSSy7R3r2VN1icMWOGbrnlFklS48aN654MQK3YpQV6KDaaKBMdotP7Pl68m/bvISg2o1Dv/7nL6hgAEHBeF1L333+/LrzwQiUlJZXf9v333+v222/XlClTfJkNQC3ZYZ1UKE7rKxOK66QSs4s0fU2C1TFgkUlL92pHiE9rBRB6vC6knnvuOV1++eX6xz/+oczMTH333Xe666679PXXX+u6667zR0YAXrLDaFAoF1KhuE7qw4W7VeJiNCpUOd1GT8/cIpebvaUAhI5aNZt47733dOqpp+qss87Svffeq2nTpumaa67xdTYAtWSHhhPxNshglR0htpdUfEahflzHaFSo25SQra/p2AgghDTy5KDZs2dXuu3KK6/UkiVLdNNNNyksLKz8mMsvv9y3CQF4jal91tqZki+ny61GDWvdGDWovL9wl5yMREDSm/OidfFJndXtiGZWRwEAv/OokLryyisP+7Uvv/xSX375pSQpLCxMLhedewCr2WJEKoQLqRKnW7EZBTqmYyuro/hdTHqBZm7YZ3UM2ERhiUvP/bxVn98xUGFhYVbHAQC/8ujtUrfb7dEHRRRgDzHp1hYxBQ6n0vNLLM1gtR1JodFw4r0FO8VgFA72Z1Sqft+SVPOBABDkQmPeCRBi0vOtbYGekBW6o1FlokJgndTu1Dz9smm/1TFgQ8/P3q6cwlKrYwCAX3ldSD3yyCN6//33K93+4Ycf6rHHHvNFJgA+YOU6KTt0DbRaVAiMSE1YsEuG0ShUIT3fofF/7LA6BgD4ldeF1IwZM3T22WdXun3w4MH66aeffBIKQN1ZWcwkhPD6qDJR9XwvqajkXP2+melbOLzpaxO0am+G1TEAwG+8LqQyMjIUERFR6fbWrVsrPT3dJ6EA1J2VDScYkTqwQW1OUf2d2jRh/k6rIyAIPDNzi4pLWT8NoH7yupA65phjNHfu3Eq3//HHHzrqqKN8EgpA3cVYOLUvlDv2HSy6no5KbU3M0bxtKVbHQBDYm16gjxbttjoGAPiFR+3PD/bEE0/ooYceUlpamoYOHSpJ+vPPP/X222/r3Xff9XU+ALUUZ+GIFFP7DohKztUZvdtaHcPnGI2CNyYu3qOR/brquM71fzsAAKHF60Lq7rvvlsPh0CuvvKKXXnpJknTkkUdq4sSJuv32230eEEDtWNUC3eU2dO37n/rYAj0yPkt/RqVaHQNBxOk2Gjtzs34aPVgNGrC3FID6o1btz++//37t27dPKSkpys3N1d69e2tVRI0fP16nn366WrVqpY4dO+rKK69UdHR0bSIBOER6vkN5xYFfo5OcW6xSF63cpPrZAn3Cgl1WR0AQ2hCfrW9Xx1kdAwB8qk77SHXo0EEtW7as9fcvWbJEDz74oFatWqX58+fL6XTq4osvVkGBdVOSgPrEiqYPVk4ptJvo5Dy569FutetiM7V0Z5rVMRCkXp8braScIqtjAIDPeD21T5J++ukn/fDDD4qPj1dJSUmFr23YsMHj+zm0acXkyZPVsWNHrV+/Xuedd15togE4SGxGgfp2q9xl059YH/W3whKXErIK1atdC6uj+MTb/2VtFGov3+HUc79s06TbTlNYGFP8AAQ/r0ek3n//fd11113q2LGjIiMjdcYZZ6hdu3bau3evhg8fXqcwOTk5kqS2batenO1wOJSbm1vhA8DhWTMiRSF1sB1J9eP31Io96VrJnkCoo/nbUzRvW7LVMQDAJ7wupD7++GNNmjRJH374oZo0aaIxY8Zo/vz5euSRR8oLodowxuiJJ57QOeeco759+1Z5zPjx4xUREVH+0aNHj1qfDwgFVrRAp/V5RfWh4YQxhk598JnnftlWr/dYAxA6vC6k4uPjNXjwYElSs2bNlJd34I+E2267TdOmTat1kIceekibN2+u9j7Gjh2rnJyc8o+EhIRanw8IBbEWFFJM7auoPjScWL47XWtjs6yOgXoiNc+hN+ZGWR0DAOrM60Kqc+fOysg4ML2jV69eWrVqlSQpJiZGxtRuUfXDDz+s2bNna9GiRerevfthjwsPD1fr1q0rfAA4vFgrpvZRSFUQFeSb8hpjWBsFn/t2dbzWxmZaHQMA6sTrQmro0KH69ddfJUmjRo3S448/rosuukg33HCDrrrqKq/uyxijhx56SDNnztTChQvVu3dvb+MAqEagW6DnFJUqu5ApOweLyyhUgcNpdYxaWxSdqo0J2VbHQD309IzNcjhdVscAgFrzumvfpEmT5Ha7JUmjR49W27ZttXz5cl122WUaPXq0V/f14IMP6rvvvtMvv/yiVq1aKTn5wALUiIgINWvWzNtoAKoQl1EYsM59TOurWnRKnk7t2cbqGF4zxugd1kbBT/akFWji4j167B/HWh0FAGrF60KqQYMGatDg74Gs66+/Xtdff32tTj5x4kRJ0gUXXFDh9smTJ+vOO++s1X0CqCiQLdBpNFG1qKTgK6TcbqNpa+O1NTH413jBvj5etEcj+3XRMR1bWR0FALzmUSG1efNmj++wX79+Hh9b2zVVADwXyIYTFFJVC6aGE6m5xfpx/T5NWxOvfVlsngr/KnG5NXbmFn3/z0Fq0IC9pQAEF48Kqf79+yssLKzGwicsLEwuF/OdATsJZMMJ9pCqWpTNW6C73UbLd6fru9XxWrAjRU43b3IhcNbGZmna2njdcmYvq6MAgFc8KqRiYmL8nQOAnwRyRIo1UlXbkZwrY4zCwuz1jntqXrF+XLdP09fGKyGT0SdY57U5UfrHCZ3UqXVTq6MAgMc8KqR69eJdIiBYxWYErpCKywz8vlXBIK/Yqf05xep2hPVNdNxuo7/2pGvamnj9dxujT7CHPIdTz8/epom3nmZ1FADwmNfNJjIyMtSuXTtJUkJCgj777DMVFRXp8ssv17nnnuvzgADqJj2/RHnFpWrVtLFfz1Pqcmt/drFfzxHMopJyLS2k0vIc+mn9gdEnpmDCjv7Ymqz/bkvWxSd1tjqKXzmcLn2zMk4FDpfOO7a9+nU/Qg1ZHwYEJY8LqS1btuiyyy5TQkKC+vTpo+nTp2vYsGEqKChQgwYNNGHCBP3000+68sor/RgXQG0EogV6UnaxXIxuHFZUcp4uPKFTQM/pdhut3Juh71bH67/bk1Xq4v8H9vbcL9s06Oh2fn/jxwrGGP13e4penbOj/M2MCQt26ojmjXX2Me11fp8OOu/YDuocwfRGIFh4XEiNGTNGJ598sqZOnaqpU6dq5MiRGjFihD7//HNJ0sMPP6zXXnuNQgqwoUC0QGdaX/W2JwWuc196/v9Gn9bEB7TZCFBXybnFenNetF68oq/VUXxqR1KuXvx1u1buzaj0tezCUv2+OUm/b06SJB3bqaXOP/ZAUXX6kW3VtHHDQMcF4CGPC6m1a9dq4cKF6tevn/r3769JkybpgQceKN9T6uGHH9ZZZ53lt6AAai8QDSdofV69KD8XUsb8Pfo0bxujTwhe36yK0xX9u+m0XsG191pV0vMdevu/O/X92nh5OmC/MyVfO1Py9dmyGDVt3EBn9m6n847toPOPba+jO7S0XdMaIJR5XEhlZmaqc+cD85ZbtmypFi1aqG3btuVfb9OmjfLy7N3iFwhVMen+L3LiGfmoVkx6gYpLXT5/dzmzoEQ/rU/QtDUJiglgh0bAX4yRxs7crN8ePldNGjWwOk6tOJwuTfkrVh8u3K08h7PW91Nc6taSnWlasjNNL0nqGtH0f0VVBw0+pr0imtW/KZBAMPGq2cSh74LwrggQHOIC0LmPEanquY20KyVfJ3ev+xRLY4xW7c3Ud2viNW9rskpcbh8kBOxjZ0q+Pl2yRw9f2MfqKF6pah2UL+3PKdb0tQmavjZBDRuEqX+PI3Renw40rQAs4lUhdeeddyo8PFySVFxcrNGjR6tFixaSJIfD4ft0AHwiEC3Q6QRXsx3JuXUqpDILSjRzwz59tyZee9MYfUL99sHC3RrRr4uO7tDS6ige2b4/Vy/9VvU6KH9wuY3Wx2VpfVwWTSsAi3hcSN1xxx0VPr/11lsrHXP77bfXPREAn/N3C3RjDJvxeiAqyfvpz8YYrYk5MPr0xxZGnxA6SlxuPTNzi6bde5Ya2Hik5cA6qGhNX5sgY+HSxEObVhzXqZXOO7Y9TSsAP/K4kJo8ebI/cwDwM3+2QM8uLK3TOoBQEZXsecOJ7MIS/bR+n6atidceRp8QolbHZOqHdQm68YyeVkeppGwd1AcLdyvfhr//olPyFJ2SR9MKwI+83pAXQHCKSfdfC/Q4RqM8siMpV8aYw/4BY4zR2tgsTVsTr9+3JKnEyegT8OqcHRp6Qkd1bGWPqWrGGM3bdmAdVLCsDT20aUW3I5rp3D7taVoB1BGFFBAi/NlwIlj+mLBaVmGp0vIc6ti64h+EOYWlmrHhwOjTrtR8i9IB9pRb7NQLv27XRzefanUUbdufo5d+265VezOtjlInidlFNK0AfIBCCggR/myBHh+AZhb1xY7kPHVs3VTGHFgo/t3qA6NPDkafgMP6fXOSrh6QogtP6GTJ+dPyHHpnvvXroPyBphVA7VFIASGCESl7WBOToZi0fE1bk6DoFPbeAzz1fz9v1ZlHtVPL8MD96eJwujT5f/tB2XEdlD9U1bTis9sHqme75hYnA+yHQgoIEf5sgU4h5bmPFu2xOgIQlPbnFOutedF6/vKT/H6uA+ugkvXqnKiQ//0WnZKnR6ZH6sfRg9S4YXBukAz4Cz8RQIgoa4HuD/HsIQUgAL5aGauNCdl+Pce2/Tm66bNVGj11Q8gXUWU2JmTrvQW7rI4B2A6FFBBC/LFprsPpUlJusc/vFwAOZYz09IzNKvXDfmppeQ49PWOzRn6wPOibSfjDR4t3a1WANhsGggWFFBBCYtJ9P71vX1ZRvVt8DcC+opLz9NmyvT67v+JSlyYu3qMhby2ul80kfMUY6fHvNyq7sMTqKIBtUEgBISTWD4UUU18ABNp7C3bV+feZMUZztybpoglL9PrcqJBpJlEXSTnFenrGFhmqTUAShRQQUmL9MLUvgUIKQIA5nG49M6v2f9BvTczRjZMOrINKyCzycbr6be62ZE1fm2B1DMAWKKSAEOKPzn3+WHcFADVZsSdDP63f59X3pOYV698/bdZlHy7X6hjWQdXWC79u0242DwcopIBQ4o+9pJjaB8Aqr8zZofR8R43Hla2DGvrWEn2/jnVQdVVc6tYj0yLlcLqsjgJYikIKCCH+aIFO63MAVskuLNVLv20/7NeNMfpjC+ug/GF7Uq7emBttdQzAUhRSQIiJTfdd4WOMYUQKgKV+2bhfi6JTK92+NTFHN0xapfu/ZR2Uv3yxPEaLq3juUbNNCdn6a3e61TFQRxRSQIjx5Tqp9PwSFZUytQOAtZ6dtVUF/xttSs0r1pifNumyD5drDeug/O6pHzcpLa/m6ZX4W0JmoUZ9tU6jp67X7tQ8q+OgDiikgBDjyxbo8Zm+X3MFAN5KzC7SG3Oj9PHi3Rry5mL9sG4f66ACJD2/RP/6aZPcbp5wT+QUleruKWuVnu9QXrFTd01ZqwwP1vnBniikgBDjyxboTOsDYBdfrYzTG3OjVVDCKHmgLY5O05QVsVbHsL0Sp1sPfLteuw7qeJiQWaR/frNexczuCEoUUkCI8eXUPlqfAwAk6bU/orR9f67VMWzLGKP/zNqiv3ZnVPra+rgsjflpMxsdByEKKSDE+HZqH4UUAEAqcbn1yPRIFTEiWKUPF+7Wj9XsezZ7035NWLArgIngCxRSQIjJKChRro9aoNP6HABQZndqvl76/fDt6EPVLxsT9fb8nTUe9/6fuzQr0rtNpmEtCikgBMX5qAU6I1IAgIN9tzpec7cmWx3DNtbEZOpfP272+Ph//7SFbpNBhEIKCEG+WCdVVOJSKi1vAQCHeHrmZiXlsHfX3rR8/fObdSpxuT3+nhKXW/d9s86n0/DhPxRSQAjyxS/ohCxGowAAlWUXlurx7zfKFcIt0TPyHbprylplF3o/lT6r8ECL9OzCEj8kgy9RSAEhKMYHI1KsjwIAHM6qvZn6ZMkeq2NYorjUpXu/XlenzrZ70ws0eup6lTg9H81C4FFIASHIF23L41gfBQCoxjvzdyoyPsvqGAHldhs9+cMmbYjPrvN9rdqbqf/M2kJbdBujkAJCkE+m9lFIAQCq4XIbPTp9o/IdTqujBMwb86L1+5Ykn93fj+v36ePFoTmyFwwopIAQ5IsW6HTsAwDUJD6zUM/9vNXqGAExbU28X6YzvjkvWr9v9l1xBt+hkAJCVF1boMf5YJ0VAKD+mxmZqJ8jE62O4VdLdqbpWT8WjE/8sDHkpkkGAwopIETVpeGE222UkEVrWwCAZ579eWu9bVK0IylXD367wa9dCh1Ot+79eh3T6m2GQgoIUXF1WCeVkldMJyEAgMfyHU49+n2kSr3YUykYpOQW6+4pawOyDiw9v0Sjvlpb56n58B0KKSBE1WVEqr6+qwgA8J/I+Gy9/+cuq2P4TIHDqbunrFVSTnHAzrkzJV8PfrtBznpWkAYrCikgRNWlcx+NJgAAtfHhot1atTfD6hh15nS59fC0SG3bnxvwcy/bla5xs7fRFt0GKKSAEFWXvaQopAAAtWGM9Pj3G5VTGLzT04wxevG37VoYlWpZhm9Xx+vLv2ItOz8OoJACQlRdWqBTSAEAaispp1hPz9wctCMqXyyP0dcr46yOoZd/364F21OsjhHSKKSAEFbbFuh1Gc0CAOCPrcn6fm2C1TG8Nndrsl6Zs8PqGJIOjO49Mj1SWxNzrI4SsiikgBBW24YTtF8FANTVC79u1+7UfKtjeGxjQrYe+z5SdhpIKyxxadRXa5UcwIYX+BuFFBDCatNwIt/hVEZBiR/SAABCSVGpS49Mi5TD6bI6So0SMgt1z1drVVxqv255KbkOjfpqrQoC0IIdFVFIASEsthYjUrQ+BwD4yvakXL05N9rqGNXKKSzVXVPWKj3fvm8ibtufq0enb/TrpsCojEIKCGG1GZGi0QQAwJc+Xx6jJTvTrI5RpRKnW6Onrg+KKYgLdqToVZus3woVFFJACIutxehSfGbt958CAKAqT/6wSen5DqtjVGCM0diZW7QyiPa9+mJ5jL5ZZX1HwVBBIQWEsMyCEuUUedcCnREpAICvpec79K8fN9mqJfoHC3drxoZ9Vsfw2vOzt9l2hK++oZACQlycl+ukaH0OAPCHRdFpmrIi1uoYkqRZkfv0zvydVseoFZfb6KFvNyg6Oc/qKPUehRQQ4ryd3kfrcwCAv4yfE6UdSbmWZli1N0NjftpsaYa6ynM4dfeUtUrLs9d0yfrG0kJq6dKluuyyy9S1a1eFhYXp559/tjIOEJK8aTjhchvtyyryYxoAQCgrcbn18LRIFZVY0xJ9T1q+7vtmvUpd9pliWFuJ2UW65+t1Ki61f3v5YGVpIVVQUKBTTjlFH374oZUxgJDmTSG1P7tITlqrAgD8aHdqvl7+fXvAz5uR79Bdk9d6vXbYzjYlZOvJHzbJzbXbLxpZefLhw4dr+PDhVkYAQp43e0kxrQ8AEAjfro7Xecd20CUndQ7I+YpLXbrn63X1sqHS71uSdGT75vrXJcdbHaXeYY0UEOK8WSMVVw8vMAAAe/r3jM1Kzin2+3ncbqMnftioyPhsv5/LKh8t2qMf1yVYHaPeCapCyuFwKDc3t8IHgLrxpgV6fXynDgBgT9mFpXr8+41y+Xla2uvzojRnS7Jfz2EHz8zaopV7gmdPrGAQVIXU+PHjFRERUf7Ro0cPqyMB9YKnLdAppAAAgbRyb4Y+XbrHb/f/7eo4fbpkr9/u305KXUajp67XnrR8q6PUG0FVSI0dO1Y5OTnlHwkJDFECvhDjYcOJePaQAgAE2Dv/3amNCdk+v9/F0al67pdtPr9fO8spKtXdU9Yqs6DE6ij1QlAVUuHh4WrdunWFDwB15+kmu4xIAQACzek2enR6pPIdTp/d5/b9uXrw2w1+nzZoR3EZhRr9zXo5nLRFrytLC6n8/Hxt3LhRGzdulCTFxMRo48aNio+PtzIWEHI8aYGeU1har1rCAgCCR1xGoZ77ZatP7is5p1h3T1mrAov2qrKDNbGZenrGFhkTeoWkL1laSK1bt04DBgzQgAEDJElPPPGEBgwYoOeee87KWEDI8aQFOqNRAAArzdyQqF82JtbpPvIdTt09Za2Sc/3fDdDuZkUm6oOFu62OEdQs3UfqggsuoBIGbMCTFugUUgAAqz07a6tO7dlGPdo29/p7nS63Hv5ug7Yn0fW5zDvzd6pXu+a6on83q6MEpaBaIwXAPzxpgR6X6fnGvQAA+EOew6lHp0fK6XJ79X3GGD3/6zYtik7zU7Lg9a+fNmt9XKbVMYIShRQASTW3QE9gRAoAYAMb4rP1/p+7vPqez5fFaOoq1uBXpcTp1r1fr6czby1QSAGQVHMLdE87+wEA4G8fLtqt1Xs921z2jy1JevWPHX5OFNwyC0p015Q1NJXyEoUUAElSbHr1hRJrpAAAduE20uPfb1ROYfV/+EfGZ+mx7zeKJfk125NWoAe+Xa9SL6dNhjIKKQCSqp/aV+J0a392UQDTAABQvf05xRo7a/NhG5clZBbqnq/WyeGkMPDUX7sz9H8/b6UZnIcopABIkmKqKaT2ZxcpBPcsBADY3JwtyfphXUKl23MKS3Xn5DXKKCixIFVwm742QZOW7rU6RlCgkAIgqfo1UEzrAwDY1fOzt2tPWn755yVOt+6buk570ug2W1uvzY3S3K1JVsewPQopAJKqb4EeRyEFALCpolKXHpkWKYfTJWOMnp6xWav20s67LoyRHvt+ozbvy7Y6iq1RSAEoF3uYzn20PgcA2Nm2/bl6a1603vtzl2ZGJlodp14oLnVr1FfrWCNdDQopAOViD7NOqqY9pgAAsNpny2L07gLv9pdC9dLyHLp7ylrlO5xWR7ElCikA5Q7XAj0+k3ejAAAIRVHJeXr4uw1y0ha9EgopAOWqGnkyxjC1DwCAELYoOk0v/86mxoeikAJQrqoW6JkFJQzpAwAQ4qasiNWUv2KsjmErFFIAylXVbILW5wAAQJJe/G27FkWlWh3DNiikAJTLKixVTmHFFugUUgAAQJLcRnrouw3avj/X6ii2QCEFoIJDO/fFV7NRLwAACC0FJS6N+mqtUnOLrY5iOQopABVUKqQYkQIAAAdJyinWqK/WqbAktNdQU0gBqODQFuhxFFIAAOAQWxJz9Pj3G+V2G6ujWIZCCkAFh45I0focAABUZd62FL0+N8rqGJahkAJQwcGFVHGpS8nMgQYAAIfx6dK9mrYm3uoYlqCQAlDBwS3Q92UVyYTuiD0AAPDA//28Vct3pVsdI+AopABUcHALdKb1AQCAmjjdRvd/u167U/OsjhJQFFIAKimb3heXUXmDXgAAgEPlFTt115S1Ss93WB0lYCikAFRSVkjFZxZZnAQAAASLhMwi/fPrdSoudVkdJSAopABUUtYCPT6TESkAAOC5DfHZ+tdPm2VCYJE1hRSASv4ekWKNFAAA8M6vm/ZrwoJdVsfwOwopAJXEpBfIGEMhBQAAauX9P3dpVuQ+q2P4FYUUgEriMgqUludQcanb6igAACBI/funLVoTk2l1DL+hkAJQSVZhqbYk5lgdAwAABLESl1v//GZdhT0q6xMKKQBVWrozzeoIAAAgyGUXluruKWuVXVhidRSfo5ACUKWlIbhDOQAA8L296QUaPXW9Spz1a8kAhRSAKsXU02F4AAAQeKv2ZuqZWVvqVVt0CikAAAAAfvfT+n36ePEeq2P4DIUUAAAAgIB4c160ft+cZHUMn6CQAgAAABAwT/ywUZHxWVbHqDMKKQAAAAAB43C6de/X65SQWWh1lDqhkAIAAAAQUOn5JRr11VrlFpdaHaXWKKQAAAAABNzOlHw9+O0GOV3B2RadQgoAAACAJZbtSte42duCsi06hRQAAAAAy3y7Ol5fLI+xOobXKKQAAAAAWOqVOTs0f3uK1TG8QiEFAAAAwFLGSI9Mi9TWxByro3iMQgoAAACA5YpKXRr11Vol5xRbHcUjFFIAAAAAbCEl16FRX61VgcNpdZQaUUgBAAAAsI1t+3P16PRIudz27uRHIQUAAADAVhbsSNWrc3ZYHaNaFFIAAAAAbOeL5TH6ZlWc1TEOi0IKAAAAgC09P3ubluxMszpGlSikAAAAANiSy2304LcbFJ2cZ3WUSiikAAAAANhWvsOpu6esVWqevdqiU0gBAAAAsLXE7CLd+/V6FZe6rI5SjkIKAAAAgO1tSsjWkz9sktsmbdEppAAAAAAEhd+3JOmt/0ZbHUMShRQAAACAIPLx4j36YV2C1TEopAAAAAAEl2dmbtGKPemWZqCQAgAAABBUnG6j+6du0J60fMsyWF5Iffzxx+rdu7eaNm2q0047TcuWLbM6EgAAAACbyykq1d1T1iqzoMSS81taSH3//fd67LHH9J///EeRkZE699xzNXz4cMXHx1sZCwAAAEAQiMso1H3frJPDGfi26JYWUu+8845GjRqle+65RyeccILeffdd9ejRQxMnTrQyFgAAAIAgsTY2S0/P2CJjAtsWvVFAz3aQkpISrV+/Xk8//XSF2y+++GKtWLGiyu9xOBxyOBzln+fm5vo1IwAAAAD7mxWZqC7NQqSQSk9Pl8vlUqdOnSrc3qlTJyUnJ1f5PePHj9cLL7wQiHh+Me6yk5TvcFodAwAAAKh3CvPzAno+ywqpMmFhYRU+N8ZUuq3M2LFj9cQTT5R/npubqx49evg1ny+d1quN1REAAACAeik3Nzyg57OskGrfvr0aNmxYafQpNTW10ihVmfDwcIWHB/YJAgAAAIBDWdZsokmTJjrttNM0f/78CrfPnz9fgwcPtigVAAAAANTM0ql9TzzxhG677TYNHDhQgwYN0qRJkxQfH6/Ro0dbGQsAAAAAqmVpIXXDDTcoIyNDL774opKSktS3b1/NmTNHvXr1sjIWAAAAAFQrzAS64boP5ebmKiIiQjk5OWrdurXVcQAAAABYJNC1gaUb8gIAAABAMKKQAgAAAAAvUUgBAAAAgJcopAAAAADASxRSAAAAAOAlCikAAAAA8BKFFAAAAAB4iUIKAAAAALxEIQUAAAAAXqKQAgAAAAAvUUgBAAAAgJcopAAAAADASxRSAAAAAOClRlYHqAtjjCQpNzfX4iQAAAAArFRWE5TVCP4W1IVURkaGJKlHjx4WJwEAAABgBxkZGYqIiPD7eYK6kGrbtq0kKT4+PiBPVl3k5uaqR48eSkhIUOvWra2OUy2y+gdZ/SOYskrBlZes/kFW/yCrf5DVP8jqHzk5OerZs2d5jeBvQV1INWhwYIlXRESE7f9jy7Ru3ZqsfkBW/yCr/wRTXrL6B1n9g6z+QVb/IKt/lNUIfj9PQM4CAAAAAPUIhRQAAAAAeCmoC6nw8HCNGzdO4eHhVkepEVn9g6z+QVb/Caa8ZPUPsvoHWf2DrP5BVv8IdNYwE6j+gAAAAABQTwT1iBQAAAAAWIFCCgAAAAC8RCEFAAAAAF6ikAIAAAAAL1laSI0fP16nn366WrVqpY4dO+rKK69UdHR0hWOMMXr++efVtWtXNWvWTBdccIG2bdtW4RiHw6GHH35Y7du3V4sWLXT55Zdr3759FY555ZVXNHjwYDVv3lxHHHGEbbPGxsZq1KhR6t27t5o1a6ajjz5a48aNU0lJiS3zStLll1+unj17qmnTpurSpYtuu+027d+/35ZZDz62f//+CgsL08aNG22Z9cgjj1RYWFiFj6efftqWWSXp999/15lnnqlmzZqpffv2uvrqq22XdfHixZWe07KPtWvX2iqrJO3cuVNXXHGF2rdvr9atW+vss8/WokWLPMoZ6KwbNmzQRRddpCOOOELt2rXTP//5T+Xn5wc866RJk3TBBReodevWCgsLU3Z2dqVzZWVl6bbbblNERIQiIiJ02223VXmcHbLa5dpVU1ZfXLsC+bza5brlSdYyVl+3PMlql+uWp8+rHa5bNWW103XLk+fVLtctT7LW9bpVFsYyl1xyiZk8ebLZunWr2bhxo7n00ktNz549TX5+fvkxr732mmnVqpWZMWOG2bJli7nhhhtMly5dTG5ubvkxo0ePNt26dTPz5883GzZsMEOGDDGnnHKKcTqd5cc899xz5p133jFPPPGEiYiIsG3WP/74w9x5551m3rx5Zs+ePeaXX34xHTt2NE8++aQt8xpjzDvvvGNWrlxpYmNjzV9//WUGDRpkBg0aZMusZR555BEzfPhwI8lERkbaMmuvXr3Miy++aJKSkso/8vLybJn1p59+Mm3atDETJ0400dHRJioqyvz444+2y+pwOCo8n0lJSeaee+4xRx55pHG73bbKaowxxxxzjBkxYoTZtGmT2blzp3nggQdM8+bNTVJSkq2yJiYmmjZt2pjRo0ebqKgos2bNGjN48GBzzTXXeJTTl1knTJhgxo8fb8aPH28kmaysrErnGjZsmOnbt69ZsWKFWbFihenbt68ZOXKkLbPa5dpVU1ZfXLsC+bza5brlSdYyVl+3PMlql+uWJ1ntct2qKaudrluePK92uW7VlNUX1y1jjLG0kDpUamqqkWSWLFlijDHG7Xabzp07m9dee638mOLiYhMREWE++eQTY4wx2dnZpnHjxmb69OnlxyQmJpoGDRqYuXPnVjrH5MmTa3UxsiJrmTfeeMP07t07aPL+8ssvJiwszJSUlNgy65w5c8zxxx9vtm3b5vUFKZBZe/XqZSZMmFDrbIHKWlpaarp162Y+//xz22c9VElJienYsaN58cUXbZc1LS3NSDJLly4tPyY3N9dIMgsWLLBV1k8//dR07NjRuFyu8mMiIyONJLNr166AZT3YokWLqrx4bt++3Ugyq1atKr9t5cqVRpKJioqyVdaDWXnt8jZrmbpeuwKZ1YrrljdZrb5ueZrVDtctT7La5brlSdZDWXXd8iSrXa5bnmT11XXLVmukcnJyJElt27aVJMXExCg5OVkXX3xx+THh4eE6//zztWLFCknS+vXrVVpaWuGYrl27qm/fvuXHBHvWnJyc8vPYPW9mZqa+/fZbDR48WI0bN7Zd1pSUFN1777365ptv1Lx581rlC1RWSXr99dfVrl079e/fX6+88orXUzwDkXXDhg1KTExUgwYNNGDAAHXp0kXDhw+vNMxuh6yHmj17ttLT03XnnXfaLmu7du10wgkn6Ouvv1ZBQYGcTqc+/fRTderUSaeddpqtsjocDjVp0kQNGvx9SWnWrJkkafny5QHL6omVK1cqIiJCZ555ZvltZ511liIiImp9zfBXVn8IZNa6XrsCldWq65an7HDd8obV1y1P2OW6VRtWXbc8YZfrlid8dd2yTSFljNETTzyhc845R3379pUkJScnS5I6depU4dhOnTqVfy05OVlNmjRRmzZtDntMMGfds2ePPvjgA40ePdrWef/973+rRYsWateuneLj4/XLL7/YLqsxRnfeeadGjx6tgQMH1ipfoLJK0qOPPqrp06dr0aJFeuihh/Tuu+/qgQcesF3WvXv3SpKef/55Pfvss/rtt9/Upk0bnX/++crMzLRV1kN98cUXuuSSS9SjRw+vc/o7a1hYmObPn6/IyEi1atVKTZs21YQJEzR37txarZXxZ9ahQ4cqOTlZb775pkpKSpSVlaVnnnlGkpSUlBSwrJ5ITk5Wx44dK93esWPHWl0z/JnV1wKZta7XrkBktfq65el92+G65Sk7XLc8YZfrVm1Ydd3yhF2uW57w1XXLNoXUQw89pM2bN2vatGmVvhYWFlbhc2NMpdsO5ckxtRWorPv379ewYcN03XXX6Z577rF13n/961+KjIzUf//7XzVs2FC33367jDG2yvrBBx8oNzdXY8eO9TpXoLNK0uOPP67zzz9f/fr10z333KNPPvlEX3zxhTIyMmyV1e12S5L+85//6JprrtFpp52myZMnKywsTD/++KOtsh5s3759mjdvnkaNGuV1xkBkNcbogQceUMeOHbVs2TKtWbNGV1xxhUaOHFmr4sSfWU866SR99dVXevvtt9W8eXN17txZRx11lDp16qSGDRtanrWm+6jt/Uj+z+pLgcrqi2tXILLa9bp1MLtftw5l5+vWwex+3TocO163Dj3eztetg/nqumWLQurhhx/W7NmztWjRInXv3r389s6dO0tSpQozNTW1vBLt3LlzeSV5uGOCMev+/fs1ZMgQDRo0SJMmTbJ93vbt2+vYY4/VRRddpOnTp2vOnDlatWqVrbIuXLhQq1atUnh4uBo1aqRjjjlGkjRw4EDdcccdtspalbPOOkuStHv3bltl7dKliyTpxBNPLP96eHi4jjrqKMXHx9sq68EmT56sdu3a6fLLL/cqY6CyLly4UL/99pumT5+us88+W6eeeqo+/vhjNWvWTF999ZWtskrSzTffrOTkZCUmJiojI0PPP/+80tLS1Lt374Bl9UTnzp2VkpJS6fa0tDSvrxn+zupLgcrqi2tXoLJafd3yhF2uW7VlxXXLE3a5bnnLyuuWJ+xy3fKUT65bHq+m8gO3220efPBB07VrV7Nz584qv965c2fz+uuvl9/mcDiqXAj9/ffflx+zf/9+nzebCGTWffv2mT59+pgbb7yxyo5zdst7qPj4eCPJLFq0yFZZ4+LizJYtW8o/5s2bZySZn376ySQkJNgqa1V+/fVXI8nExcXZKmtOTo4JDw+vsGi3bDHsp59+aqusB99f7969ve6GGciss2fPNg0aNKjU8erYY481r7zyiq2yVuWLL74wzZs392ihv6+yHqymZhOrV68uv23VqlVeNZsIVNaDWXnt8jRrXa9dVjyvZay4bnmS1S7XLU+yVsWK65YnWe1y3fIk68H3Z+V1y5OsdrlueZK1Kt5et4yxuGvf/fffbyIiIszixYsrtHUsLCwsP+a1114zERERZubMmWbLli3mpptuqrI1b/fu3c2CBQvMhg0bzNChQyu1EY6LizORkZHmhRdeMC1btjSRkZEmMjLS47acgcqamJhojjnmGDN06FCzb9++Cuey43O7evVq88EHH5jIyEgTGxtrFi5caM455xxz9NFHm+LiYltlPVRMTIzX3Y8ClXXFihXmnXfeMZGRkWbv3r3m+++/N127djWXX3657bIaY8yjjz5qunXrZubNm2eioqLMqFGjTMeOHU1mZqbtshpjzIIFC4wks337do+fz0BnTUtLM+3atTNXX3212bhxo4mOjjZPPfWUady4sdm4caOtshpjzAcffGDWr19voqOjzYcffmiaNWtm3nvvvYA/r0lJSSYyMtJ89tln5d2jIiMjTUZGRvkxw4YNM/369TMrV640K1euNCeffLJX7c8DmdUu166asvri2hWorHa6bnnyGjiYldetmrLa6brlyfNql+uWp68BO1y3aspqp+uWJ89rXa9bxlhcSEmq8mPy5Mnlx7jdbjNu3DjTuXNnEx4ebs477zyzZcuWCvdTVFRkHnroIdO2bVvTrFkzM3LkSBMfH1/hmDvuuKPKc3n67lOgsk6ePPmw5/JGoPJu3rzZDBkyxLRt29aEh4ebI4880owePdrs27fPdlkPVZsLUqCyrl+/3px55pkmIiLCNG3a1Bx33HFm3LhxpqCgwHZZjTnwTt6TTz5pOnbsaFq1amX+8Y9/mK1bt9oyqzHG3HTTTWbw4MEe57Mq69q1a83FF19s2rZta1q1amXOOussM2fOHFtmve2220zbtm1NkyZNTL9+/czXX3/tcU5fZh03blyN95ORkWFuueUW06pVK9OqVStzyy23ePcOZACz2uXaVVNWX1y7ApXVTtctT14DB7PyulVTVjtdtzx5Xu1y3fL0NWCH65YnWe1y3fIka12vW8YYE/a/0AAAAAAAD9mi2QQAAAAABBMKKQAAAADwEoUUAAAAAHiJQgoAAAAAvEQhBQAAAABeopACAAAAAC9RSAEAAACAlyikAAAAAMBLFFIAAAAA4CUKKQAAAADwEoUUAAAAAHiJQgoAAAAAvPT/7qEA9zlcgS4AAAAASUVORK5CYII=\n",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.collections.PolyCollection at 0x7efe85658fd0>"
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'myeloma: Black/ Black Heritage Ratio Over the Years')"
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Black/ Black Heritage Ratio')"
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "(2005.0, 2018.0)"
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.axis.XTick at 0x7efe856add00>,\n",
       " <matplotlib.axis.XTick at 0x7efe856adcd0>,\n",
       " <matplotlib.axis.XTick at 0x7efe856adbb0>,\n",
       " <matplotlib.axis.XTick at 0x7efe856658b0>,\n",
       " <matplotlib.axis.XTick at 0x7efe8566e040>,\n",
       " <matplotlib.axis.XTick at 0x7efe8566e820>,\n",
       " <matplotlib.axis.XTick at 0x7efe85674040>,\n",
       " <matplotlib.axis.XTick at 0x7efe85674700>,\n",
       " <matplotlib.axis.XTick at 0x7efe85674e50>,\n",
       " <matplotlib.axis.XTick at 0x7efe85674760>,\n",
       " <matplotlib.axis.XTick at 0x7efe85665fd0>,\n",
       " <matplotlib.axis.XTick at 0x7efe85678340>,\n",
       " <matplotlib.axis.XTick at 0x7efe85678a90>,\n",
       " <matplotlib.axis.XTick at 0x7efe85683220>,\n",
       " <matplotlib.axis.XTick at 0x7efe85683970>]"
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.collections.PolyCollection at 0x7efe8569e910>"
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'prostate: Black/ Black Heritage Ratio Over the Years')"
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Black/ Black Heritage Ratio')"
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "(2003.0, 2019.0)"
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.axis.XTick at 0x7efe8562b9d0>,\n",
       " <matplotlib.axis.XTick at 0x7efe8562b9a0>,\n",
       " <matplotlib.axis.XTick at 0x7efe85614820>,\n",
       " <matplotlib.axis.XTick at 0x7efe856f8070>,\n",
       " <matplotlib.axis.XTick at 0x7efe856f8910>,\n",
       " <matplotlib.axis.XTick at 0x7efe856ec790>,\n",
       " <matplotlib.axis.XTick at 0x7efe856ecf40>,\n",
       " <matplotlib.axis.XTick at 0x7efe856f2100>,\n",
       " <matplotlib.axis.XTick at 0x7efe856f29d0>,\n",
       " <matplotlib.axis.XTick at 0x7efe856ec4f0>,\n",
       " <matplotlib.axis.XTick at 0x7efe85705fa0>,\n",
       " <matplotlib.axis.XTick at 0x7efe856fffd0>,\n",
       " <matplotlib.axis.XTick at 0x7efe856ff280>,\n",
       " <matplotlib.axis.XTick at 0x7efe85734910>,\n",
       " <matplotlib.axis.XTick at 0x7efe85734eb0>,\n",
       " <matplotlib.axis.XTick at 0x7efe857340d0>,\n",
       " <matplotlib.axis.XTick at 0x7efe856ff670>,\n",
       " <matplotlib.axis.XTick at 0x7efe856ecc70>]"
      ]
     },
     "execution_count": 290,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Set the \"year\" column as the index\n",
    "black_year_cancer_ratio.set_index('year', inplace=True)\n",
    "\n",
    "# Get the unique list of cancers\n",
    "cancers = black_year_cancer_ratio['cancer'].unique()\n",
    "\n",
    "# Plot separate area graphs for each cancer\n",
    "for cancer in cancers:\n",
    "    fig, ax = plt.subplots(figsize=(10, 6))\n",
    "    data = black_year_cancer_ratio[black_year_cancer_ratio['cancer'] == cancer]\n",
    "    ax.fill_between(data.index, data['Black/ Black Heritage'])\n",
    "    ax.set_title(f'{cancer}: Black/ Black Heritage Ratio Over the Years')\n",
    "    ax.set_ylabel('Black/ Black Heritage Ratio')\n",
    "    \n",
    "    # Set x-axis limits and ticks based on the data for the specific cancer\n",
    "    min_year = data.index.min()\n",
    "    max_year = data.index.max()\n",
    "    ax.set_xlim(min_year, max_year)\n",
    "    ax.set_xticks(np.arange(min_year-1, max_year+1))\n",
    "    \n",
    "    # Save the figure\n",
    "    plt.savefig(r'/project/approved_drugs_charts_data/'f'black_heritage_ratio_{cancer}.png')\n",
    "    \n",
    "    plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 291,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_268/1357259274.py:1: FutureWarning: The default value of numeric_only in DataFrameGroupBy.sum is deprecated. In a future version, numeric_only will default to False. Either specify numeric_only or select only columns which should be valid for the function.\n",
      "  race_cancer_2 = race_cancer_groups.groupby(['cancer']).sum()\n"
     ]
    }
   ],
   "source": [
    "race_cancer_2 = race_cancer_groups.groupby(['cancer']).sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 292,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_cancer_2.drop(['year'],axis=1,inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 293,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Calculate the total for each row\n",
    "race_cancer_2['total participants'] = race_cancer_2.sum(axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 294,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "      <th>total participants</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>cancer</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>Other</th>\n",
       "      <td>35.0</td>\n",
       "      <td>2686.0</td>\n",
       "      <td>947.0</td>\n",
       "      <td>34.0</td>\n",
       "      <td>1208.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>15.0</td>\n",
       "      <td>362.0</td>\n",
       "      <td>1329.0</td>\n",
       "      <td>38267.0</td>\n",
       "      <td>44883.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>myeloma</th>\n",
       "      <td>25.0</td>\n",
       "      <td>1611.0</td>\n",
       "      <td>1727.0</td>\n",
       "      <td>20.0</td>\n",
       "      <td>680.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>82.0</td>\n",
       "      <td>253.0</td>\n",
       "      <td>4881.0</td>\n",
       "      <td>34983.0</td>\n",
       "      <td>44262.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>prostate</th>\n",
       "      <td>563.0</td>\n",
       "      <td>1981.0</td>\n",
       "      <td>2014.0</td>\n",
       "      <td>26.0</td>\n",
       "      <td>871.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>9.0</td>\n",
       "      <td>7.0</td>\n",
       "      <td>1042.0</td>\n",
       "      <td>39169.0</td>\n",
       "      <td>45684.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "          American Indian/ Alaska Native  Asian/ Asian Heritage  \\\n",
       "cancer                                                            \n",
       "Other                               35.0                 2686.0   \n",
       "myeloma                             25.0                 1611.0   \n",
       "prostate                           563.0                 1981.0   \n",
       "\n",
       "          Black/ Black Heritage  Hawaiian/ Other Pacific Islander  \\\n",
       "cancer                                                              \n",
       "Other                     947.0                              34.0   \n",
       "myeloma                  1727.0                              20.0   \n",
       "prostate                 2014.0                              26.0   \n",
       "\n",
       "          Hispanic/ Latino  Middle Eastern  Mixed  Other  \\\n",
       "cancer                                                     \n",
       "Other               1208.0             0.0   15.0  362.0   \n",
       "myeloma              680.0             0.0   82.0  253.0   \n",
       "prostate             871.0             2.0    9.0    7.0   \n",
       "\n",
       "          Unknown or Not Reported  White/ White Heritage  total participants  \n",
       "cancer                                                                        \n",
       "Other                      1329.0                38267.0             44883.0  \n",
       "myeloma                    4881.0                34983.0             44262.0  \n",
       "prostate                   1042.0                39169.0             45684.0  "
      ]
     },
     "execution_count": 294,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_cancer_2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 295,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>cancer</th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Other</td>\n",
       "      <td>0.08</td>\n",
       "      <td>5.98</td>\n",
       "      <td>2.11</td>\n",
       "      <td>0.08</td>\n",
       "      <td>2.69</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.03</td>\n",
       "      <td>0.81</td>\n",
       "      <td>2.96</td>\n",
       "      <td>85.26</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>myeloma</td>\n",
       "      <td>0.06</td>\n",
       "      <td>3.64</td>\n",
       "      <td>3.90</td>\n",
       "      <td>0.05</td>\n",
       "      <td>1.54</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.57</td>\n",
       "      <td>11.03</td>\n",
       "      <td>79.04</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>prostate</td>\n",
       "      <td>1.23</td>\n",
       "      <td>4.34</td>\n",
       "      <td>4.41</td>\n",
       "      <td>0.06</td>\n",
       "      <td>1.91</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.02</td>\n",
       "      <td>2.28</td>\n",
       "      <td>85.74</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     cancer  American Indian/ Alaska Native  Asian/ Asian Heritage  \\\n",
       "0     Other                            0.08                   5.98   \n",
       "1   myeloma                            0.06                   3.64   \n",
       "2  prostate                            1.23                   4.34   \n",
       "\n",
       "   Black/ Black Heritage  Hawaiian/ Other Pacific Islander  Hispanic/ Latino  \\\n",
       "0                   2.11                              0.08              2.69   \n",
       "1                   3.90                              0.05              1.54   \n",
       "2                   4.41                              0.06              1.91   \n",
       "\n",
       "   Middle Eastern  Mixed  Other  Unknown or Not Reported  \\\n",
       "0             0.0   0.03   0.81                     2.96   \n",
       "1             0.0   0.19   0.57                    11.03   \n",
       "2             0.0   0.02   0.02                     2.28   \n",
       "\n",
       "   White/ White Heritage  \n",
       "0                  85.26  \n",
       "1                  79.04  \n",
       "2                  85.74  "
      ]
     },
     "execution_count": 295,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Calculate the ratio for each race/ethnic group\n",
    "race_cancer_2_ratio = race_cancer_2.div(race_cancer_2['total participants'], axis=0)\n",
    "\n",
    "# Drop the 'total participants' column\n",
    "race_cancer_2_ratio.drop('total participants', axis=1, inplace=True)\n",
    "\n",
    "# Multiply each value by 100\n",
    "race_cancer_2_ratio = race_cancer_2_ratio.multiply(100)\n",
    "\n",
    "# Round the values to 2 decimal places\n",
    "race_cancer_2_ratio = race_cancer_2_ratio.round(2)\n",
    "\n",
    "race_cancer_2_ratio.reset_index(inplace=True)\n",
    "race_cancer_2_ratio.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 296,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Calculate the ratios\n",
    "race_cancer_2_ratio['black_white_ratio'] = race_cancer_2_ratio['Black/ Black Heritage'] / race_cancer_2_ratio['White/ White Heritage']\n",
    "race_cancer_2_ratio['asian_white_ratio'] = race_cancer_2_ratio['Asian/ Asian Heritage'] / race_cancer_2_ratio['White/ White Heritage']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 297,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>cancer</th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "      <th>black_white_ratio</th>\n",
       "      <th>asian_white_ratio</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Other</td>\n",
       "      <td>0.08</td>\n",
       "      <td>5.98</td>\n",
       "      <td>2.11</td>\n",
       "      <td>0.08</td>\n",
       "      <td>2.69</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.03</td>\n",
       "      <td>0.81</td>\n",
       "      <td>2.96</td>\n",
       "      <td>85.26</td>\n",
       "      <td>0.024748</td>\n",
       "      <td>0.070138</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>myeloma</td>\n",
       "      <td>0.06</td>\n",
       "      <td>3.64</td>\n",
       "      <td>3.90</td>\n",
       "      <td>0.05</td>\n",
       "      <td>1.54</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.19</td>\n",
       "      <td>0.57</td>\n",
       "      <td>11.03</td>\n",
       "      <td>79.04</td>\n",
       "      <td>0.049342</td>\n",
       "      <td>0.046053</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>prostate</td>\n",
       "      <td>1.23</td>\n",
       "      <td>4.34</td>\n",
       "      <td>4.41</td>\n",
       "      <td>0.06</td>\n",
       "      <td>1.91</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.02</td>\n",
       "      <td>2.28</td>\n",
       "      <td>85.74</td>\n",
       "      <td>0.051435</td>\n",
       "      <td>0.050618</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     cancer  American Indian/ Alaska Native  Asian/ Asian Heritage  \\\n",
       "0     Other                            0.08                   5.98   \n",
       "1   myeloma                            0.06                   3.64   \n",
       "2  prostate                            1.23                   4.34   \n",
       "\n",
       "   Black/ Black Heritage  Hawaiian/ Other Pacific Islander  Hispanic/ Latino  \\\n",
       "0                   2.11                              0.08              2.69   \n",
       "1                   3.90                              0.05              1.54   \n",
       "2                   4.41                              0.06              1.91   \n",
       "\n",
       "   Middle Eastern  Mixed  Other  Unknown or Not Reported  \\\n",
       "0             0.0   0.03   0.81                     2.96   \n",
       "1             0.0   0.19   0.57                    11.03   \n",
       "2             0.0   0.02   0.02                     2.28   \n",
       "\n",
       "   White/ White Heritage  black_white_ratio  asian_white_ratio  \n",
       "0                  85.26           0.024748           0.070138  \n",
       "1                  79.04           0.049342           0.046053  \n",
       "2                  85.74           0.051435           0.050618  "
      ]
     },
     "execution_count": 297,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_cancer_2_ratio"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 298,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_to_white = race_cancer_2_ratio[['cancer','black_white_ratio', 'asian_white_ratio']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 299,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>cancer</th>\n",
       "      <th>black_white_ratio</th>\n",
       "      <th>asian_white_ratio</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Other</td>\n",
       "      <td>0.024748</td>\n",
       "      <td>0.070138</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>myeloma</td>\n",
       "      <td>0.049342</td>\n",
       "      <td>0.046053</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>prostate</td>\n",
       "      <td>0.051435</td>\n",
       "      <td>0.050618</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     cancer  black_white_ratio  asian_white_ratio\n",
       "0     Other           0.024748           0.070138\n",
       "1   myeloma           0.049342           0.046053\n",
       "2  prostate           0.051435           0.050618"
      ]
     },
     "execution_count": 299,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_to_white"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 300,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_268/2137843853.py:2: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  race_to_white.rename(columns={'black_white_ratio': 'black_trials', 'asian_white_ratio': 'asian_trials'}, inplace=True)\n"
     ]
    }
   ],
   "source": [
    "# Rename the columns\n",
    "race_to_white.rename(columns={'black_white_ratio': 'black_trials', 'asian_white_ratio': 'asian_trials'}, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 301,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Drop the row with the \"Other\" cancer type\n",
    "race_to_white = race_to_white[race_to_white['cancer'] != 'Other']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 302,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_268/2672048182.py:6: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  race_to_white['black_cancer'] = race_to_white['cancer'].map(black_cancer_values)\n",
      "/tmp/ipykernel_268/2672048182.py:7: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  race_to_white['asian_cancer'] = race_to_white['cancer'].map(asian_cancer_values)\n"
     ]
    }
   ],
   "source": [
    "# Define the values for black_cancer and asian_cancer\n",
    "black_cancer_values = {'prostate': 2.10, 'myeloma': 2.80}\n",
    "asian_cancer_values = {'prostate': 0.54, 'myeloma': 0.92}\n",
    "\n",
    "# Add the black_cancer and asian_cancer columns\n",
    "race_to_white['black_cancer'] = race_to_white['cancer'].map(black_cancer_values)\n",
    "race_to_white['asian_cancer'] = race_to_white['cancer'].map(asian_cancer_values)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 303,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>cancer</th>\n",
       "      <th>black_trials</th>\n",
       "      <th>asian_trials</th>\n",
       "      <th>black_cancer</th>\n",
       "      <th>asian_cancer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>myeloma</td>\n",
       "      <td>0.049342</td>\n",
       "      <td>0.046053</td>\n",
       "      <td>2.8</td>\n",
       "      <td>0.92</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>prostate</td>\n",
       "      <td>0.051435</td>\n",
       "      <td>0.050618</td>\n",
       "      <td>2.1</td>\n",
       "      <td>0.54</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     cancer  black_trials  asian_trials  black_cancer  asian_cancer\n",
       "1   myeloma      0.049342      0.046053           2.8          0.92\n",
       "2  prostate      0.051435      0.050618           2.1          0.54"
      ]
     },
     "execution_count": 303,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_to_white"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 304,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create the dataframe\n",
    "myeloma_ratios = pd.DataFrame({\n",
    "    'race': ['black', 'asian'],\n",
    "    'trials': [0.049342, 0.046053],\n",
    "    'diagnosed': [2.8, 0.92]\n",
    "})\n",
    "\n",
    "# Create the dataframe\n",
    "prostate_ratios = pd.DataFrame({\n",
    "    'race': ['black', 'asian'],\n",
    "    'trials': [0.051435, 0.050618],\n",
    "    'diagnosed': [2.1, 0.54]\n",
    "})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 305,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.collections.PathCollection at 0x7efe876e8490>"
      ]
     },
     "execution_count": 305,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.collections.PathCollection at 0x7efe87898cd0>"
      ]
     },
     "execution_count": 305,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.lines.Line2D at 0x7efe877364f0>]"
      ]
     },
     "execution_count": 305,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.lines.Line2D at 0x7efe877365e0>]"
      ]
     },
     "execution_count": 305,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.axis.YTick at 0x7efe8768b340>,\n",
       " <matplotlib.axis.YTick at 0x7efe8768ba00>]"
      ]
     },
     "execution_count": 305,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[Text(0, 0.0, 'asian'), Text(0, 0.3, 'black')]"
      ]
     },
     "execution_count": 305,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.axis.XTick at 0x7efe8768b850>,\n",
       " <matplotlib.axis.XTick at 0x7efe8768b760>,\n",
       " <matplotlib.axis.XTick at 0x7efe8760f760>,\n",
       " <matplotlib.axis.XTick at 0x7efe87736d60>]"
      ]
     },
     "execution_count": 305,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[Text(0, 0, '0'), Text(1, 0, '1'), Text(2, 0, '2'), Text(3, 0, '3')]"
      ]
     },
     "execution_count": 305,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 0, 'Ratio')"
      ]
     },
     "execution_count": 305,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Race')"
      ]
     },
     "execution_count": 305,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'Myeloma Ratios')"
      ]
     },
     "execution_count": 305,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x7efe8769a610>"
      ]
     },
     "execution_count": 305,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 800x400 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Reverse the order of rows to match the desired y-axis order\n",
    "myeloma_ratios = myeloma_ratios.iloc[::-1]\n",
    "\n",
    "# Extract the race categories\n",
    "categories = myeloma_ratios['race']\n",
    "\n",
    "# Create the plot\n",
    "fig, ax = plt.subplots(figsize=(8, 4))\n",
    "\n",
    "# Define the positions for each category\n",
    "positions = [0, 0.3]\n",
    "\n",
    "# Plot the \"trials\" and \"diagnosed\" values for each category with larger dots\n",
    "ax.scatter(myeloma_ratios['trials'], positions, color='#d69c8c', label='Trials', s=120)\n",
    "ax.scatter(myeloma_ratios['diagnosed'], positions, color='#55a4a6', label='Diagnosed', s=120)\n",
    "\n",
    "# Connect the dots with a faded grey line for each category\n",
    "for category, pos in zip(categories, positions):\n",
    "    ax.plot([myeloma_ratios.loc[myeloma_ratios['race'] == category, 'trials'].values[0],\n",
    "             myeloma_ratios.loc[myeloma_ratios['race'] == category, 'diagnosed'].values[0]],\n",
    "            [pos, pos], color='grey', alpha=0.5, linewidth=3)\n",
    "\n",
    "# Set the y-axis ticks and labels\n",
    "ax.set_yticks(positions)\n",
    "ax.set_yticklabels(categories)\n",
    "\n",
    "# Set the x-axis ticks and labels\n",
    "ax.set_xticks([0, 1, 2, 3])\n",
    "ax.set_xticklabels([0, 1, 2, 3])\n",
    "\n",
    "# Set the axis labels and title\n",
    "ax.set_xlabel('Ratio')\n",
    "ax.set_ylabel('Race')\n",
    "ax.set_title('Myeloma Ratios', pad=20)\n",
    "\n",
    "# Move the legend between the title and the plot\n",
    "legend = ax.legend(['Trials', 'Diagnosed'], loc='upper center', bbox_to_anchor=(0.5, 1.117), ncol=2, frameon=False)\n",
    "ax.add_artist(legend)\n",
    "\n",
    "# Adjust the layout and margins\n",
    "plt.tight_layout(pad=1.5)\n",
    "\n",
    "# Save the chart as an image file\n",
    "plt.savefig('/project/approved_drugs_charts_data/charts_myeloma_ratios_dot_plot.png', dpi=300)\n",
    "\n",
    "# Display the plot\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 306,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.collections.PathCollection at 0x7efe876c2670>"
      ]
     },
     "execution_count": 306,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.collections.PathCollection at 0x7efe876c29a0>"
      ]
     },
     "execution_count": 306,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.lines.Line2D at 0x7efe876d2a00>]"
      ]
     },
     "execution_count": 306,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.lines.Line2D at 0x7efe876d26d0>]"
      ]
     },
     "execution_count": 306,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.axis.YTick at 0x7efe8769a1f0>,\n",
       " <matplotlib.axis.YTick at 0x7efe856fff10>]"
      ]
     },
     "execution_count": 306,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[Text(0, 0.0, 'asian'), Text(0, 0.3, 'black')]"
      ]
     },
     "execution_count": 306,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[<matplotlib.axis.XTick at 0x7efe85683e20>,\n",
       " <matplotlib.axis.XTick at 0x7efe85683e50>,\n",
       " <matplotlib.axis.XTick at 0x7efe877b60d0>,\n",
       " <matplotlib.axis.XTick at 0x7efe876d2280>]"
      ]
     },
     "execution_count": 306,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "[Text(0, 0, '0'), Text(1, 0, '1'), Text(2, 0, '2'), Text(3, 0, '3')]"
      ]
     },
     "execution_count": 306,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 0, 'Ratio')"
      ]
     },
     "execution_count": 306,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Race')"
      ]
     },
     "execution_count": 306,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'Prostate Ratios')"
      ]
     },
     "execution_count": 306,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x7efe878b1400>"
      ]
     },
     "execution_count": 306,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 800x400 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Reverse the order of rows to match the desired y-axis order\n",
    "prostate_ratios = prostate_ratios.iloc[::-1]\n",
    "\n",
    "# Extract the race categories\n",
    "categories = prostate_ratios['race']\n",
    "\n",
    "# Create the plot\n",
    "fig, ax = plt.subplots(figsize=(8, 4))\n",
    "\n",
    "# Define the positions for each category\n",
    "positions = [0, 0.3]\n",
    "\n",
    "# Plot the \"trials\" and \"diagnosed\" values for each category with larger dots\n",
    "ax.scatter(prostate_ratios['trials'], positions, color='#d69c8c', label='Trials', s=120)\n",
    "ax.scatter(prostate_ratios['diagnosed'], positions, color='#55a4a6', label='Diagnosed', s=120)\n",
    "\n",
    "# Connect the dots with a faded grey line for each category\n",
    "for category, pos in zip(categories, positions):\n",
    "    ax.plot([prostate_ratios.loc[prostate_ratios['race'] == category, 'trials'].values[0],\n",
    "             prostate_ratios.loc[prostate_ratios['race'] == category, 'diagnosed'].values[0]],\n",
    "            [pos, pos], color='grey', alpha=0.5, linewidth=3)\n",
    "\n",
    "# Set the y-axis ticks and labels\n",
    "ax.set_yticks(positions)\n",
    "ax.set_yticklabels(categories)\n",
    "\n",
    "# Set the x-axis ticks and labels\n",
    "ax.set_xticks([0, 1, 2, 3])\n",
    "ax.set_xticklabels([0, 1, 2, 3])\n",
    "\n",
    "# Set the axis labels and title\n",
    "ax.set_xlabel('Ratio')\n",
    "ax.set_ylabel('Race')\n",
    "ax.set_title('Prostate Ratios', pad=20)\n",
    "\n",
    "# Move the legend between the title and the plot\n",
    "legend = ax.legend(['Trials', 'Diagnosed'], loc='upper center', bbox_to_anchor=(0.5, 1.117), ncol=2, frameon=False)\n",
    "ax.add_artist(legend)\n",
    "\n",
    "# Adjust the layout and margins\n",
    "plt.tight_layout(pad=1.5)\n",
    "\n",
    "# Save the chart as an image file\n",
    "plt.savefig('/project/approved_drugs_charts_data/charts_prostate_ratios_dot_plot.png', dpi=300)\n",
    "\n",
    "# Display the plot\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 307,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_268/157122580.py:1: FutureWarning: The default value of numeric_only in DataFrameGroupBy.sum is deprecated. In a future version, numeric_only will default to False. Either specify numeric_only or select only columns which should be valid for the function.\n",
      "  race_drugs_cancer =  race_columns_drugs.groupby(['cancer','drug']).sum()\n"
     ]
    }
   ],
   "source": [
    "race_drugs_cancer =  race_columns_drugs.groupby(['cancer','drug']).sum()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    " "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 308,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_drugs_cancer.reset_index(inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 309,
   "metadata": {},
   "outputs": [],
   "source": [
    "# List of columns to sum\n",
    "ethnic_group_columns = [\n",
    "    'American Indian/ Alaska Native',\n",
    "    'Asian/ Asian Heritage',\n",
    "    'Hawaiian/ Other Pacific Islander',\n",
    "    'Hispanic/ Latino',\n",
    "    'Middle Eastern',\n",
    "    'Mixed',\n",
    "    'Other',\n",
    "    'Unknown or Not Reported'\n",
    "]\n",
    "\n",
    "# Sum the ethnic group columns along axis=1 to get the total for each row\n",
    "race_drugs_cancer['Remaining Ethnic Groups'] = race_drugs_cancer[ethnic_group_columns].sum(axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 310,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>cancer</th>\n",
       "      <th>drug</th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "      <th>year</th>\n",
       "      <th>Remaining Ethnic Groups</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Other</td>\n",
       "      <td>bortezomib</td>\n",
       "      <td>2.0</td>\n",
       "      <td>23.0</td>\n",
       "      <td>40.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>39.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>74.0</td>\n",
       "      <td>1351.0</td>\n",
       "      <td>26070</td>\n",
       "      <td>140.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Other</td>\n",
       "      <td>carfilzomib</td>\n",
       "      <td>0.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>47.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>19.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>9.0</td>\n",
       "      <td>632.0</td>\n",
       "      <td>24168</td>\n",
       "      <td>41.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Other</td>\n",
       "      <td>daratumumab</td>\n",
       "      <td>18.0</td>\n",
       "      <td>285.0</td>\n",
       "      <td>64.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>64.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>304.0</td>\n",
       "      <td>2984.0</td>\n",
       "      <td>18148</td>\n",
       "      <td>679.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Other</td>\n",
       "      <td>denosumab</td>\n",
       "      <td>2.0</td>\n",
       "      <td>1553.0</td>\n",
       "      <td>312.0</td>\n",
       "      <td>16.0</td>\n",
       "      <td>652.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>80.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>14910.0</td>\n",
       "      <td>14058</td>\n",
       "      <td>2306.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Other</td>\n",
       "      <td>docetaxel</td>\n",
       "      <td>1.0</td>\n",
       "      <td>58.0</td>\n",
       "      <td>115.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>37.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>38.0</td>\n",
       "      <td>1822.0</td>\n",
       "      <td>30058</td>\n",
       "      <td>134.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  cancer         drug  American Indian/ Alaska Native  Asian/ Asian Heritage  \\\n",
       "0  Other   bortezomib                             2.0                   23.0   \n",
       "1  Other  carfilzomib                             0.0                   10.0   \n",
       "2  Other  daratumumab                            18.0                  285.0   \n",
       "3  Other    denosumab                             2.0                 1553.0   \n",
       "4  Other    docetaxel                             1.0                   58.0   \n",
       "\n",
       "   Black/ Black Heritage  Hawaiian/ Other Pacific Islander  Hispanic/ Latino  \\\n",
       "0                   40.0                               2.0              39.0   \n",
       "1                   47.0                               1.0              19.0   \n",
       "2                   64.0                               2.0              64.0   \n",
       "3                  312.0                              16.0             652.0   \n",
       "4                  115.0                               0.0              37.0   \n",
       "\n",
       "   Middle Eastern  Mixed  Other  Unknown or Not Reported  \\\n",
       "0             0.0    0.0    0.0                     74.0   \n",
       "1             0.0    0.0    2.0                      9.0   \n",
       "2             0.0    2.0    4.0                    304.0   \n",
       "3             0.0    0.0   80.0                      3.0   \n",
       "4             0.0    0.0    0.0                     38.0   \n",
       "\n",
       "   White/ White Heritage   year  Remaining Ethnic Groups  \n",
       "0                 1351.0  26070                    140.0  \n",
       "1                  632.0  24168                     41.0  \n",
       "2                 2984.0  18148                    679.0  \n",
       "3                14910.0  14058                   2306.0  \n",
       "4                 1822.0  30058                    134.0  "
      ]
     },
     "execution_count": 310,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_drugs_cancer.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 311,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_drugs_cancer.to_csv('/project/approved_drugs_charts_data/race_drugs_cancer.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The above data is to be used to create a chart for the website."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 312,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_268/2458795950.py:1: FutureWarning: The default value of numeric_only in DataFrameGroupBy.sum is deprecated. In a future version, numeric_only will default to False. Either specify numeric_only or select only columns which should be valid for the function.\n",
      "  race_drugs_groups = race_columns_drugs.groupby('drug').sum()\n"
     ]
    }
   ],
   "source": [
    "race_drugs_groups = race_columns_drugs.groupby('drug').sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 313,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_drugs_groups.reset_index(inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 314,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_drugs_groups.drop(['year'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 315,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>drug</th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>bortezomib</td>\n",
       "      <td>2.0</td>\n",
       "      <td>26.0</td>\n",
       "      <td>50.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>43.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>79.0</td>\n",
       "      <td>1509.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>carfilzomib</td>\n",
       "      <td>7.0</td>\n",
       "      <td>723.0</td>\n",
       "      <td>393.0</td>\n",
       "      <td>7.0</td>\n",
       "      <td>261.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>35.0</td>\n",
       "      <td>112.0</td>\n",
       "      <td>961.0</td>\n",
       "      <td>12085.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>daratumumab</td>\n",
       "      <td>18.0</td>\n",
       "      <td>437.0</td>\n",
       "      <td>189.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>165.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>54.0</td>\n",
       "      <td>777.0</td>\n",
       "      <td>7175.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>degarelix</td>\n",
       "      <td>526.0</td>\n",
       "      <td>80.0</td>\n",
       "      <td>1013.0</td>\n",
       "      <td>8.0</td>\n",
       "      <td>152.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>20.0</td>\n",
       "      <td>13787.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>denosumab</td>\n",
       "      <td>2.0</td>\n",
       "      <td>1553.0</td>\n",
       "      <td>312.0</td>\n",
       "      <td>16.0</td>\n",
       "      <td>652.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>80.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>14910.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "          drug  American Indian/ Alaska Native  Asian/ Asian Heritage  \\\n",
       "0   bortezomib                             2.0                   26.0   \n",
       "1  carfilzomib                             7.0                  723.0   \n",
       "2  daratumumab                            18.0                  437.0   \n",
       "3    degarelix                           526.0                   80.0   \n",
       "4    denosumab                             2.0                 1553.0   \n",
       "\n",
       "   Black/ Black Heritage  Hawaiian/ Other Pacific Islander  Hispanic/ Latino  \\\n",
       "0                   50.0                               2.0              43.0   \n",
       "1                  393.0                               7.0             261.0   \n",
       "2                  189.0                               4.0             165.0   \n",
       "3                 1013.0                               8.0             152.0   \n",
       "4                  312.0                              16.0             652.0   \n",
       "\n",
       "   Middle Eastern  Mixed  Other  Unknown or Not Reported  \\\n",
       "0             0.0    0.0    0.0                     79.0   \n",
       "1             0.0   35.0  112.0                    961.0   \n",
       "2             0.0    2.0   54.0                    777.0   \n",
       "3             0.0    0.0    0.0                     20.0   \n",
       "4             0.0    0.0   80.0                      3.0   \n",
       "\n",
       "   White/ White Heritage  \n",
       "0                 1509.0  \n",
       "1                12085.0  \n",
       "2                 7175.0  \n",
       "3                13787.0  \n",
       "4                14910.0  "
      ]
     },
     "execution_count": 315,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_drugs_groups.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 316,
   "metadata": {},
   "outputs": [],
   "source": [
    "race_drugs_groups.to_csv('/project/approved_drugs_charts_data/cancer_black_asian_drugs_race.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 317,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'Race Distribution by Drug')"
      ]
     },
     "execution_count": 317,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 0, 'Drug')"
      ]
     },
     "execution_count": 317,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Count')"
      ]
     },
     "execution_count": 317,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x7efe8569afa0>"
      ]
     },
     "execution_count": 317,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Define the race group colors and order\n",
    "race_colors = ['#fde624', '#3b518b', '#21908c', '#5cc862', 'orange', '#430154', 'black', 'skyblue', 'green']\n",
    "race_order = ['White/ White Heritage', 'Black/ Black Heritage', 'Hispanic/ Latino', 'Asian/ Asian Heritage',\n",
    "              'American Indian/ Alaska Native', 'Middle Eastern', 'Hawaiian/ Other Pacific Islander',\n",
    "              'Other', 'Mixed', 'Unknown or Not Reported']\n",
    "\n",
    "# Set the drug column as the index\n",
    "race_drugs_groups.set_index('drug', inplace=True)\n",
    "\n",
    "# Plot the stacked bar chart with custom colors\n",
    "ax = race_drugs_groups.plot(kind='bar', stacked=True, figsize=(10, 6), color=race_colors)\n",
    "\n",
    "# Set the title and labels\n",
    "plt.title('Race Distribution by Drug')\n",
    "plt.xlabel('Drug')\n",
    "plt.ylabel('Count')\n",
    "\n",
    "# Display the legend with custom race labels and colors\n",
    "legend_labels = [race_order[i] for i in range(len(race_order)) if race_order[i] in race_drugs_groups.columns]\n",
    "legend_handles = [plt.Rectangle((0, 0), 1, 1, color=race_colors[i]) for i in range(len(race_colors)) if race_order[i] in race_drugs_groups.columns]\n",
    "plt.legend(legend_handles, legend_labels, title='Race')\n",
    "\n",
    "# Save the chart as an image file\n",
    "plt.savefig('/project/approved_drugs_charts_data//all_races_matched_drugs.png', dpi=300)\n",
    "\n",
    "# Show the plot\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 319,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Figure size 800x600 with 0 Axes>"
      ]
     },
     "execution_count": 319,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<BarContainer object of 3 artists>"
      ]
     },
     "execution_count": 319,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'Representation Comparison: Black/Black, Asian/Asian, and White/White')"
      ]
     },
     "execution_count": 319,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 0, 'Count')"
      ]
     },
     "execution_count": 319,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Race Category')"
      ]
     },
     "execution_count": 319,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 800x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Define the race categories to compare\n",
    "race_categories = ['Black/ Black Heritage', 'Asian/ Asian Heritage', 'White/ White Heritage']\n",
    "\n",
    "# Subset the data for the specified race categories\n",
    "subset_data = race_drugs_groups[race_categories]\n",
    "\n",
    "# Calculate the total count for each race category\n",
    "total_counts = subset_data.sum()\n",
    "\n",
    "# Create the horizontal bar chart\n",
    "plt.figure(figsize=(8, 6))\n",
    "plt.barh(race_categories, total_counts)\n",
    "\n",
    "# Set the title and labels\n",
    "plt.title('Representation Comparison: Black/Black, Asian/Asian, and White/White')\n",
    "plt.xlabel('Count')\n",
    "plt.ylabel('Race Category')\n",
    "\n",
    "# Save the chart as an image file\n",
    "plt.savefig('/project/approved_drugs_charts_data/comparison_black_asian_white.png', dpi=300)\n",
    "\n",
    "# Show the plot\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 320,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>drug</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>bortezomib</th>\n",
       "      <td>2.0</td>\n",
       "      <td>26.0</td>\n",
       "      <td>50.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>43.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>79.0</td>\n",
       "      <td>1509.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>carfilzomib</th>\n",
       "      <td>7.0</td>\n",
       "      <td>723.0</td>\n",
       "      <td>393.0</td>\n",
       "      <td>7.0</td>\n",
       "      <td>261.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>35.0</td>\n",
       "      <td>112.0</td>\n",
       "      <td>961.0</td>\n",
       "      <td>12085.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>daratumumab</th>\n",
       "      <td>18.0</td>\n",
       "      <td>437.0</td>\n",
       "      <td>189.0</td>\n",
       "      <td>4.0</td>\n",
       "      <td>165.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>54.0</td>\n",
       "      <td>777.0</td>\n",
       "      <td>7175.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>degarelix</th>\n",
       "      <td>526.0</td>\n",
       "      <td>80.0</td>\n",
       "      <td>1013.0</td>\n",
       "      <td>8.0</td>\n",
       "      <td>152.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>20.0</td>\n",
       "      <td>13787.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>denosumab</th>\n",
       "      <td>2.0</td>\n",
       "      <td>1553.0</td>\n",
       "      <td>312.0</td>\n",
       "      <td>16.0</td>\n",
       "      <td>652.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>80.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>14910.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>docetaxel</th>\n",
       "      <td>1.0</td>\n",
       "      <td>58.0</td>\n",
       "      <td>145.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>45.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>40.0</td>\n",
       "      <td>2131.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>enzalutamide</th>\n",
       "      <td>21.0</td>\n",
       "      <td>2031.0</td>\n",
       "      <td>852.0</td>\n",
       "      <td>19.0</td>\n",
       "      <td>719.0</td>\n",
       "      <td>2.0</td>\n",
       "      <td>8.0</td>\n",
       "      <td>10.0</td>\n",
       "      <td>770.0</td>\n",
       "      <td>23589.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>lenalidomide</th>\n",
       "      <td>46.0</td>\n",
       "      <td>1365.0</td>\n",
       "      <td>1731.0</td>\n",
       "      <td>24.0</td>\n",
       "      <td>719.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>60.0</td>\n",
       "      <td>366.0</td>\n",
       "      <td>4593.0</td>\n",
       "      <td>36981.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>radium_223</th>\n",
       "      <td>0.0</td>\n",
       "      <td>5.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>3.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>9.0</td>\n",
       "      <td>252.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              American Indian/ Alaska Native  Asian/ Asian Heritage  \\\n",
       "drug                                                                  \n",
       "bortezomib                               2.0                   26.0   \n",
       "carfilzomib                              7.0                  723.0   \n",
       "daratumumab                             18.0                  437.0   \n",
       "degarelix                              526.0                   80.0   \n",
       "denosumab                                2.0                 1553.0   \n",
       "docetaxel                                1.0                   58.0   \n",
       "enzalutamide                            21.0                 2031.0   \n",
       "lenalidomide                            46.0                 1365.0   \n",
       "radium_223                               0.0                    5.0   \n",
       "\n",
       "              Black/ Black Heritage  Hawaiian/ Other Pacific Islander  \\\n",
       "drug                                                                    \n",
       "bortezomib                     50.0                               2.0   \n",
       "carfilzomib                   393.0                               7.0   \n",
       "daratumumab                   189.0                               4.0   \n",
       "degarelix                    1013.0                               8.0   \n",
       "denosumab                     312.0                              16.0   \n",
       "docetaxel                     145.0                               0.0   \n",
       "enzalutamide                  852.0                              19.0   \n",
       "lenalidomide                 1731.0                              24.0   \n",
       "radium_223                      3.0                               0.0   \n",
       "\n",
       "              Hispanic/ Latino  Middle Eastern  Mixed  Other  \\\n",
       "drug                                                           \n",
       "bortezomib                43.0             0.0    0.0    0.0   \n",
       "carfilzomib              261.0             0.0   35.0  112.0   \n",
       "daratumumab              165.0             0.0    2.0   54.0   \n",
       "degarelix                152.0             0.0    0.0    0.0   \n",
       "denosumab                652.0             0.0    0.0   80.0   \n",
       "docetaxel                 45.0             0.0    0.0    0.0   \n",
       "enzalutamide             719.0             2.0    8.0   10.0   \n",
       "lenalidomide             719.0             0.0   60.0  366.0   \n",
       "radium_223                 3.0             0.0    1.0    0.0   \n",
       "\n",
       "              Unknown or Not Reported  White/ White Heritage  \n",
       "drug                                                          \n",
       "bortezomib                       79.0                 1509.0  \n",
       "carfilzomib                     961.0                12085.0  \n",
       "daratumumab                     777.0                 7175.0  \n",
       "degarelix                        20.0                13787.0  \n",
       "denosumab                         3.0                14910.0  \n",
       "docetaxel                        40.0                 2131.0  \n",
       "enzalutamide                    770.0                23589.0  \n",
       "lenalidomide                   4593.0                36981.0  \n",
       "radium_223                        9.0                  252.0  "
      ]
     },
     "execution_count": 320,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "race_drugs_groups"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 321,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Calculate the total for each row\n",
    "race_drugs_groups['total participants'] = race_drugs_groups.sum(axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 322,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>American Indian/ Alaska Native</th>\n",
       "      <th>Asian/ Asian Heritage</th>\n",
       "      <th>Black/ Black Heritage</th>\n",
       "      <th>Hawaiian/ Other Pacific Islander</th>\n",
       "      <th>Hispanic/ Latino</th>\n",
       "      <th>Middle Eastern</th>\n",
       "      <th>Mixed</th>\n",
       "      <th>Other</th>\n",
       "      <th>Unknown or Not Reported</th>\n",
       "      <th>White/ White Heritage</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>drug</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>bortezomib</th>\n",
       "      <td>0.12</td>\n",
       "      <td>1.52</td>\n",
       "      <td>2.92</td>\n",
       "      <td>0.12</td>\n",
       "      <td>2.51</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>4.62</td>\n",
       "      <td>88.19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>carfilzomib</th>\n",
       "      <td>0.05</td>\n",
       "      <td>4.96</td>\n",
       "      <td>2.69</td>\n",
       "      <td>0.05</td>\n",
       "      <td>1.79</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.24</td>\n",
       "      <td>0.77</td>\n",
       "      <td>6.59</td>\n",
       "      <td>82.86</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>daratumumab</th>\n",
       "      <td>0.20</td>\n",
       "      <td>4.95</td>\n",
       "      <td>2.14</td>\n",
       "      <td>0.05</td>\n",
       "      <td>1.87</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.02</td>\n",
       "      <td>0.61</td>\n",
       "      <td>8.81</td>\n",
       "      <td>81.34</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>degarelix</th>\n",
       "      <td>3.37</td>\n",
       "      <td>0.51</td>\n",
       "      <td>6.50</td>\n",
       "      <td>0.05</td>\n",
       "      <td>0.98</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.13</td>\n",
       "      <td>88.46</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>denosumab</th>\n",
       "      <td>0.01</td>\n",
       "      <td>8.86</td>\n",
       "      <td>1.78</td>\n",
       "      <td>0.09</td>\n",
       "      <td>3.72</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.46</td>\n",
       "      <td>0.02</td>\n",
       "      <td>85.06</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>docetaxel</th>\n",
       "      <td>0.04</td>\n",
       "      <td>2.40</td>\n",
       "      <td>5.99</td>\n",
       "      <td>0.00</td>\n",
       "      <td>1.86</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.00</td>\n",
       "      <td>1.65</td>\n",
       "      <td>88.06</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>enzalutamide</th>\n",
       "      <td>0.07</td>\n",
       "      <td>7.25</td>\n",
       "      <td>3.04</td>\n",
       "      <td>0.07</td>\n",
       "      <td>2.57</td>\n",
       "      <td>0.01</td>\n",
       "      <td>0.03</td>\n",
       "      <td>0.04</td>\n",
       "      <td>2.75</td>\n",
       "      <td>84.18</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>lenalidomide</th>\n",
       "      <td>0.10</td>\n",
       "      <td>2.97</td>\n",
       "      <td>3.77</td>\n",
       "      <td>0.05</td>\n",
       "      <td>1.57</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.13</td>\n",
       "      <td>0.80</td>\n",
       "      <td>10.01</td>\n",
       "      <td>80.59</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>radium_223</th>\n",
       "      <td>0.00</td>\n",
       "      <td>1.83</td>\n",
       "      <td>1.10</td>\n",
       "      <td>0.00</td>\n",
       "      <td>1.10</td>\n",
       "      <td>0.00</td>\n",
       "      <td>0.37</td>\n",
       "      <td>0.00</td>\n",
       "      <td>3.30</td>\n",
       "      <td>92.31</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              American Indian/ Alaska Native  Asian/ Asian Heritage  \\\n",
       "drug                                                                  \n",
       "bortezomib                              0.12                   1.52   \n",
       "carfilzomib                             0.05                   4.96   \n",
       "daratumumab                             0.20                   4.95   \n",
       "degarelix                               3.37                   0.51   \n",
       "denosumab                               0.01                   8.86   \n",
       "docetaxel                               0.04                   2.40   \n",
       "enzalutamide                            0.07                   7.25   \n",
       "lenalidomide                            0.10                   2.97   \n",
       "radium_223                              0.00                   1.83   \n",
       "\n",
       "              Black/ Black Heritage  Hawaiian/ Other Pacific Islander  \\\n",
       "drug                                                                    \n",
       "bortezomib                     2.92                              0.12   \n",
       "carfilzomib                    2.69                              0.05   \n",
       "daratumumab                    2.14                              0.05   \n",
       "degarelix                      6.50                              0.05   \n",
       "denosumab                      1.78                              0.09   \n",
       "docetaxel                      5.99                              0.00   \n",
       "enzalutamide                   3.04                              0.07   \n",
       "lenalidomide                   3.77                              0.05   \n",
       "radium_223                     1.10                              0.00   \n",
       "\n",
       "              Hispanic/ Latino  Middle Eastern  Mixed  Other  \\\n",
       "drug                                                           \n",
       "bortezomib                2.51            0.00   0.00   0.00   \n",
       "carfilzomib               1.79            0.00   0.24   0.77   \n",
       "daratumumab               1.87            0.00   0.02   0.61   \n",
       "degarelix                 0.98            0.00   0.00   0.00   \n",
       "denosumab                 3.72            0.00   0.00   0.46   \n",
       "docetaxel                 1.86            0.00   0.00   0.00   \n",
       "enzalutamide              2.57            0.01   0.03   0.04   \n",
       "lenalidomide              1.57            0.00   0.13   0.80   \n",
       "radium_223                1.10            0.00   0.37   0.00   \n",
       "\n",
       "              Unknown or Not Reported  White/ White Heritage  \n",
       "drug                                                          \n",
       "bortezomib                       4.62                  88.19  \n",
       "carfilzomib                      6.59                  82.86  \n",
       "daratumumab                      8.81                  81.34  \n",
       "degarelix                        0.13                  88.46  \n",
       "denosumab                        0.02                  85.06  \n",
       "docetaxel                        1.65                  88.06  \n",
       "enzalutamide                     2.75                  84.18  \n",
       "lenalidomide                    10.01                  80.59  \n",
       "radium_223                       3.30                  92.31  "
      ]
     },
     "execution_count": 322,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Calculate the ratio for each race/ethnic group\n",
    "race_drugs_groups_ratio = race_drugs_groups.div(race_drugs_groups['total participants'], axis=0)\n",
    "\n",
    "# Drop the 'total participants' column\n",
    "race_drugs_groups_ratio.drop('total participants', axis=1, inplace=True)\n",
    "\n",
    "# Multiply each value by 100\n",
    "race_drugs_groups_ratio = race_drugs_groups_ratio.multiply(100)\n",
    "\n",
    "# Round the values to 2 decimal places\n",
    "race_drugs_groups_ratio = race_drugs_groups_ratio.round(2)\n",
    "\n",
    "race_drugs_groups_ratio"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 323,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<Figure size 1000x600 with 0 Axes>"
      ]
     },
     "execution_count": 323,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<AxesSubplot:ylabel='drug'>"
      ]
     },
     "execution_count": 323,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 1.0, 'Race/Ethnicity Distribution')"
      ]
     },
     "execution_count": 323,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0.5, 0, 'Ratio (%)')"
      ]
     },
     "execution_count": 323,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "Text(0, 0.5, 'Drug')"
      ]
     },
     "execution_count": 323,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x7efe85599f70>"
      ]
     },
     "execution_count": 323,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "text/plain": [
       "<Figure size 1000x600 with 0 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Define the colors for each race/ethnicity\n",
    "colors = ['#4789e2', '#d0d0d0', '#d0d0d0', '#d0d0d0', '#d0d0d0', '#d0d0d0', '#d0d0d0', '#d0d0d0', '#d0d0d0', '#CD3333']\n",
    "\n",
    "# Reorder the columns in the DataFrame to have black and asian first and white last\n",
    "race_order = ['Black/ Black Heritage', 'Asian/ Asian Heritage', 'American Indian/ Alaska Native',\n",
    "              'Hawaiian/ Other Pacific Islander', 'Hispanic/ Latino', 'Middle Eastern', 'Mixed', 'Other',\n",
    "              'Unknown or Not Reported', 'White/ White Heritage']\n",
    "race_drugs_groups_ratio_ordered = race_drugs_groups_ratio[race_order]\n",
    "\n",
    "# Plot the stacked bar chart\n",
    "plt.figure(figsize=(10, 6))\n",
    "race_drugs_groups_ratio_ordered.plot.barh(stacked=True, color=colors)\n",
    "\n",
    "# Set the title and labels\n",
    "plt.title('Race/Ethnicity Distribution')\n",
    "plt.xlabel('Ratio (%)')\n",
    "plt.ylabel('Drug')\n",
    "\n",
    "# Update the legend colors\n",
    "# Update the legend colors\n",
    "legend_colors = {'Black/ Black Heritage': '#4789e2', 'Asian/ Asian Heritage': '#d0d0d0',\n",
    "                 'American Indian/ Alaska Native': '#d0d0d0', 'Hawaiian/ Other Pacific Islander': '#d0d0d0',\n",
    "                 'Hispanic/ Latino': '#d0d0d0', 'Middle Eastern': '#d0d0d0', 'Mixed': '#d0d0d0', 'Other': '#d0d0d0',\n",
    "                 'Unknown or Not Reported': '#d0d0d0', 'White/ White Heritage': '#CD3333'}\n",
    "\n",
    "# Create new legend handles and labels for grouping\n",
    "grouped_legend_handles = []\n",
    "grouped_legend_labels = []\n",
    "\n",
    "# Group \"Black/ Black Heritage\" and \"Asian/ Asian Heritage\" as \"Black and Asian\"\n",
    "grouped_legend_handles.append(plt.Rectangle((0, 0), 1, 1, color=legend_colors['Black/ Black Heritage']))\n",
    "grouped_legend_labels.append('Black')\n",
    "\n",
    "# Group \"Other\" labels together\n",
    "grouped_legend_handles.append(plt.Rectangle((0, 0), 1, 1, color=legend_colors['Other']))\n",
    "grouped_legend_labels.append('Remaining Ethnic Groups')\n",
    "\n",
    "# Group \"White/ White Heritage\" as \"White\"\n",
    "grouped_legend_handles.append(plt.Rectangle((0, 0), 1, 1, color=legend_colors['White/ White Heritage']))\n",
    "grouped_legend_labels.append('White')\n",
    "\n",
    "# Show the updated legend\n",
    "plt.legend(grouped_legend_handles, grouped_legend_labels, loc='lower center',  bbox_to_anchor=(0.5, -0.25), ncol=3)\n",
    "\n",
    "# Adjust the layout to prevent cutoff\n",
    "plt.tight_layout()\n",
    "\n",
    "# Save the chart as an image file\n",
    "plt.savefig('/project/approved_drugs_charts_data/100_hbar_comparison_black_asian_white.png', dpi=300)\n",
    "\n",
    "# Show the plot\n",
    "plt.show()"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python [conda env:Python3] *",
   "language": "python",
   "name": "conda-env-Python3-py"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.15"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
